GENENAME;TYPE;PMID;OMIMGENE;ORIGINALENTRY;OMIMDISEASE
A1CF;Cayler cardiofacial syndrome;17357067;125520;Cayler cardiofacial syndrome (2);0
A2M;Alpha-2-macroglobulin deficiency;17357067;103950;Alpha-2-macroglobulin deficiency, 614036 (1);614036
A2M;Alzheimer disease, susceptibility to;17357067;103950;{Alzheimer disease, susceptibility to}, 104300 (3);104300
A4GALT;Blood group, P1Pk system, P(2) phenotype;17357067;607922;[Blood group, P1Pk system, P(2) phenotype], 111400 (3);111400
A4GALT;Blood group, P1Pk system, p phenotype;17357067;607922;[Blood group, P1Pk system, p phenotype], 111400 (3);111400
A4GALT;NOR polyagglutination syndrome;17357067;607922;NOR polyagglutination syndrome, 111400 (3);111400
AAAS;Achalasia-addisonianism-alacrimia syndrome;17357067;605378;Achalasia-addisonianism-alacrimia syndrome, 231550 (3);231550
AAGAB;Keratoderma, palmoplantar, punctate type IA;17357067;614888;Keratoderma, palmoplantar, punctate type IA, 148600 (3);148600
AANAT;Delayed sleep phase syndrome, susceptibility to;17357067;600950;{Delayed sleep phase syndrome, susceptibility to}, 614163 (3);614163
AARS;Charcot-Marie-Tooth disease, axonal, type 2N;17357067;601065;Charcot-Marie-Tooth disease, axonal, type 2N, 613287 (3);613287
AARS;Epileptic encephalopathy, early infantile, 29;17357067;601065;Epileptic encephalopathy, early infantile, 29, 616339 (3);616339
AARS2;Combined oxidative phosphorylation deficiency 8;17357067;612035;Combined oxidative phosphorylation deficiency 8, 614096 (3);614096
AARS2;Leukoencephalopathy, progressive, with ovarian failure;17357067;612035;Leukoencephalopathy, progressive, with ovarian failure, 615889 (3);615889
AASS;Hyperlysinemia;17357067;605113;Hyperlysinemia, 238700 (3);238700
AASS;Saccharopinuria;17357067;605113;Saccharopinuria, 268700 (1);268700
ABAT;GABA-transaminase deficiency;17357067;137150;GABA-transaminase deficiency, 613163 (3);613163
ABCA1;Coronary artery disease in familial hypercholesterolemia, protection against;17357067;600046;{Coronary artery disease in familial hypercholesterolemia, protection against}, 143890 (3);143890
ABCA1;HDL deficiency, type 2;17357067;600046;HDL deficiency, type 2, 604091 (3);604091
ABCA1;Tangier disease;17357067;600046;Tangier disease, 205400 (3);205400
ABCA12;Ichthyosis, autosomal recessive 4B (harlequin);17357067;607800;Ichthyosis, autosomal recessive 4B (harlequin), 242500 (3);242500
ABCA12;Ichthyosis, congenital, autosomal recessive 4A;17357067;607800;Ichthyosis, congenital, autosomal recessive 4A, 601277 (3);601277
ABCA3;Surfactant metabolism dysfunction, pulmonary, 3;17357067;601615;Surfactant metabolism dysfunction, pulmonary, 3, 610921 (3);610921
ABCA4;Cone-rod dystrophy 3;17357067;601691;Cone-rod dystrophy 3, 604116 (3);604116
ABCA4;Fundus flavimaculatus;17357067;601691;Fundus flavimaculatus, 248200 (3);248200
ABCA4;Macular degeneration, age-related, 2;17357067;601691;{Macular degeneration, age-related, 2}, 153800 (3);153800
ABCA4;Retinal dystrophy, early-onset severe;17357067;601691;Retinal dystrophy, early-onset severe, 248200 (3);248200
ABCA4;Retinitis pigmentosa 19;17357067;601691;Retinitis pigmentosa 19, 601718 (3);601718
ABCA4;Stargardt disease 1;17357067;601691;Stargardt disease 1, 248200 (3);248200
ABCB1;Colchicine resistance;17357067;171050;{Colchicine resistance}, 120080 (3);120080
ABCB1;Inflammatory bowel disease 13;17357067;171050;{Inflammatory bowel disease 13}, 612244 (3);612244
ABCB11;Cholestasis, benign recurrent intrahepatic, 2;17357067;603201;Cholestasis, benign recurrent intrahepatic, 2, 605479 (3);605479
ABCB11;Cholestasis, progressive familial intrahepatic 2;17357067;603201;Cholestasis, progressive familial intrahepatic 2, 601847 (3);601847
ABCB4;Cholestasis, intrahepatic, of pregnancy, 3;17357067;171060;Cholestasis, intrahepatic, of pregnancy, 3, 614972 (3);614972
ABCB4;Cholestasis, progressive familial intrahepatic 3;17357067;171060;Cholestasis, progressive familial intrahepatic 3, 602347 (3);602347
ABCB4;Gallbladder disease 1;17357067;171060;Gallbladder disease 1, 600803 (3);600803
ABCB6;Blood group, Langereis system;17357067;605452;[Blood group, Langereis system], 111600 (3);111600
ABCB6;Dyschromatosis universalis hereditaria 3;17357067;605452;Dyschromatosis universalis hereditaria 3, 615402 (3);615402
ABCB6;Microphthalmia, isolated, with coloboma 7;17357067;605452;Microphthalmia, isolated, with coloboma 7, 614497 (3);614497
ABCB7;Anemia, sideroblastic, with ataxia;17357067;300135;Anemia, sideroblastic, with ataxia, 301310 (3);301310
ABCC11;Axillary odor, variation in;17357067;607040;[Axillary odor, variation in], 117800 (3);117800
ABCC11;Colostrum secretion, variation in;17357067;607040;[Colostrum secretion, variation in], 117800 (3);117800
ABCC11;Earwax, wet/dry;17357067;607040;[Earwax, wet/dry], 117800 (3);117800
ABCC2;Dubin-Johnson syndrome;17357067;601107;Dubin-Johnson syndrome, 237500 (3);237500
ABCC6;Arterial calcification, generalized, of infancy, 2;17357067;603234;Arterial calcification, generalized, of infancy, 2, 614473 (3);614473
ABCC6;Pseudoxanthoma elasticum;17357067;603234;Pseudoxanthoma elasticum, 264800 (3);264800
ABCC6;Pseudoxanthoma elasticum, forme fruste;17357067;603234;Pseudoxanthoma elasticum, forme fruste, 177850 (3);177850
ABCC8;Diabetes mellitus, noninsulin-dependent;17357067;600509;Diabetes mellitus, noninsulin-dependent, 125853 (3);125853
ABCC8;Diabetes mellitus, permanent neonatal;17357067;600509;Diabetes mellitus, permanent neonatal, 606176 (3);606176
ABCC8;Diabetes mellitus, permanent neonatal, with neurologic features;17357067;600937;Diabetes mellitus, permanent neonatal, with neurologic features, 606176 (3);606176
ABCC8;Diabetes mellitus, transient neonatal 2;17357067;600509;Diabetes mellitus, transient neonatal 2, 610374 (3);610374
ABCC8;Diabetes mellitus, transient neonatal, 3;17357067;600937;Diabetes mellitus, transient neonatal, 3, 610582 (3);610582
ABCC8;Diabetes mellitus, type 2, susceptibility to;17357067;600937;{Diabetes mellitus, type 2, susceptibility to}, 125853 (3);125853
ABCC8;Diabetes, permanent neonatal;17357067;600937;Diabetes, permanent neonatal, 606176 (3);606176
ABCC8;Hyperinsulinemic hypoglycemia, familial, 1;17357067;600509;Hyperinsulinemic hypoglycemia, familial, 1, 256450 (3);256450
ABCC8;Hyperinsulinemic hypoglycemia, familial, 2;17357067;600937;Hyperinsulinemic hypoglycemia, familial, 2, 601820 (3);601820
ABCC8;Hypoglycemia of infancy, leucine-sensitive;17357067;600509;Hypoglycemia of infancy, leucine-sensitive, 240800 (3);240800
ABCC8;Maturity-onset diabetes of the young, type 13;17357067;600937;Maturity-onset diabetes of the young, type 13, 616329 (3);616329
ABCC9;Atrial fibrillation, familial, 12;17357067;601439;Atrial fibrillation, familial, 12, 614050 (3);614050
ABCC9;Cardiomyopathy, dilated, 1O;17357067;601439;Cardiomyopathy, dilated, 1O, 608569 (3);608569
ABCC9;Hypertrichotic osteochondrodysplasia;17357067;601439;Hypertrichotic osteochondrodysplasia, 239850 (3);239850
ABCD1;Adrenoleukodystrophy;17357067;300371;Adrenoleukodystrophy, 300100 (3);300100
ABCD1;Adrenomyeloneuropathy, adult;17357067;300371;Adrenomyeloneuropathy, adult, 300100 (3);300100
ABCD4;Methylmalonic aciduria and homocystinuria, cblJ type;17357067;603214;Methylmalonic aciduria and homocystinuria, cblJ type, 614857 (3);614857
ABCG2;Junior blood group system;17357067;603756;[Junior blood group system], 614490 (3);614490
ABCG2;Uric acid concentration, serum, QTL1;17357067;603756;[Uric acid concentration, serum, QTL1], 138900 (3);138900
ABCG5;Sitosterolemia;17357067;605459;Sitosterolemia, 210250 (3);210250
ABCG8;Gallbladder disease 4;17357067;605460;Gallbladder disease 4, 611465 (3);611465
ABCG8;Sitosterolemia;17357067;605460;Sitosterolemia, 210250 (3);210250
ABHD12;Polyneuropathy, hearing loss, ataxia, retinitis pigmentosa, and cataract;17357067;613599;Polyneuropathy, hearing loss, ataxia, retinitis pigmentosa, and cataract, 612674 (3);612674
ABHD5;Chanarin-Dorfman syndrome;17357067;604780;Chanarin-Dorfman syndrome, 275630 (3);275630
ABL1;Leukemia, Philadelphia chromosome-positive, resistant to imatinib;17357067;189980;Leukemia, Philadelphia chromosome-positive, resistant to imatinib (3);0
ABL2;Leukemia, acute myeloid, with eosinophilia;17357067;164690;Leukemia, acute myeloid, with eosinophilia (1);0
ABO;Blood group, ABO system;17357067;110300;[Blood group, ABO system], 616093 (3);616093
ACACA;Acetyl-CoA carboxylase deficiency;17357067;200350;Acetyl-CoA carboxylase deficiency, 613933 (1);613933
ACAD8;Isobutyryl-CoA dehydrogenase deficiency;17357067;604773;Isobutyryl-CoA dehydrogenase deficiency, 611283 (3);611283
ACAD9;Mitochondrial complex I deficiency due to ACAD9 deficiency;17357067;611103;Mitochondrial complex I deficiency due to ACAD9 deficiency, 611126 (3);611126
ACADM;Acyl-CoA dehydrogenase, medium chain, deficiency of;17357067;607008;Acyl-CoA dehydrogenase, medium chain, deficiency of, 201450 (3);201450
ACADS;Acyl-CoA dehydrogenase, short-chain, deficiency of;17357067;606885;Acyl-CoA dehydrogenase, short-chain, deficiency of, 201470 (3);201470
ACADSB;2-methylbutyrylglycinuria;17357067;600301;2-methylbutyrylglycinuria, 610006 (3);610006
ACADVL;VLCAD deficiency;17357067;609575;VLCAD deficiency, 201475 (3);201475
ACAN;Osteochondritis dissecans, short stature, and early-onset osteoarthritis;17357067;155760;Osteochondritis dissecans, short stature, and early-onset osteoarthritis, 165800 (3);165800
ACAN;Spondyloepimetaphyseal dysplasia, aggrecan type;17357067;155760;Spondyloepimetaphyseal dysplasia, aggrecan type, 612813 (3);612813
ACAN;Spondyloepiphyseal dysplasia, Kimberley type;17357067;155760;Spondyloepiphyseal dysplasia, Kimberley type, 608361 (3);608361
ACAT1;Alpha-methylacetoacetic aciduria;17357067;607809;Alpha-methylacetoacetic aciduria, 203750 (3);203750
ACE;Alzheimer disease, susceptibility to;17357067;106180;{Alzheimer disease, susceptibility to}, 104300 (3);104300
ACE;Angiotensin I-converting enzyme, benign serum increase;17357067;106180;[Angiotensin I-converting enzyme, benign serum increase] (3);0
ACE;Microvascular complications of diabetes 3;17357067;106180;{Microvascular complications of diabetes 3}, 612624 (3);612624
ACE;Myocardial infarction, susceptibility to;17357067;106180;{Myocardial infarction, susceptibility to} (3);0
ACE;Renal tubular dysgenesis;17357067;106180;Renal tubular dysgenesis, 267430 (3);267430
ACE;SARS, progression of;17357067;106180;{SARS, progression of} (3);0
ACE;Stroke, hemorrhagic;17357067;106180;{Stroke, hemorrhagic}, 614519 (3);614519
ACHE;Blood group, Yt system;17357067;100740;[Blood group, Yt system], 112100 (3);112100
ACKR1;Blood group, Duffy system;17357067;613665;[Blood group, Duffy system], 110700 (3);110700
ACKR1;Malaria, vivax, protection against;17357067;613665;{Malaria, vivax, protection against}, 611162 (3);611162
ACKR1;White blood cell count QTL;17357067;613665;[White blood cell count QTL], 611862 (3);611862
ACKR4;Photoparoxysmal response 1;17357067;132100;Photoparoxysmal response 1 (2);0
ACO2;Infantile cerebellar-retinal degeneration;17357067;100850;Infantile cerebellar-retinal degeneration, 614559 (3);614559
ACOT12;Leukoencephalopathy with vanishing white matter;17357067;603945;Leukoencephalopathy with vanishing white matter, 603896 (3);603896
ACOT12;Ovarioleukodystrophy;17357067;603945;Ovarioleukodystrophy, 603896 (3);603896
ACOX1;Peroxisomal acyl-CoA oxidase deficiency;17357067;609751;Peroxisomal acyl-CoA oxidase deficiency, 264470 (3);264470
ACP5;Spondyloenchondrodysplasia with immune dysregulation;17357067;171640;Spondyloenchondrodysplasia with immune dysregulation, 607944 (3);607944
ACSF3;Combined malonic and methylmalonic aciduria;17357067;614245;Combined malonic and methylmalonic aciduria, 614265 (3);614265
ACSL4;Mental retardation, X-linked 63;17357067;300157;Mental retardation, X-linked 63, 300387 (3);300387
ACSL6;Myelodysplastic syndrome;17357067;604443;Myelodysplastic syndrome (3);0
ACSL6;Myelogenous leukemia, acute;17357067;604443;Myelogenous leukemia, acute (3);0
ACTA1;Myopathy, actin, congenital, with cores;17357067;102610;Myopathy, actin, congenital, with cores, 161800 (3);161800
ACTA1;Myopathy, actin, congenital, with excess of thin myofilaments;17357067;102610;Myopathy, actin, congenital, with excess of thin myofilaments, 161800 (3);161800
ACTA1;Myopathy, congenital, with fiber-type disproportion 1;17357067;102610;Myopathy, congenital, with fiber-type disproportion 1, 255310 (3);255310
ACTA1;Nemaline myopathy 3, autosomal dominant or recessive;17357067;102610;Nemaline myopathy 3, autosomal dominant or recessive, 161800 (3);161800
ACTA2;Aortic aneurysm, familial thoracic 6;17357067;102620;Aortic aneurysm, familial thoracic 6, 611788 (3);611788
ACTA2;Moyamoya disease 5;17357067;102620;Moyamoya disease 5, 614042 (3);614042
ACTA2;Multisystemic smooth muscle dysfunction syndrome;17357067;102620;Multisystemic smooth muscle dysfunction syndrome, 613834 (3);613834
ACTB;Baraitser-Winter syndrome 1;17357067;102630;Baraitser-Winter syndrome 1, 243310 (3);243310
ACTB;Dystonia, juvenile-onset;17357067;102630;Dystonia, juvenile-onset, 607371 (3);607371
ACTC1;Atrial septal defect 5;17357067;102540;Atrial septal defect 5, 612794 (3);612794
ACTC1;Cardiomyopathy, dilated, 1R;17357067;102540;Cardiomyopathy, dilated, 1R, 613424 (3);613424
ACTC1;Cardiomyopathy, hypertrophic, 11;17357067;102540;Cardiomyopathy, hypertrophic, 11, 612098 (3);612098
ACTC1;Left ventricular noncompaction 4;17357067;102540;Left ventricular noncompaction 4, 613424 (3);613424
ACTG1;Baraitser-Winter syndrome 2;17357067;102560;Baraitser-Winter syndrome 2, 614583 (3);614583
ACTG1;Deafness, autosomal dominant 20/26;17357067;102560;Deafness, autosomal dominant 20/26, 604717 (3);604717
ACTG2;Visceral myopathy;17357067;102545;Visceral myopathy, 155310 (3);155310
ACTN1;Bleeding disorder, platelet-type, 15;17357067;102575;Bleeding disorder, platelet-type, 15, 615193 (3);615193
ACTN2;Cardiomyopathy, dilated, 1AA, with or without LVNC;17357067;102573;Cardiomyopathy, dilated, 1AA, with or without LVNC, 612158 (3);612158
ACTN2;Cardiomyopathy, hypertrophic, 23, with or without LVNC;17357067;102573;Cardiomyopathy, hypertrophic, 23, with or without LVNC, 612158 (3);612158
ACTN3;Alpha-actinin-3 deficiency;17357067;102574;[Alpha-actinin-3 deficiency] (3);0
ACTN3;Sprinting performance;17357067;102574;[Sprinting performance] (3);0
ACTN4;Glomerulosclerosis, focal segmental, 1;17357067;604638;Glomerulosclerosis, focal segmental, 1, 603278 (3);603278
ACVR1;Fibrodysplasia ossificans progressiva;17357067;102576;Fibrodysplasia ossificans progressiva, 135100 (3);135100
ACVR1B;Pancreatic cancer, somatic;17357067;601300;Pancreatic cancer, somatic (3);0
ACVR2B;Heterotaxy, visceral, 4, autosomal;17357067;602730;Heterotaxy, visceral, 4, autosomal, 613751 (3);613751
ACVRL1;Telangiectasia, hereditary hemorrhagic, type 2;17357067;601284;Telangiectasia, hereditary hemorrhagic, type 2, 600376 (3);600376
ACY1;Aminoacylase 1 deficiency;17357067;104620;Aminoacylase 1 deficiency, 609924 (3);609924
ADA;Adenosine deaminase deficiency, partial;17357067;608958;Adenosine deaminase deficiency, partial, 102700 (3);102700
ADA;Severe combined immunodeficiency due to ADA deficiency;17357067;608958;Severe combined immunodeficiency due to ADA deficiency, 102700 (3);102700
ADAM10;Alzheimer disease 18, susceptibility to;17357067;602192;{Alzheimer disease 18, susceptibility to}, 615590 (3);615590
ADAM10;Reticulate acropigmentation of Kitamura;17357067;602192;Reticulate acropigmentation of Kitamura, 615537 (3);615537
ADAM8;Multiple sclerosis, susceptibility to, 2;17357067;612594;{Multiple sclerosis, susceptibility to, 2} (2);0
ADAM9;Cone-rod dystrophy 9;17357067;602713;Cone-rod dystrophy 9, 612775 (3);612775
ADAMTS10;Weill-Marchesani syndrome 1, recessive;17357067;608990;Weill-Marchesani syndrome 1, recessive, 277600 (3);277600
ADAMTS13;Thrombotic thrombocytopenic purpura, familial;17357067;604134;Thrombotic thrombocytopenic purpura, familial, 274150 (3);274150
ADAMTS17;Weill-Marchesani-like syndrome;17357067;607511;Weill-Marchesani-like syndrome, 613195 (3);613195
ADAMTS18;Microcornea, myopic chorioretinal atrophy, and telecanthus;17357067;607512;Microcornea, myopic chorioretinal atrophy, and telecanthus, 615458 (3);615458
ADAMTS2;Ehlers-Danlos syndrome, type VIIC;17357067;604539;Ehlers-Danlos syndrome, type VIIC, 225410 (3);225410
ADAMTSL2;Geleophysic dysplasia 1;17357067;612277;Geleophysic dysplasia 1, 231050 (3);231050
ADAMTSL4;Ectopia lentis et pupillae;17357067;610113;Ectopia lentis et pupillae, 225200 (3);225200
ADAMTSL4;Ectopia lentis, isolated, autosomal recessive;17357067;610113;Ectopia lentis, isolated, autosomal recessive, 225100 (3);225100
ADAR;Aicardi-Goutieres syndrome 6;17357067;146920;Aicardi-Goutieres syndrome 6, 615010 (3);615010
ADAR;Dyschromatosis symmetrica hereditaria;17357067;146920;Dyschromatosis symmetrica hereditaria, 127400 (3);127400
ADAT3;Mental retardation, autosomal recessive 36;17357067;615302;Mental retardation, autosomal recessive 36, 615286 (3);615286
ADCK3;Coenzyme Q10 deficiency, primary, 4;17357067;606980;Coenzyme Q10 deficiency, primary, 4, 612016 (3);612016
ADCK4;Nephrotic syndrome, type 9;17357067;615567;Nephrotic syndrome, type 9, 615573 (3);615573
ADCY10;Hypercalciuria, absorptive, susceptibility to;17357067;605205;{Hypercalciuria, absorptive, susceptibility to}, 143870 (3);143870
ADCY5;Dyskinesia, familial, with facial myokymia;17357067;600293;Dyskinesia, familial, with facial myokymia, 606703 (3);606703
ADD1;Hypertension, essential, salt-sensitive;17357067;102680;{Hypertension, essential, salt-sensitive}, 145500 (3);145500
ADH1B;Aerodigestive tract cancer, squamous cell, alcohol-related, protection against;17357067;103720;{Aerodigestive tract cancer, squamous cell, alcohol-related, protection against} (3);0
ADH1B;Alcohol dependence, protection against;17357067;103720;{Alcohol dependence, protection against}, 103780 (3);103780
ADH1C;Alcohol dependence, protection against;17357067;103730;{Alcohol dependence, protection against}, 103780 (3);103780
ADH1C;Parkinson disease, susceptibility to;17357067;103730;{Parkinson disease, susceptibility to}, 168600 (3);168600
ADIPOQ;Adiponectin deficiency;17357067;605441;Adiponectin deficiency, 612556 (3);612556
ADK;Hypermethioninemia due to adenosine kinase deficiency;17357067;102750;Hypermethioninemia due to adenosine kinase deficiency, 614300 (3);614300
ADNP;Helsmoortel-van der Aa syndrome;17357067;611386;Helsmoortel-van der Aa syndrome, 615873 (3);615873
ADRA2B;Epilepsy, myoclonic, familial adult, 2;17357067;104260;Epilepsy, myoclonic, familial adult, 2, 607876 (3);607876
ADRA2C;Congestive heart failure and beta-blocker response, modifier of;17357067;104250;{Congestive heart failure and beta-blocker response, modifier of} (3);0
ADRB1;Congestive heart failure and beta-blocker response, modifier of;17357067;109630;{Congestive heart failure and beta-blocker response, modifier of} (3);0
ADRB1;Resting heart rate;17357067;109630;[Resting heart rate], 607276 (3);607276
ADRB2;Asthma, nocturnal, susceptibility to;17357067;109690;{Asthma, nocturnal, susceptibility to}, 600807 (3);600807
ADRB2;Beta-2-adrenoreceptor agonist, reduced response to;17357067;109690;Beta-2-adrenoreceptor agonist, reduced response to (3);0
ADRB2;Obesity, susceptibility to;17357067;109690;{Obesity, susceptibility to}, 601665 (3);601665
ADRB3;Obesity, susceptibility to;17357067;109691;{Obesity, susceptibility to}, 601665 (3);601665
ADSL;Adenylosuccinase deficiency;17357067;608222;Adenylosuccinase deficiency, 103050 (3);103050
AFF2;Mental retardation, X-linked, FRAXE type;17357067;300806;Mental retardation, X-linked, FRAXE type, 309548 (3);309548
AFF4;CHOPS syndrome;17357067;604417;CHOPS syndrome, 616368 (3);616368
AFG3L2;Ataxia, spastic, 5, autosomal recessive;17357067;604581;Ataxia, spastic, 5, autosomal recessive, 614487 (3);614487
AFG3L2;Spinocerebellar ataxia 28;17357067;604581;Spinocerebellar ataxia 28, 610246 (3);610246
AFP;Alpha-fetoprotein deficiency;17357067;104150;Alpha-fetoprotein deficiency, 615969 (3);615969
AFP;Hereditary persistence of alpha-fetoprotein;17357067;104150;[Hereditary persistence of alpha-fetoprotein], 615970 (3);615970
AGA;Aspartylglucosaminuria;17357067;613228;Aspartylglucosaminuria, 208400 (3);208400
AGBL1;Corneal dystrophy, Fuchs endothelial, 8;17357067;615496;Corneal dystrophy, Fuchs endothelial, 8, 615523 (3);615523
AGK;Cataract 38, autosomal recessive;17357067;610345;Cataract 38, autosomal recessive, 614691 (3);614691
AGK;Sengers syndrome;17357067;610345;Sengers syndrome, 212350 (3);212350
AGL;Glycogen storage disease IIIa;17357067;610860;Glycogen storage disease IIIa, 232400 (3);232400
AGL;Glycogen storage disease IIIb;17357067;610860;Glycogen storage disease IIIb, 232400 (3);232400
AGPAT2;Lipodystrophy, congenital generalized, type 1;17357067;603100;Lipodystrophy, congenital generalized, type 1, 608594 (3);608594
AGPS;Chondrodysplasia punctata, rhizomelic, type 3;17357067;603051;Chondrodysplasia punctata, rhizomelic, type 3, 600121 (3);600121
AGRN;Myasthenic syndrome, congenital, 8, with pre- and postsynaptic defects;17357067;103320;Myasthenic syndrome, congenital, 8, with pre- and postsynaptic defects, 615120 (3);615120
AGRP;Leanness, inherited;17357067;602311;{Leanness, inherited} (3);0
AGRP;Obesity, late-onset;17357067;602311;{Obesity, late-onset}, 601665 (3);601665
AGT;Hypertension, essential, susceptibility to;17357067;106150;{Hypertension, essential, susceptibility to}, 145500 (3);145500
AGT;Preeclampsia, susceptibility to;17357067;106150;{Preeclampsia, susceptibility to} (3);0
AGT;Renal tubular dysgenesis;17357067;106150;Renal tubular dysgenesis, 267430 (3);267430
AGTR1;Hypertension, essential;17357067;106165;{Hypertension, essential}, 145500 (3);145500
AGTR1;Renal tubular dysgenesis;17357067;106165;Renal tubular dysgenesis, 267430 (3);267430
AGTR2;Mental retardation, X-linked 88;17357067;300852;Mental retardation, X-linked 88 (2);0
AGXT;Hyperoxaluria, primary, type 1;17357067;604285;Hyperoxaluria, primary, type 1, 259900 (3);259900
AHCY;Hypermethioninemia with deficiency of S-adenosylhomocysteine hydrolase;17357067;180960;Hypermethioninemia with deficiency of S-adenosylhomocysteine hydrolase, 613752 (3);613752
AHDC1;Xia-Gibbs syndrome;17357067;615790;Xia-Gibbs syndrome, 615829 (3);615829
AHI1;Joubert syndrome-3;17357067;608894;Joubert syndrome-3, 608629 (3);608629
AICDA;Immunodeficiency with hyper-IgM, type 2;17357067;605257;Immunodeficiency with hyper-IgM, type 2, 605258 (3);605258
AIFM1;Combined oxidative phosphorylation deficiency 6;17357067;300169;Combined oxidative phosphorylation deficiency 6, 300816 (3);300816
AIFM1;Cowchock syndrome;17357067;300169;Cowchock syndrome, 310490 (3);310490
AIM1;Albinism, oculocutaneous, type IV;17357067;606202;Albinism, oculocutaneous, type IV, 606574 (3);606574
AIM1;Skin/hair/eye pigmentation 5, black/nonblack hair;17357067;606202;[Skin/hair/eye pigmentation 5, black/nonblack hair], 227240 (3);227240
AIM1;Skin/hair/eye pigmentation 5, dark/fair skin;17357067;606202;[Skin/hair/eye pigmentation 5, dark/fair skin], 227240 (3);227240
AIM1;Skin/hair/eye pigmentation 5, dark/light eyes;17357067;606202;[Skin/hair/eye pigmentation 5, dark/light eyes], 227240 (3);227240
AIMP1;Leukodystrophy, hypomyelinating, 3;17357067;603605;Leukodystrophy, hypomyelinating, 3, 260600 (3);260600
AIP;Pituitary adenoma, ACTH-secreting;17357067;605555;Pituitary adenoma, ACTH-secreting, 219090 (3);219090
AIP;Pituitary adenoma, growth hormone-secreting;17357067;605555;Pituitary adenoma, growth hormone-secreting, 102200 (3);102200
AIP;Pituitary adenoma, prolactin-secreting;17357067;605555;Pituitary adenoma, prolactin-secreting, 600634 (3);600634
AIPL1;Cone-rod dystrophy;17357067;604392;Cone-rod dystrophy, 604393 (3);604393
AIPL1;Leber congenital amaurosis 4;17357067;604392;Leber congenital amaurosis 4, 604393 (3);604393
AIPL1;Retinitis pigmentosa, juvenile;17357067;604392;Retinitis pigmentosa, juvenile, 604393 (3);604393
AIRE;Autoimmune polyendocrinopathy syndrome , type I, with or without reversible metaphyseal dysplasia;17357067;607358;Autoimmune polyendocrinopathy syndrome , type I, with or without reversible metaphyseal dysplasia, 240300 (3);240300
AIRN;Acute insulin response;17357067;601676;Acute insulin response (2);0
AK1;Hemolytic anemia due to adenylate kinase deficiency;17357067;103000;Hemolytic anemia due to adenylate kinase deficiency, 612631 (3);612631
AK2;Reticular dysgenesis;17357067;103020;Reticular dysgenesis, 267500 (3);267500
AKAP10;Cardiac conduction defect, susceptibility to;17357067;604694;{Cardiac conduction defect, susceptibility to}, 115080 (3);115080
AKR1C1;Developmental dysplasia of the hip 1;17357067;142700;Developmental dysplasia of the hip 1 (2);0
AKR1C2;46XY sex reversal 8;17357067;600450;46XY sex reversal 8, 614279 (3);614279
AKR1C2;Developmental dysplasia of the hip 2;17357067;615612;Developmental dysplasia of the hip 2 (2);0
AKR1C2;Obesity, hyperphagia, and developmental delay;17357067;600450;Obesity, hyperphagia, and developmental delay (3);0
AKR1C4;46XY sex reversal 8, modifier of;17357067;600451;{46XY sex reversal 8, modifier of}, 614279 (3);614279
AKR1D1;Bile acid synthesis defect, congenital, 2;17357067;604741;Bile acid synthesis defect, congenital, 2, 235555 (3);235555
AKT1;Breast cancer, somatic;17357067;164730;Breast cancer, somatic, 114480 (3);114480
AKT1;Colorectal cancer, somatic;17357067;164730;Colorectal cancer, somatic, 114500 (3);114500
AKT1;Cowden syndrome 6;17357067;164730;Cowden syndrome 6, 615109 (3);615109
AKT1;Ovarian cancer, somatic;17357067;164730;Ovarian cancer, somatic, 167000 (3);167000
AKT1;Proteus syndrome, somatic;17357067;164730;Proteus syndrome, somatic, 176920 (3);176920
AKT1;Schizophrenia, susceptibility to;17357067;164730;{Schizophrenia, susceptibility to}, 181500 (2);181500
AKT2;Diabetes mellitus, type II;17357067;164731;Diabetes mellitus, type II, 125853 (3);125853
AKT2;Hypoinsulinemic hypoglycemia with hemihypertrophy;17357067;164731;Hypoinsulinemic hypoglycemia with hemihypertrophy, 240900 (3);240900
AKT3;Megalencephaly-polymicrogyria-polydactyly-hydrocephalus syndrome 2;17357067;611223;Megalencephaly-polymicrogyria-polydactyly-hydrocephalus syndrome 2, 615937 (3);615937
ALAD;Lead poisoning, susceptibility to;17357067;125270;{Lead poisoning, susceptibility to}, 612740 (3);612740
ALAD;Porphyria, acute hepatic;17357067;125270;Porphyria, acute hepatic, 612740 (3);612740
ALAS2;Anemia, sideroblastic, X-linked;17357067;301300;Anemia, sideroblastic, X-linked, 300751 (3);300751
ALAS2;Protoporphyria, erythropoietic, X-linked;17357067;301300;Protoporphyria, erythropoietic, X-linked, 300752 (3);300752
ALB;Analbuminemia;17357067;103600;Analbuminemia, 616000 (3);616000
ALB;Dysalbuminemic hyperthyroxinemia;17357067;103600;[Dysalbuminemic hyperthyroxinemia], 615999 (3);615999
ALDH18A1;Cutis laxa, autosomal recessive, type IIIA;17357067;138250;Cutis laxa, autosomal recessive, type IIIA, 219150 (3);219150
ALDH1A3;Microphthalmia, isolated 8;17357067;600463;Microphthalmia, isolated 8, 615113 (3);615113
ALDH2;Alcohol sensitivity, acute;17357067;100650;Alcohol sensitivity, acute, 610251 (3);610251
ALDH2;Esophageal cancer, alcohol-related, susceptibility to;17357067;100650;{Esophageal cancer, alcohol-related, susceptibility to} (3);0
ALDH2;Hangover, susceptibility to;17357067;100650;{Hangover, susceptibility to}, 610251 (3);610251
ALDH2;Sublingual nitroglycerin, susceptibility to poor response to;17357067;100650;{Sublingual nitroglycerin, susceptibility to poor response to} (3);0
ALDH3A2;Sjogren-Larsson syndrome;17357067;609523;Sjogren-Larsson syndrome, 270200 (3);270200
ALDH4A1;Hyperprolinemia, type II;17357067;606811;Hyperprolinemia, type II, 239510 (3);239510
ALDH5A1;Succinic semialdehyde dehydrogenase deficiency;17357067;610045;Succinic semialdehyde dehydrogenase deficiency, 271980 (3);271980
ALDH6A1;Methylmalonate semialdehyde dehydrogenase deficiency;17357067;603178;Methylmalonate semialdehyde dehydrogenase deficiency, 614105 (3);614105
ALDH7A1;Epilepsy, pyridoxine-dependent;17357067;107323;Epilepsy, pyridoxine-dependent, 266100 (3);266100
ALDOA;Glycogen storage disease XII;17357067;103850;Glycogen storage disease XII, 611881 (3);611881
ALDOB;Fructose intolerance;17357067;612724;Fructose intolerance, 229600 (3);229600
ALG1;Congenital disorder of glycosylation, type Ik;17357067;605907;Congenital disorder of glycosylation, type Ik, 608540 (3);608540
ALG10;Long QT syndrome, acquired, reduced susceptibility to;17357067;603313;{Long QT syndrome, acquired, reduced susceptibility to}, 613688 (3);613688
ALG10B;Long QT syndrome, acquired, reduced susceptibility to;17357067;603313;{Long QT syndrome, acquired, reduced susceptibility to}, 613688 (3);613688
ALG11;Congenital disorder of glycosylation, type Ip;17357067;613666;Congenital disorder of glycosylation, type Ip, 613661 (3);613661
ALG12;Congenital disorder of glycosylation, type Ig;17357067;607144;Congenital disorder of glycosylation, type Ig, 607143 (3);607143
ALG13;Congenital disorder of glycosylation, type Is;17357067;300776;Congenital disorder of glycosylation, type Is, 300884 (3);300884
ALG2;Myasthenic syndrome, congenital, 14, with tubular aggregates;17357067;607905;Myasthenic syndrome, congenital, 14, with tubular aggregates, 616228 (3);616228
ALG3;Congenital disorder of glycosylation, type Id;17357067;608750;Congenital disorder of glycosylation, type Id, 601110 (3);601110
ALG6;Congenital disorder of glycosylation, type Ic;17357067;604566;Congenital disorder of glycosylation, type Ic, 603147 (3);603147
ALG8;Congenital disorder of glycosylation, type Ih;17357067;608103;Congenital disorder of glycosylation, type Ih, 608104 (3);608104
ALG9;Congenital disorder of glycosylation, type Il;17357067;606941;Congenital disorder of glycosylation, type Il, 608776 (3);608776
ALK;Neuroblastoma, susceptibility to, 3;17357067;105590;{Neuroblastoma, susceptibility to, 3}, 613014 (3);613014
ALMS1;Alstrom syndrome;17357067;606844;Alstrom syndrome, 203800 (3);203800
ALOX12B;Ichthyosis, congenital, autosomal recessive 2;17357067;603741;Ichthyosis, congenital, autosomal recessive 2, 242100 (3);242100
ALOX5;Asthma, diminished response to antileukotriene treatment in;17357067;152390;{Asthma, diminished response to antileukotriene treatment in}, 600807 (3);600807
ALOX5;Atherosclerosis, susceptibility to;17357067;152390;{Atherosclerosis, susceptibility to} (3);0
ALOX5AP;Stroke, susceptibility to;17357067;603700;{Stroke, susceptibility to}, 601367 (3);601367
ALOXE3;Ichthyosis, congenital, autosomal recessive 3;17357067;607206;Ichthyosis, congenital, autosomal recessive 3, 606545 (3);606545
ALPL;Hypophosphatasia, adult;17357067;171760;Hypophosphatasia, adult, 146300 (3);146300
ALPL;Hypophosphatasia, childhood;17357067;171760;Hypophosphatasia, childhood, 241510 (3);241510
ALPL;Hypophosphatasia, infantile;17357067;171760;Hypophosphatasia, infantile, 241500 (3);241500
ALPL;Odontohypophosphatasia;17357067;171760;Odontohypophosphatasia, 146300 (3);146300
ALS2;Amyotrophic lateral sclerosis 2, juvenile;17357067;606352;Amyotrophic lateral sclerosis 2, juvenile, 205100 (3);205100
ALS2;Primary lateral sclerosis, juvenile;17357067;606352;Primary lateral sclerosis, juvenile, 606353 (3);606353
ALS2;Spastic paralysis, infantile onset ascending;17357067;606352;Spastic paralysis, infantile onset ascending, 607225 (3);607225
ALX3;Frontonasal dysplasia 1;17357067;606014;Frontonasal dysplasia 1, 136760 (3);136760
ALX4;Craniosynostosis 5, susceptibility to;17357067;605420;{Craniosynostosis 5, susceptibility to}, 615529 (3);615529
ALX4;Frontonasal dysplasia 2;17357067;605420;Frontonasal dysplasia 2, 613451 (3);613451
ALX4;Parietal foramina 2;17357067;605420;Parietal foramina 2, 609597 (3);609597
AMACR;Alpha-methylacyl-CoA racemase deficiency;17357067;604489;Alpha-methylacyl-CoA racemase deficiency, 614307 (3);614307
AMACR;Bile acid synthesis defect, congenital, 4;17357067;604489;Bile acid synthesis defect, congenital, 4, 214950 (3);214950
AMBN;Amelogenesis imperfecta, type IF;17357067;601259;Amelogenesis imperfecta, type IF, 616270 (3);616270
AMELX;Amelogenesis imperfecta, type 1E;17357067;300391;Amelogenesis imperfecta, type 1E, 301200 (3);301200
AMER1;Osteopathia striata with cranial sclerosis;17357067;300647;Osteopathia striata with cranial sclerosis, 300373 (3);300373
AMH;Persistent Mullerian duct syndrome, type I;17357067;600957;Persistent Mullerian duct syndrome, type I, 261550 (3);261550
AMHR2;Persistent Mullerian duct syndrome, type II;17357067;600956;Persistent Mullerian duct syndrome, type II, 261550 (3);261550
AMN;Adrenoleukodystrophy;17357067;300371;Adrenoleukodystrophy, 300100 (3);300100
AMN;Adrenomyeloneuropathy, adult;17357067;300371;Adrenomyeloneuropathy, adult, 300100 (3);300100
AMN;Megaloblastic anemia-1, Norwegian type;17357067;605799;Megaloblastic anemia-1, Norwegian type, 261100 (3);261100
AMPD1;Myopathy due to myoadenylate deaminase deficiency;17357067;102770;Myopathy due to myoadenylate deaminase deficiency, 615511 (3);615511
AMPD2;Pontocerebellar hypoplasia, type 9;17357067;102771;Pontocerebellar hypoplasia, type 9, 615809 (3);615809
AMPD3;AMP deaminase deficiency, erythrocytic;17357067;102772;[AMP deaminase deficiency, erythrocytic], 612874 (3);612874
AMT;Glycine encephalopathy;17357067;238310;Glycine encephalopathy, 605899 (3);605899
ANCR;Angelman syndrome;17357067;601623;Angelman syndrome, 105830 (3);105830
ANG;Amyotrophic lateral sclerosis 9;17357067;105850;Amyotrophic lateral sclerosis 9, 611895 (3);611895
ANGPTL3;Hypobetalipoproteinemia, familial, 2;17357067;604774;Hypobetalipoproteinemia, familial, 2, 605019 (3);605019
ANGPTL4;Plasma triglyceride level QTL, low;17357067;605910;Plasma triglyceride level QTL, low, 615881 (3);615881
ANK1;Spherocytosis, type 1;17357067;612641;Spherocytosis, type 1, 182900 (3);182900
ANK2;Cardiac arrhythmia, ankyrin-B-related;17357067;106410;Cardiac arrhythmia, ankyrin-B-related, 600919 (3);600919
ANK2;Long QT syndrome 4;17357067;106410;Long QT syndrome 4, 600919 (3);600919
ANKH;Chondrocalcinosis 2;17357067;605145;Chondrocalcinosis 2, 118600 (3);118600
ANKH;Craniometaphyseal dysplasia;17357067;605145;Craniometaphyseal dysplasia, 123000 (3);123000
ANKK1;Dopamine receptor D2, reduced brain density of;17357067;608774;Dopamine receptor D2, reduced brain density of (3);0
ANKRD11;KBG syndrome;17357067;611192;KBG syndrome, 148050 (3);148050
ANKRD26;Thrombocytopenia 2;17357067;610855;Thrombocytopenia 2, 188000 (3);188000
ANKS6;Nephronophthisis 16;17357067;615370;Nephronophthisis 16, 615382 (3);615382
ANLN;Focal segmental glomerulosclerosis 8;17357067;616027;Focal segmental glomerulosclerosis 8, 616032 (3);616032
ANO10;Spinocerebellar ataxia, autosomal recessive 10;17357067;613726;Spinocerebellar ataxia, autosomal recessive 10, 613728 (3);613728
ANO3;Dystonia 24;17357067;610110;Dystonia 24, 615034 (3);615034
ANO5;Gnathodiaphyseal dysplasia;17357067;608662;Gnathodiaphyseal dysplasia, 166260 (3);166260
ANO5;Miyoshi muscular dystrophy 3;17357067;608662;Miyoshi muscular dystrophy 3, 613319 (3);613319
ANO5;Muscular dystrophy, limb-girdle, type 2L;17357067;608662;Muscular dystrophy, limb-girdle, type 2L, 611307 (3);611307
ANO6;Scott syndrome;17357067;608663;Scott syndrome, 262890 (3);262890
ANTXR1;GAPO syndrome;17357067;606410;GAPO syndrome, 230740 (3);230740
ANTXR1;Hemangioma, capillary infantile, susceptibility to;17357067;606410;{Hemangioma, capillary infantile, susceptibility to}, 602089 (3);602089
ANTXR2;Hyaline fibromatosis syndrome;17357067;608041;Hyaline fibromatosis syndrome, 228600 (3);228600
ANXA5;Pregnancy loss, recurrent, susceptibility to, 3;17357067;131230;{Pregnancy loss, recurrent, susceptibility to, 3}, 614391 (3);614391
AP1S1;MEDNIK syndrome;17357067;603531;MEDNIK syndrome, 609313 (3);609313
AP1S2;Mental retardation, X-linked syndromic 5;17357067;300629;Mental retardation, X-linked syndromic 5, 304340 (3);304340
AP1S3;Psoriasis 15, pustular, susceptibility to;17357067;615781;{Psoriasis 15, pustular, susceptibility to}, 616106 (3);616106
AP2S1;Hypocalciuric hypercalcemia, familial, type III;17357067;602242;Hypocalciuric hypercalcemia, familial, type III, 600740 (3);600740
AP3B1;Hermansky-Pudlak syndrome 2;17357067;603401;Hermansky-Pudlak syndrome 2, 608233 (3);608233
AP4B1;Spastic paraplegia 47, autosomal recessive;17357067;607245;Spastic paraplegia 47, autosomal recessive, 614066 (3);614066
AP4E1;Spastic paraplegia 51, autosomal recessive;17357067;607244;Spastic paraplegia 51, autosomal recessive, 613744 (3);613744
AP4M1;Spastic paraplegia 50, autosomal recessive;17357067;602296;Spastic paraplegia 50, autosomal recessive, 612936 (3);612936
AP4S1;Spastic paraplegia 52, autosomal recessive;17357067;607243;Spastic paraplegia 52, autosomal recessive, 614067 (3);614067
AP5Z1;Spastic paraplegia 48, autosomal recessive;17357067;613653;Spastic paraplegia 48, autosomal recessive, 613647 (3);613647
APAF1;Nephronophthisis 13;17357067;608151;Nephronophthisis 13, 614377 (3);614377
APAF1;Senior-Loken syndrome 8;17357067;608151;Senior-Loken syndrome 8, 616307 (3);616307
APBB2;Alzheimer disease, late-onset;17357067;602710;{Alzheimer disease, late-onset}, 104300 (3);104300
APC;Adenoma, periampullary, somatic;17357067;611731;Adenoma, periampullary, somatic (3);0
APC;Adenomatous polyposis coli;17357067;611731;Adenomatous polyposis coli, 175100 (3);175100
APC;Brain tumor-polyposis syndrome 2;17357067;611731;Brain tumor-polyposis syndrome 2, 175100 (3);175100
APC;Colorectal cancer, somatic;17357067;611731;Colorectal cancer, somatic, 114500 (3);114500
APC;Desmoid disease, hereditary;17357067;611731;Desmoid disease, hereditary, 135290 (3);135290
APC;Gardner syndrome;17357067;611731;Gardner syndrome, 175100 (3);175100
APC;Gastric cancer, somatic;17357067;611731;Gastric cancer, somatic, 613659 (3);613659
APC;Hepatoblastoma, somatic;17357067;611731;Hepatoblastoma, somatic, 114550 (3);114550
APCDD1;Hypotrichosis 1;17357067;607479;Hypotrichosis 1, 605389 (3);605389
APOA1;Amyloidosis, 3 or more types;17357067;107680;Amyloidosis, 3 or more types, 105200 (3);105200
APOA1;ApoA-I and apoC-III deficiency, combined;17357067;107680;ApoA-I and apoC-III deficiency, combined (3);0
APOA1;Corneal clouding, autosomal recessive;17357067;107680;Corneal clouding, autosomal recessive (3);0
APOA1;Hypoalphalipoproteinemia;17357067;107680;Hypoalphalipoproteinemia, 604091 (3);604091
APOA2;Apolipoprotein A-II deficiency;17357067;107670;Apolipoprotein A-II deficiency (3);0
APOA2;Hypercholesterolemia, familial, modifier of;17357067;107670;{Hypercholesterolemia, familial, modifier of}, 143890 (3);143890
APOA5;Hyperchylomicronemia, late-onset;17357067;606368;Hyperchylomicronemia, late-onset, 144650 (3);144650
APOA5;Hypertriglyceridemia, susceptibility to;17357067;606368;{Hypertriglyceridemia, susceptibility to}, 145750 (3);145750
APOB;Hypercholesterolemia, due to ligand-defective apo B;17357067;107730;Hypercholesterolemia, due to ligand-defective apo B, 144010 (3);144010
APOB;Hypobetalipoproteinemia;17357067;107730;Hypobetalipoproteinemia, 615558 (3);615558
APOC2;Hyperlipoproteinemia, type Ib;17357067;608083;Hyperlipoproteinemia, type Ib, 207750 (3);207750
APOC3;Apolipoprotein C-III deficiency;17357067;107720;Apolipoprotein C-III deficiency, 614028 (3);614028
APOE;Alzheimer disease-2;17357067;107741;Alzheimer disease-2, 104310 (3);104310
APOE;Hyperlipoproteinemia, type III;17357067;107741;Hyperlipoproteinemia, type III (3);0
APOE;Lipoprotein glomerulopathy;17357067;107741;Lipoprotein glomerulopathy, 611771 (3);611771
APOE;Myocardial infarction susceptibility;17357067;107741;{Myocardial infarction susceptibility} (3);0
APOE;Sea-blue histiocyte disease;17357067;107741;Sea-blue histiocyte disease, 269600 (3);269600
APOL1;End-stage renal disease, nondiabetic, susceptibility to;17357067;603743;{End-stage renal disease, nondiabetic, susceptibility to}, 612551 (3);612551
APOL1;Glomerulosclerosis, focal segmental, 4, susceptibility to;17357067;603743;{Glomerulosclerosis, focal segmental, 4, susceptibility to}, 612551 (3);612551
APOL2;Schizophrenia;17357067;607252;{Schizophrenia}, 181500 (1);181500
APOL4;Schizophrenia;17357067;607254;{Schizophrenia}, 181500 (1);181500
APOPT1;Mitochondrial complex IV deficiency;17357067;616003;Mitochondrial complex IV deficiency, 220110 (3);220110
APP;Alzheimer disease 1, familial;17357067;104760;Alzheimer disease 1, familial, 104300 (3);104300
APP;Cerebral amyloid angiopathy, Dutch, Italian, Iowa, Flemish, Arctic variants;17357067;104760;Cerebral amyloid angiopathy, Dutch, Italian, Iowa, Flemish, Arctic variants, 605714 (3);605714
APPL1;Maturity-onset diabetes of the young, type 14;17357067;604299;{Maturity-onset diabetes of the young, type 14}, 616511 (3);616511
APRT;Adenine phosphoribosyltransferase deficiency;17357067;102600;Adenine phosphoribosyltransferase deficiency, 614723 (3);614723
APTX;Ataxia, early-onset, with oculomotor apraxia and hypoalbuminemia;17357067;606350;Ataxia, early-onset, with oculomotor apraxia and hypoalbuminemia, 208920 (3);208920
AQP1;Aquaporin-1 deficiency;17357067;107776;[Aquaporin-1 deficiency] (3);0
AQP1;Blood group, Colton;17357067;107776;[Blood group, Colton], 110450 (3);110450
AQP2;Diabetes insipidus, nephrogenic;17357067;107777;Diabetes insipidus, nephrogenic, 125800 (3);125800
AQP3;Blood group GIL;17357067;600170;[Blood group GIL], 607457 (3);607457
AQP5;Palmoplantar keratoderma, Bothnian type;17357067;600442;Palmoplantar keratoderma, Bothnian type, 600231 (3);600231
AQP7;Glycerol quantitative trait locus;17357067;602974;[Glycerol quantitative trait locus], 614411 (3);614411
AR;Androgen insensitivity;17357067;313700;Androgen insensitivity, 300068 (3);300068
AR;Androgen insensitivity, partial, with or without breast cancer;17357067;313700;Androgen insensitivity, partial, with or without breast cancer, 312300 (3);312300
AR;Hypospadias 1, X-linked;17357067;313700;Hypospadias 1, X-linked, 300633 (3);300633
AR;Prostate cancer, susceptibility to;17357067;313700;{Prostate cancer, susceptibility to}, 176807 (3);176807
AR;Scoliosis, idiopathic 1;17357067;181800;Scoliosis, idiopathic 1 (2);0
AR;Spinal and bulbar muscular atrophy of Kennedy;17357067;313700;Spinal and bulbar muscular atrophy of Kennedy, 313200 (3);313200
ARC;Myoclonus, familial cortical;17357067;605235;Myoclonus, familial cortical, 614937 (3);614937
ARCN1;Pulmonary disease, chronic obstructive, severe early-onset;17357067;606963;Pulmonary disease, chronic obstructive, severe early-onset (2);0
ARFGEF2;Periventricular heterotopia with microcephaly;17357067;605371;Periventricular heterotopia with microcephaly, 608097 (3);608097
ARG1;Argininemia;17357067;608313;Argininemia, 207800 (3);207800
ARHGAP26;Leukemia, juvenile myelomonocytic;17357067;605370;Leukemia, juvenile myelomonocytic, 607785 (3);607785
ARHGAP31;Adams-Oliver syndrome 1;17357067;610911;Adams-Oliver syndrome 1, 100300 (3);100300
ARHGDIA;Nephrotic syndrome, type 8;17357067;601925;Nephrotic syndrome, type 8, 615244 (3);615244
ARHGEF6;Mental retardation, X-linked 46;17357067;300267;Mental retardation, X-linked 46, 300436 (3);300436
ARHGEF9;Epileptic encephalopathy, early infantile, 8;17357067;300429;Epileptic encephalopathy, early infantile, 8, 300607 (3);300607
ARID1A;Mental retardation, autosomal dominant 14;17357067;603024;Mental retardation, autosomal dominant 14, 614607 (3);614607
ARID1B;Mental retardation, autosomal dominant 12;17357067;614556;Mental retardation, autosomal dominant 12, 614562 (3);614562
ARL13B;Joubert syndrome 8;17357067;608922;Joubert syndrome 8, 612291 (3);612291
ARL2BP;Retinitis pigmentosa with or without situs inversus;17357067;615407;Retinitis pigmentosa with or without situs inversus, 615434 (3);615434
ARL6;Bardet-Biedl syndrome 1, modifier of;17357067;608845;{Bardet-Biedl syndrome 1, modifier of}, 209900 (3);209900
ARL6;Bardet-Biedl syndrome 3;17357067;608845;Bardet-Biedl syndrome 3, 600151 (3);600151
ARMC4;Ciliary dyskinesia, primary, 23;17357067;615408;Ciliary dyskinesia, primary, 23, 615451 (3);615451
ARMC5;ACTH-independent macronodular adrenal hyperplasia 2;17357067;615549;ACTH-independent macronodular adrenal hyperplasia 2, 615954 (3);615954
ARMS2;Macular degeneration, age-related, 8;17357067;611313;{Macular degeneration, age-related, 8}, 613778 (3);613778
ARNT;Leukemia, acute myeloblastic;17357067;126110;Leukemia, acute myeloblastic (3);0
ARSA;Metachromatic leukodystrophy;17357067;607574;Metachromatic leukodystrophy, 250100 (3);250100
ARSB;Mucopolysaccharidosis type VI (Maroteaux-Lamy);17357067;611542;Mucopolysaccharidosis type VI (Maroteaux-Lamy), 253200 (3);253200
ARSE;Chondrodysplasia punctata, X-linked recessive;17357067;300180;Chondrodysplasia punctata, X-linked recessive, 302950 (3);302950
ART4;Blood group, Dombrock;17357067;110600;[Blood group, Dombrock], 616060 (3);616060
ARX;Epileptic encephalopathy, early infantile, 1;17357067;300382;Epileptic encephalopathy, early infantile, 1, 308350 (3);308350
ARX;Epileptic encephalopathy, early infantile, 2;17357067;300203;Epileptic encephalopathy, early infantile, 2, 300672 (3);300672
ARX;Hydranencephaly with abnormal genitalia;17357067;300382;Hydranencephaly with abnormal genitalia, 300215 (3);300215
ARX;Lissencephaly, X-linked 2;17357067;300382;Lissencephaly, X-linked 2, 300215 (3);300215
ARX;Mental retardation, X-linked 29 and others;17357067;300382;Mental retardation, X-linked 29 and others, 300419 (3);300419
ARX;Partington syndrome;17357067;300382;Partington syndrome, 309510 (3);309510
ARX;Proud syndrome;17357067;300382;Proud syndrome, 300004 (3);300004
ASAH1;Farber lipogranulomatosis;17357067;613468;Farber lipogranulomatosis, 228000 (3);228000
ASAH1;Spinal muscular atrophy with progressive myoclonic epilepsy;17357067;613468;Spinal muscular atrophy with progressive myoclonic epilepsy, 159950 (3);159950
ASB10;Glaucoma 1, open angle, F;17357067;615054;Glaucoma 1, open angle, F, 603383 (3);603383
ASCC1;Barrett esophagus/esophageal adenocarcinoma;17357067;614215;Barrett esophagus/esophageal adenocarcinoma, 614266 (3);614266
ASCL1;Central hypoventilation syndrome, congenital;17357067;100790;Central hypoventilation syndrome, congenital, 209880 (3);209880
ASCL1;Haddad syndrome;17357067;100790;Haddad syndrome, 209880 (3);209880
ASIP;Skin/hair/eye pigmentation 9, brown/nonbrown eyes;17357067;600201;[Skin/hair/eye pigmentation 9, brown/nonbrown eyes], 611742 (3);611742
ASIP;Skin/hair/eye pigmentation 9, dark/light hair;17357067;600201;[Skin/hair/eye pigmentation 9, dark/light hair], 611742 (3);611742
ASL;Argininosuccinic aciduria;17357067;608310;Argininosuccinic aciduria, 207900 (3);207900
ASNS;Asparagine synthetase deficiency;17357067;108370;Asparagine synthetase deficiency, 615574 (3);615574
ASPA;Canavan disease;17357067;608034;Canavan disease, 271900 (3);271900
ASPH;Traboulsi syndrome;17357067;600582;Traboulsi syndrome, 601552 (3);601552
ASPM;Microcephaly 5, primary, autosomal recessive;17357067;605481;Microcephaly 5, primary, autosomal recessive, 608716 (3);608716
ASPN;Lumbar disc degeneration;17357067;608135;{Lumbar disc degeneration}, 603932 (3);603932
ASPN;Osteoarthritis susceptibility 3;17357067;608135;{Osteoarthritis susceptibility 3}, 607850 (3);607850
ASPSCR1;Advanced sleep-phase syndrome, familial, 2;17357067;600864;Advanced sleep-phase syndrome, familial, 2, 615224 (3);615224
ASPSCR1;Alveolar soft-part sarcoma;17357067;606236;Alveolar soft-part sarcoma, 606243 (3);606243
ASS1;Citrullinemia;17357067;603470;Citrullinemia, 215700 (3);215700
ASXL1;Bohring-Opitz syndrome;17357067;612990;Bohring-Opitz syndrome, 605039 (3);605039
ASXL1;Myelodysplastic syndrome, somatic;17357067;612990;Myelodysplastic syndrome, somatic, 614286 (3);614286
ASXL3;Bainbridge-Ropers syndrome;17357067;615115;Bainbridge-Ropers syndrome, 615485 (3);615485
ATCAY;Ataxia, cerebellar, Cayman type;17357067;608179;Ataxia, cerebellar, Cayman type, 601238 (3);601238
ATG16L1;Inflammatory bowel disease 10;17357067;610767;{Inflammatory bowel disease 10}, 611081 (3);611081
ATIC;AICA-ribosiduria due to ATIC deficiency;17357067;601731;AICA-ribosiduria due to ATIC deficiency, 608688 (3);608688
ATL1;Neuropathy, hereditary sensory, type ID;17357067;606439;Neuropathy, hereditary sensory, type ID, 613708 (3);613708
ATL1;Spastic paraplegia 3A, autosomal dominant;17357067;606439;Spastic paraplegia 3A, autosomal dominant, 182600 (3);182600
ATL3;Neuropathy, hereditary sensory, type IF;17357067;609369;Neuropathy, hereditary sensory, type IF, 615632 (3);615632
ATM;Ataxia-telangiectasia;17357067;607585;Ataxia-telangiectasia, 208900 (3);208900
ATM;Breast cancer, susceptibility to;17357067;607585;{Breast cancer, susceptibility to}, 114480 (3);114480
ATM;Lymphoma, B-cell non-Hodgkin, somatic;17357067;607585;Lymphoma, B-cell non-Hodgkin, somatic (3);0
ATM;Lymphoma, mantle cell;17357067;607585;Lymphoma, mantle cell (3);0
ATM;T-cell prolymphocytic leukemia, somatic;17357067;607585;T-cell prolymphocytic leukemia, somatic (3);0
ATN1;Dentatorubro-pallidoluysian atrophy;17357067;607462;Dentatorubro-pallidoluysian atrophy, 125370 (3);125370
ATOH7;Persistent hyperplastic primary vitreous, autosomal recessive;17357067;609875;Persistent hyperplastic primary vitreous, autosomal recessive, 221900 (3);221900
ATP13A2;Kufor-Rakeb syndrome;17357067;610513;Kufor-Rakeb syndrome, 606693 (3);606693
ATP1A2;Alternating hemiplegia of childhood;17357067;182340;Alternating hemiplegia of childhood, 104290 (3);104290
ATP1A2;Migraine, familial basilar;17357067;182340;Migraine, familial basilar, 602481 (3);602481
ATP1A2;Migraine, familial hemiplegic, 2;17357067;182340;Migraine, familial hemiplegic, 2, 602481 (3);602481
ATP1A3;Alternating hemiplegia of childhood 2;17357067;182350;Alternating hemiplegia of childhood 2, 614820 (3);614820
ATP1A3;CAPOS syndrome;17357067;182350;CAPOS syndrome, 601338 (3);601338
ATP1A3;Dystonia-12;17357067;182350;Dystonia-12, 128235 (3);128235
ATP1B1;Blood pressure regulation QTL;17357067;182330;[Blood pressure regulation QTL], 145500 (2);145500
ATP2A1;Brody myopathy;17357067;108730;Brody myopathy, 601003 (3);601003
ATP2A2;Acrokeratosis verruciformis;17357067;108740;Acrokeratosis verruciformis, 101900 (3);101900
ATP2A2;Darier disease;17357067;108740;Darier disease, 124200 (3);124200
ATP2B2;Deafness, autosomal recessive 12, modifier of;17357067;108733;{Deafness, autosomal recessive 12, modifier of}, 601386 (3);601386
ATP2C1;Hailey-Hailey disease;17357067;604384;Hailey-Hailey disease, 169600 (3);169600
ATP6V0A2;Cutis laxa, autosomal recessive, type IIA;17357067;611716;Cutis laxa, autosomal recessive, type IIA, 219200 (3);219200
ATP6V0A2;Wrinkly skin syndrome;17357067;611716;Wrinkly skin syndrome, 278250 (3);278250
ATP6V0A4;Renal tubular acidosis, distal, autosomal recessive;17357067;605239;Renal tubular acidosis, distal, autosomal recessive, 602722 (3);602722
ATP6V1B1;Renal tubular acidosis with deafness;17357067;192132;Renal tubular acidosis with deafness, 267300 (3);267300
ATP6V1B2;Zimmermann-Laband syndrome 2;17357067;606939;Zimmermann-Laband syndrome 2, 616455 (3);616455
ATP7A;Menkes disease;17357067;300011;Menkes disease, 309400 (3);309400
ATP7A;Occipital horn syndrome;17357067;300011;Occipital horn syndrome, 304150 (3);304150
ATP7A;Spinal muscular atrophy, distal, X-linked 3;17357067;300011;Spinal muscular atrophy, distal, X-linked 3, 300489 (3);300489
ATP7B;Wilson disease;17357067;606882;Wilson disease, 277900 (3);277900
ATP8B1;Cholestasis, benign recurrent intrahepatic;17357067;602397;Cholestasis, benign recurrent intrahepatic, 243300 (3);243300
ATP8B1;Cholestasis, intrahepatic, of pregnancy, 1;17357067;602397;Cholestasis, intrahepatic, of pregnancy, 1, 147480 (3);147480
ATP8B1;Cholestasis, progressive familial intrahepatic 1;17357067;602397;Cholestasis, progressive familial intrahepatic 1, 211600 (3);211600
ATPAF2;Mitochondrial complex V (ATP synthase) deficiency, nuclear type 1;17357067;608918;Mitochondrial complex V (ATP synthase) deficiency, nuclear type 1, 604273 (3);604273
ATR;Cutaneous telangiectasia and cancer syndrome, familial;17357067;601215;Cutaneous telangiectasia and cancer syndrome, familial, 614564 (3);614564
ATR;GAPO syndrome;17357067;606410;GAPO syndrome, 230740 (3);230740
ATR;Hemangioma, capillary infantile, susceptibility to;17357067;606410;{Hemangioma, capillary infantile, susceptibility to}, 602089 (3);602089
ATR;Seckel syndrome 1;17357067;601215;Seckel syndrome 1, 210600 (3);210600
ATRX;Alpha-thalassemia myelodysplasia syndrome, somatic;17357067;300032;Alpha-thalassemia myelodysplasia syndrome, somatic, 300448 (3);300448
ATRX;Alpha-thalassemia/mental retardation syndrome;17357067;300032;Alpha-thalassemia/mental retardation syndrome, 301040 (3);301040
ATRX;Mental retardation-hypotonic facies syndrome, X-linked;17357067;300032;Mental retardation-hypotonic facies syndrome, X-linked, 309580 (3);309580
ATXN1;Spinocerebellar ataxia 1;17357067;601556;Spinocerebellar ataxia 1, 164400 (3);164400
ATXN10;Spinocerebellar ataxia 10;17357067;611150;Spinocerebellar ataxia 10, 603516 (3);603516
ATXN2;Amyotrophic lateral sclerosis, susceptibility to, 13;17357067;601517;{Amyotrophic lateral sclerosis, susceptibility to, 13}, 183090 (3);183090
ATXN2;Parkinson disease, late-onset, susceptibility to;17357067;601517;{Parkinson disease, late-onset, susceptibility to}, 168600 (3);168600
ATXN2;Spinocerebellar ataxia 2;17357067;601517;Spinocerebellar ataxia 2, 183090 (3);183090
ATXN3;Machado-Joseph disease;17357067;607047;Machado-Joseph disease, 109150 (3);109150
ATXN7;Spinocerebellar ataxia 7;17357067;607640;Spinocerebellar ataxia 7, 164500 (3);164500
ATXN8;Spinocerebellar ataxia 8;17357067;613289;Spinocerebellar ataxia 8, 608768 (3);608768
ATXN8OS;Spinocerebellar ataxia 8;17357067;603680;Spinocerebellar ataxia 8, 608768 (3);608768
AUH;3-methylglutaconic aciduria, type I;17357067;600529;3-methylglutaconic aciduria, type I, 250950 (3);250950
AURKA;Colon cancer, susceptibility to;17357067;603072;{Colon cancer, susceptibility to}, 114500 (3);114500
AURKC;Spermatogenic failure 5;17357067;603495;Spermatogenic failure 5, 243060 (3);243060
AUTS2;Mental retardation, autosomal dominant 26;17357067;607270;Mental retardation, autosomal dominant 26, 615834 (3);615834
AVP;Diabetes insipidus, neurohypophyseal;17357067;192340;Diabetes insipidus, neurohypophyseal, 125700 (3);125700
AVPR2;Diabetes insipidus, nephrogenic;17357067;300538;Diabetes insipidus, nephrogenic, 304800 (3);304800
AVPR2;Nephrogenic syndrome of inappropriate antidiuresis;17357067;300538;Nephrogenic syndrome of inappropriate antidiuresis, 300539 (3);300539
AXIN1;Hepatocellular carcinoma, somatic;17357067;603816;Hepatocellular carcinoma, somatic, 114550 (3);114550
AXIN2;Colorectal cancer, somatic;17357067;604025;Colorectal cancer, somatic, 114500 (3);114500
AXIN2;Oligodontia-colorectal cancer syndrome;17357067;604025;Oligodontia-colorectal cancer syndrome, 608615 (3);608615
B2M;Hypoproteinemia, hypercatabolic;17357067;109700;Hypoproteinemia, hypercatabolic, 241600 (3);241600
B3GALNT1;Blood group, P1PK system, P(k) phenotype;17357067;603094;[Blood group, P1PK system, P(k) phenotype], 111400 (3);111400
B3GALNT1;Blood group, globoside system;17357067;603094;[Blood group, globoside system], 615021 (3);615021
B3GALNT2;Muscular dystrophy-dystroglycanopathy (congenital with brain and eye anomalies, type A, 11;17357067;610194;Muscular dystrophy-dystroglycanopathy (congenital with brain and eye anomalies, type A, 11, 615181 (3);615181
B3GALT6;Ehlers-Danlos syndrome, progeroid type, 2;17357067;615291;Ehlers-Danlos syndrome, progeroid type, 2, 615349 (3);615349
B3GALT6;Spondyloepimetaphyseal dysplasia with joint laxity, type 1, with or without fractures;17357067;615291;Spondyloepimetaphyseal dysplasia with joint laxity, type 1, with or without fractures, 271640 (3);271640
B3GALTL;Peters-plus syndrome;17357067;610308;Peters-plus syndrome, 261540 (3);261540
B3GAT3;Multiple joint dislocations, short stature, craniofacial dysmorphism, and congenital heart defects;17357067;606374;Multiple joint dislocations, short stature, craniofacial dysmorphism, and congenital heart defects, 245600 (3);245600
B3GNT1;Muscular dystrophy-dystroglycanopathy (congenital with brain and eye anomalies), type A, 13;17357067;605517;Muscular dystrophy-dystroglycanopathy (congenital with brain and eye anomalies), type A, 13, 615287 (3);615287
B4GALNT1;Spastic paraplegia 26, autosomal recessive;17357067;601873;Spastic paraplegia 26, autosomal recessive, 609195 (3);609195
B4GALT1;Congenital disorder of glycosylation, type IId;17357067;137060;Congenital disorder of glycosylation, type IId, 607091 (3);607091
B4GALT7;Ehlers-Danlos syndrome, progeroid type, 1;17357067;604327;Ehlers-Danlos syndrome, progeroid type, 1, 130070 (3);130070
B9D2;Meckel syndrome 10;17357067;611951;Meckel syndrome 10, 614175 (3);614175
BAAT;Hypercholanemia, familial;17357067;602938;Hypercholanemia, familial, 607748 (3);607748
BACH1;Breast cancer, early-onset;17357067;605882;Breast cancer, early-onset, 114480 (3);114480
BACH1;Fanconi anemia, complementation group J;17357067;605882;Fanconi anemia, complementation group J, 609054 (3);609054
BAG3;Cardiomyopathy, dilated, 1HH;17357067;603883;Cardiomyopathy, dilated, 1HH, 613881 (3);613881
BAG3;Myopathy, myofibrillar, 6;17357067;603883;Myopathy, myofibrillar, 6, 612954 (3);612954
BANF1;Nestor-Guillermo progeria syndrome;17357067;603811;Nestor-Guillermo progeria syndrome, 614008 (3);614008
BAP1;Tumor predisposition syndrome;17357067;603089;Tumor predisposition syndrome, 614327 (3);614327
BARD1;Breast cancer, susceptibility to;17357067;601593;{Breast cancer, susceptibility to}, 114480 (3);114480
BAX;Colorectal cancer, somatic;17357067;600040;Colorectal cancer, somatic, 114500 (3);114500
BAX;T-cell acute lymphoblastic leukemia, somatic;17357067;600040;T-cell acute lymphoblastic leukemia, somatic, 613065 (3);613065
BBS1;Bardet-Biedl syndrome 1;17357067;209901;Bardet-Biedl syndrome 1, 209900 (3);209900
BBS10;Bardet-Biedl syndrome 10;17357067;610148;Bardet-Biedl syndrome 10, 615987 (3);615987
BBS12;Bardet-Biedl syndrome 12;17357067;610683;Bardet-Biedl syndrome 12, 615989 (3);615989
BBS2;Bardet-Biedl syndrome 2;17357067;606151;Bardet-Biedl syndrome 2, 615981 (3);615981
BBS4;Bardet-Biedl syndrome 4;17357067;600374;Bardet-Biedl syndrome 4, 615982 (3);615982
BBS5;Bardet-Biedl syndrome 5;17357067;603650;Bardet-Biedl syndrome 5, 615983 (3);615983
BBS7;Bardet-Biedl syndrome 7;17357067;607590;Bardet-Biedl syndrome 7, 615984 (3);615984
BBS9;Bardet-Biedl syndrome 9;17357067;607968;Bardet-Biedl syndrome 9, 615986 (3);615986
BCAM;Blood group, Auberger system;17357067;612773;[Blood group, Auberger system], 111200 (3);111200
BCAM;Blood group, Lutheran null;17357067;612773;[Blood group, Lutheran null], 247420 (3);247420
BCAM;Blood group, Lutheran system;17357067;612773;[Blood group, Lutheran system], 111200 (3);111200
BCAP31;Deafness, dystonia, and cerebral hypomyelination;17357067;300398;Deafness, dystonia, and cerebral hypomyelination, 300475 (3);300475
BCHE;Apnea, postanesthetic;17357067;177400;Apnea, postanesthetic (3);0
BCKDHA;Maple syrup urine disease, type Ia;17357067;608348;Maple syrup urine disease, type Ia, 248600 (3);248600
BCKDHB;Maple syrup urine disease, type Ib;17357067;248611;Maple syrup urine disease, type Ib, 248600 (3);248600
BCKDK;Branched-chain ketoacid dehydrogenase kinase deficiency;17357067;614901;Branched-chain ketoacid dehydrogenase kinase deficiency, 614923 (3);614923
BCL10;Lymphoma, MALT, somatic;17357067;603517;Lymphoma, MALT, somatic, 137245 (3);137245
BCL10;Lymphoma, follicular, somatic;17357067;603517;{Lymphoma, follicular, somatic}, 613024 (3);613024
BCL10;Male germ cell tumor, somatic, 2;17357067;603517;{Male germ cell tumor, somatic}, 273300, (3);273300
BCL10;Mesothelioma, somatic;17357067;603517;{Mesothelioma, somatic}, 156240 (3);156240
BCL10;Sezary syndrome, somatic;17357067;603517;{Sezary syndrome, somatic}, (3);0
BCL11A;Fetal hemoglobin QTL5;17357067;142335;[Fetal hemoglobin QTL5] (2);0
BCL2;Leukemia/lymphoma, B-cell, 2;17357067;151430;Leukemia/lymphoma, B-cell, 2 (3);0
BCL3;Leukemia/lymphoma, B-cell, 3;17357067;109560;Leukemia/lymphoma, B-cell, 3 (2);0
BCL6;Lymphoma, B-cell;17357067;109565;Lymphoma, B-cell (2);0
BCL7A;B-cell non-Hodgkin lymphoma, high-grade;17357067;601406;B-cell non-Hodgkin lymphoma, high-grade (3);0
BCO1;Hypercarotenemia and vitamin A deficiency, autosomal dominant;17357067;605748;Hypercarotenemia and vitamin A deficiency, autosomal dominant, 115300 (3);115300
BCOR;Microphthalmia, syndromic 2;17357067;300485;Microphthalmia, syndromic 2, 300166 (3);300166
BCR;Leukemia, acute lymphocytic;17357067;151410;Leukemia, acute lymphocytic, 613065 (3);613065
BCR;Leukemia, chronic myeloid;17357067;151410;Leukemia, chronic myeloid, 608232 (3);608232
BCS1L;Bjornstad syndrome;17357067;603647;Bjornstad syndrome, 262000 (3);262000
BCS1L;GRACILE syndrome;17357067;603647;GRACILE syndrome, 603358 (3);603358
BCS1L;Leigh syndrome;17357067;603647;Leigh syndrome, 256000 (3);256000
BCS1L;Mitochondrial complex III deficiency, nuclear type 1;17357067;603647;Mitochondrial complex III deficiency, nuclear type 1, 124000 (3);124000
BDNF;Anorexia nervosa, susceptibility to;17357067;113505;{Anorexia nervosa, susceptibility to}, 610269 (3);610269
BDNF;Bulimia nervosa, age of onset of weight loss in;17357067;113505;{Bulimia nervosa, age of onset of weight loss in}, 607499 (3);607499
BDNF;Central hypoventilation syndrome, congenital;17357067;113505;Central hypoventilation syndrome, congenital, 209880 (3);209880
BDNF;Memory impairment, susceptibility to;17357067;113505;{Memory impairment, susceptibility to} (3);0
BDNF;Obsessive-compulsive disorder, protection against;17357067;113505;{Obsessive-compulsive disorder, protection against}, 164230 (3);164230
BEST1;Bestrophinopathy, autosomal recessive;17357067;607854;Bestrophinopathy, autosomal recessive, 611809 (3);611809
BEST1;Microcornea, rod-cone dystrophy, cataract, and posterior staphyloma;17357067;607854;Microcornea, rod-cone dystrophy, cataract, and posterior staphyloma, 193220 (3);193220
BEST1;Retinitis pigmentosa, concentric;17357067;607854;Retinitis pigmentosa, concentric, 613194 (3);613194
BEST1;Retinitis pigmentosa-50;17357067;607854;Retinitis pigmentosa-50, 613194 (3);613194
BEST1;Vitelliform macular dystrophy 2;17357067;607854;Vitelliform macular dystrophy 2, 153700 (3);153700
BEST1;Vitreoretinochoroidopathy;17357067;607854;Vitreoretinochoroidopathy, 193220 (3);193220
BFSP1;Cataract 33;17357067;603307;Cataract 33, 611391 (3);611391
BFSP2;Cataract 12, multiple types;17357067;603212;Cataract 12, multiple types, 611597 (3);611597
BHLHA9;Syndactyly, mesoaxial synostotic, with phalangeal reduction;17357067;615416;Syndactyly, mesoaxial synostotic, with phalangeal reduction, 609432 (3);609432
BHLHE41;Short sleeper;17357067;606200;[Short sleeper], 612975 (3);612975
BICC1;Renal dysplasia, cystic, susceptibility to;17357067;614295;{Renal dysplasia, cystic, susceptibility to}, 601331 (3);601331
BICD2;Spinal muscular atrophy, lower extremity-predominant, 2, AD;17357067;609797;Spinal muscular atrophy, lower extremity-predominant, 2, AD, 615290 (3);615290
BIN1;Myopathy, centronuclear, autosomal recessive;17357067;601248;Myopathy, centronuclear, autosomal recessive, 255200 (3);255200
BLK;Maturity-onset diabetes of the young, type 11;17357067;191305;Maturity-onset diabetes of the young, type 11, 613375 (3);613375
BLM;Bernard-Soulier syndrome, type B;17357067;138720;Bernard-Soulier syndrome, type B, 231200 (3);231200
BLM;Bloom syndrome;17357067;604610;Bloom syndrome, 210900 (3);210900
BLM;Giant platelet disorder, isolated;17357067;138720;Giant platelet disorder, isolated, 231200 (3);231200
BLMH;Alzheimer disease, susceptibility to;17357067;602403;{Alzheimer disease, susceptibility to}, 104300 (3);104300
BLNK;Agammaglobulinemia 4;17357067;604515;Agammaglobulinemia 4, 613502 (3);613502
BLOC1S3;Hermansky-Pudlak syndrome 8;17357067;609762;Hermansky-Pudlak syndrome 8, 614077 (3);614077
BLOC1S6;Hermansky-pudlak syndrome 9;17357067;604310;Hermansky-pudlak syndrome 9, 614171 (3);614171
BLVRA;Hyperbiliverdinemia;17357067;109750;Hyperbiliverdinemia, 614156 (3);614156
BMP1;Osteogenesis imperfecta, type XIII;17357067;112264;Osteogenesis imperfecta, type XIII, 614856 (3);614856
BMP15;Ovarian dysgenesis 2;17357067;300247;Ovarian dysgenesis 2, 300510 (3);300510
BMP15;Premature ovarian failure 4;17357067;300247;Premature ovarian failure 4, 300510 (3);300510
BMP2;Brachydactyly, type A2;17357067;112261;Brachydactyly, type A2, 112600 (3);112600
BMP2;HFE hemochromatosis, modifier of;17357067;112261;{HFE hemochromatosis, modifier of}, 235200 (3);235200
BMP4;Microphthalmia, syndromic 6;17357067;112262;Microphthalmia, syndromic 6, 607932 (3);607932
BMP4;Orofacial cleft 11;17357067;112262;Orofacial cleft 11, 600625 (3);600625
BMPER;Diaphanospondylodysostosis;17357067;608699;Diaphanospondylodysostosis, 608022 (3);608022
BMPR1A;Juvenile polyposis syndrome, infantile form;17357067;601299;Juvenile polyposis syndrome, infantile form, 174900 (3);174900
BMPR1A;Polyposis syndrome, hereditary mixed, 2;17357067;601299;Polyposis syndrome, hereditary mixed, 2, 610069 (3);610069
BMPR1A;Polyposis, juvenile intestinal;17357067;601299;Polyposis, juvenile intestinal, 174900 (3);174900
BMPR1B;Brachydactyly, type A2;17357067;603248;Brachydactyly, type A2, 112600 (3);112600
BMPR1B;Chrondrodysplasia, acromesomelic, with genital anomalies;17357067;603248;Chrondrodysplasia, acromesomelic, with genital anomalies, 609441 (3);609441
BMPR2;Pulmonary hypertension, familial primary, 1, with or without HHT;17357067;600799;Pulmonary hypertension, familial primary, 1, with or without HHT, 178600 (3);178600
BMPR2;Pulmonary hypertension, primary, fenfluramine or dexfenfluramine-associated;17357067;600799;Pulmonary hypertension, primary, fenfluramine or dexfenfluramine-associated, 178600 (3);178600
BMPR2;Pulmonary venoocclusive disease 1;17357067;600799;Pulmonary venoocclusive disease 1, 265450 (3);265450
BOLA3;Multiple mitochondrial dysfunctions syndrome 2;17357067;613183;Multiple mitochondrial dysfunctions syndrome 2, 614299 (3);614299
BPGM;Erythrocytosis due to bisphosphoglycerate mutase deficiency;17357067;613896;Erythrocytosis due to bisphosphoglycerate mutase deficiency, 222800 (3);222800
BRAF;Adenocarcinoma of lung, somatic;17357067;164757;Adenocarcinoma of lung, somatic, 211980 (3);211980
BRAF;Cardiofaciocutaneous syndrome;17357067;164757;Cardiofaciocutaneous syndrome, 115150 (3);115150
BRAF;Colorectal cancer, somatic;17357067;164757;Colorectal cancer, somatic (3);0
BRAF;LEOPARD syndrome 3;17357067;164757;LEOPARD syndrome 3, 613707 (3);613707
BRAF;Melanoma, malignant, somatic;17357067;164757;Melanoma, malignant, somatic (3);0
BRAF;Nonsmall cell lung cancer, somatic;17357067;164757;Nonsmall cell lung cancer, somatic (3);0
BRAF;Noonan syndrome 7;17357067;164757;Noonan syndrome 7, 613706 (3);613706
BRAT1;Rigidity and multifocal seizure syndrome, lethal neonatal;17357067;614506;Rigidity and multifocal seizure syndrome, lethal neonatal, 614498 (3);614498
BRCA1;Breast-ovarian cancer, familial, 1;17357067;113705;{Breast-ovarian cancer, familial, 1}, 604370 (3);604370
BRCA1;Pancreatic cancer, susceptibility to, 4;17357067;113705;{Pancreatic cancer, susceptibility to, 4}, 614320 (3);614320
BRCA2;Breast cancer, male, susceptibility to;17357067;600185;{Breast cancer, male, susceptibility to}, 114480 (3);114480
BRCA2;Breast-ovarian cancer, familial, 2;17357067;600185;{Breast-ovarian cancer, familial, 2}, 612555 (3);612555
BRCA2;Fanconi anemia, complementation group D1;17357067;600185;Fanconi anemia, complementation group D1, 605724 (3);605724
BRCA2;Glioblastoma 3;17357067;600185;{Glioblastoma 3}, 613029 (3);613029
BRCA2;Medulloblastoma;17357067;600185;{Medulloblastoma}, 155255 (3);155255
BRCA2;Pancreatic cancer;17357067;600185;Pancreatic cancer, 613347 (3);613347
BRCA2;Pre-B-cell acute lymphoblastic leukemia;17357067;600185;{Pre-B-cell acute lymphoblastic leukemia} (3);0
BRCA2;Prostate cancer;17357067;600185;Prostate cancer, 176807 (3);176807
BRCA2;Wilms tumor;17357067;600185;Wilms tumor, 194070 (3);194070
BRD4;Breast cancer, somatic;17357067;171834;Breast cancer, somatic, 114480 (3);114480
BRD4;CLOVE syndrome, somatic;17357067;171834;CLOVE syndrome, somatic, 612918 (3);612918
BRD4;Colorectal cancer, somatic;17357067;171834;Colorectal cancer, somatic, 114500 (3);114500
BRD4;Cowden syndrome 5;17357067;171834;Cowden syndrome 5, 615108 (3);615108
BRD4;Gastric cancer, somatic;17357067;171834;Gastric cancer, somatic, 613659 (3);613659
BRD4;Hepatocellular carcinoma, somatic;17357067;171834;Hepatocellular carcinoma, somatic, 114550 (3);114550
BRD4;Keratosis, seborrheic, somatic;17357067;171834;Keratosis, seborrheic, somatic, 182000 (3);182000
BRD4;Megalencephaly-capillary malformation-polymicrogyria syndrome, somatic;17357067;171834;Megalencephaly-capillary malformation-polymicrogyria syndrome, somatic, 602501 (3);602501
BRD4;Nevus, epidermal, somatic;17357067;171834;Nevus, epidermal, somatic, 162900 (3);162900
BRD4;Nonsmall cell lung cancer, somatic;17357067;171834;Nonsmall cell lung cancer, somatic, 211980 (3);211980
BRD4;Ovarian cancer, somatic;17357067;171834;Ovarian cancer, somatic, 167000 (3);167000
BRF1;Cerebellofaciodental syndrome;17357067;604902;Cerebellofaciodental syndrome, 616202 (3);616202
BRIP1;Breast cancer, early-onset;17357067;605882;Breast cancer, early-onset, 114480 (3);114480
BRIP1;Fanconi anemia, complementation group J;17357067;605882;Fanconi anemia, complementation group J, 609054 (3);609054
BRWD3;Mental retardation, X-linked 93;17357067;300553;Mental retardation, X-linked 93, 300659 (3);300659
BSCL2;Encephalopathy, progressive, with or without lipodystrophy;17357067;606158;Encephalopathy, progressive, with or without lipodystrophy, 615924 (3);615924
BSCL2;Lipodystrophy, congenital generalized, type 2;17357067;606158;Lipodystrophy, congenital generalized, type 2, 269700 (3);269700
BSCL2;Neuropathy, distal hereditary motor, type VA;17357067;606158;Neuropathy, distal hereditary motor, type VA, 600794 (3);600794
BSCL2;Silver spastic paraplegia syndrome;17357067;606158;Silver spastic paraplegia syndrome, 270685 (3);270685
BSG;Blood group, OK;17357067;109480;[Blood group, OK], 111380 (3);111380
BSND;Bartter syndrome, type 4a;17357067;606412;Bartter syndrome, type 4a, 602522 (3);602522
BSND;Sensorineural deafness with mild renal dysfunction;17357067;606412;Sensorineural deafness with mild renal dysfunction, 602522 (3);602522
BTD;Biotinidase deficiency;17357067;609019;Biotinidase deficiency, 253260 (3);253260
BTK;Agammaglobulinemia and isolated hormone deficiency;17357067;300300;Agammaglobulinemia and isolated hormone deficiency, 307200 (3);307200
BTK;Agammaglobulinemia, X-linked 1;17357067;300300;Agammaglobulinemia, X-linked 1, 300755 (3);300755
BTNL2;Sarcoidosis, susceptibility to, 2;17357067;606000;{Sarcoidosis, susceptibility to, 2}, 612387 (3);612387
BUB1;Colorectal cancer with chromosomal instability, somatic;17357067;602452;Colorectal cancer with chromosomal instability, somatic (3);0
BUB1B;Colorectal cancer, somatic;17357067;602860;Colorectal cancer, somatic, 114500 (3);114500
BUB1B;Mosaic variegated aneuploidy syndrome 1;17357067;602860;Mosaic variegated aneuploidy syndrome 1, 257300 (3);257300
BUB1B;Premature chromatid separation trait;17357067;602860;[Premature chromatid separation trait], 176430 (3);176430
C10orf11;Albinism, oculocutaneous, type VII;17357067;614537;Albinism, oculocutaneous, type VII, 615179 (3);615179
C10orf2;Mitochondrial DNA depletion syndrome 4A (Alpers type);17357067;174763;Mitochondrial DNA depletion syndrome 4A (Alpers type), 203700 (3);203700
C10orf2;Mitochondrial DNA depletion syndrome 4B (MNGIE type);17357067;174763;Mitochondrial DNA depletion syndrome 4B (MNGIE type), 613662 (3);613662
C10orf2;Mitochondrial DNA depletion syndrome 7 (hepatocerebral type);17357067;606075;Mitochondrial DNA depletion syndrome 7 (hepatocerebral type), 271245 (3);271245
C10orf2;Mitochondrial recessive ataxia syndrome (includes SANDO and SCAE);17357067;174763;Mitochondrial recessive ataxia syndrome (includes SANDO and SCAE), 607459 (3);607459
C10orf2;Perrault syndrome 5;17357067;606075;Perrault syndrome 5, 616138 (3);616138
C10orf2;Progressive external ophthalmoplegia with mitochondrial DNA deletions, autosomal dominant 3;17357067;606075;Progressive external ophthalmoplegia with mitochondrial DNA deletions, autosomal dominant 3, 609286 (3);609286
C10orf2;Progressive external ophthalmoplegia, autosomal dominant;17357067;174763;Progressive external ophthalmoplegia, autosomal dominant, 157640 (3);157640
C10orf2;Progressive external ophthalmoplegia, autosomal recessive;17357067;174763;Progressive external ophthalmoplegia, autosomal recessive, 258450 (3);258450
C12orf57;Temtamy syndrome;17357067;615140;Temtamy syndrome, 218340 (3);218340
C12orf65;Combined oxidative phosphorylation deficiency 7;17357067;613541;Combined oxidative phosphorylation deficiency 7, 613559 (3);613559
C12orf65;Spastic paraplegia 55, autosomal recessive;17357067;613541;Spastic paraplegia 55, autosomal recessive, 615035 (3);615035
C14orf166;Leukoencephalopathy with vanishing white matter;17357067;603945;Leukoencephalopathy with vanishing white matter, 603896 (3);603896
C14orf166;Ovarioleukodystrophy;17357067;603945;Ovarioleukodystrophy, 603896 (3);603896
C15orf41;Dyserythropoietic anemia, congenital, type Ib;17357067;615626;Dyserythropoietic anemia, congenital, type Ib, 615631 (3);615631
C19orf12;Neurodegeneration with brain iron accumulation 4;17357067;614297;Neurodegeneration with brain iron accumulation 4, 614298 (3);614298
C1GALT1C1;Tn polyagglutination syndrome, somatic;17357067;300611;Tn polyagglutination syndrome, somatic, 300622 (3);300622
C1QA;C1q deficiency;17357067;120550;C1q deficiency, 613652 (3);613652
C1QB;C1q deficiency;17357067;120570;C1q deficiency, 613652 (3);613652
C1QC;C1q deficiency;17357067;120575;C1q deficiency, 613652 (3);613652
C1QTNF5;Retinal degeneration, late-onset, autosomal dominant;17357067;608752;Retinal degeneration, late-onset, autosomal dominant, 605670 (3);605670
C1R;C1r/C1s deficiency, combined;17357067;613785;C1r/C1s deficiency, combined, 216950 (1);216950
C1S;C1s deficiency;17357067;120580;C1s deficiency, 613783 (3);613783
C2;C2 deficiency;17357067;613927;C2 deficiency, 217000 (3);217000
C2;Macular degeneration, age-related, 14, reduced risk of;17357067;613927;{Macular degeneration, age-related, 14, reduced risk of}, 615489 (3);615489
C21orf59;Ciliary dyskinesia, primary, 26;17357067;615494;Ciliary dyskinesia, primary, 26, 615500 (3);615500
C2orf71;Retinitis pigmentosa 54;17357067;613425;Retinitis pigmentosa 54, 613428 (3);613428
C3;C3 deficiency;17357067;120700;C3 deficiency, 613779 (3);613779
C3;Hemolytic uremic syndrome, atypical, susceptibility to, 5;17357067;120700;{Hemolytic uremic syndrome, atypical, susceptibility to, 5}, 612925 (3);612925
C3;Macular degeneration, age-related, 9;17357067;120700;{Macular degeneration, age-related, 9}, 611378 (3);611378
C4A;Blood group, Rodgers;17357067;120810;[Blood group, Rodgers], 614374 (3);614374
C4A;C4a deficiency;17357067;120810;C4a deficiency, 614380 (3);614380
C4B;C4B deficiency;17357067;120820;C4B deficiency, 614379 (3);614379
C4orf26;Amelogenesis imperfecta, type IIA4;17357067;614829;Amelogenesis imperfecta, type IIA4, 614832 (3);614832
C5;C5 deficiency;17357067;120900;C5 deficiency, 609536 (3);609536
C5;Eculizumab, poor response to;17357067;120900;[Eculizumab, poor response to], 615749 (3);615749
C5orf42;Joubert syndrome 17;17357067;614571;Joubert syndrome 17, 614615 (3);614615
C5orf42;Orofaciodigital syndrome VI;17357067;614571;Orofaciodigital syndrome VI, 277170 (3);277170
C6;C6 deficiency;17357067;217050;C6 deficiency, 612446 (3);612446
C6;Combined C6/C7 deficiency;17357067;217050;Combined C6/C7 deficiency (3);0
C7;C7 deficiency;17357067;217070;C7 deficiency, 610102 (3);610102
C8A;C8 deficiency, type I;17357067;120950;C8 deficiency, type I, 613790 (3);613790
C8B;C8 deficiency, type II;17357067;120960;C8 deficiency, type II, 613789 (3);613789
C8orf37;Cone-rod dystrophy 16;17357067;614477;Cone-rod dystrophy 16, 614500 (3);614500
C8orf37;Retinitis pigmentosa 64;17357067;614477;Retinitis pigmentosa 64, 614500 (3);614500
C9;C9 deficiency;17357067;120940;C9 deficiency, 613825 (3);613825
C9;Macular degeneration, age-related, 15, susceptibility to;17357067;120940;{Macular degeneration, age-related, 15, susceptibility to}, 615591 (3);615591
C9orf72;Frontotemporal dementia and/or amyotrophic lateral sclerosis 1;17357067;614260;Frontotemporal dementia and/or amyotrophic lateral sclerosis 1, 105550 (3);105550
CA12;Hyperchlorhidrosis, isolated;17357067;603263;Hyperchlorhidrosis, isolated, 143860 (3);143860
CA2;Osteopetrosis, autosomal recessive 3, with renal tubular acidosis;17357067;611492;Osteopetrosis, autosomal recessive 3, with renal tubular acidosis, 259730 (3);259730
CA4;Retinitis pigmentosa 17;17357067;114760;Retinitis pigmentosa 17, 600852 (3);600852
CA5A;Hyperammonemia due to carbonic anhydrase VA deficiency;17357067;114761;Hyperammonemia due to carbonic anhydrase VA deficiency, 615751 (3);615751
CA8;Cerebellar ataxia and mental retardation with or without quadrupedal locomotion 3;17357067;114815;Cerebellar ataxia and mental retardation with or without quadrupedal locomotion 3, 613227 (3);613227
CABP2;Deafness, autosomal recessive 93;17357067;607314;Deafness, autosomal recessive 93, 614899 (3);614899
CABP4;Cone-rod synaptic disorder, congenital nonprogressive;17357067;608965;Cone-rod synaptic disorder, congenital nonprogressive, 610427 (3);610427
CACNA1A;Episodic ataxia, type 2;17357067;601011;Episodic ataxia, type 2, 108500 (3);108500
CACNA1A;Migraine, familial hemiplegic, 1;17357067;601011;Migraine, familial hemiplegic, 1, 141500 (3);141500
CACNA1A;Migraine, familial hemiplegic, 1, with progressive cerebellar ataxia;17357067;601011;Migraine, familial hemiplegic, 1, with progressive cerebellar ataxia, 141500 (3);141500
CACNA1A;Spinocerebellar ataxia 6;17357067;601011;Spinocerebellar ataxia 6, 183086 (3);183086
CACNA1C;Brugada syndrome 3;17357067;114205;Brugada syndrome 3, 611875 (3);611875
CACNA1C;Timothy syndrome;17357067;114205;Timothy syndrome, 601005 (3);601005
CACNA1D;Primary aldosteronism, seizures, and neurologic abnormalities;17357067;114206;Primary aldosteronism, seizures, and neurologic abnormalities, 615474 (3);615474
CACNA1D;Sinoatrial node dysfunction and deafness;17357067;114206;Sinoatrial node dysfunction and deafness, 614896 (3);614896
CACNA1F;Aland Island eye disease;17357067;300110;Aland Island eye disease, 300600 (3);300600
CACNA1F;Cone-rod dystropy, X-linked, 3;17357067;300110;Cone-rod dystropy, X-linked, 3, 300476 (3);300476
CACNA1F;Night blindness, congenital stationary (incomplete), 2A, X-linked;17357067;300110;Night blindness, congenital stationary (incomplete), 2A, X-linked, 300071 (3);300071
CACNA1H;Epilepsy, childhood absence, susceptibility to, 6;17357067;607904;{Epilepsy, childhood absence, susceptibility to, 6}, 611942 (3);611942
CACNA1H;Epilepsy, idiopathic generalized, susceptibility to, 6;17357067;607904;{Epilepsy, idiopathic generalized, susceptibility to, 6}, 611942 (3);611942
CACNA1S;Hypokalemic periodic paralysis, type 1;17357067;114208;Hypokalemic periodic paralysis, type 1, 170400 (3);170400
CACNA1S;Malignant hyperthermia susceptibility 5;17357067;114208;{Malignant hyperthermia susceptibility 5}, 601887 (3);601887
CACNA1S;Thyrotoxic periodic paralysis, susceptibility to, 1;17357067;114208;{Thyrotoxic periodic paralysis, susceptibility to, 1}, 188580 (3);188580
CACNA2D1;Malignant hyperthermia susceptibility 3;17357067;154276;{Malignant hyperthermia susceptibility 3} (2);0
CACNA2D4;Retinal cone dystrophy 4;17357067;608171;Retinal cone dystrophy 4, 610478 (3);610478
CACNB2;Brugada syndrome 4;17357067;600003;Brugada syndrome 4, 611876 (3);611876
CACNB4;Epilepsy, idiopathic generalized, susceptibility to, 9;17357067;601949;{Epilepsy, idiopathic generalized, susceptibility to, 9}, 607682 (3);607682
CACNB4;Epilepsy, juvenile myoclonic, susceptibility to, 6;17357067;601949;{Epilepsy, juvenile myoclonic, susceptibility to, 6}, 607682 (3);607682
CACNB4;Episodic ataxia, type 5;17357067;601949;Episodic ataxia, type 5, 613855 (3);613855
CACNB4;Myoclonic epilepsy, juvenile, 4;17357067;611364;Myoclonic epilepsy, juvenile, 4 (2);0
CACNG2;Mental retardation, autosomal dominant 10;17357067;602911;Mental retardation, autosomal dominant 10, 614256 (3);614256
CALCR;Osteoporosis, postmenopausal, susceptibility;17357067;114131;{Osteoporosis, postmenopausal, susceptibility}, 166710 (3);166710
CALM1;Long QT syndrome 14;17357067;114180;Long QT syndrome 14, 616247 (3);616247
CALM1;Ventricular tachycardia, catecholaminergic polymorphic, 4;17357067;114180;Ventricular tachycardia, catecholaminergic polymorphic, 4, 614916 (3);614916
CALM2;Long QT syndrome 15;17357067;114182;Long QT syndrome 15, 616249 (3);616249
CALR;Myelofibrosis, somatic;17357067;109091;Myelofibrosis, somatic, 254450 (3);254450
CALR;Osteoporosis, postmenopausal, susceptibility;17357067;114131;{Osteoporosis, postmenopausal, susceptibility}, 166710 (3);166710
CALR;Thrombocythemia, somatic;17357067;109091;Thrombocythemia, somatic, 187950 (3);187950
CAMTA1;Cerebellar ataxia, nonprogressive, with mental retardation;17357067;611501;Cerebellar ataxia, nonprogressive, with mental retardation, 614756 (3);614756
CANT1;Desbuquois dysplasia;17357067;613165;Desbuquois dysplasia, 251450 (3);251450
CAP1;Herpes simplex encephalitis, susceptibility to, 3;17357067;601896;{Herpes simplex encephalitis, susceptibility to, 3}, 614849 (3);614849
CAPN10;Diabetes mellitus, noninsulin-dependent 1;17357067;605286;{Diabetes mellitus, noninsulin-dependent 1}, 601283 (3);601283
CAPN3;Muscular dystrophy, limb-girdle, type 2A;17357067;114240;Muscular dystrophy, limb-girdle, type 2A, 253600 (3);253600
CAPN5;Vitreoretinopathy, neovascular inflammatory;17357067;602537;Vitreoretinopathy, neovascular inflammatory, 193235 (3);193235
CARD11;B-cell expansion with NFKB and T-cell anergy;17357067;607210;B-cell expansion with NFKB and T-cell anergy, 616452 (3);616452
CARD11;Immunodeficiency 11;17357067;607210;Immunodeficiency 11, 615206 (3);615206
CARD14;Pityriasis rubra pilaris;17357067;607211;Pityriasis rubra pilaris, 173200 (3);173200
CARD14;Psoriasis 2;17357067;607211;Psoriasis 2, 602723 (3);602723
CARD9;Candidiasis, familial, 2, autosomal recessive;17357067;607212;Candidiasis, familial, 2, autosomal recessive, 212050 (3);212050
CASC5;Microcephaly 4, primary, autosomal recessive;17357067;609173;Microcephaly 4, primary, autosomal recessive, 604321 (3);604321
CASK;FG syndrome 4;17357067;300172;FG syndrome 4, 300422 (3);300422
CASK;Mental retardation and microcephaly with pontine and cerebellar hypoplasia;17357067;300172;Mental retardation and microcephaly with pontine and cerebellar hypoplasia, 300749 (3);300749
CASK;Mental retardation, with or without nystagmus;17357067;300172;Mental retardation, with or without nystagmus, 300422 (3);300422
CASP10;Autoimmune lymphoproliferative syndrome, type II;17357067;601762;Autoimmune lymphoproliferative syndrome, type II, 603909 (3);603909
CASP10;Gastric cancer, somatic;17357067;601762;Gastric cancer, somatic, 613659 (3);613659
CASP10;Lymphoma, non-Hodgkin, somatic;17357067;601762;Lymphoma, non-Hodgkin, somatic, 605027 (3);605027
CASP12;Sepsis, susceptibility to;17357067;608633;{Sepsis, susceptibility to} (3);0
CASP8;Breast cancer, protection against;17357067;601763;{Breast cancer, protection against}, 114480 (3);114480
CASP8;Hepatocellular carcinoma, somatic;17357067;601763;Hepatocellular carcinoma, somatic, 114550 (3);114550
CASP8;Lung cancer, protection against;17357067;601763;{Lung cancer, protection against}, 211980 (3);211980
CASQ1;Myopathy, vacuolar, with CASQ1 aggregates;17357067;114250;Myopathy, vacuolar, with CASQ1 aggregates, 616231 (3);616231
CASQ2;Ventricular tachycardia, catecholaminergic polymorphic, 2;17357067;114251;Ventricular tachycardia, catecholaminergic polymorphic, 2, 611938 (3);611938
CASR;Calcium, serum level of;17357067;601199;{Calcium, serum level of} (3);0
CASR;Epilepsy idiopathic generalized, susceptibility to, 8;17357067;601199;{Epilepsy idiopathic generalized, susceptibility to, 8}, 612899 (3);612899
CASR;Hypercalciuric hypercalcemia;17357067;601199;Hypercalciuric hypercalcemia (3);0
CASR;Hyperparathyroidism, neonatal;17357067;601199;Hyperparathyroidism, neonatal, 239200 (3);239200
CASR;Hypocalcemia, autosomal dominant;17357067;601199;Hypocalcemia, autosomal dominant, 601198 (3);601198
CASR;Hypocalcemia, autosomal dominant, with Bartter syndrome;17357067;601199;Hypocalcemia, autosomal dominant, with Bartter syndrome, 601198 (3);601198
CASR;Hypocalciuric hypercalcemia, type I;17357067;601199;Hypocalciuric hypercalcemia, type I, 145980 (3);145980
CAST;Peeling skin with leukonychia, acral punctate keratoses, cheilitis, and knuckle pads;17357067;114090;Peeling skin with leukonychia, acral punctate keratoses, cheilitis, and knuckle pads, 616295 (3);616295
CAT;Acatalasemia;17357067;115500;Acatalasemia, 614097 (3);614097
CATSPER1;Spermatogenic failure 7;17357067;606389;Spermatogenic failure 7, 612997 (3);612997
CAV1;Pulmonary hypertension, primary, 3;17357067;601047;Pulmonary hypertension, primary, 3, 615343 (3);615343
CAV3;Cardiomyopathy, familial hypertrophic;17357067;601253;Cardiomyopathy, familial hypertrophic, 192600 (3);192600
CAV3;Creatine phosphokinase, elevated serum;17357067;601253;Creatine phosphokinase, elevated serum, 123320 (3);123320
CAV3;Long QT syndrome 9;17357067;601253;Long QT syndrome 9, 611818 (3);611818
CAV3;Muscular dystrophy, limb-girdle, type IC;17357067;601253;Muscular dystrophy, limb-girdle, type IC, 607801 (3);607801
CAV3;Myopathy, distal, Tateyama type;17357067;601253;Myopathy, distal, Tateyama type, 614321 (3);614321
CAV3;Rippling muscle disease;17357067;601253;Rippling muscle disease, 606072 (3);606072
CBFB;Myeloid leukemia, acute, M4/M4Eo subtype, somatic;17357067;121360;Myeloid leukemia, acute, M4/M4Eo subtype, somatic, 601626 (1);601626
CBL;Noonan syndrome-like disorder with or without juvenile myelomonocytic leukemia;17357067;165360;Noonan syndrome-like disorder with or without juvenile myelomonocytic leukemia, 613563 (3);613563
CBS;Homocystinuria, B6-responsive and nonresponsive types;17357067;613381;Homocystinuria, B6-responsive and nonresponsive types, 236200 (3);236200
CBS;Thrombosis, hyperhomocysteinemic;17357067;613381;Thrombosis, hyperhomocysteinemic, 236200 (3);236200
CBX2;46XY sex reversal 5;17357067;602770;46XY sex reversal 5, 613080 (3);613080
CBX8;Prostate cancer, susceptibility to, 3;17357067;608656;{Prostate cancer, susceptibility to, 3}, 176807 (2);176807
CC2D1A;Mental retardation, autosomal recessive 3;17357067;610055;Mental retardation, autosomal recessive 3, 608443 (3);608443
CC2D2A;COACH syndrome;17357067;612013;COACH syndrome, 216360 (3);216360
CC2D2A;Joubert syndrome 9;17357067;612013;Joubert syndrome 9, 612285 (3);612285
CC2D2A;Meckel syndrome 6;17357067;612013;Meckel syndrome 6, 612284 (3);612284
CCBE1;Hennekam lymphangiectasia-lymphedema syndrome 1;17357067;612753;Hennekam lymphangiectasia-lymphedema syndrome 1, 235510 (3);235510
CCDC103;Ciliary dyskinesia, primary, 17;17357067;614677;Ciliary dyskinesia, primary, 17, 614679 (3);614679
CCDC114;Ciliary dyskinesia, primary, 20;17357067;615038;Ciliary dyskinesia, primary, 20, 615067 (3);615067
CCDC151;Ciliary dyskinesia, primary, 30;17357067;615956;Ciliary dyskinesia, primary, 30, 616037 (3);616037
CCDC180;Cataract 36;17357067;611258;Cataract 36, 613887 (3);613887
CCDC28B;Bardet-Biedl syndrome 1, modifier of;17357067;610162;{Bardet-Biedl syndrome 1, modifier of}, 209900 (3);209900
CCDC39;Ciliary dyskinesia, primary, 14;17357067;613798;Ciliary dyskinesia, primary, 14, 613807 (3);613807
CCDC40;Ciliary dyskinesia, primary, 15;17357067;613799;Ciliary dyskinesia, primary, 15, 613808 (3);613808
CCDC50;Deafness, autosomal dominant 44;17357067;611051;Deafness, autosomal dominant 44, 607453 (3);607453
CCDC6;Thyroid papillary carcinoma;17357067;601985;Thyroid papillary carcinoma, 188550 (1);188550
CCDC6;Tuberculin skin test reactivity, absence of;17357067;613636;[Tuberculin skin test reactivity, absence of] (2);0
CCDC65;Ciliary dyskinesia, primary, 27;17357067;611088;Ciliary dyskinesia, primary, 27, 615504 (3);615504
CCDC78;Myopathy, centronuclear, 4;17357067;614666;Myopathy, centronuclear, 4, 614807 (3);614807
CCDC8;3-M syndrome 3;17357067;614145;3-M syndrome 3, 614205 (3);614205
CCDC88C;Hydrocephalus, nonsyndromic, autosomal recessive;17357067;611204;Hydrocephalus, nonsyndromic, autosomal recessive, 236600 (3);236600
CCL11;Asthma, susceptibility to;17357067;601156;{Asthma, susceptibility to}, 600807 (3);600807
CCL11;HIV1, resistance to;17357067;601156;{HIV1, resistance to}, 609423 (3);609423
CCL2;Coronary artery disease, modifier of;17357067;158105;{Coronary artery disease, modifier of} (3);0
CCL2;HIV-1, resistance to;17357067;158105;{HIV-1, resistance to}, 609423 (3);609423
CCL2;Mycobacterium tuberculosis, susceptibility to;17357067;158105;{Mycobacterium tuberculosis, susceptibility to}, 607948 (3);607948
CCL2;Spina bifida, susceptibility to;17357067;158105;{Spina bifida, susceptibility to}, 182940 (3);182940
CCL3;HIV infection, resistance to;17357067;182283;{HIV infection, resistance to}, 609423 (2);609423
CCL3L1;HIV/AIDS, susceptibility to;17357067;601395;{HIV/AIDS, susceptibility to}, 609423 (3);609423
CCL5;HIV-1 disease, delayed progression of;17357067;187011;{HIV-1 disease, delayed progression of} (3);0
CCL5;HIV-1 disease, rapid progression of;17357067;187011;{HIV-1 disease, rapid progression of} (3);0
CCM2;Cerebral cavernous malformations-2;17357067;607929;Cerebral cavernous malformations-2, 603284 (3);603284
CCND1;Colorectal cancer, susceptibility to;17357067;168461;{Colorectal cancer, susceptibility to}, 114500 (3);114500
CCND1;Multiple myeloma, susceptibility to;17357067;168461;{Multiple myeloma, susceptibility to}, 254500 (3);254500
CCND1;von Hippel-Lindau syndrome, modifier of;17357067;168461;{von Hippel-Lindau syndrome, modifier of}, 193300 (3);193300
CCND2;Megalencephaly-polymicrogyria-polydactyly-hydrocephalus syndrome 3;17357067;123833;Megalencephaly-polymicrogyria-polydactyly-hydrocephalus syndrome 3, 615938 (3);615938
CCNO;Ciliary dyskinesia, primary, 29;17357067;607752;Ciliary dyskinesia, primary, 29, 615872 (3);615872
CCR2;HIV infection, susceptibility/resistance to;17357067;601267;{HIV infection, susceptibility/resistance to} (3);0
CCR5;Diabetes mellitus, insulin-dependent, 22;17357067;601373;{Diabetes mellitus, insulin-dependent, 22}, 612522 (3);612522
CCR5;HIV infection, susceptibility/resistance to;17357067;601373;{HIV infection, susceptibility/resistance to} (3);0
CCR5;Hepatitis C virus, resistance to;17357067;601373;{Hepatitis C virus, resistance to}, 609532 (3);609532
CCR5;West nile virus, susceptibility to;17357067;601373;{West nile virus, susceptibility to}, 610379 (3);610379
CCT5;Neuropathy, hereditary sensory, with spastic paraplegia;17357067;610150;Neuropathy, hereditary sensory, with spastic paraplegia, 256840 (3);256840
CD151;Blood group, Raph;17357067;602243;[Blood group, Raph], 179620 (3);179620
CD151;Nephropathy with pretibial epidermolysis bullosa and deafness;17357067;602243;Nephropathy with pretibial epidermolysis bullosa and deafness, 609057 (3);609057
CD19;Immunodeficiency, common variable, 3;17357067;107265;Immunodeficiency, common variable, 3, 613493 (3);613493
CD209;Dengue fever, protection against;17357067;604672;{Dengue fever, protection against}, 614371 (3);614371
CD209;HIV type 1, susceptibility to;17357067;604672;{HIV type 1, susceptibility to}, 609423 (3);609423
CD209;Mycobacterium tuberculosis, susceptibility to;17357067;604672;{Mycobacterium tuberculosis, susceptibility to}, 607948 (3);607948
CD244;Rheumatoid arthritis, susceptibility to;17357067;605554;{Rheumatoid arthritis, susceptibility to}, 180300 (3);180300
CD27;Lymphoproliferative syndrome 2;17357067;186711;Lymphoproliferative syndrome 2, 615122 (3);615122
CD2AP;Glomerulosclerosis, focal segmental, 3;17357067;604241;Glomerulosclerosis, focal segmental, 3, 607832 (3);607832
CD320;Methylmalonic aciduria due to transcobalamin receptor defect;17357067;606475;Methylmalonic aciduria due to transcobalamin receptor defect, 613646 (3);613646
CD36;Bleeding disorder, platelet-type, 11;17357067;605546;Bleeding disorder, platelet-type, 11, 614201 (3);614201
CD36;Coronary heart disease, susceptibility to, 7;17357067;173510;{Coronary heart disease, susceptibility to, 7}, 610938 (3);610938
CD36;Macrothrombocytopenia;17357067;173510;[Macrothrombocytopenia] (1);0
CD36;Malaria, cerebral, reduced risk of;17357067;173510;{Malaria, cerebral, reduced risk of}, 611162 (3);611162
CD36;Malaria, cerebral, susceptibility to;17357067;173510;{Malaria, cerebral, susceptibility to}, 611162 (3);611162
CD36;Platelet glycoprotein IV deficiency;17357067;173510;Platelet glycoprotein IV deficiency, 608404 (3);608404
CD3D;Immunodeficiency 19;17357067;186790;Immunodeficiency 19, 615617 (3);615617
CD3E;Immunodeficiency 18;17357067;186830;Immunodeficiency 18, 615615 (3);615615
CD3E;Immunodeficiency 18, SCID variant;17357067;186830;Immunodeficiency 18, SCID variant, 615615 (3);615615
CD3G;Immunodeficiency 17, CD3 gamma deficient;17357067;186740;Immunodeficiency 17, CD3 gamma deficient, 615607 (3);615607
CD4;OKT4 epitope deficiency;17357067;186940;OKT4 epitope deficiency, 613949 (3);613949
CD40;Immunodeficiency with hyper-IgM, type 3;17357067;109535;Immunodeficiency with hyper-IgM, type 3, 606843 (3);606843
CD40LG;Immunodeficiency, X-linked, with hyper-IgM;17357067;300386;Immunodeficiency, X-linked, with hyper-IgM, 308230 (3);308230
CD44;Blood group, Indian system;17357067;107269;[Blood group, Indian system], 609027 (3);609027
CD46;Hemolytic uremic syndrome, atypical, susceptibility to, 2;17357067;120920;{Hemolytic uremic syndrome, atypical, susceptibility to, 2}, 612922 (3);612922
CD55;Blood group Cromer;17357067;125240;[Blood group Cromer], 613793 (3);613793
CD59;Hemolytic anemia, CD59-mediated, with or without immune-mediated polyneuropathy;17357067;107271;Hemolytic anemia, CD59-mediated, with or without immune-mediated polyneuropathy, 612300 (3);612300
CD79A;Agammaglobulinemia 3;17357067;112205;Agammaglobulinemia 3, 613501 (3);613501
CD79B;Agammaglobulinemia 6;17357067;147245;Agammaglobulinemia 6, 612692 (3);612692
CD81;Immunodeficiency, common variable, 6;17357067;186845;Immunodeficiency, common variable, 6, 613496 (3);613496
CD82;Prostate cancer, susceptibility to;17357067;600623;{Prostate cancer, susceptibility to}, 176807 (2);176807
CD8A;CD8 deficiency, familial;17357067;186910;CD8 deficiency, familial, 608957 (3);608957
CD96;C syndrome;17357067;606037;C syndrome, 211750 (3);211750
CDA;Craniodiaphyseal dysplasia, autosomal dominant;17357067;605740;Craniodiaphyseal dysplasia, autosomal dominant, 122860 (3);122860
CDA;Sclerosteosis 1;17357067;605740;Sclerosteosis 1, 269500 (3);269500
CDA;Van Buchem disease;17357067;605740;Van Buchem disease, 239100 (3);239100
CDAN1;Dyserythropoietic anemia, congenital, type Ia;17357067;607465;Dyserythropoietic anemia, congenital, type Ia, 224120 (3);224120
CDC6;Meier-Gorlin syndrome 5;17357067;602627;Meier-Gorlin syndrome 5, 613805 (3);613805
CDC73;Hyperparathyroidism, familial primary;17357067;607393;Hyperparathyroidism, familial primary, 145000 (3);145000
CDC73;Hyperparathyroidism-jaw tumor syndrome;17357067;607393;Hyperparathyroidism-jaw tumor syndrome, 145001 (3);145001
CDC73;Parathyroid adenoma with cystic changes;17357067;607393;Parathyroid adenoma with cystic changes, 145001 (3);145001
CDC73;Parathyroid carcinoma;17357067;607393;Parathyroid carcinoma, 608266 (3);608266
CDH1;Breast cancer, lobular;17357067;192090;{Breast cancer, lobular}, 114480 (3);114480
CDH1;Endometrial carcinoma, somatic;17357067;192090;Endometrial carcinoma, somatic, 608089 (3);608089
CDH1;Gastric cancer, familial diffuse, with or without cleft lip and/or palate;17357067;192090;Gastric cancer, familial diffuse, with or without cleft lip and/or palate, 137215 (3);137215
CDH1;Ovarian carcinoma, somatic;17357067;192090;Ovarian carcinoma, somatic, 167000 (3);167000
CDH1;Prostate cancer, susceptibility to;17357067;192090;{Prostate cancer, susceptibility to}, 176807 (3);176807
CDH15;Mental retardation, autosomal dominant 3;17357067;114019;Mental retardation, autosomal dominant 3, 612580 (3);612580
CDH19;Van Maldergem syndrome 1;17357067;603057;Van Maldergem syndrome 1, 601390 (3);601390
CDH23;Deafness, autosomal recessive 12;17357067;605516;Deafness, autosomal recessive 12, 601386 (3);601386
CDH23;Usher syndrome, type 1D;17357067;605516;Usher syndrome, type 1D, 601067 (3);601067
CDH23;Usher syndrome, type 1D/F digenic;17357067;605516;Usher syndrome, type 1D/F digenic, 601067 (3);601067
CDH3;Ectodermal dysplasia, ectrodactyly, and macular dystrophy;17357067;114021;Ectodermal dysplasia, ectrodactyly, and macular dystrophy, 225280 (3);225280
CDH3;Hypotrichosis, congenital, with juvenile macular dystrophy;17357067;114021;Hypotrichosis, congenital, with juvenile macular dystrophy, 601553 (3);601553
CDH3;Mental retardation, autosomal dominant 3;17357067;114019;Mental retardation, autosomal dominant 3, 612580 (3);612580
CDHR1;Cone-rod dystrophy 15;17357067;609502;Cone-rod dystrophy 15, 613660 (3);613660
CDHR1;Retinitis pigmentosa 65;17357067;609502;Retinitis pigmentosa 65, 613660 (3);613660
CDK13;Corneal endothelial dystrophy 1, autosomal dominant;17357067;121700;Corneal endothelial dystrophy 1, autosomal dominant (2);0
CDK4;Melanoma, cutaneous malignant, 3;17357067;123829;{Melanoma, cutaneous malignant, 3}, 609048 (3);609048
CDK5RAP2;Microcephaly 3, primary, autosomal recessive;17357067;608201;Microcephaly 3, primary, autosomal recessive, 604804 (3);604804
CDKAL1;Diabetes mellitus, noninsulin-dependent, susceptibility to;17357067;611259;{Diabetes mellitus, noninsulin-dependent, susceptibility to}, 125853 (3);125853
CDKL5;Epileptic encephalopathy, early infantile, 2;17357067;300203;Epileptic encephalopathy, early infantile, 2, 300672 (3);300672
CDKN1B;Multiple endocrine neoplasia, type IV;17357067;600778;Multiple endocrine neoplasia, type IV, 610755 (3);610755
CDKN1C;Beckwith-Wiedemann syndrome;17357067;103280;Beckwith-Wiedemann syndrome, 130650 (3);130650
CDKN1C;IMAGE syndrome;17357067;600856;IMAGE syndrome, 614732 (3);614732
CDKN1C;Silver-Russell syndrome;17357067;103280;Silver-Russell syndrome, 180860 (3);180860
CDKN1C;Wilms tumor 2;17357067;103280;Wilms tumor 2, 194071 (3);194071
CDKN2A;Melanoma and neural system tumor syndrome;17357067;600160;Melanoma and neural system tumor syndrome, 155755 (3);155755
CDKN2A;Melanoma, cutaneous malignant, 1;17357067;155600;{Melanoma, cutaneous malignant, 1} (2);0
CDKN2A;Melanoma, cutaneous malignant, 2;17357067;600160;{Melanoma, cutaneous malignant, 2}, 155601 (3);155601
CDKN2A;Orolaryngeal cancer, multiple;17357067;600160;Orolaryngeal cancer, multiple, (3);0
CDKN2A;Pancreatic cancer/melanoma syndrome;17357067;600160;Pancreatic cancer/melanoma syndrome, 606719 (3);606719
CDON;Holoprosencephaly 11;17357067;608707;Holoprosencephaly 11, 614226 (3);614226
CDS1;Breast and colorectal cancer, susceptibility to;17357067;604373;{Breast and colorectal cancer, susceptibility to} (3);0
CDS1;Breast cancer, susceptibility to;17357067;604373;{Breast cancer, susceptibility to}, 114480 (3);114480
CDS1;Li-Fraumeni syndrome;17357067;604373;Li-Fraumeni syndrome, 609265 (3);609265
CDS1;Osteosarcoma, somatic;17357067;604373;Osteosarcoma, somatic, 259500 (3);259500
CDS1;Prostate cancer, familial, susceptibility to;17357067;604373;{Prostate cancer, familial, susceptibility to}, 176807 (3);176807
CDSN;Hypotrichosis 2;17357067;602593;Hypotrichosis 2, 146520 (3);146520
CDSN;Peeling skin syndrome 1;17357067;602593;Peeling skin syndrome 1, 270300 (3);270300
CDT1;Meier-Gorlin syndrome 4;17357067;605525;Meier-Gorlin syndrome 4, 613804 (3);613804
CEBPA;Leukemia, acute myeloid, somatic;17357067;116897;Leukemia, acute myeloid, somatic, 601626 (3);601626
CEBPD;Cardiomyopathy, hypertrophic, 12;17357067;600824;Cardiomyopathy, hypertrophic, 12, 612124 (3);612124
CEBPE;Specific granule deficiency;17357067;600749;Specific granule deficiency, 245480 (3);245480
CECR;Cat eye syndrome;17357067;115470;Cat eye syndrome (4);0
CECR1;Polyarteritis nodosa, childhood-onset;17357067;607575;Polyarteritis nodosa, childhood-onset, 615688 (3);615688
CEL;Maturity-onset diabetes of the young, type VIII;17357067;114840;Maturity-onset diabetes of the young, type VIII, 609812 (3);609812
CELP;Maturity-onset diabetes of the young, type VIII;17357067;114840;Maturity-onset diabetes of the young, type VIII, 609812 (3);609812
CENPF;Ciliary dyskinesia, primary, 31;17357067;600236;Ciliary dyskinesia, primary, 31, 616369 (3);616369
CENPJ;Microcephaly 6, primary, autosomal recessive;17357067;609279;Microcephaly 6, primary, autosomal recessive, 608393 (3);608393
CENPJ;Seckel syndrome 4;17357067;609279;Seckel syndrome 4, 613676 (3);613676
CEP120;Short-rib thoracic dysplasia 13 with or without polydactyly;17357067;613446;Short-rib thoracic dysplasia 13 with or without polydactyly, 616300 (3);616300
CEP152;Microcephaly 4, primary, autosomal recessive;17357067;609173;Microcephaly 4, primary, autosomal recessive, 604321 (3);604321
CEP152;Microcephaly 9, primary, autosomal recessive;17357067;613529;Microcephaly 9, primary, autosomal recessive, 614852 (3);614852
CEP152;Seckel syndrome 5;17357067;613529;Seckel syndrome 5, 613823 (3);613823
CEP164;Nephronophthisis 15;17357067;614848;Nephronophthisis 15, 614845 (3);614845
CEP19;Morbid obesity and spermatogenic failure;17357067;615586;Morbid obesity and spermatogenic failure, 615703 (3);615703
CEP290;Joubert syndrome 5;17357067;610142;Joubert syndrome 5, 610188 (3);610188
CEP290;Leber congenital amaurosis 10;17357067;610142;Leber congenital amaurosis 10, 611755 (3);611755
CEP290;Meckel syndrome 4;17357067;610142;Meckel syndrome 4, 611134 (3);611134
CEP290;Senior-Loken syndrome 6;17357067;610142;Senior-Loken syndrome 6, 610189 (3);610189
CEP41;Joubert syndrome 15;17357067;610523;Joubert syndrome 15, 614464 (3);614464
CEP57;Mosaic variegated aneuploidy syndrome 2;17357067;607951;Mosaic variegated aneuploidy syndrome 2, 614114 (3);614114
CEP83;Nephronophthisis 18;17357067;615847;Nephronophthisis 18, 615862 (3);615862
CERKL;Retinitis pigmentosa 26;17357067;608381;Retinitis pigmentosa 26, 608380 (3);608380
CERS3;Ichthyosis, congenital, autosomal recessive 9;17357067;615276;Ichthyosis, congenital, autosomal recessive 9, 615023 (3);615023
CES1;Carboxylesterase 1 deficiency;17357067;114835;Carboxylesterase 1 deficiency (3);0
CETP;High density lipoprotein cholesterol level QTL 10;17357067;118470;[High density lipoprotein cholesterol level QTL 10], 143470 (3);143470
CETP;Hyperalphalipoproteinemia;17357067;118470;Hyperalphalipoproteinemia, 143470 (3);143470
CFAP53;Heterotaxy, visceral, 6, autosomal recessive;17357067;614759;Heterotaxy, visceral, 6, autosomal recessive, 614779 (3);614779
CFB;Hemolytic uremic syndrome, atypical, susceptibility to, 4;17357067;138470;{Hemolytic uremic syndrome, atypical, susceptibility to, 4}, 612924 (3);612924
CFB;Macular degeneration, age-related, 14, reduced risk of;17357067;138470;{Macular degeneration, age-related, 14, reduced risk of}, 615489 (3);615489
CFC1;Double-outlet right ventricle;17357067;605194;Double-outlet right ventricle, 217095 (3);217095
CFC1;Heterotaxy, visceral, 2, autosomal;17357067;605194;Heterotaxy, visceral, 2, autosomal, 605376 (3);605376
CFC1;Transposition of the great arteries, dextro-looped 2;17357067;605194;Transposition of the great arteries, dextro-looped 2, 613853 (3);613853
CFD;Complement factor D deficiency;17357067;134350;Complement factor D deficiency, 613912 (3);613912
CFD;Properdin deficiency, X-linked;17357067;300383;Properdin deficiency, X-linked, 312060 (3);312060
CFH;Basal laminar drusen;17357067;134370;Basal laminar drusen, 126700 (3);126700
CFH;Complement factor H deficiency;17357067;134370;Complement factor H deficiency, 609814 (3);609814
CFH;Hemolytic uremic syndrome, atypical, susceptibility to, 1;17357067;134370;{Hemolytic uremic syndrome, atypical, susceptibility to, 1}, 235400 (3);235400
CFH;Macular degeneration, age-related, 4;17357067;134370;{Macular degeneration, age-related, 4}, 610698 (3);610698
CFHR1;Hemolytic uremic syndrome, atypical, susceptibility to;17357067;134371;{Hemolytic uremic syndrome, atypical, susceptibility to}, 235400 (3);235400
CFHR1;Macular degeneration, age-related, reduced risk of;17357067;134371;{Macular degeneration, age-related, reduced risk of}, 603075 (3);603075
CFHR3;Hemolytic uremic syndrome, atypical, susceptibility to;17357067;605336;{Hemolytic uremic syndrome, atypical, susceptibility to}, 235400 (3);235400
CFHR3;Macular degeneration, age-related, reduced risk of;17357067;605336;{Macular degeneration, age-related, reduced risk of}, 603075 (3);603075
CFHR5;Nephropathy due to CFHR5 deficiency;17357067;608593;Nephropathy due to CFHR5 deficiency, 614809 (3);614809
CFI;Complement factor I deficiency;17357067;217030;Complement factor I deficiency, 610984 (3);610984
CFI;Hemolytic uremic syndrome, atypical, susceptibility to, 3;17357067;217030;{Hemolytic uremic syndrome, atypical, susceptibility to, 3}, 612923 (3);612923
CFI;Macular degeneration, age-related, 13, susceptibility to;17357067;217030;{Macular degeneration, age-related, 13, susceptibility to}, 615439 (3);615439
CFL2;Nemaline myopathy 7, autosomal recessive;17357067;601443;Nemaline myopathy 7, autosomal recessive, 610687 (3);610687
CFP;Properdin deficiency, X-linked;17357067;300383;Properdin deficiency, X-linked, 312060 (3);312060
CFTR;Bronchiectasis with or without elevated sweat chloride 1, modifier of;17357067;602421;{Bronchiectasis with or without elevated sweat chloride 1, modifier of}, 211400 (3);211400
CFTR;Congenital bilateral absence of vas deferens;17357067;602421;Congenital bilateral absence of vas deferens, 277180 (3);277180
CFTR;Cystic fibrosis;17357067;602421;Cystic fibrosis, 219700 (3);219700
CFTR;Hypertrypsinemia, neonatal;17357067;602421;{Hypertrypsinemia, neonatal} (3);0
CFTR;Pancreatitis, idiopathic;17357067;602421;{Pancreatitis, idiopathic}, 167800 (3);167800
CFTR;Sweat chloride elevation without CF;17357067;602421;Sweat chloride elevation without CF (3);0
CHAT;Myasthenic syndrome, congenital, 6, presynaptic;17357067;118490;Myasthenic syndrome, congenital, 6, presynaptic, 254210 (3);254210
CHCHD10;Frontotemporal dementia and/or amyotrophic lateral sclerosis 2;17357067;615903;Frontotemporal dementia and/or amyotrophic lateral sclerosis 2, 615911 (3);615911
CHCHD10;Spinal muscular atrophy, Jokela type;17357067;615903;Spinal muscular atrophy, Jokela type, 615048 (3);615048
CHD2;Epileptic encephalopathy, childhood-onset;17357067;602119;Epileptic encephalopathy, childhood-onset, 615369 (3);615369
CHD7;CHARGE syndrome;17357067;608892;CHARGE syndrome, 214800 (3);214800
CHD7;Hypogonadotropic hypogonadism 5 with or without anosmia;17357067;608892;Hypogonadotropic hypogonadism 5 with or without anosmia, 612370 (3);612370
CHD8;Autism, susceptibility to, 18;17357067;610528;{Autism, susceptibility to, 18}, 615032 (3);615032
CHEK2;Breast and colorectal cancer, susceptibility to;17357067;604373;{Breast and colorectal cancer, susceptibility to} (3);0
CHEK2;Breast cancer, susceptibility to;17357067;604373;{Breast cancer, susceptibility to}, 114480 (3);114480
CHEK2;Li-Fraumeni syndrome;17357067;604373;Li-Fraumeni syndrome, 609265 (3);609265
CHEK2;Osteosarcoma, somatic;17357067;604373;Osteosarcoma, somatic, 259500 (3);259500
CHEK2;Prostate cancer, familial, susceptibility to;17357067;604373;{Prostate cancer, familial, susceptibility to}, 176807 (3);176807
CHI3L1;Asthma-related traits, susceptibility to, 7;17357067;601525;{Asthma-related traits, susceptibility to, 7}, 611960 (3);611960
CHI3L1;Schizophrenia, susceptibility to;17357067;601525;{Schizophrenia, susceptibility to}, 181500 (3);181500
CHIC2;Leukemia, acute myeloid;17357067;604332;{Leukemia, acute myeloid}, 601626 (3);601626
CHIT1;Chitotriosidase deficiency;17357067;600031;[Chitotriosidase deficiency], 614122 (3);614122
CHKB;Muscular dystrophy, congenital, megaconial type;17357067;612395;Muscular dystrophy, congenital, megaconial type, 602541 (3);602541
CHM;Charcot-Marie-Tooth disease, dominant intermediate D;17357067;159440;Charcot-Marie-Tooth disease, dominant intermediate D, 607791 (3);607791
CHM;Charcot-Marie-Tooth disease, type 1B;17357067;159440;Charcot-Marie-Tooth disease, type 1B, 118200 (3);118200
CHM;Charcot-Marie-Tooth disease, type 2I;17357067;159440;Charcot-Marie-Tooth disease, type 2I, 607677 (3);607677
CHM;Charcot-Marie-Tooth disease, type 2J;17357067;159440;Charcot-Marie-Tooth disease, type 2J, 607736 (3);607736
CHM;Choroideremia;17357067;300390;Choroideremia, 303100 (3);303100
CHM;Dejerine-Sottas disease;17357067;159440;Dejerine-Sottas disease, 145900 (3);145900
CHM;Neuropathy, congenital hypomyelinating;17357067;159440;Neuropathy, congenital hypomyelinating, 605253 (3);605253
CHM;Roussy-Levy syndrome;17357067;159440;Roussy-Levy syndrome, 180800 (3);180800
CHMP1A;Pontocerebellar hypoplasia, type 8;17357067;164010;Pontocerebellar hypoplasia, type 8, 614961 (3);614961
CHMP2B;Amyotrophic lateral sclerosis 17;17357067;609512;Amyotrophic lateral sclerosis 17, 614696 (3);614696
CHMP2B;Dementia, familial, nonspecific;17357067;609512;Dementia, familial, nonspecific, 600795 (3);600795
CHMP4B;Cataract 31, multiple types;17357067;610897;Cataract 31, multiple types, 605387 (3);605387
CHN1;Duane retraction syndrome 2;17357067;118423;Duane retraction syndrome 2, 604356 (3);604356
CHRDL1;Hodgkin lymphoma, susceptibility to;17357067;613169;{Hodgkin lymphoma, susceptibility to}, 246000 (3);246000
CHRDL1;Megalocornea 1, X-linked;17357067;300350;Megalocornea 1, X-linked 309300 (3);309300
CHRNA1;Multiple pterygium syndrome, lethal type;17357067;100690;Multiple pterygium syndrome, lethal type, 253290 (3);253290
CHRNA1;Myasthenic syndrome, congenital, 1A, slow-channel;17357067;100690;Myasthenic syndrome, congenital, 1A, slow-channel, 601462 (3);601462
CHRNA1;Myasthenic syndrome, congenital, 1B, fast-channel;17357067;100690;Myasthenic syndrome, congenital, 1B, fast-channel, 608930 (3);608930
CHRNA2;Epilepsy, nocturnal frontal lobe, type 4;17357067;118502;Epilepsy, nocturnal frontal lobe, type 4, 610353 (3);610353
CHRNA3;Lung cancer susceptibility 2;17357067;118503;{Lung cancer susceptibility 2}, 612052 (3);612052
CHRNA4;Epilepsy, nocturnal frontal lobe, 1;17357067;118504;Epilepsy, nocturnal frontal lobe, 1, 600513 (3);600513
CHRNA4;Nicotine addiction, susceptibility to;17357067;118504;{Nicotine addiction, susceptibility to}, 188890 (3);188890
CHRNA5;Lung cancer susceptibility 2;17357067;118505;{Lung cancer susceptibility 2}, 612052 (3);612052
CHRNA5;Nicotine dependence, susceptibility to;17357067;118505;{Nicotine dependence, susceptibility to}, 612052 (3);612052
CHRNA7;Schizophrenia, neurophysiologic defect in;17357067;118511;Schizophrenia, neurophysiologic defect in (2);0
CHRNB1;Myasthenic syndrome, congenital, 2A, slow-channel;17357067;100710;Myasthenic syndrome, congenital, 2A, slow-channel, 616313 (3);616313
CHRNB2;Epilepsy, nocturnal frontal lobe, 3;17357067;118507;Epilepsy, nocturnal frontal lobe, 3, 605375 (3);605375
CHRND;Multiple pterygium syndrome, lethal type;17357067;100690;Multiple pterygium syndrome, lethal type, 253290 (3);253290
CHRND;Myasthenic syndrome, congenital, 1A, slow-channel;17357067;100690;Myasthenic syndrome, congenital, 1A, slow-channel, 601462 (3);601462
CHRND;Myasthenic syndrome, congenital, 1B, fast-channel;17357067;100690;Myasthenic syndrome, congenital, 1B, fast-channel, 608930 (3);608930
CHRND;Myasthenic syndrome, congenital, 3B, fast-channel;17357067;100720;Myasthenic syndrome, congenital, 3B, fast-channel, 616322 (3);616322
CHRNE;Myasthenic syndrome, congenital, 4A, slow-channel;17357067;100725;Myasthenic syndrome, congenital, 4A, slow-channel, 605809 (3);605809
CHRNE;Myasthenic syndrome, congenital, 4B, fast-channel;17357067;100725;Myasthenic syndrome, congenital, 4B, fast-channel, 616324 (3);616324
CHRNE;Myasthenic syndrome, congenital, 4C, associated with acetylcholine receptor deficiency;17357067;100725;Myasthenic syndrome, congenital, 4C, associated with acetylcholine receptor deficiency, 608931 (3);608931
CHRNG;Escobar syndrome;17357067;100730;Escobar syndrome, 265000 (3);265000
CHRNG;Multiple pterygium syndrome, lethal type;17357067;100730;Multiple pterygium syndrome, lethal type, 253290 (3);253290
CHST14;Ehlers-Danlos syndrome, musculocontractural type 1;17357067;608429;Ehlers-Danlos syndrome, musculocontractural type 1, 601776 (3);601776
CHST3;Spondyloepiphyseal dysplasia with congenital joint dislocations;17357067;603799;Spondyloepiphyseal dysplasia with congenital joint dislocations, 143095 (3);143095
CHST6;Macular corneal dystrophy;17357067;605294;Macular corneal dystrophy, 217800 (3);217800
CHSY1;Temtamy preaxial brachydactyly syndrome;17357067;608183;Temtamy preaxial brachydactyly syndrome, 605282 (3);605282
CHUK;Cocoon syndrome;17357067;600664;Cocoon syndrome, 613630 (3);613630
CIB2;Deafness, autosomal recessive 48;17357067;605564;Deafness, autosomal recessive 48, 609439 (3);609439
CIB2;Usher syndrome, type IJ;17357067;605564;Usher syndrome, type IJ, 614869 (3);614869
CIITA;Bare lymphocyte syndrome, type II, complementation group A;17357067;600005;Bare lymphocyte syndrome, type II, complementation group A, 209920 (3);209920
CIITA;Rheumatoid arthritis, susceptibility to;17357067;600005;{Rheumatoid arthritis, susceptibility to}, 180300 (3);180300
CILP;Lumbar disc disease, susceptibility to;17357067;603489;{Lumbar disc disease, susceptibility to}, 603932 (3);603932
CIRH1A;Cirrhosis, North American Indian childhood type;17357067;607456;Cirrhosis, North American Indian childhood type, 604901 (3);604901
CISD2;Wolfram syndrome 2;17357067;611507;Wolfram syndrome 2, 604928 (3);604928
CISH;Bacteremia, susceptibility to;17357067;602441;{Bacteremia, susceptibility to}, 614383 (3);614383
CISH;Malaria, susceptibility to;17357067;602441;{Malaria, susceptibility to}, 611162 (3);611162
CISH;Tuberculosis, susceptibility to;17357067;602441;{Tuberculosis, susceptibility to}, 607948 (3);607948
CITED2;Atrial septal defect 8;17357067;602937;Atrial septal defect 8, 614433 (3);614433
CITED2;Ventricular septal defect 2;17357067;602937;Ventricular septal defect 2, 614431 (3);614431
CKAP2L;Filippi syndrome;17357067;616174;Filippi syndrome, 272440 (3);272440
CLC;Cold-induced sweating syndrome 2;17357067;607672;Cold-induced sweating syndrome 2, 610313 (3);610313
CLCF1;Cold-induced sweating syndrome 2;17357067;607672;Cold-induced sweating syndrome 2, 610313 (3);610313
CLCN1;Myotonia congenita, dominant;17357067;118425;Myotonia congenita, dominant, 160800 (3);160800
CLCN1;Myotonia congenita, recessive;17357067;118425;Myotonia congenita, recessive, 255700 (3);255700
CLCN1;Myotonia levior, recessive;17357067;118425;Myotonia levior, recessive (3);0
CLCN2;Epilepsy, idiopathic generalized, susceptibility to, 11;17357067;600570;{Epilepsy, idiopathic generalized, susceptibility to, 11}, 607628 (3);607628
CLCN2;Epilepsy, idiopathic generalized, susceptibility to, 9;17357067;601949;{Epilepsy, idiopathic generalized, susceptibility to, 9}, 607682 (3);607682
CLCN2;Epilepsy, juvenile absence, susceptibility to, 2;17357067;600570;{Epilepsy, juvenile absence, susceptibility to, 2}, 607628 (3);607628
CLCN2;Epilepsy, juvenile myoclonic, susceptibility to, 6;17357067;601949;{Epilepsy, juvenile myoclonic, susceptibility to, 6}, 607682 (3);607682
CLCN2;Epilepsy, juvenile myoclonic, susceptibility to, 8;17357067;600570;{Epilepsy, juvenile myoclonic, susceptibility to, 8}, 607628 (3);607628
CLCN2;Episodic ataxia, type 5;17357067;601949;Episodic ataxia, type 5, 613855 (3);613855
CLCN2;Leukoencephalopathy with ataxia;17357067;600570;Leukoencephalopathy with ataxia, 615651 (3);615651
CLCN5;Dent disease;17357067;300008;Dent disease, 300009 (3);300009
CLCN5;Dent disease 2;17357067;300535;Dent disease 2, 300555 (3);300555
CLCN5;Hypophosphatemic rickets;17357067;300008;Hypophosphatemic rickets, 300554 (3);300554
CLCN5;Lowe syndrome;17357067;300535;Lowe syndrome, 309000 (3);309000
CLCN5;Nephrolithiasis, type I;17357067;300008;Nephrolithiasis, type I, 310468 (3);310468
CLCN5;Proteinuria, low molecular weight, with hypercalciuric nephrocalcinosis;17357067;300008;Proteinuria, low molecular weight, with hypercalciuric nephrocalcinosis, 308990 (3);308990
CLCN7;Osteopetrosis, autosomal dominant 2;17357067;602727;Osteopetrosis, autosomal dominant 2, 166600 (3);166600
CLCN7;Osteopetrosis, autosomal recessive 4;17357067;602727;Osteopetrosis, autosomal recessive 4, 611490 (3);611490
CLCNKA;Bartter syndrome, type 4b, digenic;17357067;602024;Bartter syndrome, type 4b, digenic, 613090 (3);613090
CLCNKB;Bartter syndrome, type 3;17357067;602023;Bartter syndrome, type 3, 607364 (3);607364
CLCNKB;Bartter syndrome, type 4b, digenic;17357067;602023;Bartter syndrome, type 4b, digenic, 613090 (3);613090
CLDN1;Ichthyosis, leukocyte vacuoles, alopecia, and sclerosing cholangitis;17357067;603718;Ichthyosis, leukocyte vacuoles, alopecia, and sclerosing cholangitis, 607626 (3);607626
CLDN14;Deafness, autosomal recessive 29;17357067;605608;Deafness, autosomal recessive 29, 614035 (3);614035
CLDN16;Hypomagnesemia 3, renal;17357067;603959;Hypomagnesemia 3, renal, 248250 (3);248250
CLDN19;Hypomagnesemia 5, renal, with ocular involvement;17357067;610036;Hypomagnesemia 5, renal, with ocular involvement, 248190 (3);248190
CLEC10A;Myopathy with lactic acidosis, hereditary;17357067;611911;Myopathy with lactic acidosis, hereditary, 255125 (3);255125
CLEC4M;SARS infection, protection against;17357067;605872;SARS infection, protection against (2);0
CLEC7A;Aspergillosis, susceptibility to;17357067;606264;{Aspergillosis, susceptibility to}, 614079 (3);614079
CLEC7A;Candidiasis, familial, 4, autosomal recessive;17357067;606264;Candidiasis, familial, 4, autosomal recessive, 613108 (3);613108
CLK1;3MC syndrome 2;17357067;612502;3MC syndrome 2, 265050 (3);265050
CLMP;Congenital short bowel syndrome;17357067;611693;Congenital short bowel syndrome, 615237 (3);615237
CLN3;Ceroid lipofuscinosis, neuronal, 3;17357067;607042;Ceroid lipofuscinosis, neuronal, 3, 204200 (3);204200
CLN5;Ceroid lipofuscinosis, neuronal, 5;17357067;608102;Ceroid lipofuscinosis, neuronal, 5, 256731 (3);256731
CLN6;Ceroid lipofuscinosis, neuronal, 6;17357067;606725;Ceroid lipofuscinosis, neuronal, 6, 601780 (3);601780
CLN6;Ceroid lipofuscinosis, neuronal, Kufs type, adult onset;17357067;606725;Ceroid lipofuscinosis, neuronal, Kufs type, adult onset, 204300 (3);204300
CLN8;Ceroid lipofuscinosis, neuronal, 8;17357067;607837;Ceroid lipofuscinosis, neuronal, 8, 600143 (3);600143
CLN8;Ceroid lipofuscinosis, neuronal, 8, Northern epilepsy variant;17357067;607837;Ceroid lipofuscinosis, neuronal, 8, Northern epilepsy variant, 610003 (3);610003
CLP1;Pontocerebellar hypoplasia, type 10;17357067;608757;Pontocerebellar hypoplasia, type 10, 615803 (3);615803
CLPB;3-methylglutaconic aciduria, type VII, with cataracts, neurologic involvement and neutropenia;17357067;616254;3-methylglutaconic aciduria, type VII, with cataracts, neurologic involvement and neutropenia, 616271 (3);616271
CLPP;Perrault syndrome 3;17357067;601119;Perrault syndrome 3, 614129 (3);614129
CLRN1;Retinitis pigmentosa 61;17357067;606397;Retinitis pigmentosa 61, 614180 (3);614180
CLRN1;Usher syndrome, type 3A;17357067;606397;Usher syndrome, type 3A, 276902 (3);276902
CMC1;Capillary malformations, congenital, 1, somatic, mosaic;17357067;600998;Capillary malformations, congenital, 1, somatic, mosaic, 163000 (3);163000
CMC1;Sturge-Weber syndrome, somatic, mosaic;17357067;600998;Sturge-Weber syndrome, somatic, mosaic, 185300 (3);185300
CNBP;Myotonic dystrophy 2;17357067;116955;Myotonic dystrophy 2, 602668 (3);602668
CNGA1;Retinitis pigmentosa 49;17357067;123825;Retinitis pigmentosa 49, 613756 (3);613756
CNGA3;Achromatopsia-2;17357067;600053;Achromatopsia-2, 216900 (3);216900
CNGB1;Retinitis pigmentosa 45;17357067;600724;Retinitis pigmentosa 45, 613767 (3);613767
CNGB3;Achromatopsia-3;17357067;605080;Achromatopsia-3, 262300 (3);262300
CNGB3;Macular degeneration, juvenile;17357067;605080;Macular degeneration, juvenile, 248200 (3);248200
CNNM2;Hypomagnesemia 6, renal;17357067;607803;Hypomagnesemia 6, renal, 613882 (3);613882
CNNM2;Hypomagnesemia, seizures, and mental retardation;17357067;607803;Hypomagnesemia, seizures, and mental retardation, 616418 (3);616418
CNNM4;Jalili syndrome;17357067;607805;Jalili syndrome, 217080 (3);217080
CNTD2;Cataract 27, nuclear progressive;17357067;607304;Cataract 27, nuclear progressive (2);0
CNTNAP1;Lethal congenital contracture syndrome 7;17357067;602346;Lethal congenital contracture syndrome 7, 616286 (3);616286
CNTNAP2;Autism susceptibility 15;17357067;604569;{Autism susceptibility 15}, 612100 (3);612100
CNTNAP2;Cortical dysplasia-focal epilepsy syndrome;17357067;604569;Cortical dysplasia-focal epilepsy syndrome, 610042 (3);610042
CNTNAP2;Pitt-Hopkins like syndrome 1;17357067;604569;Pitt-Hopkins like syndrome 1, 610042 (3);610042
COA6;Cardioencephalomyopathy, fatal infantile, due to cytochrome c oxidase deficiency 4;17357067;614772;Cardioencephalomyopathy, fatal infantile, due to cytochrome c oxidase deficiency 4, 616501 (3);616501
COASY;Neurodegeneration with brain iron accumulation 6;17357067;609855;Neurodegeneration with brain iron accumulation 6, 615643 (3);615643
COCH;Deafness, autosomal dominant 31;17357067;608645;Deafness, autosomal dominant 31 (2);0
COCH;Deafness, autosomal dominant 9;17357067;603196;Deafness, autosomal dominant 9, 601369 (3);601369
COG1;Congenital disorder of glycosylation, type IIg;17357067;606973;Congenital disorder of glycosylation, type IIg, 611209 (3);611209
COG4;Congenital disorder of glycosylation, type IIj;17357067;606976;Congenital disorder of glycosylation, type IIj, 613489 (3);613489
COG5;Congenital disorder of glycosylation, type IIi;17357067;606821;Congenital disorder of glycosylation, type IIi, 613612 (3);613612
COG6;Cone dystrophy, progressive X-linked, 2;17357067;300085;Cone dystrophy, progressive X-linked, 2 (2);0
COG6;Congenital disorder of glycosylation, type IIl;17357067;606977;Congenital disorder of glycosylation, type IIl, 614576 (3);614576
COG6;Shaheen syndrome;17357067;606977;Shaheen syndrome, 615328 (3);615328
COG7;Congenital disorder of glycosylation, type IIe;17357067;606978;Congenital disorder of glycosylation, type IIe, 608779 (3);608779
COG8;Congenital disorder of glycosylation, type IIh;17357067;606979;Congenital disorder of glycosylation, type IIh, 611182 (3);611182
COL10A1;Metaphyseal chondrodysplasia, Schmid type;17357067;120110;Metaphyseal chondrodysplasia, Schmid type, 156500 (3);156500
COL11A1;Fibrochondrogenesis 1;17357067;120280;Fibrochondrogenesis 1, 228520 (3);228520
COL11A1;Lumbar disc herniation, susceptibility to;17357067;120280;{Lumbar disc herniation, susceptibility to}, 603932 (3);603932
COL11A1;Marshall syndrome;17357067;120280;Marshall syndrome, 154780 (3);154780
COL11A1;Stickler syndrome, type II;17357067;120280;Stickler syndrome, type II, 604841 (3);604841
COL11A2;Deafness, autosomal dominant 13;17357067;120290;Deafness, autosomal dominant 13, 601868 (3);601868
COL11A2;Deafness, autosomal recessive 53;17357067;120290;Deafness, autosomal recessive 53, 609706 (3);609706
COL11A2;Fibrochondrogenesis 2;17357067;120290;Fibrochondrogenesis 2, 614524 (3);614524
COL11A2;Otospondylomegaepiphyseal dysplasia;17357067;120290;Otospondylomegaepiphyseal dysplasia, 215150 (3);215150
COL11A2;Stickler syndrome, type III;17357067;120290;Stickler syndrome, type III, 184840 (3);184840
COL11A2;Weissenbacher-Zweymuller syndrome;17357067;120290;Weissenbacher-Zweymuller syndrome, 277610 (3);277610
COL12A1;Bethlem myopathy 2;17357067;120320;Bethlem myopathy 2, 616471 (3);616471
COL17A1;Epidermolysis bullosa, junctional, non-Herlitz type;17357067;113811;Epidermolysis bullosa, junctional, non-Herlitz type, 226650 (3);226650
COL18A1;Knobloch syndrome, type 1;17357067;120328;Knobloch syndrome, type 1, 267750 (3);267750
COL1A1;Bone mineral density variation QTL, osteoporosis;17357067;120150;{Bone mineral density variation QTL, osteoporosis}, 166710 (3);166710
COL1A1;Caffey disease;17357067;120150;Caffey disease, 114000 (3);114000
COL1A1;Ehlers-Danlos syndrome, classic;17357067;120150;Ehlers-Danlos syndrome, classic, 130000 (3);130000
COL1A1;Ehlers-Danlos syndrome, type VIIA;17357067;120150;Ehlers-Danlos syndrome, type VIIA, 130060 (3);130060
COL1A1;Osteogenesis imperfecta, type I;17357067;120150;Osteogenesis imperfecta, type I, 166200 (3);166200
COL1A1;Osteogenesis imperfecta, type II;17357067;120150;Osteogenesis imperfecta, type II, 166210 (3);166210
COL1A1;Osteogenesis imperfecta, type III;17357067;120150;Osteogenesis imperfecta, type III, 259420 (3);259420
COL1A1;Osteogenesis imperfecta, type IV;17357067;120150;Osteogenesis imperfecta, type IV, 166220 (3);166220
COL1A2;Ehlers-Danlos syndrome, cardiac valvular form;17357067;120160;Ehlers-Danlos syndrome, cardiac valvular form, 225320 (3);225320
COL1A2;Ehlers-Danlos syndrome, type VIIB;17357067;120160;Ehlers-Danlos syndrome, type VIIB, 130060 (3);130060
COL1A2;Osteogenesis imperfecta, type II;17357067;120160;Osteogenesis imperfecta, type II, 166210 (3);166210
COL1A2;Osteogenesis imperfecta, type III;17357067;120160;Osteogenesis imperfecta, type III, 259420 (3);259420
COL1A2;Osteogenesis imperfecta, type IV;17357067;120160;Osteogenesis imperfecta, type IV, 166220 (3);166220
COL1A2;Osteoporosis, postmenopausal;17357067;120160;{Osteoporosis, postmenopausal}, 166710 (3);166710
COL25A1;Fibrosis of extraocular muscles, congenital, 5;17357067;610004;Fibrosis of extraocular muscles, congenital, 5, 616219 (3);616219
COL2A1;Achondrogenesis, type II or hypochondrogenesis;17357067;120140;Achondrogenesis, type II or hypochondrogenesis, 200610 (3);200610
COL2A1;Avascular necrosis of the femoral head;17357067;120140;Avascular necrosis of the femoral head, 608805 (3);608805
COL2A1;Czech dysplasia;17357067;120140;Czech dysplasia, 609162 (3);609162
COL2A1;Epiphyseal dysplasia, multiple, with myopia and deafness;17357067;120140;Epiphyseal dysplasia, multiple, with myopia and deafness, 132450 (3);132450
COL2A1;Kniest dysplasia;17357067;120140;Kniest dysplasia, 156550 (3);156550
COL2A1;Legg-Calve-Perthes disease;17357067;120140;Legg-Calve-Perthes disease, 150600 (3);150600
COL2A1;Osteoarthritis with mild chondrodysplasia;17357067;120140;Osteoarthritis with mild chondrodysplasia, 604864 (3);604864
COL2A1;Otospondylomegaepiphyseal dysplasia;17357067;120140;Otospondylomegaepiphyseal dysplasia, 215150 (3);215150
COL2A1;Platyspondylic skeletal dysplasia, Torrance type;17357067;120140;Platyspondylic skeletal dysplasia, Torrance type, 151210 (3);151210
COL2A1;SED congenita;17357067;120140;SED congenita, 183900 (3);183900
COL2A1;SED, Namaqualand type;17357067;120140;SED, Namaqualand type (3);0
COL2A1;SMED Strudwick type;17357067;120140;SMED Strudwick type, 184250 (3);184250
COL2A1;Spondyloperipheral dysplasia;17357067;120140;Spondyloperipheral dysplasia, 271700 (3);271700
COL2A1;Stickler sydrome, type I, nonsyndromic ocular;17357067;120140;Stickler sydrome, type I, nonsyndromic ocular, 609508 (3);609508
COL2A1;Stickler syndrome, type I;17357067;120140;Stickler syndrome, type I, 108300 (3);108300
COL2A1;Vitreoretinopathy with phalangeal epiphyseal dysplasia;17357067;120140;Vitreoretinopathy with phalangeal epiphyseal dysplasia (3);0
COL3A1;Ehlers-Danlos syndrome, type III;17357067;120180;Ehlers-Danlos syndrome, type III, 130020 (3);130020
COL3A1;Ehlers-Danlos syndrome, type IV;17357067;120180;Ehlers-Danlos syndrome, type IV, 130050 (3);130050
COL4A1;Angiopathy, hereditary, with nephropathy, aneurysms, and muscle cramps;17357067;120130;Angiopathy, hereditary, with nephropathy, aneurysms, and muscle cramps, 611773 (3);611773
COL4A1;Brain small vessel disease with or without ocular anomalies;17357067;120130;Brain small vessel disease with or without ocular anomalies, 607595 (3);607595
COL4A1;Hemorrhage, intracerebral, susceptibility to;17357067;120130;{Hemorrhage, intracerebral, susceptibility to}, 614519 (3);614519
COL4A1;Porencephaly 1;17357067;120130;Porencephaly 1, 175780 (3);175780
COL4A2;Hemorrhage, intracerebral, susceptibility to;17357067;120090;{Hemorrhage, intracerebral, susceptibility to}, 614519 (3);614519
COL4A2;Porencephaly 2;17357067;120090;Porencephaly 2, 614483 (3);614483
COL4A3;Alport syndrome, autosomal dominant;17357067;120070;Alport syndrome, autosomal dominant, 104200 (3);104200
COL4A3;Alport syndrome, autosomal recessive;17357067;120070;Alport syndrome, autosomal recessive, 203780 (3);203780
COL4A3;Hematuria, benign familial;17357067;120070;Hematuria, benign familial, 141200 (3);141200
COL4A3BP;Mental retardation, autosomal dominant 34;17357067;604677;Mental retardation, autosomal dominant 34, 616351 (3);616351
COL4A4;Alport syndrome, autosomal recessive;17357067;120131;Alport syndrome, autosomal recessive, 203780 (3);203780
COL4A4;Hematuria, familial benign;17357067;120131;Hematuria, familial benign (3);0
COL4A5;Alport syndrome;17357067;303630;Alport syndrome, 301050 (3);301050
COL4A5;Arterial tortuosity syndrome;17357067;606145;Arterial tortuosity syndrome, 208050 (3);208050
COL5A1;Ehlers-Danlos syndrome, classic type;17357067;120215;Ehlers-Danlos syndrome, classic type, 130000 (3);130000
COL5A2;Ehlers-Danlos syndrome, classic type;17357067;120190;Ehlers-Danlos syndrome, classic type, 130000 (3);130000
COL6A1;Bethlem myopathy 1;17357067;120220;Bethlem myopathy 1, 158810 (3);158810
COL6A1;Ullrich congenital muscular dystrophy 1;17357067;120220;Ullrich congenital muscular dystrophy 1, 254090 (3);254090
COL6A2;Bethlem myopathy 1;17357067;120240;Bethlem myopathy 1, 158810 (3);158810
COL6A2;Ullrich congenital muscular dystrophy 1;17357067;120240;Ullrich congenital muscular dystrophy 1, 254090 (3);254090
COL6A3;Bethlem myopathy 1;17357067;120250;Bethlem myopathy 1, 158810 (3);158810
COL6A3;Dystonia 27;17357067;120250;Dystonia 27, 616411 (3);616411
COL6A3;Ullrich congenital muscular dystrophy 1;17357067;120250;Ullrich congenital muscular dystrophy 1, 254090 (3);254090
COL7A1;EBD inversa;17357067;120120;EBD inversa, 226600 (3);226600
COL7A1;EBD, Bart type;17357067;120120;EBD, Bart type, 132000 (3);132000
COL7A1;EBD, localisata variant;17357067;120120;EBD, localisata variant (3);0
COL7A1;Epidermolysis bullosa dystrophica, AD;17357067;120120;Epidermolysis bullosa dystrophica, AD, 131750 (3);131750
COL7A1;Epidermolysis bullosa dystrophica, AR;17357067;120120;Epidermolysis bullosa dystrophica, AR, 226600 (3);226600
COL7A1;Epidermolysis bullosa pruriginosa;17357067;120120;Epidermolysis bullosa pruriginosa, 604129 (3);604129
COL7A1;Epidermolysis bullosa, pretibial;17357067;120120;Epidermolysis bullosa, pretibial, 131850 (3);131850
COL7A1;Toenail dystrophy, isolated;17357067;120120;Toenail dystrophy, isolated, 607523 (3);607523
COL7A1;Transient bullous of the newborn;17357067;120120;Transient bullous of the newborn, 131705 (3);131705
COL8A2;Corneal dystrophy, Fuchs endothelial, 1;17357067;120252;Corneal dystrophy, Fuchs endothelial, 1, 136800 (3);136800
COL8A2;Corneal dystrophy, posterior polymorphous 2;17357067;120252;Corneal dystrophy, posterior polymorphous 2, 609140 (3);609140
COL9A1;Stickler syndrome, type IV;17357067;120210;Stickler syndrome, type IV, 614134 (3);614134
COL9A2;Epiphyseal dysplasia, multiple, 2;17357067;120260;Epiphyseal dysplasia, multiple, 2, 600204 (3);600204
COL9A2;Intervertebral disc disease, susceptibility to;17357067;120260;{Intervertebral disc disease, susceptibility to}, 603932 (3);603932
COL9A3;Epiphyseal dysplasia, multiple, 3;17357067;120270;Epiphyseal dysplasia, multiple, 3, 600969 (3);600969
COL9A3;Epiphyseal dysplasia, multiple, with myopathy;17357067;120270;Epiphyseal dysplasia, multiple, with myopathy (3);0
COL9A3;Intervertebral disc disease, susceptibility to;17357067;120270;{Intervertebral disc disease, susceptibility to}, 603932 (3);603932
COLEC11;3MC syndrome 2;17357067;612502;3MC syndrome 2, 265050 (3);265050
COLQ;Myasthenic syndrome, congenital, 5;17357067;603033;Myasthenic syndrome, congenital, 5, 603034 (3);603034
COMP;Epiphyseal dysplasia, multiple 1;17357067;600310;Epiphyseal dysplasia, multiple 1, 132400 (3);132400
COMP;Pseudoachondroplasia;17357067;600310;Pseudoachondroplasia, 177170 (3);177170
COMT;Panic disorder, susceptibility to;17357067;116790;{Panic disorder, susceptibility to}, 167870 (3);167870
COMT;Schizophrenia, susceptibility to;17357067;116790;{Schizophrenia, susceptibility to}, 181500 (3);181500
COPA;Autoimmune interstitial lung, joint, and kidney disease;17357067;601924;{Autoimmune interstitial lung, joint, and kidney disease}, 616414 (3);616414
COPRS;Ataxia with isolated vitamin E deficiency;17357067;600415;Ataxia with isolated vitamin E deficiency, 277460 (3);277460
COQ2;Coenzyme Q10 deficiency, primary, 1;17357067;609825;Coenzyme Q10 deficiency, primary, 1, 607426 (3);607426
COQ2;Multiple system atrophy, susceptibility to;17357067;609825;{Multiple system atrophy, susceptibility to}, 146500 (3);146500
COQ4;Coenzyme Q10 deficiency, primary, 7;17357067;612898;Coenzyme Q10 deficiency, primary, 7, 616276 (3);616276
COQ6;Coenzyme Q10 deficiency, primary, 6;17357067;614647;Coenzyme Q10 deficiency, primary, 6, 614650 (3);614650
COQ9;Coenzyme Q10 deficiency, primary, 5;17357067;612837;Coenzyme Q10 deficiency, primary, 5, 614654 (3);614654
CORIN;Preeclampsia/eclampsia 5;17357067;605236;Preeclampsia/eclampsia 5, 614595 (3);614595
CORO1A;Immunodeficiency 8;17357067;605000;Immunodeficiency 8, 615401 (3);615401
COX10;Leigh syndrome due to mitochondrial COX4 deficiency;17357067;602125;Leigh syndrome due to mitochondrial COX4 deficiency, 256000 (3);256000
COX10;Mitochondrial complex IV deficiency;17357067;602125;Mitochondrial complex IV deficiency, 220110 (3);220110
COX15;Cardioencephalomyopathy, fatal infantile, due to cytochrome c oxidase deficiency 2;17357067;603646;Cardioencephalomyopathy, fatal infantile, due to cytochrome c oxidase deficiency 2, 615119 (3);615119
COX15;Leigh syndrome due to cytochrome c oxidase deficiency;17357067;603646;Leigh syndrome due to cytochrome c oxidase deficiency, 256000 (3);256000
COX20;Mitochondrial complex IV deficiency;17357067;614698;Mitochondrial complex IV deficiency, 220110 (3);220110
COX4I2;Exocrine pancreatic insufficiency, dyserythropoietic anemia, and calvarial hyperostosis;17357067;607976;Exocrine pancreatic insufficiency, dyserythropoietic anemia, and calvarial hyperostosis, 612714 (3);612714
COX6A1;Charcot-Marie-Tooth disease, recessive intermediate D;17357067;602072;Charcot-Marie-Tooth disease, recessive intermediate D, 616039 (3);616039
COX7B;Linear skin defects with multiple congenital anomalies;17357067;300885;Linear skin defects with multiple congenital anomalies, 300887 (3);300887
CP;Cerebellar ataxia;17357067;117700;Cerebellar ataxia, 604290 (3);604290
CP;Hemosiderosis, systemic, due to aceruloplasminemia;17357067;117700;Hemosiderosis, systemic, due to aceruloplasminemia, 604290 (3);604290
CP;Hypoceruloplasminemia, hereditary;17357067;117700;[Hypoceruloplasminemia, hereditary], 604290 (3);604290
CPA6;Epilepsy, familial temporal lobe, 5;17357067;609562;Epilepsy, familial temporal lobe, 5, 614417 (3);614417
CPA6;Febrile seizures, familial, 11;17357067;609562;Febrile seizures, familial, 11, 614418 (3);614418
CPN1;Carboxypeptidase N deficiency;17357067;603103;Carboxypeptidase N deficiency, 212070 (3);212070
CPOX;Coproporphyria;17357067;612732;Coproporphyria, 121300 (3);121300
CPOX;Harderoporphyria;17357067;612732;Harderoporphyria, 121300 (3);121300
CPS1;Carbamoylphosphate synthetase I deficiency;17357067;608307;Carbamoylphosphate synthetase I deficiency, 237300 (3);237300
CPS1;Pulmonary hypertension, neonatal, susceptibility to;17357067;608307;{Pulmonary hypertension, neonatal, susceptibility to}, 615371 (3);615371
CPS1;Venoocclusive disease after bone marrow transplantation;17357067;608307;{Venoocclusive disease after bone marrow transplantation} (3);0
CPT1A;CPT deficiency, hepatic, type IA;17357067;600528;CPT deficiency, hepatic, type IA, 255120 (3);255120
CPT2;CPT II deficiency, lethal neonatal;17357067;600650;CPT II deficiency, lethal neonatal, 608836 (3);608836
CPT2;CPT deficiency, hepatic, type II;17357067;600650;CPT deficiency, hepatic, type II, 600649 (3);600649
CPT2;Encephalopathy, acute, infection-induced, 4, susceptibility to;17357067;600650;{Encephalopathy, acute, infection-induced, 4, susceptibility to}, 614212 (3);614212
CPT2;Myopathy due to CPT II deficiency;17357067;600650;Myopathy due to CPT II deficiency, 255110 (3);255110
CR1;Blood group, Knops system;17357067;120620;[Blood group, Knops system], 607486 (3);607486
CR1;CR1 deficiency;17357067;120620;CR1 deficiency (1);0
CR1;Malaria, severe, resistance to;17357067;120620;{Malaria, severe, resistance to}, 611162 (3);611162
CR2;Immunodeficiency, common variable, 7;17357067;120650;Immunodeficiency, common variable, 7, 614699 (3);614699
CR2;Systemic lupus erythematosus, susceptibility to, 9;17357067;120650;{Systemic lupus erythematosus, susceptibility to, 9}, 610927 (3);610927
CRADD;Mental retardation, autosomal recessive 34;17357067;603454;Mental retardation, autosomal recessive 34, 614499 (3);614499
CRB1;Leber congenital amaurosis 8;17357067;604210;Leber congenital amaurosis 8, 613835 (3);613835
CRB1;Pigmented paravenous chorioretinal atrophy;17357067;604210;Pigmented paravenous chorioretinal atrophy, 172870 (3);172870
CRB1;Retinitis pigmentosa-12, autosomal recessive;17357067;604210;Retinitis pigmentosa-12, autosomal recessive, 600105 (3);600105
CRB2;Focal segmental glomerulosclerosis 9;17357067;609720;Focal segmental glomerulosclerosis 9, 616220 (3);616220
CRB2;Ventriculomegaly with cystic kidney disease;17357067;609720;Ventriculomegaly with cystic kidney disease, 219730 (3);219730
CRBN;Mental retardation, autosomal recessive 2;17357067;609262;Mental retardation, autosomal recessive 2, 607417 (3);607417
CREB1;Histiocytoma, angiomatoid fibrous, somatic;17357067;123810;Histiocytoma, angiomatoid fibrous, somatic, 612160 (3);612160
CREBBP;Rubinstein-Taybi syndrome;17357067;600140;Rubinstein-Taybi syndrome, 180849 (3);180849
CRELD1;Atrioventricular septal defect, partial, with heterotaxy syndrome;17357067;607170;Atrioventricular septal defect, partial, with heterotaxy syndrome, 606217 (3);606217
CRELD1;Atrioventricular septal defect, susceptibility to, 2;17357067;607170;{Atrioventricular septal defect, susceptibility to, 2}, 606217 (3);606217
CRIPT;Short stature with microcephaly and distinctive facies;17357067;604594;Short stature with microcephaly and distinctive facies, 615789 (3);615789
CRISP3;Craniosynostosis 3;17357067;600480;Craniosynostosis 3, 615314 (3);615314
CRISP3;Craniosynostosis, Adelaide type;17357067;600593;Craniosynostosis, Adelaide type (2);0
CRLF1;Cold-induced sweating syndrome 1;17357067;604237;Cold-induced sweating syndrome 1, 272430 (3);272430
CRTAP;Osteogenesis imperfecta, type VII;17357067;605497;Osteogenesis imperfecta, type VII, 610682 (3);610682
CRTC1;Mucoepidermoid salivary gland carcinoma;17357067;607536;Mucoepidermoid salivary gland carcinoma (3);0
CRX;Cone-rod retinal dystrophy-2;17357067;602225;Cone-rod retinal dystrophy-2, 120970 (3);120970
CRX;Leber congenital amaurosis 7;17357067;602225;Leber congenital amaurosis 7, 613829 (3);613829
CRYAA;Cataract 9, multiple types;17357067;123580;Cataract 9, multiple types, 604219 (3);604219
CRYAB;Cardiomyopathy, dilated, 1II;17357067;123590;Cardiomyopathy, dilated, 1II, 615184 (3);615184
CRYAB;Cataract 16, multiple types;17357067;123590;Cataract 16, multiple types, 613763 (3);613763
CRYAB;Myopathy, myofibrillar, 2;17357067;123590;Myopathy, myofibrillar, 2, 608810 (3);608810
CRYAB;Myopathy, myofibrillar, fatal infantile hypertrophy, alpha-B crystallin-related;17357067;123590;Myopathy, myofibrillar, fatal infantile hypertrophy, alpha-B crystallin-related, 613869 (3);613869
CRYBA1;Cataract 10, multiple types;17357067;123610;Cataract 10, multiple types, 600881 (3);600881
CRYBA4;Cataract 23;17357067;123631;Cataract 23, 610425 (3);610425
CRYBB1;Cataract 17, multiple types;17357067;600929;Cataract 17, multiple types, 611544 (3);611544
CRYBB2;Cataract 3, multiple types;17357067;123620;Cataract 3, multiple types, 601547 (3);601547
CRYBB3;Cataract 22, autosomal recessive;17357067;123630;Cataract 22, autosomal recessive, 609741 (3);609741
CRYGB;Cataract 39, multiple types, autosomal dominant;17357067;123670;Cataract 39, multiple types, autosomal dominant, 615188 (3);615188
CRYGC;Cataract 2, multiple types;17357067;123680;Cataract 2, multiple types, 604307 (3);604307
CRYGD;Cataract 4, multiple types;17357067;123690;Cataract 4, multiple types, 115700 (3);115700
CRYGEP;Cataract 2, multiple types;17357067;123680;Cataract 2, multiple types, 604307 (3);604307
CRYGS;Cataract 20, multiple types;17357067;123730;Cataract 20, multiple types, 116100 (3);116100
CRYM;Deafness, autosomal dominant 40;17357067;123740;Deafness, autosomal dominant 40, 616357 (3);616357
CSAD;Corneal dystrophy, Avellino type;17357067;601692;Corneal dystrophy, Avellino type, 607541 (3);607541
CSAD;Corneal dystrophy, Groenouw type I;17357067;601692;Corneal dystrophy, Groenouw type I, 121900 (3);121900
CSAD;Corneal dystrophy, Reis-Bucklers type;17357067;601692;Corneal dystrophy, Reis-Bucklers type, 608470 (3);608470
CSAD;Corneal dystrophy, Thiel-Behnke type;17357067;601692;Corneal dystrophy, Thiel-Behnke type, 602082 (3);602082
CSAD;Corneal dystrophy, epithelial basement membrane;17357067;601692;Corneal dystrophy, epithelial basement membrane, 121820 (3);121820
CSAD;Corneal dystrophy, lattice type I;17357067;601692;Corneal dystrophy, lattice type I, 122200 (3);122200
CSAD;Corneal dystrophy, lattice type IIIA;17357067;601692;Corneal dystrophy, lattice type IIIA, 608471 (3);608471
CSAD;Prostate cancer, susceptibility to;17357067;602759;{Prostate cancer, susceptibility to}, 176807 (2);176807
CSF1R;Leukoencephalopathy, diffuse hereditary, with spheroids;17357067;164770;Leukoencephalopathy, diffuse hereditary, with spheroids, 221820 (3);221820
CSF2RA;Surfactant metabolism dysfunction, pulmonary, 4;17357067;306250;Surfactant metabolism dysfunction, pulmonary, 4, 300770 (3);300770
CSF2RB;Surfactant metabolism dysfunction, pulmonary, 5;17357067;138981;Surfactant metabolism dysfunction, pulmonary, 5, 614370 (3);614370
CSH1;Placental lactogen deficiency;17357067;150200;[Placental lactogen deficiency] (1);0
CSNK1D;Advanced sleep-phase syndrome, familial, 2;17357067;600864;Advanced sleep-phase syndrome, familial, 2, 615224 (3);615224
CSPP1;Joubert syndrome 21;17357067;611654;Joubert syndrome 21, 615636 (3);615636
CSRP3;Cardiomyopathy, hypertrophic, 12;17357067;600824;Cardiomyopathy, hypertrophic, 12, 612124 (3);612124
CST3;Cerebral amyloid angiopathy;17357067;604312;Cerebral amyloid angiopathy, 105150 (3);105150
CST3;Macular degeneration, age-related, 11;17357067;604312;Macular degeneration, age-related, 11, 611953 (3);611953
CSTA;Exfoliative ichthyosis, autosomal recessive, ichthyosis bullosa of Siemens-like;17357067;184600;Exfoliative ichthyosis, autosomal recessive, ichthyosis bullosa of Siemens-like, 607936 (3);607936
CSTB;Epilepsy, progressive myoclonic 1A (Unverricht and Lundborg);17357067;601145;Epilepsy, progressive myoclonic 1A (Unverricht and Lundborg), 254800 (3);254800
CTC1;Cerebroretinal microangiopathy with calcifications and cysts;17357067;613129;Cerebroretinal microangiopathy with calcifications and cysts, 612199 (3);612199
CTCF;Mental retardation, autosomal dominant 21;17357067;604167;Mental retardation, autosomal dominant 21, 615502 (3);615502
CTDP1;Congenital cataracts, facial dysmorphism, and neuropathy;17357067;604927;Congenital cataracts, facial dysmorphism, and neuropathy, 604168 (3);604168
CTDP1;Fetal hemoglobin quantitative trait locus 3;17357067;305435;Fetal hemoglobin quantitative trait locus 3 (2);0
CTDSP2;Osteoarthritis susceptibility 4;17357067;610839;{Osteoarthritis susceptibility 4} (2);0
CTDSPL;Pregnancy loss, susceptibility to;17357067;604759;{Pregnancy loss, susceptibility to} (3);0
CTDSPL;Spermatogenic failure 4;17357067;604759;Spermatogenic failure 4, 270960 (3);270960
CTH;Cystathioninuria;17357067;607657;Cystathioninuria, 219500 (3);219500
CTH;Homocysteine, total plasma, elevated;17357067;607657;Homocysteine, total plasma, elevated (3);0
CTHRC1;Barrett esophagus/esophageal adenocarcinoma;17357067;610635;Barrett esophagus/esophageal adenocarcinoma, 614266 (3);614266
CTLA4;Autoimmune lymphoproliferative syndrome, type V;17357067;123890;Autoimmune lymphoproliferative syndrome, type V, 616100 (3);616100
CTLA4;Celiac disease, susceptibility to, 3;17357067;123890;{Celiac disease, susceptibility to, 3}, 609755 (3);609755
CTLA4;Diabetes mellitus, insulin-dependent, 12;17357067;123890;{Diabetes mellitus, insulin-dependent, 12}, 601388 (3);601388
CTLA4;Hashimoto thyroiditis;17357067;123890;{Hashimoto thyroiditis}, 140300 (3);140300
CTLA4;Systemic lupus erythematosus, susceptibility to;17357067;123890;{Systemic lupus erythematosus, susceptibility to}, 152700 (3);152700
CTNNA3;Arrhythmogenic right ventricular dysplasia, familial, 13;17357067;607667;Arrhythmogenic right ventricular dysplasia, familial, 13, 615616 (3);615616
CTNNB1;Colorectal cancer, somatic;17357067;116806;Colorectal cancer, somatic, 114500 (3);114500
CTNNB1;Hepatocellular carcinoma, somatic;17357067;116806;Hepatocellular carcinoma, somatic, 114550 (3);114550
CTNNB1;Mental retardation, autosomal dominant 19;17357067;116806;Mental retardation, autosomal dominant 19, 615075 (3);615075
CTNNB1;Ovarian cancer, somatic;17357067;116806;Ovarian cancer, somatic, 167000 (3);167000
CTNNB1;Pilomatricoma, somatic;17357067;116806;Pilomatricoma, somatic, 132600 (3);132600
CTNS;Cystinosis, atypical nephropathic;17357067;606272;Cystinosis, atypical nephropathic, 219800 (3);219800
CTNS;Cystinosis, late-onset juvenile or adolescent nephropathic;17357067;606272;Cystinosis, late-onset juvenile or adolescent nephropathic, 219900 (3);219900
CTNS;Cystinosis, nephropathic;17357067;606272;Cystinosis, nephropathic, 219800 (3);219800
CTNS;Cystinosis, ocular nonnephropathic;17357067;606272;Cystinosis, ocular nonnephropathic, 219750 (3);219750
CTPS1;Immunodeficiency 24;17357067;123860;Immunodeficiency 24, 615897 (3);615897
CTRC;Pancreatitis, chronic, susceptibility to;17357067;601405;{Pancreatitis, chronic, susceptibility to}, 167800 (3);167800
CTSA;Galactosialidosis;17357067;613111;Galactosialidosis, 256540 (3);256540
CTSC;Haim-Munk syndrome;17357067;602365;Haim-Munk syndrome, 245010 (3);245010
CTSC;Papillon-Lefevre syndrome;17357067;602365;Papillon-Lefevre syndrome, 245000 (3);245000
CTSC;Periodontitis 1, juvenile;17357067;602365;Periodontitis 1, juvenile, 170650 (3);170650
CTSD;Ceroid lipofuscinosis, neuronal, 10;17357067;116840;Ceroid lipofuscinosis, neuronal, 10, 610127 (3);610127
CTSF;Ceroid lipofuscinosis, neuronal, 13, Kufs type;17357067;603539;Ceroid lipofuscinosis, neuronal, 13, Kufs type, 615362 (3);615362
CTSK;Pycnodysostosis;17357067;601105;Pycnodysostosis, 265800 (3);265800
CUBN;Megaloblastic anemia-1, Finnish type;17357067;602997;Megaloblastic anemia-1, Finnish type, 261100 (3);261100
CUL3;Pseudohypoaldosteronism, type IIE;17357067;603136;Pseudohypoaldosteronism, type IIE, 614496 (3);614496
CUL4B;Mental retardation, X-linked, syndromic 15 (Cabezas type);17357067;300304;Mental retardation, X-linked, syndromic 15 (Cabezas type), 300354 (3);300354
CUL7;3-M syndrome 1;17357067;609577;3-M syndrome 1, 273750 (3);273750
CX3CR1;Coronary artery disease, resistance to;17357067;601470;{Coronary artery disease, resistance to}, 607339 (3);607339
CX3CR1;Macular degeneration, age-related, 12;17357067;601470;{Macular degeneration, age-related, 12}, 613784 (3);613784
CX3CR1;Rapid progression to AIDS from HIV1 infection;17357067;601470;{Rapid progression to AIDS from HIV1 infection}, 609423 (3);609423
CXCL12;AIDS, resistance to;17357067;600835;{AIDS, resistance to}, 609423 (3);609423
CXCR1;AIDS, slow progression to;17357067;146929;{AIDS, slow progression to}, 609423 (3);609423
CXCR4;Myelokathexis, isolated;17357067;162643;Myelokathexis, isolated (3);0
CXCR4;WHIM syndrome;17357067;162643;WHIM syndrome, 193670 (3);193670
CYB5A;Methemoglobinemia, type IV;17357067;613218;Methemoglobinemia, type IV, 250790 (3);250790
CYB5R3;Methemoglobinemia, type I;17357067;613213;Methemoglobinemia, type I, 250800 (3);250800
CYB5R3;Methemoglobinemia, type II;17357067;613213;Methemoglobinemia, type II, 250800 (3);250800
CYBA;Chronic granulomatous disease, autosomal, due to deficiency of CYBA;17357067;608508;Chronic granulomatous disease, autosomal, due to deficiency of CYBA, 233690 (3);233690
CYBB;Chronic granulomatous disease, X-linked;17357067;300481;Chronic granulomatous disease, X-linked, 306400 (3);306400
CYBB;Immunodeficiency 34, mycobacteriosis, X-linked;17357067;300481;Immunodeficiency 34, mycobacteriosis, X-linked, 300645 (3);300645
CYC1;Mitochondrial complex III deficiency, nuclear type 6;17357067;123980;Mitochondrial complex III deficiency, nuclear type 6, 615453 (3);615453
CYCS;Thrombocytopenia 4;17357067;123970;Thrombocytopenia 4, 612004 (3);612004
CYLD;Brooke-Spiegler syndrome;17357067;605018;Brooke-Spiegler syndrome, 605041 (3);605041
CYLD;Cylindromatosis, familial;17357067;605018;Cylindromatosis, familial, 132700 (3);132700
CYLD;Trichoepithelioma, multiple familial, 1;17357067;605018;Trichoepithelioma, multiple familial, 1, 601606 (3);601606
CYP11A1;Adrenal insufficiency, congenital, with 46XY sex reversal, partial or complete;17357067;118485;Adrenal insufficiency, congenital, with 46XY sex reversal, partial or complete, 613743 (3);613743
CYP11B1;Adrenal hyperplasia, congenital, due to 11-beta-hydroxylase deficiency;17357067;610613;Adrenal hyperplasia, congenital, due to 11-beta-hydroxylase deficiency, 202010 (3);202010
CYP11B1;Aldosteronism, glucocorticoid-remediable;17357067;610613;Aldosteronism, glucocorticoid-remediable, 103900 (3);103900
CYP11B2;Aldosterone to renin ratio raised;17357067;124080;Aldosterone to renin ratio raised (3);0
CYP11B2;Hypoaldosteronism, congenital, due to CMO I deficiency;17357067;124080;Hypoaldosteronism, congenital, due to CMO I deficiency, 203400 (3);203400
CYP11B2;Hypoaldosteronism, congenital, due to CMO II deficiency;17357067;124080;Hypoaldosteronism, congenital, due to CMO II deficiency, 610600 (3);610600
CYP11B2;Low renin hypertension, susceptibility to;17357067;124080;{Low renin hypertension, susceptibility to} (3);0
CYP17A1;17,20-lyase deficiency, isolated;17357067;609300;17,20-lyase deficiency, isolated, 202110 (3);202110
CYP17A1;17-alpha-hydroxylase/17,20-lyase deficiency;17357067;609300;17-alpha-hydroxylase/17,20-lyase deficiency, 202110 (3);202110
CYP19A1;Aromatase deficiency;17357067;107910;Aromatase deficiency, 613546 (3);613546
CYP19A1;Aromatase excess syndrome;17357067;107910;Aromatase excess syndrome, 139300 (3);139300
CYP1B1;Glaucoma 3A, primary open angle, congenital, juvenile, or adult onset;17357067;601771;Glaucoma 3A, primary open angle, congenital, juvenile, or adult onset, 231300 (3);231300
CYP1B1;Peters anomaly;17357067;601771;Peters anomaly, 604229 (3);604229
CYP21A2;Adrenal hyperplasia, congenital, due to 21-hydroxylase deficiency;17357067;613815;Adrenal hyperplasia, congenital, due to 21-hydroxylase deficiency, 201910 (3);201910
CYP21A2;Hyperandrogenism, nonclassic type, due to 21-hydroxylase deficiency;17357067;613815;Hyperandrogenism, nonclassic type, due to 21-hydroxylase deficiency, 201910 (3);201910
CYP24A1;Hypercalcemia, infantile;17357067;126065;Hypercalcemia, infantile, 143880 (3);143880
CYP26B1;Craniosynostosis with radiohumeral fusions and other skeletal and craniofacial anomalies;17357067;605207;Craniosynostosis with radiohumeral fusions and other skeletal and craniofacial anomalies, 614416 (3);614416
CYP26C1;Focal facial dermal dysplasia 4;17357067;608428;Focal facial dermal dysplasia 4, 614974 (3);614974
CYP27A1;Cerebrotendinous xanthomatosis;17357067;606530;Cerebrotendinous xanthomatosis, 213700 (3);213700
CYP27B1;Vitamin D-dependent rickets, type I;17357067;609506;Vitamin D-dependent rickets, type I, 264700 (3);264700
CYP2A;Coumarin resistance;17357067;122720;Coumarin resistance, 122700 (3);122700
CYP2A;Lung cancer, resistance to;17357067;122720;{Lung cancer, resistance to}, 211980 (3);211980
CYP2A;Nicotine addiction, protection from;17357067;122720;{Nicotine addiction, protection from}, 188890 (3);188890
CYP2A6;Coumarin resistance;17357067;122720;Coumarin resistance, 122700 (3);122700
CYP2A6;Lung cancer, resistance to;17357067;122720;{Lung cancer, resistance to}, 211980 (3);211980
CYP2A6;Nicotine addiction, protection from;17357067;122720;{Nicotine addiction, protection from}, 188890 (3);188890
CYP2B6;Efavirenz central nervous system toxicity, susceptibility to;17357067;123930;{Efavirenz central nervous system toxicity, susceptibility to}, 614546 (3);614546
CYP2B6;Efavirenz, poor metabolism of;17357067;123930;Efavirenz, poor metabolism of, 614546 (3);614546
CYP2C19;Clopidogrel, impaired responsiveness to;17357067;124020;Clopidogrel, impaired responsiveness to, 609535 (3);609535
CYP2C19;Mephenytoin poor metabolizer;17357067;124020;Mephenytoin poor metabolizer, 609535 (3);609535
CYP2C19;Opremazole poor metabolizer;17357067;124020;Opremazole poor metabolizer, 609535 (3);609535
CYP2C19;Proguanil poor metabolizer;17357067;124020;Proguanil poor metabolizer, 609535 (3);609535
CYP2C8;Rhabdomyolysis, cerivastatin-induced;17357067;601129;Rhabdomyolysis, cerivastatin-induced (3);0
CYP2C9;Tolbutamide poor metabolizer;17357067;601130;Tolbutamide poor metabolizer (3);0
CYP2C9;Warfarin sensitivity;17357067;601130;Warfarin sensitivity, 122700 (3);122700
CYP2D6;Codeine sensitivity;17357067;124030;{Codeine sensitivity}, 608902 (3);608902
CYP2D6;Debrisoquine sensitivity;17357067;124030;{Debrisoquine sensitivity}, 608902 (3);608902
CYP2R1;Rickets due to defect in vitamin D 25-hydroxylation;17357067;608713;Rickets due to defect in vitamin D 25-hydroxylation, 600081 (3);600081
CYP2U1;Spastic paraplegia 49, autosomal recessive;17357067;615000;Spastic paraplegia 49, autosomal recessive, 615031 (3);615031
CYP2U1;Spastic paraplegia 56, autosomal recessive;17357067;610670;Spastic paraplegia 56, autosomal recessive, 615030 (3);615030
CYP3A5;Hypertension, salt-sensitive essential, susceptibility to;17357067;605325;{Hypertension, salt-sensitive essential, susceptibility to}, 145500 (3);145500
CYP4F22;Ichthyosis, congenital, autosomal recessive 5;17357067;611495;Ichthyosis, congenital, autosomal recessive 5, 604777 (3);604777
CYP4V2;Bietti crystalline corneoretinal dystrophy;17357067;608614;Bietti crystalline corneoretinal dystrophy, 210370 (3);210370
CYP7B1;Bile acid synthesis defect, congenital, 3;17357067;603711;Bile acid synthesis defect, congenital, 3, 613812 (3);613812
CYP7B1;Spastic paraplegia 5A, autosomal recessive;17357067;603711;Spastic paraplegia 5A, autosomal recessive, 270800 (3);270800
D2HGDH;D-2-hydroxyglutaric aciduria;17357067;609186;D-2-hydroxyglutaric aciduria, 600721 (3);600721
DAB1;Ciliary dyskinesia, primary, 2;17357067;614566;Ciliary dyskinesia, primary, 2, 606763 (3);606763
DAG1;Muscular dystrophy-dystroglycanopathy (limb-girdle), type C, 9;17357067;128239;Muscular dystrophy-dystroglycanopathy (limb-girdle), type C, 9, 613818 (3);613818
DAO;Schizophrenia;17357067;124050;{Schizophrenia}, 181500 (2);181500
DAOA;Schizophrenia;17357067;607408;{Schizophrenia}, 181500 (2);181500
DARS;Hypomyelination with brainstem and spinal cord involvement and leg spasticity;17357067;603084;Hypomyelination with brainstem and spinal cord involvement and leg spasticity, 615281 (3);615281
DARS2;Leukoencephalopathy with brain stem and spinal cord involvement and lactate elevation;17357067;610956;Leukoencephalopathy with brain stem and spinal cord involvement and lactate elevation, 611105 (3);611105
DAZL;Spermatogenic failure, susceptibility to;17357067;601486;{Spermatogenic failure, susceptibility to} (3);0
DBH;Dopamine beta-hydroxylase deficiency;17357067;609312;Dopamine beta-hydroxylase deficiency, 223360 (3);223360
DBH;Dopamine-beta-hydroxylase activity levels, plasma;17357067;609312;[Dopamine-beta-hydroxylase activity levels, plasma] (3);0
DBH;Leukemia, chronic lymphocytic, susceptibility to, 2;17357067;109543;{Leukemia, chronic lymphocytic, susceptibility to, 2} (2);0
DBT;Maple syrup urine disease, type II;17357067;248610;Maple syrup urine disease, type II, 248600 (3);248600
DCAF17;Woodhouse-Sakati syndrome;17357067;612515;Woodhouse-Sakati syndrome, 241080 (3);241080
DCC;Colorectal cancer, somatic;17357067;120470;Colorectal cancer, somatic, 114500 (3);114500
DCC;Esophageal carcinoma, somatic;17357067;120470;Esophageal carcinoma, somatic 133239 (3);133239
DCC;Mirror movements 1;17357067;120470;Mirror movements 1, 157600 (3);157600
DCDC2;Nephronophthisis 19;17357067;605755;Nephronophthisis 19, 616217 (3);616217
DCHS1;Van Maldergem syndrome 1;17357067;603057;Van Maldergem syndrome 1, 601390 (3);601390
DCLRE1C;Omenn syndrome;17357067;605988;Omenn syndrome, 603554 (3);603554
DCLRE1C;Severe combined immunodeficiency, Athabascan type;17357067;605988;Severe combined immunodeficiency, Athabascan type, 602450 (3);602450
DCN;Corneal dystrophy, congenital stromal;17357067;125255;Corneal dystrophy, congenital stromal, 610048 (3);610048
DCPS;Al-Raqad syndrome;17357067;610534;Al-Raqad syndrome, 616459 (3);616459
DCR;Down syndrome;17357067;190685;Down syndrome (4);0
DCTN1;Amyotrophic lateral sclerosis, susceptibility to;17357067;601143;{Amyotrophic lateral sclerosis, susceptibility to}, 105400 (3);105400
DCTN1;Neuropathy, distal hereditary motor, type VIIB;17357067;601143;Neuropathy, distal hereditary motor, type VIIB, 607641 (3);607641
DCTN1;Perry syndrome;17357067;601143;Perry syndrome, 168605 (3);168605
DCX;Lissencephaly, X-linked;17357067;300121;Lissencephaly, X-linked, 300067 (3);300067
DCX;Subcortical laminal heteropia, X-linked;17357067;300121;Subcortical laminal heteropia, X-linked, 300067 (3);300067
DCXR;Pentosuria;17357067;608347;[Pentosuria], 260800 (3);260800
DDB2;Xeroderma pigmentosum, group E, DDB-negative subtype;17357067;600811;Xeroderma pigmentosum, group E, DDB-negative subtype, 278740 (3);278740
DDC;Aromatic L-amino acid decarboxylase deficiency;17357067;107930;Aromatic L-amino acid decarboxylase deficiency, 608643 (3);608643
DDHD1;Spastic paraplegia 28, autosomal recessive;17357067;614603;Spastic paraplegia 28, autosomal recessive, 609340 (3);609340
DDHD2;Spastic paraplegia 54, autosomal recessive;17357067;615003;Spastic paraplegia 54, autosomal recessive, 615033 (3);615033
DDIT3;Myxoid liposarcoma;17357067;126337;Myxoid liposarcoma, 613488 (1);613488
DDR2;Spondylometaepiphyseal dysplasia, short limb-hand type;17357067;191311;Spondylometaepiphyseal dysplasia, short limb-hand type, 271665 (3);271665
DDX11;Warsaw breakage syndrome;17357067;601150;Warsaw breakage syndrome, 613398 (3);613398
DDX58;Singleton-Merten syndrome 2;17357067;609631;Singleton-Merten syndrome 2, 616298 (3);616298
DDX59;Orofaciodigital syndrome V;17357067;615464;Orofaciodigital syndrome V, 174300 (3);174300
DEAF1;Mental retardation, autosomal dominant 24;17357067;602635;Mental retardation, autosomal dominant 24, 615828 (3);615828
DEC1;Esophageal squamous cell carcinoma;17357067;604767;Esophageal squamous cell carcinoma, 133239 (1);133239
DEK;Leukemia, acute nonlymphocytic;17357067;125264;Leukemia, acute nonlymphocytic (2);0
DEPDC5;Epilepsy, familial focal, with variable foci;17357067;614191;Epilepsy, familial focal, with variable foci, 604364 (3);604364
DES;Cardiomyopathy, dilated, 1I;17357067;125660;Cardiomyopathy, dilated, 1I, 604765 (3);604765
DES;Myopathy, myofibrillar, 1;17357067;125660;Myopathy, myofibrillar, 1, 601419 (3);601419
DES;Scapuloperoneal syndrome, neurogenic, Kaeser type;17357067;125660;Scapuloperoneal syndrome, neurogenic, Kaeser type, 181400 (3);181400
DFNA5;Deafness, autosomal dominant 5;17357067;608798;Deafness, autosomal dominant 5, 600994 (3);600994
DFNB31;Deafness, autosomal recessive 31;17357067;607928;Deafness, autosomal recessive 31, 607084 (3);607084
DFNB31;Usher syndrome, type 2D;17357067;607928;Usher syndrome, type 2D, 611383 (3);611383
DFNB59;Deafness, autosomal recessive 59;17357067;610219;Deafness, autosomal recessive 59, 610220 (3);610220
DGCR;Conotruncal anomaly face syndrome;17357067;602054;Conotruncal anomaly face syndrome, 217095 (3);217095
DGCR;DiGeorge syndrome;17357067;602054;DiGeorge syndrome, 188400 (3);188400
DGCR;Tetralogy of Fallot;17357067;602054;Tetralogy of Fallot, 187500 (3);187500
DGCR;Velocardiofacial syndrome;17357067;602054;Velocardiofacial syndrome, 192430 (3);192430
DGCR2;Blood group, Langereis system;17357067;605452;[Blood group, Langereis system], 111600 (3);111600
DGCR2;DiGeorge syndrome/velocardiofacial syndrome complex-2;17357067;601362;DiGeorge syndrome/velocardiofacial syndrome complex-2 (2);0
DGCR2;Dyschromatosis universalis hereditaria 3;17357067;605452;Dyschromatosis universalis hereditaria 3, 615402 (3);615402
DGCR2;Microphthalmia, isolated, with coloboma 7;17357067;605452;Microphthalmia, isolated, with coloboma 7, 614497 (3);614497
DGKE;Hemolytic uremic syndrome, atypical, susceptibility to, 7;17357067;601440;{Hemolytic uremic syndrome, atypical, susceptibility to, 7}, 615008 (3);615008
DGKE;Nephrotic syndrome, type 7;17357067;601440;Nephrotic syndrome, type 7, 615008 (3);615008
DGUOK;Mitochondrial DNA depletion syndrome 3 (hepatocerebral type);17357067;601465;Mitochondrial DNA depletion syndrome 3 (hepatocerebral type), 251880 (3);251880
DHCR24;Desmosterolosis;17357067;606418;Desmosterolosis, 602398 (3);602398
DHCR7;Smith-Lemli-Opitz syndrome;17357067;602858;Smith-Lemli-Opitz syndrome, 270400 (3);270400
DHDDS;Choriodal dystrophy, central areolar 2;17357067;179605;Choriodal dystrophy, central areolar 2, 613105 (3);613105
DHDDS;Leber congenital amaurosis 18;17357067;179605;Leber congenital amaurosis 18, 608133 (3);608133
DHDDS;Macular dystrophy, patterned, 1;17357067;179605;Macular dystrophy, patterned, 1, 169150 (3);169150
DHDDS;Macular dystrophy, vitelliform, 3;17357067;179605;Macular dystrophy, vitelliform, 3, 608161 (3);608161
DHDDS;Retinitis pigmentosa 59;17357067;608172;Retinitis pigmentosa 59, 613861 (3);613861
DHDDS;Retinitis pigmentosa 7 and digenic;17357067;179605;Retinitis pigmentosa 7 and digenic, 608133 (3);608133
DHDDS;Retinitis punctata albescens;17357067;179605;Retinitis punctata albescens, 136880 (3);136880
DHFR;Megaloblastic anemia due to dihydrofolate reductase deficiency;17357067;126060;Megaloblastic anemia due to dihydrofolate reductase deficiency, 613839 (3);613839
DHH;46XY partial gonadal dysgenesis, with minifascicular neuropathy;17357067;605423;46XY partial gonadal dysgenesis, with minifascicular neuropathy, 607080 (3);607080
DHH;46XY sex reversal 7;17357067;605423;46XY sex reversal 7, 233420 (3);233420
DHODH;Miller syndrome;17357067;126064;Miller syndrome, 263750 (3);263750
DHTKD1;2-aminoadipic 2-oxoadipic aciduria;17357067;614984;2-aminoadipic 2-oxoadipic aciduria, 204750 (3);204750
DIABLO;Deafness, autosomal dominant 64;17357067;605219;Deafness, autosomal dominant 64, 614152 (3);614152
DIAPH1;Deafness, autosomal dominant 1;17357067;602121;Deafness, autosomal dominant 1, 124900 (3);124900
DIAPH2;Auditory neuropathy, autosomal dominant, 1;17357067;614567;Auditory neuropathy, autosomal dominant, 1, 609129 (3);609129
DIAPH2;Premature ovarian failure;17357067;300108;Premature ovarian failure, 300511 (3);300511
DIAPH3;Auditory neuropathy, autosomal dominant, 1;17357067;614567;Auditory neuropathy, autosomal dominant, 1, 609129 (3);609129
DICER1;Goiter, multinodular 1, with or without Sertoli-Leydig cell tumors;17357067;606241;Goiter, multinodular 1, with or without Sertoli-Leydig cell tumors, 138800 (3);138800
DICER1;Pleuropulmonary blastoma;17357067;606241;Pleuropulmonary blastoma, 601200 (3);601200
DICER1;Rhabdomyosarcoma, embryonal, 2;17357067;606241;Rhabdomyosarcoma, embryonal, 2, 180295 (3);180295
DIP2B;Mental retardation, FRA12A type;17357067;611379;Mental retardation, FRA12A type, 136630 (3);136630
DIRC2;Renal cell carcinoma;17357067;602773;Renal cell carcinoma, 144700 (2);144700
DIS3L2;Perlman syndrome;17357067;614184;Perlman syndrome, 267000 (3);267000
DISC1;Schizoaffective disorder, susceptibility to;17357067;605210;{Schizoaffective disorder, susceptibility to}, 181500 (3);181500
DISC1;Schizophrenia, susceptibility to;17357067;605210;{Schizophrenia, susceptibility to}, 604906 (3);604906
DISC2;Schizophrenia;17357067;606271;Schizophrenia, 181500 (2);181500
DKC1;Dyskeratosis congenita, X-linked;17357067;300126;Dyskeratosis congenita, X-linked, 305000 (3);305000
DLAT;Pyruvate dehydrogenase E2 deficiency;17357067;608770;Pyruvate dehydrogenase E2 deficiency, 245348 (3);245348
DLC1;Colorectal cancer, somatic;17357067;604258;Colorectal cancer, somatic, 114500 (3);114500
DLC1;Esophageal cancer;17357067;604050;Esophageal cancer, 133239 (1);133239
DLC1;Lung cancer;17357067;604050;Lung cancer, 211980 (1);211980
DLD;Dihydrolipoamide dehydrogenase deficiency;17357067;238331;Dihydrolipoamide dehydrogenase deficiency, 246900 (3);246900
DLD;Leukocyte adhesion deficiency;17357067;600065;Leukocyte adhesion deficiency, 116920 (3);116920
DLEC1;Esophageal cancer;17357067;604050;Esophageal cancer, 133239 (1);133239
DLEC1;Lung cancer;17357067;604050;Lung cancer, 211980 (1);211980
DLG3;Mental retardation, X-linked 90;17357067;300189;Mental retardation, X-linked 90, 300850 (3);300850
DLK1;Fanconi anemia, complementation group A;17357067;607139;Fanconi anemia, complementation group A, 227650 (3);227650
DLL3;Spondylocostal dysostosis 1, autosomal recessive;17357067;602768;Spondylocostal dysostosis 1, autosomal recessive, 277300 (3);277300
DLX2;Dyslexia, susceptibility to, 2;17357067;609269;{Dyslexia, susceptibility to, 2}, 600202 (3);600202
DLX3;Amelogenesis imperfecta, type IV;17357067;600525;Amelogenesis imperfecta, type IV, 104510 (3);104510
DLX3;Trichodontoosseous syndrome;17357067;600525;Trichodontoosseous syndrome, 190320 (3);190320
DMD;Becker muscular dystrophy;17357067;300377;Becker muscular dystrophy, 300376 (3);300376
DMD;Cardiomyopathy, dilated, 3B;17357067;300377;Cardiomyopathy, dilated, 3B, 302045 (3);302045
DMD;Duchenne muscular dystrophy;17357067;300377;Duchenne muscular dystrophy, 310200 (3);310200
DMGDH;Dimethylglycine dehydrogenase deficiency;17357067;605849;Dimethylglycine dehydrogenase deficiency, 605850 (3);605850
DMP1;Hypophosphatemic rickets, AR;17357067;600980;Hypophosphatemic rickets, AR, 241520 (3);241520
DMPK;Myotonic dystrophy 1;17357067;605377;Myotonic dystrophy 1, 160900 (3);160900
DNA2;Progressive external ophthalmoplegia with mitochondrial DNA deletions, autosomal dominant, 6;17357067;601810;Progressive external ophthalmoplegia with mitochondrial DNA deletions, autosomal dominant, 6, 615156 (3);615156
DNAAF1;Ciliary dyskinesia, primary, 13;17357067;613190;Ciliary dyskinesia, primary, 13, 613193 (3);613193
DNAAF2;Ciliary dyskinesia, primary, 10;17357067;612517;Ciliary dyskinesia, primary, 10, 612518 (3);612518
DNAAF3;Ciliary dyskinesia, primary, 2;17357067;614566;Ciliary dyskinesia, primary, 2, 606763 (3);606763
DNAAF5;Ciliary dyskinesia, primary, 18;17357067;614864;Ciliary dyskinesia, primary, 18, 614874 (3);614874
DNAH11;Ciliary dyskinesia, primary, 7, with or without situs inversus;17357067;603339;Ciliary dyskinesia, primary, 7, with or without situs inversus, 611884 (3);611884
DNAH5;Ciliary dyskinesia, primary, 3, with or without situs inversus;17357067;603335;Ciliary dyskinesia, primary, 3, with or without situs inversus, 608644 (3);608644
DNAI1;Ciliary dyskinesia, primary, 1, with or without situs inversus;17357067;604366;Ciliary dyskinesia, primary, 1, with or without situs inversus, 244400 (3);244400
DNAI2;Ciliary dyskinesia, primary, 9, with or without situs inversus;17357067;605483;Ciliary dyskinesia, primary, 9, with or without situs inversus, 612444 (3);612444
DNAJB2;Spinal muscular atrophy, distal, autosomal recessive, 5;17357067;604139;Spinal muscular atrophy, distal, autosomal recessive, 5, 614881 (3);614881
DNAJB6;Cardiomyopathy, dilated, 1F and limb-girdle muscular dystrophy type 1D;17357067;602067;Cardiomyopathy, dilated, 1F and limb-girdle muscular dystrophy type 1D (2);0
DNAJB6;Muscular dystrophy, limb-girdle, type 1E;17357067;611332;Muscular dystrophy, limb-girdle, type 1E, 603511 (3);603511
DNAJC13;Parkinson disease 21;17357067;614334;Parkinson disease 21, 616361 (3);616361
DNAJC19;3-methylglutaconic aciduria, type V;17357067;608977;3-methylglutaconic aciduria, type V, 610198 (3);610198
DNAJC5;Ceroid lipofuscinosis, neuronal, 4, Parry type;17357067;611203;Ceroid lipofuscinosis, neuronal, 4, Parry type, 162350 (3);162350
DNAJC6;Parkinson disease 19, juvenile-onset;17357067;608375;Parkinson disease 19, juvenile-onset, 615528 (3);615528
DNAL1;Ciliary dyskinesia, primary, 16;17357067;610062;Ciliary dyskinesia, primary, 16, 614017 (3);614017
DNASE1;Systemic lupus erythematosus, susceptibility to;17357067;125505;{Systemic lupus erythematosus, susceptibility to}, 152700 (3);152700
DNASE1L3;Systemic lupus erythematosus 16;17357067;602244;Systemic lupus erythematosus 16, 614420 (3);614420
DNM1;Epileptic encephalopathy, early infantile, 31;17357067;602377;Epileptic encephalopathy, early infantile, 31, 616346 (3);616346
DNM1L;Encephalopahty, lethal, due to defective mitochondrial peroxisomal fission;17357067;603850;Encephalopahty, lethal, due to defective mitochondrial peroxisomal fission, 614388 (3);614388
DNM2;Charcot-Marie-Tooth disease, axonal, type 2M;17357067;602378;Charcot-Marie-Tooth disease, axonal, type 2M, 606482 (3);606482
DNM2;Charcot-Marie-Tooth disease, dominant intermediate B;17357067;602378;Charcot-Marie-Tooth disease, dominant intermediate B, 606482 (3);606482
DNM2;Lethal congenital contracture syndrome 5;17357067;602378;Lethal congenital contracture syndrome 5, 615368 (3);615368
DNM2;Myopathy, centronuclear;17357067;602378;Myopathy, centronuclear, 160150 (3);160150
DNMT1;Cerebellar ataxia, deafness, and narcolepsy, autosomal dominant;17357067;126375;Cerebellar ataxia, deafness, and narcolepsy, autosomal dominant, 604121 (3);604121
DNMT1;Neuropathy, hereditary sensory, type IE;17357067;126375;Neuropathy, hereditary sensory, type IE, 614116 (3);614116
DNMT3A;Tatton-Brown-Rahman syndrome;17357067;602769;Tatton-Brown-Rahman syndrome, 615879 (3);615879
DNMT3B;Immunodeficiency-centromeric instability-facial anomalies syndrome 1;17357067;602900;Immunodeficiency-centromeric instability-facial anomalies syndrome 1, 242860 (3);242860
DOCK2;Immunodeficiency 40;17357067;603122;Immunodeficiency 40, 616433 (3);616433
DOCK6;Adams-Oliver syndrome 2;17357067;614194;Adams-Oliver syndrome 2, 614219 (3);614219
DOCK7;Epileptic encephalopathy, early infantile, 23;17357067;615730;Epileptic encephalopathy, early infantile, 23, 615859 (3);615859
DOCK8;Hyper-IgE recurrent infection syndrome, autosomal recessive;17357067;611432;Hyper-IgE recurrent infection syndrome, autosomal recessive, 243700 (3);243700
DOK1;Blood group, Dombrock;17357067;110600;[Blood group, Dombrock], 616060 (3);616060
DOK7;Myasthenic syndrome, congenital, 10;17357067;610285;Myasthenic syndrome, congenital, 10, 254300 (3);254300
DOLK;Congenital disorder of glycosylation, type Im;17357067;610746;Congenital disorder of glycosylation, type Im, 610768 (3);610768
DPAGT1;Congenital disorder of glycosylation, type Ij;17357067;191350;Congenital disorder of glycosylation, type Ij, 608093 (3);608093
DPAGT1;Myasthenic syndrome, congenital, 13, with tubular aggregates;17357067;191350;Myasthenic syndrome, congenital, 13, with tubular aggregates, 614750 (3);614750
DPCR1;Panbronchiolitis, diffuse;17357067;604809;Panbronchiolitis, diffuse (2);0
DPM1;Congenital disorder of glycosylation, type Ie;17357067;603503;Congenital disorder of glycosylation, type Ie, 608799 (3);608799
DPM2;Congenital disorder of glycosylation, type Iu;17357067;603564;Congenital disorder of glycosylation, type Iu, 615042 (3);615042
DPM3;Congenital disorder of glycosylation, type Io;17357067;605951;Congenital disorder of glycosylation, type Io, 612937 (3);612937
DPP6;Mental retardation, autosomal dominant 33;17357067;126141;Mental retardation, autosomal dominant 33, 616311 (3);616311
DPP6;Ventricular fibrillation, paroxysmal familial, 2;17357067;126141;{Ventricular fibrillation, paroxysmal familial, 2}, 612956 (3);612956
DPY19L2;Spermatogenic failure 9;17357067;613893;Spermatogenic failure 9, 613958 (3);613958
DPYD;5-fluorouracil toxicity;17357067;612779;5-fluorouracil toxicity, 274270 (3);274270
DPYD;Dihydropyrimidine dehydrogenase deficiency;17357067;612779;Dihydropyrimidine dehydrogenase deficiency, 274270 (3);274270
DPYS;Dihydropyrimidinuria;17357067;613326;Dihydropyrimidinuria, 222748 (3);222748
DRAM2;Cone-rod dystrophy 21;17357067;613360;Cone-rod dystrophy 21, 616502 (3);616502
DRC1;Ciliary dyskinesia, primary, 21;17357067;615288;Ciliary dyskinesia, primary, 21, 615294 (3);615294
DRD2;Dystonia, myoclonic;17357067;126450;Dystonia, myoclonic, 159900 (3);159900
DRD3;Essential tremor, susceptibility to;17357067;126451;{Essential tremor, susceptibility to}, 190300 (3);190300
DRD3;Schizophrenia, susceptibility to;17357067;126451;{Schizophrenia, susceptibility to}, 181500 (3);181500
DRD4;Attention deficit-hyperactivity disorder;17357067;126452;{Attention deficit-hyperactivity disorder}, 143465 (3);143465
DRD4;Autonomic nervous system dysfunction;17357067;126452;Autonomic nervous system dysfunction (3);0
DRD4;Novelty seeking personality;17357067;126452;[Novelty seeking personality], 601696 (1);601696
DRD5;Attention deficit-hyperactivity disorder, susceptibility to;17357067;126453;{Attention deficit-hyperactivity disorder, susceptibility to}, 143465 (3);143465
DRD5;Blepharospasm, primary benign;17357067;126453;{Blepharospasm, primary benign}, 606798 (3);606798
DRD5;Dystonia, primary cervical;17357067;126453;Dystonia, primary cervical (3);0
DSC2;Arrhythmogenic right ventricular dysplasia 11;17357067;125645;Arrhythmogenic right ventricular dysplasia 11, 610476 (3);610476
DSC2;Arrhythmogenic right ventricular dysplasia 11 with mild palmoplantar keratoderma and woolly hair;17357067;125645;Arrhythmogenic right ventricular dysplasia 11 with mild palmoplantar keratoderma and woolly hair, 610476 (3);610476
DSC3;Arrhythmogenic right ventricular dysplasia 11;17357067;125645;Arrhythmogenic right ventricular dysplasia 11, 610476 (3);610476
DSC3;Arrhythmogenic right ventricular dysplasia 11 with mild palmoplantar keratoderma and woolly hair;17357067;125645;Arrhythmogenic right ventricular dysplasia 11 with mild palmoplantar keratoderma and woolly hair, 610476 (3);610476
DSG1;Erythroderma, congenital, with palmoplantar keratoderma, hypotrichosis, and hyper IgE;17357067;125670;Erythroderma, congenital, with palmoplantar keratoderma, hypotrichosis, and hyper IgE, 615508 (3);615508
DSG1;Keratosis palmoplantaris striata I, AD;17357067;125670;Keratosis palmoplantaris striata I, AD, 148700 (3);148700
DSG2;Arrhythmogenic right ventricular dysplasia 10;17357067;125671;Arrhythmogenic right ventricular dysplasia 10, 610193 (3);610193
DSG2;Cardiomyopathy, dilated, 1BB;17357067;125671;Cardiomyopathy, dilated, 1BB, 612877 (3);612877
DSG4;Hypotrichosis 6;17357067;607892;Hypotrichosis 6, 607903 (3);607903
DSP;Arrhythmogenic right ventricular dysplasia 8;17357067;125647;Arrhythmogenic right ventricular dysplasia 8, 607450 (3);607450
DSP;Cardiomyopathy, dilated, with woolly hair and keratoderma;17357067;125647;Cardiomyopathy, dilated, with woolly hair and keratoderma, 605676 (3);605676
DSP;Dilated cardiomyopathy with woolly hair, keratoderma, and tooth agenesis;17357067;125647;Dilated cardiomyopathy with woolly hair, keratoderma, and tooth agenesis, 615821 (3);615821
DSP;Epidermolysis bullosa, lethal acantholytic;17357067;125647;Epidermolysis bullosa, lethal acantholytic, 609638 (3);609638
DSP;Keratosis palmoplantaris striata II;17357067;125647;Keratosis palmoplantaris striata II, 612908 (3);612908
DSP;Skin fragility-woolly hair syndrome;17357067;125647;Skin fragility-woolly hair syndrome, 607655 (3);607655
DSPP;Deafness, autosomal dominant 39, with dentinogenesis;17357067;125485;Deafness, autosomal dominant 39, with dentinogenesis, 605594 (3);605594
DSPP;Dentin dysplasia, type II;17357067;125485;Dentin dysplasia, type II, 125420 (3);125420
DSPP;Dentinogenesis imperfecta, Shields type II;17357067;125485;Dentinogenesis imperfecta, Shields type II, 125490 (3);125490
DSPP;Dentinogenesis imperfecta, Shields type III;17357067;125485;Dentinogenesis imperfecta, Shields type III, 125500 (3);125500
DST;Epidermolysis bullosa simplex, sutosomal recessive 2;17357067;113810;Epidermolysis bullosa simplex, sutosomal recessive 2, 615425 (3);615425
DSTYK;Congenital anomalies of kidney and urinary tract, susceptibility to;17357067;612666;{Congenital anomalies of kidney and urinary tract, susceptibility to}, 610805 (3);610805
DTNA;Left ventricular noncompaction 1, with or without congenital heart defects;17357067;601239;Left ventricular noncompaction 1, with or without congenital heart defects, 604169 (3);604169
DTNBP1;Hermansky-Pudlak syndrome 7;17357067;607145;Hermansky-Pudlak syndrome 7, 614076 (3);614076
DTNBP1;Schizophrenia;17357067;607145;{Schizophrenia}, 181500 (2);181500
DUOX2;Thryoid dyshormonogenesis 6;17357067;606759;Thryoid dyshormonogenesis 6, 607200 (3);607200
DUOXA2;Thyroid dyshormonogenesis 5;17357067;612772;Thyroid dyshormonogenesis 5, 274900 (3);274900
DUSP6;Hypogonadotropic hypogonadism 19 with or without anosmia;17357067;602748;Hypogonadotropic hypogonadism 19 with or without anosmia, 615269 (3);615269
DUSP8;Ectodermal dysplasia 4, hair/nail type;17357067;602767;Ectodermal dysplasia 4, hair/nail type, 602032 (3);602032
DVL1;Robinow syndrome, autosomal dominant 2;17357067;601365;Robinow syndrome, autosomal dominant 2, 616331 (3);616331
DYM;Dyggve-Melchior-Clausen disease;17357067;607461;Dyggve-Melchior-Clausen disease, 223800 (3);223800
DYM;Smith-McCort dysplasia;17357067;607461;Smith-McCort dysplasia, 607326 (3);607326
DYNC1H1;Charcot-Marie-Tooth disease, axonal, type 20;17357067;600112;Charcot-Marie-Tooth disease, axonal, type 20, 614228 (3);614228
DYNC1H1;Mental retardation, autosomal dominant 13;17357067;600112;Mental retardation, autosomal dominant 13, 614563 (3);614563
DYNC1H1;Spinal muscular atrophy, lower extremity-predominant 1, AD;17357067;600112;Spinal muscular atrophy, lower extremity-predominant 1, AD, 158600 (3);158600
DYNC2H1;Short-rib thoracic dysplasia 3 with or without polydactyly;17357067;603297;Short-rib thoracic dysplasia 3 with or without polydactyly, 613091 (3);613091
DYRK1A;Mental retardation, autosomal dominant 7;17357067;600855;Mental retardation, autosomal dominant 7, 614104 (3);614104
DYRK1B;Abdominal obesity-metabolic syndrome 3;17357067;604556;Abdominal obesity-metabolic syndrome 3, 615812 (3);615812
DYSF;Miyoshi muscular dystrophy 1;17357067;603009;Miyoshi muscular dystrophy 1, 254130 (3);254130
DYSF;Muscular dystrophy, limb-girdle, type 2B;17357067;603009;Muscular dystrophy, limb-girdle, type 2B, 253601 (3);253601
DYSF;Myopathy, distal, with anterior tibial onset;17357067;603009;Myopathy, distal, with anterior tibial onset, 606768 (3);606768
DYX1C1;Ciliary dyskinesia, primary, 25;17357067;608706;Ciliary dyskinesia, primary, 25, 615482 (3);615482
DYX1C1;Dyslexia, susceptibility to, 1;17357067;608706;{Dyslexia, susceptibility to, 1}, 127700 (3);127700
EARS2;Combined oxidative phosphorylation deficiency 12;17357067;612799;Combined oxidative phosphorylation deficiency 12, 614924 (3);614924
EBP;Chondrodysplasia punctata, X-linked dominant;17357067;300205;Chondrodysplasia punctata, X-linked dominant, 302960 (3);302960
ECE1;Hirschsprung disease, cardiac defects, and autonomic dysfunction;17357067;600423;Hirschsprung disease, cardiac defects, and autonomic dysfunction, 613870 (3);613870
ECE1;Hypertension, essential, susceptibility to;17357067;600423;{Hypertension, essential, susceptibility to}, 145500 (3);145500
ECEL1;Arthrogryposis, distal, type 5D;17357067;605896;Arthrogryposis, distal, type 5D, 615065 (3);615065
ECHS1;Mitochondrial short-chain enoyl-CoA hydratase 1 deficiency;17357067;602292;Mitochondrial short-chain enoyl-CoA hydratase 1 deficiency, 616277 (3);616277
ECM1;Urbach-Wiethe disease;17357067;602201;Urbach-Wiethe disease, 247100 (3);247100
EDA;Ectodermal dysplasia 1, hypohidrotic, X-linked;17357067;300451;Ectodermal dysplasia 1, hypohidrotic, X-linked, 305100 (3);305100
EDA;Tooth agenesis, selective, X-linked 1;17357067;300451;Tooth agenesis, selective, X-linked 1, 313500 (3);313500
EDAR;Ectodermal dysplasia 10A, hypohidrotic/hair/nail type, autosomal dominant;17357067;604095;Ectodermal dysplasia 10A, hypohidrotic/hair/nail type, autosomal dominant, 129490 (3);129490
EDAR;Ectodermal dysplasia 10B, hypohidrotic/hair/tooth type, autosomal recessive;17357067;604095;Ectodermal dysplasia 10B, hypohidrotic/hair/tooth type, autosomal recessive, 224900 (3);224900
EDAR;Ectodermal dysplasia 11A, hypohidrotic/hair/tooth type, autosomal dominant;17357067;606603;Ectodermal dysplasia 11A, hypohidrotic/hair/tooth type, autosomal dominant, 614940 (3);614940
EDAR;Ectodermal dysplasia 11B, hypohidrotic/hair/tooth type, autosomal recessive;17357067;606603;Ectodermal dysplasia 11B, hypohidrotic/hair/tooth type, autosomal recessive, 614941 (3);614941
EDAR;Hair morphology 1, hair thickness;17357067;604095;[Hair morphology 1, hair thickness], 612630 (3);612630
EDARADD;Ectodermal dysplasia 11A, hypohidrotic/hair/tooth type, autosomal dominant;17357067;606603;Ectodermal dysplasia 11A, hypohidrotic/hair/tooth type, autosomal dominant, 614940 (3);614940
EDARADD;Ectodermal dysplasia 11B, hypohidrotic/hair/tooth type, autosomal recessive;17357067;606603;Ectodermal dysplasia 11B, hypohidrotic/hair/tooth type, autosomal recessive, 614941 (3);614941
EDN1;Auriculocondylar syndrome 3;17357067;131240;Auriculocondylar syndrome 3, 615706 (3);615706
EDN1;High density lipoprotein cholesterol level QTL 7;17357067;131240;{High density lipoprotein cholesterol level QTL 7} (3);0
EDN1;Question mark ears, isolated;17357067;131240;Question mark ears, isolated, 612798 (3);612798
EDN3;Central hypoventilation syndrome, congenital;17357067;131242;Central hypoventilation syndrome, congenital, 209880 (3);209880
EDN3;Hirschsprung disease, susceptibility to, 4;17357067;131242;{Hirschsprung disease, susceptibility to, 4}, 613712 (3);613712
EDN3;Waardenburg syndrome, type 4B;17357067;131242;Waardenburg syndrome, type 4B, 613265 (3);613265
EDNRA;Mandibulofacial dysostosis with alopecia;17357067;131243;Mandibulofacial dysostosis with alopecia, 616367 (3);616367
EDNRA;Migraine, resistance to;17357067;131243;{Migraine, resistance to}, 157300 (3);157300
EDNRB;ABCD syndrome;17357067;131244;ABCD syndrome, 600501 (3);600501
EDNRB;Hirschsprung disease, susceptibility to, 2;17357067;131244;{Hirschsprung disease, susceptibility to, 2}, 600155 (3);600155
EDNRB;Waardenburg syndrome, type 4A;17357067;131244;Waardenburg syndrome, type 4A, 277580 (3);277580
EEF1A2;Epileptic encephalopathy, early infantile, 33;17357067;602959;Epileptic encephalopathy, early infantile, 33, 616409 (3);616409
EEF1A2;Mental retardation, autosomal dominant 38;17357067;602959;Mental retardation, autosomal dominant 38, 616393 (3);616393
EFEMP1;Doyne honeycomb degeneration of retina;17357067;601548;Doyne honeycomb degeneration of retina, 126600 (3);126600
EFEMP2;Cutis laxa, autosomal recessive, type IB;17357067;604633;Cutis laxa, autosomal recessive, type IB, 614437 (3);614437
EFHC1;Epilepsy, juvenile absence, susceptibility to, 1;17357067;608815;{Epilepsy, juvenile absence, susceptibility to, 1}, 607631 (3);607631
EFHC1;Myoclonic epilepsy, juvenile, susceptibility to, 1;17357067;608815;{Myoclonic epilepsy, juvenile, susceptibility to, 1}, 254770 (3);254770
EFNB1;Craniofrontonasal dysplasia;17357067;300035;Craniofrontonasal dysplasia, 304110 (3);304110
EFTUD2;Mandibulofacial dysostosis, Guion-Almeida type;17357067;603892;Mandibulofacial dysostosis, Guion-Almeida type, 610536 (3);610536
EGF;Hypomagnesemia 4, renal;17357067;131530;Hypomagnesemia 4, renal, 611718 (3);611718
EGFR;Adenocarcinoma of lung, response to tyrosine kinase inhibitor in;17357067;131550;Adenocarcinoma of lung, response to tyrosine kinase inhibitor in, 211980 (3);211980
EGFR;Nonsmall cell lung cancer, response to tyrosine kinase inhibitor in;17357067;131550;Nonsmall cell lung cancer, response to tyrosine kinase inhibitor in, 211980 (3);211980
EGFR;Nonsmall cell lung cancer, susceptibility to;17357067;131550;{Nonsmall cell lung cancer, susceptibility to}, 211980 (3);211980
EGLN1;Erythrocytosis, familial, 3;17357067;606425;Erythrocytosis, familial, 3, 609820 (3);609820
EGLN1;Hemoglobin, high altitude adaptation;17357067;606425;[Hemoglobin, high altitude adaptation], 609070 (3);609070
EGR2;Charcot-Marie-Tooth disease, type 1D;17357067;129010;Charcot-Marie-Tooth disease, type 1D, 607678 (3);607678
EGR2;Dejerine-Sottas disease;17357067;129010;Dejerine-Sottas disease, 145900 (3);145900
EGR2;Neuropathy, congenital hypomyelinating, 1;17357067;129010;Neuropathy, congenital hypomyelinating, 1, 605253 (3);605253
EHBP1;Prostate cancer, hereditary, 12;17357067;609922;{Prostate cancer, hereditary, 12}, 611868 (3);611868
EHMT1;Kleefstra syndrome;17357067;607001;Kleefstra syndrome, 610253 (3);610253
EI24;Mosaic variegated aneuploidy syndrome 2;17357067;607951;Mosaic variegated aneuploidy syndrome 2, 614114 (3);614114
EIF2AK3;Wolcott-Rallison syndrome;17357067;604032;Wolcott-Rallison syndrome, 226980 (3);226980
EIF2AK4;Pulmonary venoocclusive disease 2;17357067;609280;Pulmonary venoocclusive disease 2, 234810 (3);234810
EIF2B1;Leukoencephalopathy with vanishing white matter;17357067;606686;Leukoencephalopathy with vanishing white matter, 603896 (3);603896
EIF2B2;Leukoencephalopathy with vanishing white matter;17357067;606454;Leukoencephalopathy with vanishing white matter, 603896 (3);603896
EIF2B2;Ovarioleukodystrophy;17357067;606454;Ovarioleukodystrophy, 603896 (3);603896
EIF2B3;Leukoencephalopathy with vanishing white matter;17357067;606273;Leukoencephalopathy with vanishing white matter, 603896 (3);603896
EIF2B4;Leukoencephaly with vanishing white matter;17357067;606687;Leukoencephaly with vanishing white matter, 603896 (3);603896
EIF2B4;Ovarioleukodystrophy;17357067;606687;Ovarioleukodystrophy, 603896 (3);603896
EIF2B5;Leukoencephalopathy with vanishing white matter;17357067;603945;Leukoencephalopathy with vanishing white matter, 603896 (3);603896
EIF2B5;Ovarioleukodystrophy;17357067;603945;Ovarioleukodystrophy, 603896 (3);603896
EIF4A3;Robin sequence with cleft mandible and limb anomalies;17357067;608546;Robin sequence with cleft mandible and limb anomalies, 268305 (3);268305
EIF4E;Autism, susceptibility to, 19;17357067;133440;{Autism, susceptibility to, 19}, 615091 (3);615091
EIF4G1;Parkinson disease 18;17357067;600495;{Parkinson disease 18}, 614251 (3);614251
ELAC2;Combined oxidative phosphorylation deficiency 17;17357067;605367;Combined oxidative phosphorylation deficiency 17, 615440 (3);615440
ELAC2;Prostate cancer, hereditary, 2, susceptibility to;17357067;605367;{Prostate cancer, hereditary, 2, susceptibility to}, 614731 (3);614731
ELANE;Neutropenia, cyclic;17357067;130130;Neutropenia, cyclic, 162800 (3);162800
ELANE;Neutropenia, severe congenital 1, autosomal dominant;17357067;130130;Neutropenia, severe congenital 1, autosomal dominant, 202700 (3);202700
ELAVL4;Neuropathy, paraneoplastic sensory;17357067;168360;Neuropathy, paraneoplastic sensory (1);0
ELN;Cutis laxa, AD;17357067;130160;Cutis laxa, AD, 123700 (3);123700
ELN;Supravalvar aortic stenosis;17357067;130160;Supravalvar aortic stenosis, 185500 (3);185500
ELN;Williams-Beuren syndrome;17357067;194050;Williams-Beuren syndrome (4);0
ELOVL4;Ichthyosis, spastic quadriplegia, and mental retardation;17357067;605512;Ichthyosis, spastic quadriplegia, and mental retardation, 614457 (3);614457
ELOVL4;Stargardt disease 3;17357067;605512;Stargardt disease 3, 600110 (3);600110
ELOVL5;Spinocerebellar ataxia 38;17357067;611805;Spinocerebellar ataxia 38, 615957 (3);615957
EMD;Emery-Dreifuss muscular dystrophy 1, X-linked;17357067;300384;Emery-Dreifuss muscular dystrophy 1, X-linked, 310300 (3);310300
EMG1;Bowen-Conradi syndrome;17357067;611531;Bowen-Conradi syndrome, 211180 (3);211180
EML2;Leukodystrophy, hypomyelinating, 3;17357067;603605;Leukodystrophy, hypomyelinating, 3, 260600 (3);260600
EMP2;Nephrotic syndrome, type 10;17357067;602334;Nephrotic syndrome, type 10, 615861 (3);615861
EMX2;Schizencephaly;17357067;600035;Schizencephaly, 269160 (3);269160
ENAM;Amelogenesis imperfecta, type IB;17357067;606585;Amelogenesis imperfecta, type IB, 104500 (3);104500
ENAM;Amelogenesis imperfecta, type IC;17357067;606585;Amelogenesis imperfecta, type IC, 204650 (3);204650
ENG;Telangiectasia, hereditary hemorrhagic, type 1;17357067;131195;Telangiectasia, hereditary hemorrhagic, type 1, 187300 (3);187300
ENO1;Enolase deficiency;17357067;172430;Enolase deficiency (1);0
ENPP1;Arterial calcification, generalized, of infancy, 1;17357067;173335;Arterial calcification, generalized, of infancy, 1, 208000 (3);208000
ENPP1;Cole disease;17357067;173335;Cole disease, 615522 (3);615522
ENPP1;Diabetes mellitus, non-insulin-dependent, susceptibility to;17357067;173335;{Diabetes mellitus, non-insulin-dependent, susceptibility to}, 125853 (3);125853
ENPP1;Hypophosphatemic rickets, autosomal recessive, 2;17357067;173335;Hypophosphatemic rickets, autosomal recessive, 2, 613312 (3);613312
ENPP1;Obesity, susceptibility to;17357067;173335;{Obesity, susceptibility to}, 601665 (3);601665
ENTPD1;Spastic paraplegia 64;17357067;601752;Spastic paraplegia 64, 615683 (3);615683
EOGT;Adams-Oliver syndrome 4;17357067;614789;Adams-Oliver syndrome 4, 615297 (3);615297
EP300;Colorectal cancer, somatic;17357067;602700;Colorectal cancer, somatic, 114500 (3);114500
EP300;Rubinstein-Taybi syndrome 2;17357067;602700;Rubinstein-Taybi syndrome 2, 613684 (3);613684
EPAS1;Erythrocytosis, familial, 4;17357067;603349;Erythrocytosis, familial, 4, 611783 (3);611783
EPB41;Elliptocytosis-1;17357067;130500;Elliptocytosis-1, 611804 (3);611804
EPB42;Spherocytosis, hereditary, type 5;17357067;177070;Spherocytosis, hereditary, type 5, 612690 (3);612690
EPCAM;Colorectal cancer, hereditary nonpolyposis, type 8;17357067;185535;Colorectal cancer, hereditary nonpolyposis, type 8, 613244 (3);613244
EPCAM;Diarrhea 5, with tufting enteropathy, congenital;17357067;185535;Diarrhea 5, with tufting enteropathy, congenital, 613217 (3);613217
EPG5;Vici syndrome;17357067;615068;Vici syndrome, 242840 (3);242840
EPHA2;Cataract 6, multiple types;17357067;176946;Cataract 6, multiple types, 116600 (3);116600
EPHB2;Prostate cancer/brain cancer susceptibility, somatic;17357067;600997;{Prostate cancer/brain cancer susceptibility, somatic}, 603688 (3);603688
EPHX1;Diphenylhydantoin toxicity;17357067;132810;Diphenylhydantoin toxicity (1);0
EPHX1;Hypercholanemia, familial;17357067;132810;Hypercholanemia, familial, 607748 (3);607748
EPHX1;Preeclampsia, susceptibility to;17357067;132810;{Preeclampsia, susceptibility to}, 189800 (3);189800
EPHX2;Hypercholesterolemia, familial, due to LDLR defect, modifier of;17357067;132811;{Hypercholesterolemia, familial, due to LDLR defect, modifier of}, 143890 (3);143890
EPM2A;Epilepsy, progressive myoclonic 2A (Lafora);17357067;607566;Epilepsy, progressive myoclonic 2A (Lafora), 254780 (3);254780
EPM2A;Epilepsy, progressive myoclonic 2B (Lafora);17357067;608072;Epilepsy, progressive myoclonic 2B (Lafora), 254780 (3);254780
EPO;Microvascular complications of diabetes 2;17357067;133170;{Microvascular complications of diabetes 2}, 612623 (3);612623
EPOR;Erythrocytosis, familial, 1;17357067;133171;[Erythrocytosis, familial, 1], 133100 (3);133100
EPX;Eosinophil peroxidase deficiency;17357067;131399;Eosinophil peroxidase deficiency, 261500 (3);261500
ERBB2;Adenocarcinoma of lung, somatic;17357067;164870;Adenocarcinoma of lung, somatic, 211980 (3);211980
ERBB2;Gastric cancer, somatic;17357067;164870;Gastric cancer, somatic, 613659 (3);613659
ERBB2;Glioblastoma, somatic;17357067;164870;Glioblastoma, somatic, 137800 (3);137800
ERBB2;Ovarian cancer, somatic;17357067;164870;Ovarian cancer, somatic, (3);0
ERBB3;Lethal congenital contractural syndrome 2;17357067;190151;Lethal congenital contractural syndrome 2, 607598 (3);607598
ERBB4;Amyotrophic lateral sclerosis 19;17357067;600543;Amyotrophic lateral sclerosis 19, 615515 (3);615515
ERCC1;Cerebrooculofacioskeletal syndrome 4;17357067;126380;Cerebrooculofacioskeletal syndrome 4, 610758 (3);610758
ERCC2;Cerebrooculofacioskeletal syndrome 2;17357067;126340;Cerebrooculofacioskeletal syndrome 2, 610756 (3);610756
ERCC2;Trichothiodystrophy 1, photosensitive;17357067;126340;Trichothiodystrophy 1, photosensitive, 601675 (3);601675
ERCC2;Xeroderma pigmentosum, group D;17357067;126340;Xeroderma pigmentosum, group D, 278730 (3);278730
ERCC3;Trichothiodystrophy 2, photosensitive;17357067;133510;Trichothiodystrophy 2, photosensitive, 616390 (3);616390
ERCC3;Xeroderma pigmentosum, group B;17357067;133510;Xeroderma pigmentosum, group B, 610651 (3);610651
ERCC4;Fanconi anemia, complementation group Q;17357067;133520;Fanconi anemia, complementation group Q, 615272 (3);615272
ERCC4;XFE progeroid syndrome;17357067;133520;XFE progeroid syndrome, 610965 (3);610965
ERCC4;Xeroderma pigmentosum, group F;17357067;133520;Xeroderma pigmentosum, group F, 278760 (3);278760
ERCC4;Xeroderma pigmentosum, type F/Cockayne syndrome;17357067;133520;Xeroderma pigmentosum, type F/Cockayne syndrome, 278760 (3);278760
ERCC5;Xeroderma pigmentosum, group G;17357067;133530;Xeroderma pigmentosum, group G, 278780 (3);278780
ERCC5;Xeroderma pigmentosum, group G/Cockayne syndrome;17357067;133530;Xeroderma pigmentosum, group G/Cockayne syndrome, 278780 (3);278780
ERCC6;Cerebrooculofacioskeletal syndrome 1;17357067;609413;Cerebrooculofacioskeletal syndrome 1, 214150 (3);214150
ERCC6;Cockayne syndrome, type B;17357067;609413;Cockayne syndrome, type B, 133540 (3);133540
ERCC6;De Sanctis-Cacchione syndrome;17357067;609413;De Sanctis-Cacchione syndrome, 278800 (3);278800
ERCC6;Lung cancer, susceptibility to;17357067;609413;{Lung cancer, susceptibility to}, 211980 (3);211980
ERCC6;Macular degeneration, age-related, susceptibility to 5;17357067;609413;{Macular degeneration, age-related, susceptibility to 5}, 613761 (3);613761
ERCC6;UV-sensitive syndrome 1;17357067;609413;UV-sensitive syndrome 1, 600630 (3);600630
ERCC6L2;Bone marrow failure syndrome 2;17357067;615667;Bone marrow failure syndrome 2, 615715 (3);615715
ERCC8;Cockayne syndrome, type A;17357067;609412;Cockayne syndrome, type A, 216400 (3);216400
ERCC8;UV-sensitive syndrome 2;17357067;609412;UV-sensitive syndrome 2, 614621 (3);614621
ERF;Craniosynostosis 4;17357067;611888;Craniosynostosis 4, 600775 (3);600775
ERLIN2;Spastic paraplegia 18, autosomal recessive;17357067;611605;Spastic paraplegia 18, autosomal recessive, 611225 (3);611225
ERMAP;Blood group, Radin;17357067;609017;[Blood group, Radin], 111620 (3);111620
ERMAP;Blood group, Scianna system;17357067;609017;[Blood group, Scianna system], 111750 (3);111750
ESCO2;Roberts syndrome;17357067;609353;Roberts syndrome, 268300 (3);268300
ESCO2;SC phocomelia syndrome;17357067;609353;SC phocomelia syndrome, 269000 (3);269000
ESPN;Deafness, autosomal recessive 36;17357067;606351;Deafness, autosomal recessive 36, 609006 (3);609006
ESPN;Deafness, neurosensory, without vestibular involvement, autosomal dominant;17357067;606351;Deafness, neurosensory, without vestibular involvement, autosomal dominant (3);0
ESR1;Atherosclerosis, susceptibility to;17357067;133430;{Atherosclerosis, susceptibility to} (3);0
ESR1;Breast cancer;17357067;133430;{Breast cancer}, 114480 (1);114480
ESR1;Estrogen resistance;17357067;133430;Estrogen resistance, 615363 (3);615363
ESR1;HDL response to hormone replacement, augmented;17357067;133430;{HDL response to hormone replacement, augmented} (3);0
ESR1;Migraine, susceptibility to;17357067;133430;{Migraine, susceptibility to}, 157300 (3);157300
ESR1;Myocardial infarction, susceptibility to;17357067;133430;{Myocardial infarction, susceptibility to}, 608446 (3);608446
ESRRB;Deafness, autosomal recessive 35;17357067;602167;Deafness, autosomal recessive 35, 608565 (3);608565
ETFA;Glutaric acidemia IIA;17357067;608053;Glutaric acidemia IIA, 231680 (3);231680
ETFB;Glutaric acidemia IIB;17357067;130410;Glutaric acidemia IIB, 231680 (3);231680
ETFDH;Glutaric acidemia IIC;17357067;231675;Glutaric acidemia IIC, 231680 (3);231680
ETHE1;Ethylmalonic encephalopathy;17357067;608451;Ethylmalonic encephalopathy, 602473 (3);602473
ETV6;Leukemia, acute myeloid, somatic;17357067;600618;Leukemia, acute myeloid, somatic, 601626 (3);601626
ETV6;Thrombocytopenia 5;17357067;600618;Thrombocytopenia 5, 616216 (3);616216
EVC;Ellis-van Creveld syndrome;17357067;604831;Ellis-van Creveld syndrome, 225500 (3);225500
EVC;Weyers acrodental dysostosis;17357067;604831;Weyers acrodental dysostosis, 193530 (3);193530
EVC2;Ellis-van Creveld syndrome;17357067;607261;Ellis-van Creveld syndrome, 225500 (3);225500
EVC2;Weyers acrofacial dysostosis;17357067;607261;Weyers acrofacial dysostosis, 193530 (3);193530
EWSR1;Ewing sarcoma;17357067;133450;Ewing sarcoma, 612219 (3);612219
EWSR1;Neuroepithelioma;17357067;133450;Neuroepithelioma, 612219 (3);612219
EXOSC3;Pontocerebellar hypoplasia, type 1B;17357067;606489;Pontocerebellar hypoplasia, type 1B, 614678 (3);614678
EXOSC8;Pontocerebellar hypoplasia, type 1C;17357067;606019;Pontocerebellar hypoplasia, type 1C, 616081 (3);616081
EXPH5;Epidermolysis bullosa, nonspecific, autosomal recessive;17357067;612878;Epidermolysis bullosa, nonspecific, autosomal recessive, 615028 (3);615028
EXT1;Chondrosarcoma;17357067;608177;Chondrosarcoma, 215300 (3);215300
EXT1;Exostoses, multiple, type 1;17357067;608177;Exostoses, multiple, type 1, 133700 (3);133700
EXT2;Exostoses, multiple, type 2;17357067;608210;Exostoses, multiple, type 2, 133701 (3);133701
EYA1;Anterior segment anomalies with or without cataract;17357067;601653;Anterior segment anomalies with or without cataract, 113650 (3);113650
EYA1;Branchiootic syndrome 1;17357067;601653;Branchiootic syndrome 1, 602588 (3);602588
EYA1;Branchiootorenal syndrome 1, with or without cataracts;17357067;601653;Branchiootorenal syndrome 1, with or without cataracts, 113650 (3);113650
EYA4;Cardiomyopathy, dilated, 1J;17357067;603550;Cardiomyopathy, dilated, 1J, 605362 (3);605362
EYA4;Deafness, autosomal dominant 10;17357067;603550;Deafness, autosomal dominant 10, 601316 (3);601316
EYS;Retinitis pigmentosa 25;17357067;612424;Retinitis pigmentosa 25, 602772 (3);602772
EZH1;Weaver syndrome;17357067;601573;Weaver syndrome, 277590 (3);277590
EZH2;Weaver syndrome;17357067;601573;Weaver syndrome, 277590 (3);277590
F10;Factor X deficiency;17357067;613872;Factor X deficiency, 227600 (3);227600
F11;Factor XI deficiency, autosomal dominant;17357067;264900;Factor XI deficiency, autosomal dominant, 612416 (3);612416
F11;Factor XI deficiency, autosomal recessive;17357067;264900;Factor XI deficiency, autosomal recessive, 612416 (3);612416
F12;Angioedema, hereditary, type III;17357067;610619;Angioedema, hereditary, type III, 610618 (3);610618
F12;Factor XII deficiency;17357067;610619;Factor XII deficiency, 234000 (3);234000
F13A1;Factor XIIIA deficiency;17357067;134570;Factor XIIIA deficiency, 613225 (3);613225
F13A1;Myocardial infarction, protection against;17357067;134570;{Myocardial infarction, protection against}, 608446 (3);608446
F13A1;Venous thrombosis, protection against;17357067;134570;{Venous thrombosis, protection against}, 188050 (3);188050
F13B;Factor XIIIB deficiency;17357067;134580;Factor XIIIB deficiency, 613235 (3);613235
F2;Dysprothrombinemia;17357067;176930;Dysprothrombinemia, 613679 (3);613679
F2;Hypoprothrombinemia;17357067;176930;Hypoprothrombinemia, 613679 (3);613679
F2;Pregnancy loss, recurrent, susceptibility to, 2;17357067;176930;{Pregnancy loss, recurrent, susceptibility to, 2}, 614390 (3);614390
F2;Stroke, ischemic, susceptibility to;17357067;176930;{Stroke, ischemic, susceptibility to}, 601367 (3);601367
F2;Thrombophilia due to thrombin defect;17357067;176930;Thrombophilia due to thrombin defect, 188050 (3);188050
F5;Budd-Chiari syndrome;17357067;612309;{Budd-Chiari syndrome}, 600880 (3);600880
F5;Factor V deficiency;17357067;612309;Factor V deficiency, 227400 (3);227400
F5;Pregnancy loss, recurrent, susceptibility to, 1;17357067;612309;{Pregnancy loss, recurrent, susceptibility to, 1}, 614389 (3);614389
F5;Stroke, ischemic, susceptibility to;17357067;612309;{Stroke, ischemic, susceptibility to}, 601367 (3);601367
F5;Thrombophilia due to activated protein C resistance;17357067;612309;Thrombophilia due to activated protein C resistance, 188055 (3);188055
F5;Thrombophilia, susceptibility to, due to factor V Leiden;17357067;612309;{Thrombophilia, susceptibility to, due to factor V Leiden}, 188055 (3);188055
F7;Factor VII deficiency;17357067;613878;Factor VII deficiency, 227500 (3);227500
F7;Myocardial infarction, decreased susceptibility to;17357067;613878;{Myocardial infarction, decreased susceptibility to}, 608446 (3);608446
F8;Hemophilia A;17357067;300841;Hemophilia A, 306700 (3);306700
F9;Deep venous thrombosis, protection against;17357067;300746;{Deep venous thrombosis, protection against}, 300807 (3);300807
F9;Hemophilia B;17357067;300746;Hemophilia B, 306900 (3);306900
F9;Thrombophilia, X-linked, due to factor IX defect;17357067;300746;Thrombophilia, X-linked, due to factor IX defect, 300807 (3);300807
F9;Warfarin sensitivity;17357067;300746;{Warfarin sensitivity}, 122700 (3);122700
FA2H;Spastic paraplegia 35, autosomal recessive;17357067;611026;Spastic paraplegia 35, autosomal recessive, 612319 (3);612319
FAAH;Drug addiction, susceptibility to;17357067;602935;{Drug addiction, susceptibility to}, 606581 (3);606581
FAAH;Spastic paraplegia 35, autosomal recessive;17357067;611026;Spastic paraplegia 35, autosomal recessive, 612319 (3);612319
FADD;Infections, recurrent, with encephalopathy, hepatic dysfunction, and cardiovasuclar malformations;17357067;602457;Infections, recurrent, with encephalopathy, hepatic dysfunction, and cardiovasuclar malformations, 613759 (3);613759
FAH;Tyrosinemia, type I;17357067;613871;Tyrosinemia, type I, 276700 (3);276700
FAM111A;Gracile bone dysplasia;17357067;615292;Gracile bone dysplasia, 602361 (3);602361
FAM111A;Kenny-Caffey syndrome, type 2;17357067;615292;Kenny-Caffey syndrome, type 2, 127000 (3);127000
FAM111B;Poikiloderma, hereditary fibrosing, with tendon contractures, myopathy, and pulmonary fibrosis;17357067;615584;Poikiloderma, hereditary fibrosing, with tendon contractures, myopathy, and pulmonary fibrosis, 615704 (3);615704
FAM126A;Leukodystrophy, hypomyelinating, 5;17357067;610531;Leukodystrophy, hypomyelinating, 5, 610532 (3);610532
FAM134B;Neuropathy, hereditary sensory and autonomic, type IIB;17357067;613114;Neuropathy, hereditary sensory and autonomic, type IIB, 613115 (3);613115
FAM161A;Retinitis pigmentosa 28;17357067;613596;Retinitis pigmentosa 28, 606068 (3);606068
FAM20A;Amelogenesis imperfecta, type IG (enamel-renal syndrome);17357067;611062;Amelogenesis imperfecta, type IG (enamel-renal syndrome), 204690 (3);204690
FAM20C;Raine syndrome;17357067;611061;Raine syndrome, 259775 (3);259775
FAM58A;STAR syndrome;17357067;300708;STAR syndrome, 300707 (3);300707
FAM83H;Amelogenesis imperfecta, type III;17357067;611927;Amelogenesis imperfecta, type III, 130900 (3);130900
FAN1;Interstitial nephritis, karyomegalic;17357067;613534;Interstitial nephritis, karyomegalic, 614817 (3);614817
FANCA;Fanconi anemia, complementation group A;17357067;607139;Fanconi anemia, complementation group A, 227650 (3);227650
FANCB;Fanconi anemia, complementation group B;17357067;300515;Fanconi anemia, complementation group B, 300514 (3);300514
FANCC;Fanconi anemia, complementation group C;17357067;613899;Fanconi anemia, complementation group C, 227645 (3);227645
FANCD2;Fanconi anemia, complementation group D2;17357067;613984;Fanconi anemia, complementation group D2, 227646 (3);227646
FANCE;Fanconi anemia, complementation group E;17357067;613976;Fanconi anemia, complementation group E, 600901 (3);600901
FANCF;Fanconi anemia, complementation group F;17357067;613897;Fanconi anemia, complementation group F, 603467 (3);603467
FANCG;Fanconi anemia, complementation group G;17357067;602956;Fanconi anemia, complementation group G, 614082 (3);614082
FANCI;Fanconi anemia, complementation group I;17357067;611360;Fanconi anemia, complementation group I, 609053 (3);609053
FANCL;Fanconi anemia, complementation group L;17357067;608111;Fanconi anemia, complementation group L, 614083 (3);614083
FAR1;Peroxisomal fatty acyl-CoA reductase 1 disorder;17357067;616107;Peroxisomal fatty acyl-CoA reductase 1 disorder, 616154 (3);616154
FARS2;Combined oxidative phosphorylation deficiency 14;17357067;611592;Combined oxidative phosphorylation deficiency 14, 614946 (3);614946
FAS;Autoimmune lymphoproliferative syndrome;17357067;134637;{Autoimmune lymphoproliferative syndrome}, 601859 (3);601859
FAS;Autoimmune lymphoproliferative syndrome, type IA;17357067;134637;Autoimmune lymphoproliferative syndrome, type IA, 601859 (3);601859
FAS;Squamous cell carcinoma, burn scar-related, somatic;17357067;134637;Squamous cell carcinoma, burn scar-related, somatic (3);0
FASLG;Autoimmune lymphoproliferative syndrome, type IB;17357067;134638;Autoimmune lymphoproliferative syndrome, type IB, 601859 (3);601859
FASLG;Lung cancer, susceptibility to;17357067;134638;{Lung cancer, susceptibility to}, 211980 (3);211980
FAT4;Hennekam lymphangiectasia-lymphedema syndrome 2;17357067;612411;Hennekam lymphangiectasia-lymphedema syndrome 2, 616006 (3);616006
FAT4;Van Maldergem syndrome 2;17357067;612411;Van Maldergem syndrome 2, 615546 (3);615546
FBLN1;Synpolydactyly, 3/3'4, associated with metacarpal and metatarsal synostoses;17357067;135820;Synpolydactyly, 3/3'4, associated with metacarpal and metatarsal synostoses, 608180 (4);608180
FBLN5;Cutis laxa, autosomal dominant 2;17357067;604580;Cutis laxa, autosomal dominant 2, 614434 (3);614434
FBLN5;Cutis laxa, autosomal recessive, type IA;17357067;604580;Cutis laxa, autosomal recessive, type IA, 219100 (3);219100
FBLN5;Macular degeneration, age-related, 3;17357067;604580;Macular degeneration, age-related, 3, 608895 (3);608895
FBN1;Acromicric dysplasia;17357067;134797;Acromicric dysplasia, 102370 (3);102370
FBN1;Aortic aneurysm, ascending, and dissection;17357067;134797;Aortic aneurysm, ascending, and dissection (3);0
FBN1;Ectopia lentis, familial;17357067;134797;Ectopia lentis, familial, 129600 (3);129600
FBN1;Geleophysic dysplasia 2;17357067;134797;Geleophysic dysplasia 2, 614185 (3);614185
FBN1;MASS syndrome;17357067;134797;MASS syndrome, 604308 (3);604308
FBN1;Marfan syndrome;17357067;134797;Marfan syndrome, 154700 (3);154700
FBN1;Shprintzen-Goldberg syndrome;17357067;164780;Shprintzen-Goldberg syndrome, 182212 (3);182212
FBN1;Stiff skin syndrome;17357067;134797;Stiff skin syndrome, 184900 (3);184900
FBN1;Weill-Marchesani syndrome 2, dominant;17357067;134797;Weill-Marchesani syndrome 2, dominant, 608328 (3);608328
FBN1;Williams-Beuren syndrome;17357067;194050;Williams-Beuren syndrome (4);0
FBN2;Contractural arachnodactyly, congenital;17357067;612570;Contractural arachnodactyly, congenital, 121050 (3);121050
FBN2;Macular degeneration, early-onset;17357067;612570;Macular degeneration, early-onset, 616118 (3);616118
FBP1;Fructose-1,6-bisphosphatase deficiency;17357067;611570;Fructose-1,6-bisphosphatase deficiency, 229700 (3);229700
FBXL4;Mitochondrial DNA depletion syndrome 13 (encephalomyopathic type);17357067;605654;Mitochondrial DNA depletion syndrome 13 (encephalomyopathic type), 615471 (3);615471
FBXO38;Neuronopathy, distal hereditary motor, type IID;17357067;608533;Neuronopathy, distal hereditary motor, type IID, 615575 (3);615575
FBXO7;Parkinson disease 15, autosomal recessive;17357067;605648;Parkinson disease 15, autosomal recessive, 260300 (3);260300
FBXW4;Split-hand/foot malformation 3, gene duplication syndrome;17357067;246560;Split-hand/foot malformation 3, gene duplication syndrome (4);0
FCGR1A;IgG receptor I, phagocytic, familial deficiency of;17357067;146760;[IgG receptor I, phagocytic, familial deficiency of] (3);0
FCGR2A;Lupus nephritis, susceptibility to;17357067;146790;{Lupus nephritis, susceptibility to}, 152700 (3);152700
FCGR2A;Malaria, severe, susceptibility to;17357067;146790;{Malaria, severe, susceptibility to}, 611162 (3);611162
FCGR2A;Pseudomonas aeruginosa, susceptibility to chronic infection by, in cystic fibrosis;17357067;146790;{Pseudomonas aeruginosa, susceptibility to chronic infection by, in cystic fibrosis}, 219700 (3);219700
FCGR2B;Malaria, resistance to;17357067;604590;{Malaria, resistance to}, 611162 (3);611162
FCGR2B;Systemic lupus erythematosus, susceptibility to;17357067;604590;{Systemic lupus erythematosus, susceptibility to}, 152700 (3);152700
FCGR2C;Thrombocytopenic purpura, autoimmune;17357067;612169;Thrombocytopenic purpura, autoimmune, 188030 (1);188030
FCGR3A;Immunodeficiency 20;17357067;146740;Immunodeficiency 20, 615707 (3);615707
FCGR3B;Neutropenia, alloimmune neonatal;17357067;610665;Neutropenia, alloimmune neonatal (3);0
FCN3;Immunodeficiency due to ficolin 3 deficiency;17357067;604973;Immunodeficiency due to ficolin 3 deficiency, 613860 (3);613860
FECH;Protoporphyria, erythropoietic, autosomal recessive;17357067;612386;Protoporphyria, erythropoietic, autosomal recessive, 177000 (3);177000
FERMT1;Kindler syndrome;17357067;607900;Kindler syndrome, 173650 (3);173650
FERMT3;Leukocyte adhesion deficiency, type III;17357067;607901;Leukocyte adhesion deficiency, type III, 612840 (3);612840
FEZ1;Esophageal squamous cell carcinoma;17357067;606551;Esophageal squamous cell carcinoma, 133239 (3);133239
FEZF1;Hypogonadotropic hypogonadism with or without anosmia;17357067;613301;Hypogonadotropic hypogonadism with or without anosmia, 616030 (3);616030
FEZF2;Atrial septal defect 2;17357067;600576;Atrial septal defect 2, 607941 (3);607941
FEZF2;Atrioventricular septal defect 4;17357067;600576;Atrioventricular septal defect 4, 614430 (3);614430
FEZF2;Tetralogy of Fallot;17357067;600576;Tetralogy of Fallot, 187500 (3);187500
FEZF2;Ventricular septal defect 1;17357067;600576;Ventricular septal defect 1, 614429 (3);614429
FFAR4;Obesity, susceptibility to;17357067;609044;{Obesity, susceptibility to}, 607514 (3);607514
FGA;Afibrinogenemia, congenital;17357067;134820;Afibrinogenemia, congenital, 202400 (3);202400
FGA;Amyloidosis, familial visceral;17357067;134820;Amyloidosis, familial visceral, 105200 (3);105200
FGA;Dysfibrinogenemia, congenital;17357067;134820;Dysfibrinogenemia, congenital, 616004 (3);616004
FGA;Hypodysfibrinogenemia, congenital;17357067;134820;Hypodysfibrinogenemia, congenital, 616004 (3);616004
FGB;Afibrinogenemia, congenital;17357067;134830;Afibrinogenemia, congenital, 202400 (3);202400
FGB;Dysfibrinogenemia, congenital;17357067;134830;Dysfibrinogenemia, congenital, 616004 (3);616004
FGB;Hypofibrinogenemia, congenital;17357067;134830;Hypofibrinogenemia, congenital, 202400 (3);202400
FGD1;Aarskog-Scott syndrome;17357067;300546;Aarskog-Scott syndrome, 305400 (3);305400
FGD1;Mental retardation, X-linked syndromic 16;17357067;300546;Mental retardation, X-linked syndromic 16, 305400 (3);305400
FGD2;Glucocorticoid deficiency 2;17357067;609196;Glucocorticoid deficiency 2, 607398 (3);607398
FGD3;Glucocorticoid deficiency 3;17357067;609197;Glucocorticoid deficiency 3 (2);0
FGD4;Charcot-Marie-Tooth disease, type 4H;17357067;611104;Charcot-Marie-Tooth disease, type 4H, 609311 (3);609311
FGF10;Aplasia of lacrimal and salivary glands;17357067;602115;Aplasia of lacrimal and salivary glands, 180920 (3);180920
FGF10;LADD syndrome;17357067;602115;LADD syndrome, 149730 (3);149730
FGF14;Spinocerebellar ataxia 27;17357067;601515;Spinocerebellar ataxia 27, 609307 (3);609307
FGF16;Metacarpal 4-5 fusion;17357067;300827;Metacarpal 4-5 fusion, 309630 (3);309630
FGF17;Hypogonadotropic hypogonadism 20 with or without anosmia;17357067;603725;Hypogonadotropic hypogonadism 20 with or without anosmia, 615270 (3);615270
FGF23;Hypophosphatemic rickets, autosomal dominant;17357067;605380;Hypophosphatemic rickets, autosomal dominant, 193100 (3);193100
FGF23;Osteomalacia, tumor-induced;17357067;605380;Osteomalacia, tumor-induced (1);0
FGF23;Tumoral calcinosis, hyperphosphatemic, familial;17357067;605380;Tumoral calcinosis, hyperphosphatemic, familial, 211900 (3);211900
FGF3;Deafness, congenital with inner ear agenesis, microtia, and microdontia;17357067;164950;Deafness, congenital with inner ear agenesis, microtia, and microdontia, 610706 (3);610706
FGF5;Trichomegaly;17357067;165190;Trichomegaly, 190330 (3);190330
FGF8;Hypogonadotropic hypogonadism 6 with or without anosmia;17357067;600483;Hypogonadotropic hypogonadism 6 with or without anosmia, 612702 (3);612702
FGFR1;Hartsfield syndrome;17357067;136350;Hartsfield syndrome, 615465 (3);615465
FGFR1;Hypogonadotropic hypogonadism 2 with or without anosmia;17357067;136350;Hypogonadotropic hypogonadism 2 with or without anosmia, 147950 (3);147950
FGFR1;Jackson-Weiss syndrome;17357067;136350;Jackson-Weiss syndrome, 123150 (3);123150
FGFR1;Osteoglophonic dysplasia;17357067;136350;Osteoglophonic dysplasia, 166250 (3);166250
FGFR1;Pfeiffer syndrome;17357067;136350;Pfeiffer syndrome, 101600 (3);101600
FGFR1;Trigonocephaly 1;17357067;136350;Trigonocephaly 1, 190440 (3);190440
FGFR1OP;Myeloproliferative disorder;17357067;605392;Myeloproliferative disorder (2);0
FGFR2;Antley-Bixler syndrome without genital anomalies or disordered steroidogenesis;17357067;176943;Antley-Bixler syndrome without genital anomalies or disordered steroidogenesis, 207410 (3);207410
FGFR2;Apert syndrome;17357067;176943;Apert syndrome, 101200 (3);101200
FGFR2;Beare-Stevenson cutis gyrata syndrome;17357067;176943;Beare-Stevenson cutis gyrata syndrome, 123790 (3);123790
FGFR2;Bent bone dysplasia syndrome;17357067;176943;Bent bone dysplasia syndrome, 614592 (3);614592
FGFR2;Craniofacial-skeletal-dermatologic dysplasia;17357067;176943;Craniofacial-skeletal-dermatologic dysplasia, 101600 (3);101600
FGFR2;Craniosynostosis, nonspecific;17357067;176943;Craniosynostosis, nonspecific (3);0
FGFR2;Crouzon syndrome;17357067;176943;Crouzon syndrome, 123500 (3);123500
FGFR2;Gastric cancer, somatic;17357067;176943;Gastric cancer, somatic, 613659 (3);613659
FGFR2;Jackson-Weiss syndrome;17357067;176943;Jackson-Weiss syndrome, 123150 (3);123150
FGFR2;LADD syndrome;17357067;176943;LADD syndrome, 149730 (3);149730
FGFR2;Pfeiffer syndrome;17357067;176943;Pfeiffer syndrome, 101600 (3);101600
FGFR2;Saethre-Chotzen syndrome;17357067;176943;Saethre-Chotzen syndrome, 101400 (3);101400
FGFR2;Scaphocephaly and Axenfeld-Rieger anomaly;17357067;176943;Scaphocephaly and Axenfeld-Rieger anomaly (3);0
FGFR2;Scaphocephaly, maxillary retrusion, and mental retardation;17357067;176943;Scaphocephaly, maxillary retrusion, and mental retardation, 609579 (3);609579
FGFR3;Achondroplasia;17357067;134934;Achondroplasia, 100800 (3);100800
FGFR3;Bladder cancer, somatic;17357067;134934;Bladder cancer, somatic, 109800 (3);109800
FGFR3;CATSHL syndrome;17357067;134934;CATSHL syndrome, 610474 (3);610474
FGFR3;Cervical cancer, somatic;17357067;134934;Cervical cancer, somatic, 603956 (3);603956
FGFR3;Colorectal cancer, somatic;17357067;134934;Colorectal cancer, somatic, 114500 (3);114500
FGFR3;Crouzon syndrome with acanthosis nigricans;17357067;134934;Crouzon syndrome with acanthosis nigricans, 612247 (3);612247
FGFR3;Hypochondroplasia;17357067;134934;Hypochondroplasia, 146000 (3);146000
FGFR3;LADD syndrome;17357067;134934;LADD syndrome, 149730 (3);149730
FGFR3;Muenke syndrome;17357067;134934;Muenke syndrome, 602849 (3);602849
FGFR3;Nevus, epidermal, somatic;17357067;134934;Nevus, epidermal, somatic, 162900 (3);162900
FGFR3;SADDAN;17357067;134934;SADDAN, 616482 (3);616482
FGFR3;Spermatocytic seminoma, somatic;17357067;134934;Spermatocytic seminoma, somatic, 273300 (3);273300
FGFR3;Thanatophoric dysplasia, type I;17357067;134934;Thanatophoric dysplasia, type I, 187600 (3);187600
FGFR3;Thanatophoric dysplasia, type II;17357067;134934;Thanatophoric dysplasia, type II, 187601 (3);187601
FGFR4;Cancer progression/metastasis;17357067;134935;{Cancer progression/metastasis} (3);0
FGG;Afibrinogenemia, congenital;17357067;134850;Afibrinogenemia, congenital, 202400 (3);202400
FGG;Dysfibrinogenemia, congenital;17357067;134850;Dysfibrinogenemia, congenital, 616004 (3);616004
FGG;Hypodysfibrinogenemia;17357067;134850;Hypodysfibrinogenemia, 616004 (3);616004
FGG;Hypofibrinogenemia, congenital;17357067;134850;Hypofibrinogenemia, congenital, 202400 (3);202400
FH;Fumarase deficiency;17357067;136850;Fumarase deficiency, 606812 (3);606812
FH;Hypercholesterolemia, familial;17357067;606945;Hypercholesterolemia, familial, 143890 (3);143890
FH;LDL cholesterol level QTL2;17357067;606945;LDL cholesterol level QTL2, 143890 (3);143890
FH;Leiomyomatosis and renal cell cancer;17357067;136850;Leiomyomatosis and renal cell cancer, 150800 (3);150800
FHL1;Emery-Dreifuss muscular dystrophy 6, X-linked;17357067;300163;Emery-Dreifuss muscular dystrophy 6, X-linked, 300696 (3);300696
FHL1;Hemophagocytic lymphohistiocytosis, familial, 1;17357067;267700;Hemophagocytic lymphohistiocytosis, familial, 1 (2);0
FHL1;Myopathy, X-linked, with postural muscle atrophy;17357067;300163;Myopathy, X-linked, with postural muscle atrophy, 300696 (3);300696
FHL1;Myopathy, reducing body, X-linked, childhood-onset;17357067;300163;Myopathy, reducing body, X-linked, childhood-onset, 300718 (3);300718
FHL1;Myopathy, reducing body, X-linked, severe early-onset;17357067;300163;Myopathy, reducing body, X-linked, severe early-onset, 300717 (3);300717
FHL1;Scapuloperoneal myopathy, X-linked dominant;17357067;300163;Scapuloperoneal myopathy, X-linked dominant, 300695 (3);300695
FHL3;Hemophagocytic lymphohistiocytosis, familial, 3;17357067;608897;Hemophagocytic lymphohistiocytosis, familial, 3, 608898 (3);608898
FHL5;Hemophagocytic lymphohistiocytosis, familial, 5;17357067;601717;Hemophagocytic lymphohistiocytosis, familial, 5, 613101 (3);613101
FIG4;Amyotrophic lateral sclerosis 11;17357067;609390;Amyotrophic lateral sclerosis 11, 612577 (3);612577
FIG4;Charcot-Marie-Tooth disease, type 4J;17357067;609390;Charcot-Marie-Tooth disease, type 4J, 611228 (3);611228
FIG4;Yunis-Varon syndrome;17357067;609390;Yunis-Varon syndrome, 216340 (3);216340
FIGLA;Premature ovarian failure 6;17357067;608697;Premature ovarian failure 6, 612310 (3);612310
FKBP10;Bruck syndrome 1;17357067;607063;Bruck syndrome 1, 259450 (3);259450
FKBP10;Osteogenesis imperfecta, type XI;17357067;607063;Osteogenesis imperfecta, type XI, 610968 (3);610968
FKBP14;Ehlers-Danlos syndrome with progressive kyphoscoliosis, myopathy, and hearing loss;17357067;614505;Ehlers-Danlos syndrome with progressive kyphoscoliosis, myopathy, and hearing loss, 614557 (3);614557
FKBP5;Major depressive disorder and accelerated response to antidepressant drug treatment;17357067;602623;{Major depressive disorder and accelerated response to antidepressant drug treatment}, 608516 (3);608516
FKRP;Muscular dystrophy-dystroglycanopathy (congenital with brain and eye anomalies), type A, 5;17357067;606596;Muscular dystrophy-dystroglycanopathy (congenital with brain and eye anomalies), type A, 5, 613153 (3);613153
FKRP;Muscular dystrophy-dystroglycanopathy (congenital with or without mental retardation), type B, 5;17357067;606596;Muscular dystrophy-dystroglycanopathy (congenital with or without mental retardation), type B, 5, 606612 (3);606612
FKRP;Muscular dystrophy-dystroglycanopathy (limb-girdle), type C, 5;17357067;606596;Muscular dystrophy-dystroglycanopathy (limb-girdle), type C, 5, 607155 (3);607155
FKTN;Cardiomyopathy, dilated, 1X;17357067;607440;Cardiomyopathy, dilated, 1X, 611615 (3);611615
FKTN;Muscular dystrophy-dystroglycanopathy (congenital with brain and eye anomalies), type A, 4;17357067;607440;Muscular dystrophy-dystroglycanopathy (congenital with brain and eye anomalies), type A, 4, 253800 (3);253800
FKTN;Muscular dystrophy-dystroglycanopathy (congenital without mental retardation), type B, 4;17357067;607440;Muscular dystrophy-dystroglycanopathy (congenital without mental retardation), type B, 4, 613152 (3);613152
FKTN;Muscular dystrophy-dystroglycanopathy (limb-girdle), type C, 4;17357067;607440;Muscular dystrophy-dystroglycanopathy (limb-girdle), type C, 4, 611588 (3);611588
FLCN;Birt-Hogg-Dube syndrome;17357067;607273;Birt-Hogg-Dube syndrome, 135150 (3);135150
FLCN;Colorectal cancer, somatic;17357067;607273;Colorectal cancer, somatic, 114500 (3);114500
FLCN;Pneumothorax, primary spontaneous;17357067;607273;Pneumothorax, primary spontaneous, 173600 (3);173600
FLCN;Renal carcinoma, chromophobe, somatic;17357067;607273;Renal carcinoma, chromophobe, somatic, 144700 (3);144700
FLG;Dermatitis, atopic, susceptibility to, 2;17357067;135940;{Dermatitis, atopic, susceptibility to, 2}, 605803 (3);605803
FLG;Ichthyosis vulgaris;17357067;135940;Ichthyosis vulgaris, 146700 (3);146700
FLNA;Cardiac valvular dysplasia, X-linked;17357067;300017;Cardiac valvular dysplasia, X-linked, 314400 (3);314400
FLNA;Congenital short bowel syndrome;17357067;300017;Congenital short bowel syndrome, 300048 (3);300048
FLNA;FG syndrome 2;17357067;300017;FG syndrome 2, 300321 (3);300321
FLNA;Frontometaphyseal dysplasia;17357067;300017;Frontometaphyseal dysplasia, 305620 (3);305620
FLNA;Heterotopia, periventricular;17357067;300017;Heterotopia, periventricular, 300049 (3);300049
FLNA;Heterotopia, periventricular, ED variant;17357067;300017;Heterotopia, periventricular, ED variant, 300537 (3);300537
FLNA;Intestinal pseudoobstruction, neuronal;17357067;300017;Intestinal pseudoobstruction, neuronal, 300048 (3);300048
FLNA;Melnick-Needles syndrome;17357067;300017;Melnick-Needles syndrome, 309350 (3);309350
FLNA;Otopalatodigital syndrome, type I;17357067;300017;Otopalatodigital syndrome, type I, 311300 (3);311300
FLNA;Otopalatodigital syndrome, type II;17357067;300017;Otopalatodigital syndrome, type II, 304120 (3);304120
FLNA;Terminal osseous dysplasia;17357067;300017;Terminal osseous dysplasia, 300244 (3);300244
FLNB;Atelosteogenesis, type I;17357067;603381;Atelosteogenesis, type I, 108720 (3);108720
FLNB;Atelosteogenesis, type III;17357067;603381;Atelosteogenesis, type III, 108721 (3);108721
FLNB;Boomerang dysplasia;17357067;603381;Boomerang dysplasia, 112310 (3);112310
FLNB;Larsen syndrome;17357067;603381;Larsen syndrome, 150250 (3);150250
FLNB;Spondylocarpotarsal synostosis syndrome;17357067;603381;Spondylocarpotarsal synostosis syndrome, 272460 (3);272460
FLNC;Myopathy, distal, 4;17357067;102565;Myopathy, distal, 4, 614065 (3);614065
FLNC;Myopathy, myofibrillar, 5;17357067;102565;Myopathy, myofibrillar, 5, 609524 (3);609524
FLRT3;Hypogonadotropic hypogonadism 21 with anosmia;17357067;604808;Hypogonadotropic hypogonadism 21 with anosmia, 615271 (3);615271
FLT3;Leukemia, acute lymphoblastic, somatic;17357067;136351;Leukemia, acute lymphoblastic, somatic, 613065 (3);613065
FLT3;Leukemia, acute myeloid;17357067;136351;Leukemia, acute myeloid, 601626 (3);601626
FLT3;Leukemia, acute myeloid, reduced survival in;17357067;136351;Leukemia, acute myeloid, reduced survival in, 601626 (3);601626
FLT4;Hemangioma, capillary infantile, somatic;17357067;136352;Hemangioma, capillary infantile, somatic, 602089 (3);602089
FLT4;Lymphedema, hereditary, IA;17357067;136352;Lymphedema, hereditary, IA, 153100 (3);153100
FLVCR1;Ataxia, posterior column, with retinitis pigmentosa;17357067;609144;Ataxia, posterior column, with retinitis pigmentosa, 609033 (3);609033
FLVCR2;Proliferative vasculopathy and hydraencephaly-hydrocephaly syndrome;17357067;610865;Proliferative vasculopathy and hydraencephaly-hydrocephaly syndrome, 225790 (3);225790
FMN2;Mental retardation, autosomal recessive 47;17357067;606373;Mental retardation, autosomal recessive 47, 616193 (3);616193
FMO3;Trimethylaminuria;17357067;136132;Trimethylaminuria, 602079 (3);602079
FMR1;Fragile X syndrome;17357067;309550;Fragile X syndrome, 300624 (3);300624
FMR1;Fragile X tremor/ataxia syndrome;17357067;309550;Fragile X tremor/ataxia syndrome, 300623 (3);300623
FMR1;Premature ovarian failure 1;17357067;309550;Premature ovarian failure 1, 311360 (3);311360
FN1;Glomerulopathy with fibronectin deposits 2;17357067;135600;Glomerulopathy with fibronectin deposits 2, 601894 (3);601894
FN1;Plasma fibronectin deficiency;17357067;135600;Plasma fibronectin deficiency, 614101 (1);614101
FOLR1;Neurodegeneration due to cerebral folate transport deficiency;17357067;136430;Neurodegeneration due to cerebral folate transport deficiency, 613068 (3);613068
FOXC1;Axenfeld-Rieger syndrome, type 3;17357067;601090;Axenfeld-Rieger syndrome, type 3, 602482 (3);602482
FOXC1;Iridogoniodysgenesis, type 1;17357067;601090;Iridogoniodysgenesis, type 1, 601631 (3);601631
FOXC1;Iris hypoplasia and glaucoma;17357067;601090;Iris hypoplasia and glaucoma, 601631 (3);601631
FOXC1;Rieger or Axenfeld anomalies;17357067;601090;Rieger or Axenfeld anomalies, 602482 (3);602482
FOXC2;Lymphedema-distichiasis syndrome;17357067;602402;Lymphedema-distichiasis syndrome, 153400 (3);153400
FOXC2;Lymphedema-distichiasis syndrome with renal disease and diabetes mellitus;17357067;602402;Lymphedema-distichiasis syndrome with renal disease and diabetes mellitus, 153400 (3);153400
FOXD3;Autoimmune disease, susceptibility to, 1;17357067;611539;{Autoimmune disease, susceptibility to, 1}, 607836 (3);607836
FOXE1;Bamforth-Lazarus syndrome;17357067;602617;Bamforth-Lazarus syndrome, 241850 (3);241850
FOXE3;Anterior segment mesenchymal dysgenesis;17357067;601094;Anterior segment mesenchymal dysgenesis, 107250 (3);107250
FOXE3;Aphakia, congenital primary;17357067;601094;Aphakia, congenital primary, 610256 (3);610256
FOXF1;Alveolar capillary dysplasia with misalignment of pulmonary veins;17357067;601089;Alveolar capillary dysplasia with misalignment of pulmonary veins, 265380 (3);265380
FOXG1;Rett syndrome, congenital variant;17357067;164874;Rett syndrome, congenital variant, 613454 (3);613454
FOXI1;Enlarged vestibular aqueduct;17357067;601093;Enlarged vestibular aqueduct, 600791 (3);600791
FOXL2;Blepharophimosis, epicanthus inversus, and ptosis, type 1;17357067;605597;Blepharophimosis, epicanthus inversus, and ptosis, type 1, 110100 (3);110100
FOXL2;Blepharophimosis, epicanthus inversus, and ptosis, type 2;17357067;605597;Blepharophimosis, epicanthus inversus, and ptosis, type 2, 110100 (3);110100
FOXL2;Premature ovarian failure 3;17357067;605597;Premature ovarian failure 3, 608996 (3);608996
FOXN1;T-cell immunodeficiency, congenital alopecia, and nail dystrophy;17357067;600838;T-cell immunodeficiency, congenital alopecia, and nail dystrophy, 601705 (3);601705
FOXO1;Rhabdomyosarcoma, alveolar;17357067;136533;Rhabdomyosarcoma, alveolar, 268220 (3);268220
FOXP1;Mental retardation with language impairment and with or without autistic features;17357067;605515;Mental retardation with language impairment and with or without autistic features, 613670 (3);613670
FOXP2;Speech-language disorder-1;17357067;605317;Speech-language disorder-1, 602081 (3);602081
FOXP3;Diabetes mellitus, type I, susceptibility to;17357067;300292;{Diabetes mellitus, type I, susceptibility to}, 222100 (3);222100
FOXP3;Immunodysregulation, polyendocrinopathy, and enteropathy, X-linked;17357067;300292;Immunodysregulation, polyendocrinopathy, and enteropathy, X-linked, 304790 (3);304790
FOXRED1;Leigh syndrome due to mitochondrial complex I deficiency;17357067;613622;Leigh syndrome due to mitochondrial complex I deficiency, 256000 (3);256000
FOXRED1;Mitochondrial complex I deficiency;17357067;613622;Mitochondrial complex I deficiency, 252010 (3);252010
FRAS1;Fraser syndrome;17357067;607830;Fraser syndrome, 219000 (3);219000
FRAXA;Fragile X syndrome;17357067;309550;Fragile X syndrome, 300624 (3);300624
FRAXA;Fragile X tremor/ataxia syndrome;17357067;309550;Fragile X tremor/ataxia syndrome, 300623 (3);300623
FRAXA;Premature ovarian failure 1;17357067;309550;Premature ovarian failure 1, 311360 (3);311360
FRAXE;Mental retardation, X-linked, FRAXE type;17357067;300806;Mental retardation, X-linked, FRAXE type, 309548 (3);309548
FREM1;Bifid nose with or without anorectal and renal anomalies;17357067;608944;Bifid nose with or without anorectal and renal anomalies, 608980 (3);608980
FREM1;Manitoba oculotrichoanal syndrome;17357067;608944;Manitoba oculotrichoanal syndrome, 248450 (3);248450
FREM1;Trigonocephaly 2;17357067;608944;Trigonocephaly 2, 614485 (3);614485
FREM2;Fraser syndrome;17357067;608945;Fraser syndrome, 219000 (3);219000
FRK;Alzheimer disease 18, susceptibility to;17357067;602192;{Alzheimer disease 18, susceptibility to}, 615590 (3);615590
FRK;Reticulate acropigmentation of Kitamura;17357067;602192;Reticulate acropigmentation of Kitamura, 615537 (3);615537
FRMD7;Nystagmus 1, congenital, X-linked;17357067;300628;Nystagmus 1, congenital, X-linked, 310700 (3);310700
FRMD7;Nystagmus, infantile periodic alternating, X-linked;17357067;300628;Nystagmus, infantile periodic alternating, X-linked, 310700 (3);310700
FRZB;Osteoarthritis susceptibility 1;17357067;605083;{Osteoarthritis susceptibility 1}, 165720 (3);165720
FSCN2;Retinitis pigmentosa 30;17357067;607643;Retinitis pigmentosa 30, 607921 (3);607921
FSHB;Hypogonadotropic hypogonadism 24 without anosmia;17357067;136530;Hypogonadotropic hypogonadism 24 without anosmia, 229070 (3);229070
FSHR;Ovarian dysgenesis 1;17357067;136435;Ovarian dysgenesis 1, 233300 (3);233300
FSHR;Ovarian hyperstimulation syndrome;17357067;136435;Ovarian hyperstimulation syndrome, 608115 (3);608115
FSHR;Ovarian response to FSH stimulation;17357067;136435;Ovarian response to FSH stimulation, 276400 (3);276400
FTCD;Glutamate formiminotransferase deficiency;17357067;606806;Glutamate formiminotransferase deficiency, 229100 (3);229100
FTL;Hyperferritinemia-cataract syndrome;17357067;134790;Hyperferritinemia-cataract syndrome, 600886 (3);600886
FTL;L-ferritin deficiency, dominant and recessive;17357067;134790;L-ferritin deficiency, dominant and recessive, 615604 (3);615604
FTL;Neurodegeneration with brain iron accumulation 3;17357067;134790;Neurodegeneration with brain iron accumulation 3, 606159 (3);606159
FTO;Growth retardation, developmental delay, coarse facies, and early death;17357067;610966;Growth retardation, developmental delay, coarse facies, and early death, 612938 (3);612938
FTSJ1;Mental retardation, X-linked 9;17357067;300499;Mental retardation, X-linked 9, 309549 (3);309549
FUCA1;Fucosidosis;17357067;612280;Fucosidosis, 230000 (3);230000
FUS;Amyotrophic lateral sclerosis 6, with or without frontotemporal dementia;17357067;137070;Amyotrophic lateral sclerosis 6, with or without frontotemporal dementia, 608030 (3);608030
FUS;Tremor, hereditary essential, 4;17357067;137070;Tremor, hereditary essential, 4, 614782 (3);614782
FUT1;Bombay phenotype;17357067;211100;[Bombay phenotype] (3);0
FUT2;Bombay phenotype;17357067;182100;[Bombay phenotype] (3);0
FUT2;Norwalk virus infection, resistance to;17357067;182100;{Norwalk virus infection, resistance to} (3);0
FUT2;Vitamin B12 plasma level QTL1;17357067;182100;{Vitamin B12 plasma level QTL1}, 612542 (3);612542
FUT3;Blood group, Lewis;17357067;111100;[Blood group, Lewis] (3);0
FUT6;Fucosyltransferase 6 deficiency;17357067;136836;Fucosyltransferase 6 deficiency, 613852 (3);613852
FUZ;Neural tube defects;17357067;610622;Neural tube defects, 182940 (3);182940
FXN;Fanconi anemia, complementation group A;17357067;607139;Fanconi anemia, complementation group A, 227650 (3);227650
FXN;Friedreich ataxia;17357067;606829;Friedreich ataxia, 229300 (3);229300
FXN;Friedreich ataxia with retained reflexes;17357067;606829;Friedreich ataxia with retained reflexes, 229300 (3);229300
FXYD2;Hypomagnesemia-2, renal;17357067;601814;Hypomagnesemia-2, renal, 154020 (3);154020
FYCO1;Cataract 18, autosomal recessive;17357067;607182;Cataract 18, autosomal recessive, 610019 (3);610019
FZD4;Exudative vitreoretinopathy 1;17357067;604579;Exudative vitreoretinopathy 1, 133780 (3);133780
FZD4;Retinopathy of prematurity;17357067;604579;Retinopathy of prematurity, 133780 (3);133780
FZD6;Nail disorder, nonsyndromic congenital, 10, (claw-shaped nails);17357067;603409;Nail disorder, nonsyndromic congenital, 10, (claw-shaped nails), 614157 (3);614157
G6PC;Glycogen storage disease Ia;17357067;613742;Glycogen storage disease Ia, 232200 (3);232200
G6PC3;Dursun syndrome;17357067;611045;Dursun syndrome, 612541 (3);612541
G6PC3;Neutropenia, severe congenital 4, autosomal recessive;17357067;611045;Neutropenia, severe congenital 4, autosomal recessive, 612541 (3);612541
G6PD;Favism;17357067;305900;Favism, 134700 (3);134700
G6PD;Hemolytic anemia due to G6PD deficiency;17357067;305900;Hemolytic anemia due to G6PD deficiency, 300908 (3);300908
G6PD;Resistance to malaria due to G6PD deficiency;17357067;305900;{Resistance to malaria due to G6PD deficiency}, 611162 (3);611162
GAA;Glycogen storage disease II;17357067;606800;Glycogen storage disease II, 232300 (3);232300
GABBR2;Nicotine dependence, protection against;17357067;607340;{Nicotine dependence, protection against}, 188890 (3);188890
GABBR2;Nicotine dependence, susceptibility to;17357067;607340;{Nicotine dependence, susceptibility to}, 188890 (3);188890
GABRA1;Epilepsy, childhood absence, susceptibility to, 4;17357067;137160;{Epilepsy, childhood absence, susceptibility to, 4}, 611136 (3);611136
GABRA1;Epilepsy, juvenile myoclonic, susceptibility to, 5;17357067;137160;{Epilepsy, juvenile myoclonic, susceptibility to, 5}, 611136 (3);611136
GABRA1;Epileptic encephalopathy, early infantile, 19;17357067;137160;Epileptic encephalopathy, early infantile, 19, 615744 (3);615744
GABRA2;Alcohol dependence, susceptibility to;17357067;137140;{Alcohol dependence, susceptibility to}, 103780 (3);103780
GABRB3;Epilepsy, childhood absence, susceptibility to, 5;17357067;137192;{Epilepsy, childhood absence, susceptibility to, 5}, 612269 (3);612269
GABRD;Epilepsy, generalized, with febrile seizures plus, type 5, susceptibility to;17357067;137163;{Epilepsy, generalized, with febrile seizures plus, type 5, susceptibility to}, 613060 (3);613060
GABRD;Epilepsy, idiopathic generalized, 10;17357067;137163;{Epilepsy, idiopathic generalized, 10}, 613060 (3);613060
GABRD;Epilepsy, juvenile myoclonic, susceptibility to;17357067;137163;{Epilepsy, juvenile myoclonic, susceptibility to}, 613060 (3);613060
GABRG2;Epilepsy, childhood absence, susceptibility to, 2;17357067;137164;{Epilepsy, childhood absence, susceptibility to, 2}, 607681 (3);607681
GABRG2;Epilepsy, generalized, with febrile seizures plus, type 3;17357067;137164;Epilepsy, generalized, with febrile seizures plus, type 3, 611277 (3);611277
GABRG2;Febrile seizures, familial, 8;17357067;137164;Febrile seizures, familial, 8, 611277 (3);611277
GAD1;Cerebral palsy, spastic quadriplegic, 1;17357067;605363;Cerebral palsy, spastic quadriplegic, 1, 603513 (3);603513
GALC;Krabbe disease;17357067;606890;Krabbe disease, 245200 (3);245200
GALE;Galactose epimerase deficiency;17357067;606953;Galactose epimerase deficiency, 230350 (3);230350
GALK1;Galactokinase deficiency with cataracts;17357067;604313;Galactokinase deficiency with cataracts, 230200 (3);230200
GALNS;Mucopolysaccharidosis IVA;17357067;612222;Mucopolysaccharidosis IVA, 253000 (3);253000
GALNT12;Colorectal cancer, susceptibility to, 1;17357067;610290;{Colorectal cancer, susceptibility to, 1}, 608812 (3);608812
GALNT3;Hypotrichosis 1;17357067;607479;Hypotrichosis 1, 605389 (3);605389
GALNT3;Tumoral calcinosis, hyperphosphatemic, familial;17357067;601756;Tumoral calcinosis, hyperphosphatemic, familial, 211900 (3);211900
GALT;Galactosemia;17357067;606999;Galactosemia, 230400 (3);230400
GAMT;Cerebral creatine deficiency syndrome 2;17357067;601240;Cerebral creatine deficiency syndrome 2, 612736 (3);612736
GAN;Giant axonal neuropathy-1;17357067;605379;Giant axonal neuropathy-1, 256850 (3);256850
GARS;Charcot-Marie-Tooth disease, type 2D;17357067;600287;Charcot-Marie-Tooth disease, type 2D, 601472 (3);601472
GARS;Neuropathy, distal hereditary motor, type VA;17357067;600287;Neuropathy, distal hereditary motor, type VA, 600794 (3);600794
GATA1;Anemia, X-linked, with/without neutropenia and/or platelet abnormalities;17357067;305371;Anemia, X-linked, with/without neutropenia and/or platelet abnormalities, 300835 (3);300835
GATA1;Leukemia, megakaryoblastic, with or without Down syndrome, somatic;17357067;305371;Leukemia, megakaryoblastic, with or without Down syndrome, somatic, 190685 (3);190685
GATA1;Thrombocytopenia with beta-thalassemia, X-linked;17357067;305371;Thrombocytopenia with beta-thalassemia, X-linked, 314050 (3);314050
GATA1;Thrombocytopenia, X-linked, with or without dyserythropoietic anemia;17357067;305371;Thrombocytopenia, X-linked, with or without dyserythropoietic anemia, 300367 (3);300367
GATA2;Emberger syndrome;17357067;137295;Emberger syndrome, 614038 (3);614038
GATA2;Immunodeficiency 21;17357067;137295;Immunodeficiency 21, 614172 (3);614172
GATA2;Leukemia, acute myeloid, susceptibility to;17357067;137295;{Leukemia, acute myeloid, susceptibility to}, 601626 (3);601626
GATA2;Myelodysplastic syndrome, susceptibility to;17357067;137295;{Myelodysplastic syndrome, susceptibility to}, 614286 (3);614286
GATA3;Hypoparathyroidism, sensorineural deafness, and renal dysplasia;17357067;131320;Hypoparathyroidism, sensorineural deafness, and renal dysplasia, 146255 (3);146255
GATA4;Atrial septal defect 2;17357067;600576;Atrial septal defect 2, 607941 (3);607941
GATA4;Atrioventricular septal defect 4;17357067;600576;Atrioventricular septal defect 4, 614430 (3);614430
GATA4;Tetralogy of Fallot;17357067;600576;Tetralogy of Fallot, 187500 (3);187500
GATA4;Ventricular septal defect 1;17357067;600576;Ventricular septal defect 1, 614429 (3);614429
GATA6;Atrial septal defect 9;17357067;601656;Atrial septal defect 9, 614475 (3);614475
GATA6;Atrioventricular septal defect 5;17357067;601656;Atrioventricular septal defect 5, 614474 (3);614474
GATA6;Pancreatic agenesis and congenital heart defects;17357067;601656;Pancreatic agenesis and congenital heart defects, 600001 (3);600001
GATA6;Persistent truncus arteriosus;17357067;601656;Persistent truncus arteriosus, 217095 (3);217095
GATA6;Tetralogy of Fallot;17357067;601656;Tetralogy of Fallot, 187500 (3);187500
GATAD2B;Mental retardation, autosomal dominant 18;17357067;614998;Mental retardation, autosomal dominant 18, 615074 (3);615074
GATM;Cerebral creatine deficiency syndrome 3;17357067;602360;Cerebral creatine deficiency syndrome 3, 612718 (3);612718
GBA;Gaucher disease, perinatal lethal;17357067;606463;Gaucher disease, perinatal lethal, 608013 (3);608013
GBA;Gaucher disease, type I, 23080;17357067;606463;Gaucher disease, type I, 230800(3);0
GBA;Gaucher disease, type II;17357067;606463;Gaucher disease, type II, 230900 (3);230900
GBA;Gaucher disease, type III;17357067;606463;Gaucher disease, type III, 231000 (3);231000
GBA;Gaucher disease, type IIIC;17357067;606463;Gaucher disease, type IIIC, 231005 (3);231005
GBA;Lewy body dementia, susceptibility to;17357067;606463;{Lewy body dementia, susceptibility to}, 127750 (3);127750
GBA;Parkinson disease, late-onset, susceptibility to;17357067;606463;{Parkinson disease, late-onset, susceptibility to}, 168600 (3);168600
GBA2;Spastic paraplegia 46, autosomal recessive;17357067;609471;Spastic paraplegia 46, autosomal recessive, 614409 (3);614409
GBE1;Glycogen storage disease IV;17357067;607839;Glycogen storage disease IV, 232500 (3);232500
GBE1;Polyglucosan body disease, adult form;17357067;607839;Polyglucosan body disease, adult form, 263570 (3);263570
GCDH;Glutaricaciduria, type I;17357067;608801;Glutaricaciduria, type I, 231670 (3);231670
GCGR;Diabetes mellitus, noninsulin-dependent;17357067;138033;{Diabetes mellitus, noninsulin-dependent}, 125853 (3);125853
GCH1;Dystonia, DOPA-responsive, with or without hyperphenylalaninemia;17357067;600225;Dystonia, DOPA-responsive, with or without hyperphenylalaninemia, 128230 (3);128230
GCH1;Hyperphenylalaninemia, BH4-deficient, B;17357067;600225;Hyperphenylalaninemia, BH4-deficient, B, 233910 (3);233910
GCK;Diabetes mellitus, noninsulin-dependent, late onset;17357067;138079;Diabetes mellitus, noninsulin-dependent, late onset, 125853 (3);125853
GCK;Diabetes mellitus, permanent neonatal;17357067;138079;Diabetes mellitus, permanent neonatal, 606176 (3);606176
GCK;Hyperinsulinemic hypoglycemia, familial, 3;17357067;138079;Hyperinsulinemic hypoglycemia, familial, 3, 602485 (3);602485
GCK;MODY, type II;17357067;138079;MODY, type II, 125851 (3);125851
GCKR;Fasting plasma glucose level QTL 5;17357067;600842;[Fasting plasma glucose level QTL 5], 613463 (3);613463
GCLC;Hemolytic anemia due to gamma-glutamylcysteine synthetase deficiency;17357067;606857;Hemolytic anemia due to gamma-glutamylcysteine synthetase deficiency, 230450 (3);230450
GCLC;Myocardial infarction, susceptibility to;17357067;606857;{Myocardial infarction, susceptibility to}, 608446 (3);608446
GCLM;Myocardial infarction, susceptibility to;17357067;601176;{Myocardial infarction, susceptibility to}, 608446 (3);608446
GCM2;Hypoparathyroidism, familial isolated;17357067;603716;Hypoparathyroidism, familial isolated, 146200 (3);146200
GCNT2;Adult i phenotype without cataract;17357067;600429;Adult i phenotype without cataract, 110800 (3);110800
GCNT2;Blood group, Ii;17357067;600429;[Blood group, Ii], 110800 (3);110800
GCNT2;Cataract 13 with adult i phenotype;17357067;600429;Cataract 13 with adult i phenotype, 116700 (3);116700
GCSH;Glycine encephalopathy;17357067;238330;Glycine encephalopathy, 605899 (3);605899
GDAP1;Charcot-Marie-Tooth disease, axonal, type 2K;17357067;606598;Charcot-Marie-Tooth disease, axonal, type 2K, 607831 (3);607831
GDAP1;Charcot-Marie-Tooth disease, axonal, with vocal cord paresis;17357067;606598;Charcot-Marie-Tooth disease, axonal, with vocal cord paresis, 607706 (3);607706
GDAP1;Charcot-Marie-Tooth disease, recessive intermediate, A;17357067;606598;Charcot-Marie-Tooth disease, recessive intermediate, A, 608340 (3);608340
GDAP1;Charcot-Marie-Tooth disease, type 4A;17357067;606598;Charcot-Marie-Tooth disease, type 4A, 214400 (3);214400
GDF1;Double-outlet right ventricle;17357067;602880;Double-outlet right ventricle, 217095 (3);217095
GDF1;Right atrial isomerism;17357067;602880;Right atrial isomerism, 208530 (3);208530
GDF1;Tetralogy of Fallot;17357067;602880;Tetralogy of Fallot, 187500 (3);187500
GDF1;Transposition of great arteries, dextro-looped 3;17357067;602880;Transposition of great arteries, dextro-looped 3, 613854 (3);613854
GDF2;Telangiectasia, hereditary hemorrhagic, type 5;17357067;605120;Telangiectasia, hereditary hemorrhagic, type 5, 615506 (3);615506
GDF3;Klippel-Feil syndrome 3, autosomal dominant;17357067;606522;Klippel-Feil syndrome 3, autosomal dominant, 613702 (3);613702
GDF3;Microphthalmia with coloboma 6;17357067;606522;Microphthalmia with coloboma 6, 613703 (3);613703
GDF3;Microphthalmia, isolated 7;17357067;606522;Microphthalmia, isolated 7, 613704 (3);613704
GDF5;Acromesomelic dysplasia, Hunter-Thompson type;17357067;601146;Acromesomelic dysplasia, Hunter-Thompson type, 201250 (3);201250
GDF5;Brachydactyly, type A1, C;17357067;601146;Brachydactyly, type A1, C, 615072 (3);615072
GDF5;Brachydactyly, type A2;17357067;601146;Brachydactyly, type A2, 112600 (3);112600
GDF5;Brachydactyly, type C;17357067;601146;Brachydactyly, type C, 113100 (3);113100
GDF5;Chondrodysplasia, Grebe type;17357067;601146;Chondrodysplasia, Grebe type, 200700 (3);200700
GDF5;Du Pan syndrome;17357067;601146;Du Pan syndrome, 228900 (3);228900
GDF5;Multiple synostoses syndrome 2;17357067;601146;Multiple synostoses syndrome 2, 610017 (3);610017
GDF5;Osteoarthritis-5;17357067;601146;{Osteoarthritis-5}, 612400 (3);612400
GDF5;Symphalangism, proximal, 1B;17357067;601146;Symphalangism, proximal, 1B, 615298 (3);615298
GDF6;Klippel-Feil syndrome 1, autosomal dominant;17357067;601147;Klippel-Feil syndrome 1, autosomal dominant, 118100 (3);118100
GDF6;Leber congenital amaurosis 17;17357067;601147;Leber congenital amaurosis 17, 615360 (3);615360
GDF6;Microphthalmia with coloboma 6, digenic;17357067;601147;Microphthalmia with coloboma 6, digenic, 613703 (3);613703
GDF6;Microphthalmia, isolated 4;17357067;601147;Microphthalmia, isolated 4, 613094 (3);613094
GDI1;Mental retardation, X-linked 41;17357067;300104;Mental retardation, X-linked 41, 300849 (3);300849
GDNF;Central hypoventilation syndrome;17357067;600837;Central hypoventilation syndrome, 209880 (3);209880
GDNF;Hirschsprung disease, susceptibility to, 3;17357067;600837;{Hirschsprung disease, susceptibility to, 3}, 613711 (3);613711
GDNF;Pheochromocytoma, modifier of;17357067;600837;{Pheochromocytoma, modifier of}, 171300 (3);171300
GFAP;Alexander disease;17357067;137780;Alexander disease, 203450 (3);203450
GFER;Myopathy, mitochondrial progressive, with congenital cataract, hearing loss, and developmental delay;17357067;600924;Myopathy, mitochondrial progressive, with congenital cataract, hearing loss, and developmental delay, 613076 (3);613076
GFI1;Neutropenia, nonimmune chronic idiopathic, of adults;17357067;600871;Neutropenia, nonimmune chronic idiopathic, of adults, 607847 (3);607847
GFI1;Neutropenia, severe congenital 2, autosomal dominant;17357067;600871;Neutropenia, severe congenital 2, autosomal dominant, 613107 (3);613107
GFI1B;Bleeding disorder, platelet-type, 17;17357067;604383;Bleeding disorder, platelet-type, 17, 187900 (3);187900
GFM1;Combined oxidative phosphorylation deficiency 1;17357067;606639;Combined oxidative phosphorylation deficiency 1, 609060 (3);609060
GFPT1;Myasthenia, congenital, 12, with tubular aggregates;17357067;138292;Myasthenia, congenital, 12, with tubular aggregates, 610542 (3);610542
GGCX;Pseudoxanthoma elasticum-like disorder with multiple coagulation factor deficiency;17357067;137167;Pseudoxanthoma elasticum-like disorder with multiple coagulation factor deficiency, 610842 (3);610842
GGCX;Vitamin K-dependent clotting factors, combined deficiency of, 1;17357067;137167;Vitamin K-dependent clotting factors, combined deficiency of, 1, 277450 (3);277450
GGT1;Glutathioninuria;17357067;231950;Glutathioninuria (1);0
GGT2;Gamma-glutamyltransferase, familial high serum;17357067;137181;[Gamma-glutamyltransferase, familial high serum] (2);0
GH1;Growth hormone deficiency, isolated, type IA;17357067;139250;Growth hormone deficiency, isolated, type IA, 262400 (3);262400
GH1;Growth hormone deficiency, isolated, type IB;17357067;139250;Growth hormone deficiency, isolated, type IB, 612781 (3);612781
GH1;Growth hormone deficiency, isolated, type II;17357067;139250;Growth hormone deficiency, isolated, type II, 173100 (3);173100
GH1;Kowarski syndrome;17357067;139250;Kowarski syndrome, 262650 (3);262650
GHR;Growth hormone insensitivity, partial;17357067;600946;Growth hormone insensitivity, partial, 604271 (3);604271
GHR;Hypercholesterolemia, familial, modifier of;17357067;600946;{Hypercholesterolemia, familial, modifier of}, 143890 (3);143890
GHR;Increased responsiveness to growth hormone;17357067;600946;Increased responsiveness to growth hormone (3);0
GHR;Laron dwarfism;17357067;600946;Laron dwarfism, 262500 (3);262500
GHRH;Gigantism due to GHRF hypersecretion;17357067;139190;Gigantism due to GHRF hypersecretion (1);0
GHRHR;Growth hormone deficiency, isolated, type IB;17357067;139191;Growth hormone deficiency, isolated, type IB, 612781 (3);612781
GHRL;Obesity, susceptibility to;17357067;605353;{Obesity, susceptibility to}, 601665 (3);601665
GHSR;Growth hormone deficiency, isolated partial;17357067;601898;Growth hormone deficiency, isolated partial, 615925 (3);615925
GIF;Intrinsic factor deficiency;17357067;609342;Intrinsic factor deficiency, 261000 (3);261000
GIGYF2;Parkinson disease 11;17357067;612003;{Parkinson disease 11}, 607688 (3);607688
GIP;Pituitary ACTH-secreting adenoma;17357067;139360;Pituitary ACTH-secreting adenoma (3);0
GIP;Ventricular tachycardia, idiopathic;17357067;139360;Ventricular tachycardia, idiopathic, 192605 (3);192605
GIPC3;Deafness, autosomal recessive 15;17357067;608792;Deafness, autosomal recessive 15, 601869 (3);601869
GIPR;Plasma glucose, 2-hour, QTL 2;17357067;137241;[Plasma glucose, 2-hour, QTL 2] (2);0
GJA1;Atrioventricular septal defect 3;17357067;121014;Atrioventricular septal defect 3, 600309 (3);600309
GJA1;Craniometaphyseal dysplasia, autosomal recessive;17357067;121014;Craniometaphyseal dysplasia, autosomal recessive, 218400 (3);218400
GJA1;Erythrokeratodermia variabilis et progressiva;17357067;121014;Erythrokeratodermia variabilis et progressiva, 133200 (3);133200
GJA1;Hypoplastic left heart syndrome 1;17357067;121014;Hypoplastic left heart syndrome 1, 241550 (3);241550
GJA1;Oculodentodigital dysplasia;17357067;121014;Oculodentodigital dysplasia, 164200 (3);164200
GJA1;Oculodentodigital dysplasia, autosomal recessive;17357067;121014;Oculodentodigital dysplasia, autosomal recessive, 257850 (3);257850
GJA1;Palmoplantar keratoderma with congenital alopecia;17357067;121014;Palmoplantar keratoderma with congenital alopecia, 104100 (3);104100
GJA1;Syndactyly, type III;17357067;121014;Syndactyly, type III, 186100 (3);186100
GJA3;Cataract 14, multiple types;17357067;121015;Cataract 14, multiple types, 601885 (3);601885
GJA5;Atrial fibrillation, familial, 11;17357067;121013;Atrial fibrillation, familial, 11, 614049 (3);614049
GJA5;Atrial standstill, digenic (GJA5/SCN5A);17357067;121013;Atrial standstill, digenic (GJA5/SCN5A), 108770 (3);108770
GJA8;Cataract 1, multiple types;17357067;600897;Cataract 1, multiple types, 116200 (3);116200
GJB1;Charcot-Marie-Tooth neuropathy, X-linked dominant, 1;17357067;304040;Charcot-Marie-Tooth neuropathy, X-linked dominant, 1, 302800 (3);302800
GJB2;Bart-Pumphrey syndrome;17357067;121011;Bart-Pumphrey syndrome, 149200 (3);149200
GJB2;Deafness, autosomal dominant 3A;17357067;121011;Deafness, autosomal dominant 3A, 601544 (3);601544
GJB2;Deafness, autosomal recessive 1A;17357067;121011;Deafness, autosomal recessive 1A, 220290 (3);220290
GJB2;Hystrix-like ichthyosis with deafness;17357067;121011;Hystrix-like ichthyosis with deafness, 602540 (3);602540
GJB2;Keratitis-ichthyosis-deafness syndrome;17357067;121011;Keratitis-ichthyosis-deafness syndrome, 148210 (3);148210
GJB2;Keratoderma, palmoplantar, with deafness;17357067;121011;Keratoderma, palmoplantar, with deafness, 148350 (3);148350
GJB2;Vohwinkel syndrome;17357067;121011;Vohwinkel syndrome, 124500 (3);124500
GJB3;Deafness, autosomal dominant 2B;17357067;603324;Deafness, autosomal dominant 2B, 612644 (3);612644
GJB3;Deafness, autosomal dominant, with peripheral neuropathy;17357067;603324;Deafness, autosomal dominant, with peripheral neuropathy (3);0
GJB3;Deafness, autosomal recessive;17357067;603324;Deafness, autosomal recessive (3);0
GJB3;Deafness, digenic, GJB2/GJB3;17357067;603324;Deafness, digenic, GJB2/GJB3, 220290 (3);220290
GJB3;Erythrokeratodermia variabilis et progressiva;17357067;603324;Erythrokeratodermia variabilis et progressiva, 133200 (3);133200
GJB4;Erythrokeratodermia variabilis with erythema gyratum repens;17357067;605425;Erythrokeratodermia variabilis with erythema gyratum repens, 133200 (3);133200
GJB6;Deafness, autosomal dominant 3B;17357067;604418;Deafness, autosomal dominant 3B, 612643 (3);612643
GJB6;Deafness, autosomal recessive 1B;17357067;604418;Deafness, autosomal recessive 1B, 612645 (3);612645
GJB6;Deafness, digenic GJB2/GJB6;17357067;604418;Deafness, digenic GJB2/GJB6, 220290 (3);220290
GJB6;Ectodermal dysplasia 2, Clouston type;17357067;604418;Ectodermal dysplasia 2, Clouston type, 129500 (3);129500
GJC2;Leukodystrophy, hypomyelinating, 2;17357067;608803;Leukodystrophy, hypomyelinating, 2, 608804 (3);608804
GJC2;Lymphedema, hereditary, IC;17357067;608803;Lymphedema, hereditary, IC, 613480 (3);613480
GJC2;Spastic paraplegia 44, autosomal recessive;17357067;608803;Spastic paraplegia 44, autosomal recessive, 613206 (3);613206
GK;Glycerol kinase deficiency;17357067;300474;Glycerol kinase deficiency, 307030 (3);307030
GLA;Fabry disease;17357067;300644;Fabry disease, 301500 (3);301500
GLA;Fabry disease, cardiac variant;17357067;300644;Fabry disease, cardiac variant, 301500 (3);301500
GLB1;GM1-gangliosidosis, type I;17357067;611458;GM1-gangliosidosis, type I, 230500 (3);230500
GLB1;GM1-gangliosidosis, type II;17357067;611458;GM1-gangliosidosis, type II, 230600 (3);230600
GLB1;GM1-gangliosidosis, type III;17357067;611458;GM1-gangliosidosis, type III, 230650 (3);230650
GLB1;Mucopolysaccharidosis type IVB (Morquio);17357067;611458;Mucopolysaccharidosis type IVB (Morquio), 253010 (3);253010
GLCCI1;Glucocorticoid therapy, response to;17357067;614283;{Glucocorticoid therapy, response to}, 614400 (3);614400
GLDC;Glycine encephalopathy;17357067;238300;Glycine encephalopathy, 605899 (3);605899
GLE1;Arthrogryposis, lethal, with anterior horn cell disease;17357067;603371;Arthrogryposis, lethal, with anterior horn cell disease, 611890 (3);611890
GLE1;Lethal congenital contracture syndrome 1;17357067;603371;Lethal congenital contracture syndrome 1, 253310 (3);253310
GLI2;Culler-Jones syndrome;17357067;165230;Culler-Jones syndrome, 615849 (3);615849
GLI2;Holoprosencephaly-9;17357067;165230;Holoprosencephaly-9, 610829 (3);610829
GLI3;Acrocallosal syndrome;17357067;611254;Acrocallosal syndrome, 200990 (3);200990
GLI3;Greig cephalopolysyndactyly syndrome;17357067;165240;Greig cephalopolysyndactyly syndrome, 175700 (3);175700
GLI3;Hydrolethalus syndrome 2;17357067;611254;Hydrolethalus syndrome 2, 614120 (3);614120
GLI3;Hypothalamic hamartomas, somatic;17357067;165240;{Hypothalamic hamartomas, somatic}, 241800 (3);241800
GLI3;Joubert syndrome 12;17357067;611254;Joubert syndrome 12, 200990 (3);200990
GLI3;Pallister-Hall syndrome;17357067;165240;Pallister-Hall syndrome, 146510 (3);146510
GLI3;Polydactyly, postaxial, types A1 and B;17357067;165240;Polydactyly, postaxial, types A1 and B, 174200 (3);174200
GLI3;Polydactyly, preaxial, type IV;17357067;165240;Polydactyly, preaxial, type IV, 174700 (3);174700
GLIS2;Nephronophthisis 7;17357067;608539;Nephronophthisis 7, 611498 (3);611498
GLIS3;Diabetes mellitus, neonatal, with congenital hypothyroidism;17357067;610192;Diabetes mellitus, neonatal, with congenital hypothyroidism, 610199 (3);610199
GLMN;Glomuvenous malformations;17357067;601749;Glomuvenous malformations, 138000 (3);138000
GLRA1;Hyperekplexia, hereditary 1, autosomal dominant or recessive;17357067;138491;Hyperekplexia, hereditary 1, autosomal dominant or recessive, 149400 (3);149400
GLRB;Hyperekplexia 2, autosomal recessive;17357067;138492;Hyperekplexia 2, autosomal recessive, 614619 (3);614619
GLUD1;Hyperinsulinism-hyperammonemia syndrome;17357067;138130;Hyperinsulinism-hyperammonemia syndrome, 606762 (3);606762
GLUL;Glutamine deficiency, congenital;17357067;138290;Glutamine deficiency, congenital, 610015 (3);610015
GLYCTK;D-glyceric aciduria;17357067;610516;D-glyceric aciduria, 220120 (3);220120
GM2A;GM2-gangliosidosis, AB variant;17357067;613109;GM2-gangliosidosis, AB variant, 272750 (3);272750
GMPPA;Alacrima, achalasia, and mental retardation syndrome;17357067;615495;Alacrima, achalasia, and mental retardation syndrome, 615510 (3);615510
GMPPB;Muscular dystrophy-dystroglycanopathy (congenital with brain and eye anomalies), type A, 14;17357067;615320;Muscular dystrophy-dystroglycanopathy (congenital with brain and eye anomalies), type A, 14, 615350 (3);615350
GMPPB;Muscular dystrophy-dystroglycanopathy (congenital with mental retardation), type B, 14;17357067;615320;Muscular dystrophy-dystroglycanopathy (congenital with mental retardation), type B, 14, 615351 (3);615351
GMPPB;Muscular dystrophy-dystroglycanopathy (limb-girdle), type C, 14;17357067;615320;Muscular dystrophy-dystroglycanopathy (limb-girdle), type C, 14, 615352 (3);615352
GMPS;Leukemia, acute myelogenous;17357067;600358;Leukemia, acute myelogenous, 601626 (3);601626
GNA11;Hypocalcemia, autosomal dominant 2;17357067;139313;Hypocalcemia, autosomal dominant 2, 615361 (3);615361
GNA11;Hypocalciuric hypercalcemia, type II;17357067;139313;Hypocalciuric hypercalcemia, type II, 145981 (3);145981
GNAI2;Pituitary ACTH-secreting adenoma;17357067;139360;Pituitary ACTH-secreting adenoma (3);0
GNAI2;Ventricular tachycardia, idiopathic;17357067;139360;Ventricular tachycardia, idiopathic, 192605 (3);192605
GNAI3;Auriculocondylar syndrome 1;17357067;139370;Auriculocondylar syndrome 1, 602483 (3);602483
GNAL;Dystonia 25;17357067;139312;Dystonia 25, 615073 (3);615073
GNAO1;Epileptic encephalopathy, early infantile, 17;17357067;139311;Epileptic encephalopathy, early infantile, 17, 615473 (3);615473
GNAQ;Capillary malformations, congenital, 1, somatic, mosaic;17357067;600998;Capillary malformations, congenital, 1, somatic, mosaic, 163000 (3);163000
GNAQ;Sturge-Weber syndrome, somatic, mosaic;17357067;600998;Sturge-Weber syndrome, somatic, mosaic, 185300 (3);185300
GNAS;ACTH-independent macronodular adrenal hyperplasia;17357067;139320;ACTH-independent macronodular adrenal hyperplasia, 219080 (3);219080
GNAS;Acromegaly, somatic;17357067;139320;Acromegaly, somatic, 102200 (3);102200
GNAS;McCune-Albright syndrome, somatic, mosaic;17357067;139320;McCune-Albright syndrome, somatic, mosaic 174800 (3);174800
GNAS;Osseous heteroplasia, progressive;17357067;139320;Osseous heteroplasia, progressive, 166350 (3);166350
GNAS;Pseudohypoparathyroidism Ia;17357067;139320;Pseudohypoparathyroidism Ia, 103580 (3);103580
GNAS;Pseudohypoparathyroidism Ib;17357067;139320;Pseudohypoparathyroidism Ib, 603233 (3);603233
GNAS;Pseudohypoparathyroidism Ic;17357067;139320;Pseudohypoparathyroidism Ic, 612462 (3);612462
GNAS;Pseudopseudohypoparathyroidism;17357067;139320;Pseudopseudohypoparathyroidism, 612463 (3);612463
GNAS-AS1;Pseudohypoparathyroidism, type IB;17357067;610540;Pseudohypoparathyroidism, type IB, 603233 (3);603233
GNAT1;Night blindness, congenital stationary, autosomal dominant 3;17357067;139330;Night blindness, congenital stationary, autosomal dominant 3, 610444 (3);610444
GNAT2;Achromatopsia-4;17357067;139340;Achromatopsia-4, 613856 (3);613856
GNB3;Hypertension, essential, susceptibility to;17357067;139130;{Hypertension, essential, susceptibility to}, 145500 (3);145500
GNB4;Charcot-Marie-Tooth disease, dominant intermediate F;17357067;610863;Charcot-Marie-Tooth disease, dominant intermediate F, 615185 (3);615185
GNE;Inclusion body myopathy, autosomal recessive;17357067;603824;Inclusion body myopathy, autosomal recessive, 600737 (3);600737
GNE;Nonaka myopathy;17357067;603824;Nonaka myopathy, 605820 (3);605820
GNE;Sialuria;17357067;603824;Sialuria, 269921 (3);269921
GNMT;Glycine N-methyltransferase deficiency;17357067;606628;Glycine N-methyltransferase deficiency, 606664 (3);606664
GNPAT;Chondrodysplasia punctata, rhizomelic, type 2;17357067;602744;Chondrodysplasia punctata, rhizomelic, type 2, 222765 (3);222765
GNPTAB;Mucolipidosis II alpha/beta;17357067;607840;Mucolipidosis II alpha/beta, 252500 (3);252500
GNPTAB;Mucolipidosis III alpha/beta;17357067;607840;Mucolipidosis III alpha/beta, 252600 (3);252600
GNPTG;Mucolipidosis III gamma;17357067;607838;Mucolipidosis III gamma, 252605 (3);252605
GNRHR;Hypogonadotropic hypogonadism 7 without anosmia;17357067;138850;Hypogonadotropic hypogonadism 7 without anosmia, 146110 (3);146110
GNS;Mucopolysaccharidosis type IIID;17357067;607664;Mucopolysaccharidosis type IIID, 252940 (3);252940
GOLGA5;Thyroid carcinoma, papillary;17357067;606918;Thyroid carcinoma, papillary, 188550 (3);188550
GOLGA6A;Alcohol dependence, susceptibility to;17357067;607867;{Alcohol dependence, susceptibility to}, 103780 (3);103780
GOLGA6A;Beta-glycopyranoside tasting;17357067;607867;[Beta-glycopyranoside tasting] (3);0
GORAB;Geroderma osteodysplasticum;17357067;607983;Geroderma osteodysplasticum, 231070 (3);231070
GOSR2;Anterior segment anomalies with or without cataract;17357067;601653;Anterior segment anomalies with or without cataract, 113650 (3);113650
GOSR2;Branchiootic syndrome 1;17357067;601653;Branchiootic syndrome 1, 602588 (3);602588
GOSR2;Branchiootorenal syndrome 1, with or without cataracts;17357067;601653;Branchiootorenal syndrome 1, with or without cataracts, 113650 (3);113650
GOSR2;Epilepsy, progressive myoclonic 6;17357067;604027;Epilepsy, progressive myoclonic 6, 614018 (3);614018
GOT1;Aspartate aminotransferase, serum level of, QTL1;17357067;138180;Aspartate aminotransferase, serum level of, QTL1, 614419 (3);614419
GP1BA;Bernard-Soulier syndrome, type A1 (recessive);17357067;606672;Bernard-Soulier syndrome, type A1 (recessive), 231200 (3);231200
GP1BA;Bernard-Soulier syndrome, type A2 (dominant);17357067;606672;Bernard-Soulier syndrome, type A2 (dominant), 153670 (3);153670
GP1BA;Nonarteritic anterior ischemic optic neuropathy, susceptibility to;17357067;606672;{Nonarteritic anterior ischemic optic neuropathy, susceptibility to}, 258660 (3);258660
GP1BA;von Willebrand disease, platelet-type;17357067;606672;von Willebrand disease, platelet-type, 177820 (3);177820
GP1BB;Bernard-Soulier syndrome, type B;17357067;138720;Bernard-Soulier syndrome, type B, 231200 (3);231200
GP1BB;Giant platelet disorder, isolated;17357067;138720;Giant platelet disorder, isolated, 231200 (3);231200
GP6;Bleeding disorder, platelet-type, 11;17357067;605546;Bleeding disorder, platelet-type, 11, 614201 (3);614201
GP9;Bernard-Soulier syndrome, type C;17357067;173515;Bernard-Soulier syndrome, type C, 231200 (3);231200
GPC3;Simpson-Golabi-Behmel syndrome, type 1;17357067;300037;Simpson-Golabi-Behmel syndrome, type 1, 312870 (3);312870
GPC3;Wilms tumor, somatic;17357067;300037;Wilms tumor, somatic, 194070 (3);194070
GPC6;Omodysplasia 1;17357067;604404;Omodysplasia 1, 258315 (3);258315
GPD1;Hypertriglyceridemia, transient infantile;17357067;138420;Hypertriglyceridemia, transient infantile, 614480 (3);614480
GPD1L;Brugada syndrome 2;17357067;611778;Brugada syndrome 2, 611777 (3);611777
GPD2;Diabetes, type 2, susceptibility to;17357067;138430;{Diabetes, type 2, susceptibility to}, 125853 (3);125853
GPHN;Molybdenum cofactor deficiency C;17357067;603930;Molybdenum cofactor deficiency C, 615501 (3);615501
GPI;Hemolytic anemia, nonspherocytic, due to glucose phosphate isomerase deficiency;17357067;172400;Hemolytic anemia, nonspherocytic, due to glucose phosphate isomerase deficiency, 613470 (3);613470
GPIHBP1;Hyperlipoproteinemia, type 1D;17357067;612757;Hyperlipoproteinemia, type 1D, 615947 (3);615947
GPR101;Pituitary adenoma, growth hormone-secreting 2;17357067;300393;Pituitary adenoma, growth hormone-secreting 2, 300943 (3);300943
GPR126;Lethal congenital contracture syndrome 9;17357067;612243;Lethal congenital contracture syndrome 9, 616503 (3);616503
GPR143;Nystagmus 6, congenital, X-linked;17357067;300808;Nystagmus 6, congenital, X-linked, 300814 (3);300814
GPR143;Ocular albinism, type I, Nettleship-Falls type;17357067;300808;Ocular albinism, type I, Nettleship-Falls type, 300500 (3);300500
GPR179;Night blindness, congenital stationary (complete), 1E, autosomal recessive;17357067;614515;Night blindness, congenital stationary (complete), 1E, autosomal recessive, 614565 (3);614565
GPR56;Polymicrogyria, bilateral frontoparietal;17357067;604110;Polymicrogyria, bilateral frontoparietal, 606854 (3);606854
GPR56;Polymicrogyria, bilateral perisylvian;17357067;604110;Polymicrogyria, bilateral perisylvian, 615752 (3);615752
GPR98;Febrile seizures, familial, 4;17357067;602851;Febrile seizures, familial, 4, 604352 (3);604352
GPR98;Usher syndrome, type 2C;17357067;602851;Usher syndrome, type 2C, 605472 (3);605472
GPR98;Usher syndrome, type 2C, GPR98/PDZD7 digenic;17357067;602851;Usher syndrome, type 2C, GPR98/PDZD7 digenic, 605472 (3);605472
GPSM2;Chudley-McCullough syndrome;17357067;609245;Chudley-McCullough syndrome, 604213 (3);604213
GPX1;Hemolytic anemia due to glutathione peroxidase deficiency;17357067;138320;Hemolytic anemia due to glutathione peroxidase deficiency, 614164 (1);614164
GRAP2;Multicentric osteolysis, nodulosis, and arthropathy;17357067;120360;Multicentric osteolysis, nodulosis, and arthropathy, 259600 (3);259600
GREM1;Colorectal cancer, susceptibility to, 4;17357067;601228;{Colorectal cancer, susceptibility to, 4} (4);0
GREM1;Polyposis syndrome, mixed hereditary 1;17357067;601228;Polyposis syndrome, mixed hereditary 1 (4);0
GRHL2;Deafness, autosomal dominant 28;17357067;608576;Deafness, autosomal dominant 28, 608641 (3);608641
GRHL2;Ectodermal dysplasia/short stature syndrome;17357067;608576;Ectodermal dysplasia/short stature syndrome, 616029 (3);616029
GRHL3;Van der Woude syndrome 2;17357067;608317;Van der Woude syndrome 2, 606713 (3);606713
GRHPR;Hyperoxaluria, primary, type II;17357067;604296;Hyperoxaluria, primary, type II, 260000 (3);260000
GRIA3;Mental retardation, X-linked 94;17357067;305915;Mental retardation, X-linked 94, 300699 (3);300699
GRID2;Spinocerebellar ataxia, autosomal recessive 18;17357067;602368;Spinocerebellar ataxia, autosomal recessive 18, 616204 (3);616204
GRIK2;Mental retardation, autosomal recessive, 6;17357067;138244;Mental retardation, autosomal recessive, 6, 611092 (3);611092
GRIN1;Mental retardation, autosomal dominant 8;17357067;138249;Mental retardation, autosomal dominant 8, 614254 (3);614254
GRIN2A;Epilepsy, focal, with speech disorder and with or without mental retardation;17357067;138253;Epilepsy, focal, with speech disorder and with or without mental retardation, 245570 (3);245570
GRIN2B;Epileptic encephalopathy, early infantile, 27;17357067;138252;Epileptic encephalopathy, early infantile, 27, 616139 (3);616139
GRIN2B;Mental retardation, autosomal dominant 6;17357067;138252;Mental retardation, autosomal dominant 6, 613970 (3);613970
GRIP1;Fraser syndrome;17357067;604597;Fraser syndrome, 219000 (3);219000
GRK1;Oguchi disease-2;17357067;180381;Oguchi disease-2, 613411 (3);613411
GRM1;Spinocerebellar ataxia, autosomal recessive 13;17357067;604473;Spinocerebellar ataxia, autosomal recessive 13, 614831 (3);614831
GRM6;Night blindness, congenital stationary (complete), 1B, autosomal recessive;17357067;604096;Night blindness, congenital stationary (complete), 1B, autosomal recessive, 257270 (3);257270
GRN;Aphasia, primary progressive;17357067;138945;Aphasia, primary progressive, 607485 (3);607485
GRN;Ceroid lipofuscinosis, neuronal, 11;17357067;138945;Ceroid lipofuscinosis, neuronal, 11, 614706 (3);614706
GRN;Frontotemporal lobar degeneration with ubiquitin-positive inclusions;17357067;138945;Frontotemporal lobar degeneration with ubiquitin-positive inclusions, 607485 (3);607485
GRXCR1;Deafness, autosomal recessive 25;17357067;613283;Deafness, autosomal recessive 25, 613285 (3);613285
GSC;Short stature, auditory canal atresia, mandibular hypoplasia, skeletal abnormalities;17357067;138890;Short stature, auditory canal atresia, mandibular hypoplasia, skeletal abnormalities, 602471 (3);602471
GSN;Amyloidosis, Finnish type;17357067;137350;Amyloidosis, Finnish type, 105120 (3);105120
GSR;Hemolytic anemia due to glutathione reductase deficiency;17357067;138300;Hemolytic anemia due to glutathione reductase deficiency (1);0
GSS;Glutathione synthetase deficiency;17357067;601002;Glutathione synthetase deficiency, 266130 (3);266130
GSS;Hemolytic anemia due to glutathione synthetase deficiency;17357067;601002;Hemolytic anemia due to glutathione synthetase deficiency, 231900 (3);231900
GSTZ1;Tyrosinemia, type Ib;17357067;603758;Tyrosinemia, type Ib (1);0
GTF2H5;Trichothiodystrophy 3, photosensitive;17357067;608780;Trichothiodystrophy 3, photosensitive, 616395 (3);616395
GTPBP3;Combined oxidative phosphorylation deficiency 23;17357067;608536;Combined oxidative phosphorylation deficiency 23, 616198 (3);616198
GUCA1A;Cone dystrophy-3;17357067;600364;Cone dystrophy-3, 602093 (3);602093
GUCA1A;Cone-rod dystrophy 14;17357067;600364;Cone-rod dystrophy 14, 602093 (3);602093
GUCA1B;Retinitis pigmentosa 48;17357067;602275;Retinitis pigmentosa 48, 613827 (3);613827
GUCA2A;Retinitis pigmentosa 48;17357067;602275;Retinitis pigmentosa 48, 613827 (3);613827
GUCY1A3;Moyamoya 6 with achalasia;17357067;139396;Moyamoya 6 with achalasia, 615750 (3);615750
GUCY2C;Diarrhea 6;17357067;601330;Diarrhea 6, 614616 (3);614616
GUCY2C;Meconium ileus;17357067;601330;Meconium ileus, 614665 (3);614665
GUCY2D;Cone-rod dystrophy 6, 60177;17357067;600179;Cone-rod dystrophy 6, 601777(3);0
GUCY2D;Leber congenital amaurosis 1;17357067;600179;Leber congenital amaurosis 1, 204000 (3);204000
GULOP;Scurvy;17357067;240400;Scurvy (3);0
GUSB;Mucopolysaccharidosis VII;17357067;611499;Mucopolysaccharidosis VII, 253220 (3);253220
GYG1;Polyglucosan body myopathy 2;17357067;603942;Polyglucosan body myopathy 2, 616199 (3);616199
GYPA;Blood group, MN;17357067;111300;[Blood group, MN] (3);0
GYPA;Malaria, resistance to;17357067;111300;{Malaria, resistance to}, 611162 (3);611162
GYPB;Blood group, Ss;17357067;111740;[Blood group, Ss] (3);0
GYPB;Malaria, resistance to;17357067;111740;{Malaria, resistance to}, 611162 (3);611162
GYPC;Blood group, Gerbich;17357067;110750;[Blood group, Gerbich], 616089 (3);616089
GYPC;Malaria, resistance to;17357067;110750;{Malaria, resistance to}, 611162 (3);611162
GYS1;Glycogen storage disease 0, muscle;17357067;138570;Glycogen storage disease 0, muscle, 611556 (3);611556
GYS2;Glycogen storage disease 0, liver;17357067;138571;Glycogen storage disease 0, liver, 240600 (3);240600
H19;Beckwith-Wiedemann syndrome;17357067;103280;Beckwith-Wiedemann syndrome, 130650 (3);130650
H19;Silver-Russell syndrome;17357067;103280;Silver-Russell syndrome, 180860 (3);180860
H19;Wilms tumor 2;17357067;103280;Wilms tumor 2, 194071 (3);194071
H6PD;Cortisone reductase deficiency 1;17357067;138090;Cortisone reductase deficiency 1, 604931 (3);604931
HABP2;Carotid stenosis, susceptibility to;17357067;603924;{Carotid stenosis, susceptibility to} (3);0
HABP2;Venous thromboembolism, susceptibility to;17357067;603924;{Venous thromboembolism, susceptibility to}, 188050 (3);188050
HADH;3-hydroxyacyl-CoA dehydrogenase deficiency;17357067;601609;3-hydroxyacyl-CoA dehydrogenase deficiency, 231530 (3);231530
HADH;Hyperinsulinemic hypoglycemia, familial, 4;17357067;601609;Hyperinsulinemic hypoglycemia, familial, 4, 609975 (3);609975
HADHA;Fatty liver, acute, of pregnancy;17357067;600890;Fatty liver, acute, of pregnancy, 609016 (3);609016
HADHA;HELLP syndrome, maternal, of pregnancy;17357067;600890;HELLP syndrome, maternal, of pregnancy, 609016 (3);609016
HADHA;LCHAD deficiency;17357067;600890;LCHAD deficiency, 609016 (3);609016
HADHA;Trifunctional protein deficiency;17357067;600890;Trifunctional protein deficiency, 609015 (3);609015
HADHB;Trifunctional protein deficiency;17357067;143450;Trifunctional protein deficiency, 609015 (3);609015
HAGH;Glyoxalase II deficiency;17357067;138760;[Glyoxalase II deficiency], 614033 (1);614033
HAL;Histidinemia;17357067;609457;[Histidinemia], 235800 (3);235800
HAMP;Hemochromatosis, type 2B;17357067;606464;Hemochromatosis, type 2B, 613313 (3);613313
HARS;Usher syndrome type 3B;17357067;142810;Usher syndrome type 3B, 614504 (3);614504
HARS2;Perrault syndrome 2;17357067;600783;Perrault syndrome 2, 614926 (3);614926
HAVCR1;Atopy, resistance to;17357067;606518;{Atopy, resistance to}, 147050 (3);147050
HAX1;Neutropenia, severe congenital 3, autosomal recessive;17357067;605998;Neutropenia, severe congenital 3, autosomal recessive, 610738 (3);610738
HBA1;Erythremias, alpha-;17357067;141800;Erythremias, alpha- (3);0
HBA1;Heinz body anemias, alpha-;17357067;141800;Heinz body anemias, alpha-, 140700 (3);140700
HBA1;Hemoglobin H disease, nondeletional;17357067;141800;Hemoglobin H disease, nondeletional, 613978 (3);613978
HBA1;Methemoglobinemias, alpha-;17357067;141800;Methemoglobinemias, alpha- (3);0
HBA1;Thalassemias, alpha-;17357067;141800;Thalassemias, alpha-, 604131 (3);604131
HBA2;Erythrocytosis;17357067;141850;Erythrocytosis (3);0
HBA2;Heinz body anemia;17357067;141850;Heinz body anemia, 140700 (3);140700
HBA2;Hemoglobin H disease, nondeletional;17357067;141850;Hemoglobin H disease, nondeletional, 613978 (3);613978
HBA2;Hypochromic microcytic anemia;17357067;141850;Hypochromic microcytic anemia (3);0
HBA2;Thalassemia, alpha-;17357067;141850;Thalassemia, alpha-, 604131 (3);604131
HBB;Delta-beta thalassemia;17357067;141900;Delta-beta thalassemia, 141749 (3);141749
HBB;Erythremias, beta-;17357067;141900;Erythremias, beta- (3);0
HBB;Heinz body anemias, beta-;17357067;141900;Heinz body anemias, beta-, 140700 (3);140700
HBB;Hereditary persistence of fetal hemoglobin;17357067;141900;Hereditary persistence of fetal hemoglobin, 141749 (3);141749
HBB;Malaria, resistance to;17357067;141900;{Malaria, resistance to}, 611162 (3);611162
HBB;Methemoglobinemias, beta-;17357067;141900;Methemoglobinemias, beta- (3);0
HBB;Sickle cell anemia;17357067;141900;Sickle cell anemia, 603903 (3);603903
HBB;Thalassemia-beta, dominant inclusion-body;17357067;141900;Thalassemia-beta, dominant inclusion-body, 603902 (3);603902
HBB;Thalassemias, beta-;17357067;141900;Thalassemias, beta-, 613985 (3);613985
HBD;Thalassemia due to Hb Lepore;17357067;142000;Thalassemia due to Hb Lepore (3);0
HBD;Thalassemia, delta-;17357067;142000;Thalassemia, delta- (3);0
HBEGF;Diphtheria, susceptibility to;17357067;126150;{Diphtheria, susceptibility to} (1);0
HBG1;Fetal hemoglobin quantitative trait locus 1;17357067;142200;Fetal hemoglobin quantitative trait locus 1, 141749 (3);141749
HBG2;Cyanosis, transient neonatal;17357067;142250;Cyanosis, transient neonatal, 613977 (3);613977
HBG2;Fetal hemoglobin quantitative trait locus 1;17357067;142250;Fetal hemoglobin quantitative trait locus 1, 141749 (3);141749
HCAR1;Hypercalciuria, absorptive;17357067;607258;Hypercalciuria, absorptive (2);0
HCCS;Linear skin defects with multiple congenital anomalies 1;17357067;300056;Linear skin defects with multiple congenital anomalies 1, 309801 (3);309801
HCFC1;Mental retardation, X-linked 3 (methylmalonic acidemia and homocysteinemia, cblX type );17357067;300019;Mental retardation, X-linked 3 (methylmalonic acidemia and homocysteinemia, cblX type ), 309541 (3);309541
HCN1;Epileptic encephalopathy, early infantile, 24;17357067;602780;Epileptic encephalopathy, early infantile, 24, 615871 (3);615871
HCN4;Brugada syndrome 8;17357067;605206;Brugada syndrome 8, 613123 (3);613123
HCN4;Sick sinus syndrome 2;17357067;605206;Sick sinus syndrome 2, 163800 (3);163800
HDAC4;Brachydactyly-mental retardation syndrome;17357067;605314;Brachydactyly-mental retardation syndrome, 600430 (3);600430
HDAC8;Cornelia de Lange syndrome 5;17357067;300269;Cornelia de Lange syndrome 5, 300882 (3);300882
HDAC8;Wilson-Turner syndrome;17357067;300269;Wilson-Turner syndrome, 309585 (3);309585
HDC;Gilles de la Tourette syndrome, susceptibility to;17357067;142704;{Gilles de la Tourette syndrome, susceptibility to}, 137580 (3);137580
HEPACAM;Megalencephalic leukoencephalopathy with subcortical cysts 2A;17357067;611642;Megalencephalic leukoencephalopathy with subcortical cysts 2A, 613925 (3);613925
HEPACAM;Megalencephalic leukoencephalopathy with subcortical cysts 2B, remitting, with or without mental retardation;17357067;611642;Megalencephalic leukoencephalopathy with subcortical cysts 2B, remitting, with or without mental retardation, 613926 (3);613926
HERC2;Mental retardation, autosomal recessive 38;17357067;605837;Mental retardation, autosomal recessive 38, 615516 (3);615516
HERC2;Skin/hair/eye pigmentation 1, blond/brown hair;17357067;605837;[Skin/hair/eye pigmentation 1, blond/brown hair], 227220 (3);227220
HERC2;Skin/hair/eye pigmentation 1, blue/nonblue eyes;17357067;605837;[Skin/hair/eye pigmentation 1, blue/nonblue eyes], 227220 (3);227220
HES7;Spondylocostal dysostosis 4, autosomal recessive;17357067;608059;Spondylocostal dysostosis 4, autosomal recessive, 613686 (3);613686
HESX1;Growth hormone deficiency with pituitary anomalies;17357067;601802;Growth hormone deficiency with pituitary anomalies, 182230 (3);182230
HESX1;Pituitary hormone deficiency, combined, 5;17357067;601802;Pituitary hormone deficiency, combined, 5, 182230 (3);182230
HESX1;Septooptic dysplasia;17357067;601802;Septooptic dysplasia, 182230 (3);182230
HEXA;GM2-gangliosidosis, several forms;17357067;606869;GM2-gangliosidosis, several forms, 272800 (3);272800
HEXA;Hex A pseudodeficiency;17357067;606869;[Hex A pseudodeficiency], 272800 (3);272800
HEXA;Tay-Sachs disease;17357067;606869;Tay-Sachs disease, 272800 (3);272800
HEXB;Sandhoff disease, infantile, juvenile, and adult forms;17357067;606873;Sandhoff disease, infantile, juvenile, and adult forms, 268800 (3);268800
HFE;Alzheimer disease, susceptibility to;17357067;613609;{Alzheimer disease, susceptibility to}, 104300 (3);104300
HFE;Hemochromatosis;17357067;613609;Hemochromatosis, 235200 (3);235200
HFE;Microvascular complications of diabetes 7;17357067;613609;{Microvascular complications of diabetes 7}, 612635 (3);612635
HFE;Porphyria cutanea tarda, susceptibility to;17357067;613609;{Porphyria cutanea tarda, susceptibility to}, 176100 (3);176100
HFE;Porphyria variegata, susceptibility to;17357067;613609;{Porphyria variegata, susceptibility to}, 176200 (3);176200
HFE;Transferrin serum level QTL2;17357067;613609;[Transferrin serum level QTL2], 614193 (3);614193
HFE2;Hemochromatosis, type 2A;17357067;608374;Hemochromatosis, type 2A, 602390 (3);602390
HFM1;Premature ovarian failure 9;17357067;615684;Premature ovarian failure 9, 615724 (3);615724
HGD;Alkaptonuria;17357067;607474;Alkaptonuria, 203500 (3);203500
HGF;Crohn disease-associated growth failure;17357067;147620;{Crohn disease-associated growth failure}, 266600 (3);266600
HGF;Deafness, autosomal recessive 39;17357067;142409;Deafness, autosomal recessive 39, 608265 (3);608265
HGF;Diabetes, susceptibility to, 222100;17357067;147620;{Diabetes, susceptibility to}, 222100, 125853 (3);125853
HGF;Fibromatosis, gingival;17357067;182530;Fibromatosis, gingival, 135300 (3);135300
HGF;Intracranial hemorrhage in brain cerebrovascular malformations, susceptibility to;17357067;147620;{Intracranial hemorrhage in brain cerebrovascular malformations, susceptibility to}, 108010 (3);108010
HGF;Kaposi sarcoma, susceptibility to;17357067;147620;{Kaposi sarcoma, susceptibility to}, 148000 (3);148000
HGF;Noonan syndrome 4;17357067;182530;Noonan syndrome 4, 610733 (3);610733
HGF;Rheumatoid arthritis, systemic juvenile;17357067;147620;{Rheumatoid arthritis, systemic juvenile}, 604302 (3);604302
HGSNAT;Mucopolysaccharidosis type IIIC (Sanfilippo C);17357067;610453;Mucopolysaccharidosis type IIIC (Sanfilippo C), 252930 (3);252930
HIBCH;3-hydroxyisobutryl-CoA hydrolase deficiency;17357067;610690;3-hydroxyisobutryl-CoA hydrolase deficiency, 250620 (3);250620
HINT1;Neuromyotonia and axonal neuropathy, autosomal recessive;17357067;601314;Neuromyotonia and axonal neuropathy, autosomal recessive, 137200 (3);137200
HIP1;Prostate cancer, progression of;17357067;601767;{Prostate cancer, progression of}, 176807 (1);176807
HK1;Hemolytic anemia due to hexokinase deficiency;17357067;142600;Hemolytic anemia due to hexokinase deficiency, 235700 (3);235700
HK1;Neuropathy, hereditary motor and sensory, Russe type;17357067;142600;Neuropathy, hereditary motor and sensory, Russe type, 605285 (3);605285
HLA-A;Hypersensitivity syndrome, carbamazepine-induced, susceptibility to;17357067;142800;{Hypersensitivity syndrome, carbamazepine-induced, susceptibility to}, 608579 (3);608579
HLA-B;Abacavir hypersensitivity, susceptibility to;17357067;142830;{Abacavir hypersensitivity, susceptibility to} (3);0
HLA-B;Drug-induced liver injury due to flucloxacillin;17357067;142830;{Drug-induced liver injury due to flucloxacillin} (3);0
HLA-B;Spondyloarthropathy, susceptibility to, 1;17357067;142830;{Spondyloarthropathy, susceptibility to, 1}, 106300 (3);106300
HLA-B;Stevens-Johnson syndrome, susceptibility to;17357067;142830;{Stevens-Johnson syndrome, susceptibility to}, 608579 (3);608579
HLA-B;Synovitis, chronic, susceptibility to;17357067;142830;{Synovitis, chronic, susceptibility to} (3);0
HLA-B;Toxic epidermal necrolysis, susceptibility to;17357067;142830;{Toxic epidermal necrolysis, susceptibility to}, 608579 (3);608579
HLA-C;HIV-1 viremia, susceptibility to;17357067;142840;{HIV-1 viremia, susceptibility to}, 609423 (3);609423
HLA-C;Psoriasis susceptibility 1;17357067;142840;{Psoriasis susceptibility 1}, 177900 (3);177900
HLA-DPB1;Beryllium disease, chronic, susceptibility to;17357067;142858;{Beryllium disease, chronic, susceptibility to} (3);0
HLA-DQA1;Celiac disease, susceptibility to;17357067;146880;{Celiac disease, susceptibility to}, 212750 (3);212750
HLA-DQB1;Celiac disease, susceptibility to;17357067;604305;{Celiac disease, susceptibility to}, 212750 (3);212750
HLA-DQB1;Creutzfeldt-Jakob disease, variant, resistance to;17357067;604305;{Creutzfeldt-Jakob disease, variant, resistance to}, 123400 (3);123400
HLA-DQB1;Multiple sclerosis, susceptibility to, 1;17357067;604305;{Multiple sclerosis, susceptibility to, 1}, 126200 (3);126200
HLA-DRB1;Multiple sclerosis, susceptibility to, 1;17357067;142857;{Multiple sclerosis, susceptibility to, 1}, 126200 (3);126200
HLA-DRB1;Pemphigoid, susceptibility to;17357067;142857;{Pemphigoid, susceptibility to} (2);0
HLA-DRB1;Rheumatoid arthritis, susceptibility to;17357067;142857;{Rheumatoid arthritis, susceptibility to}, 180300 (3);180300
HLA-DRB1;Sarcoidosis, susceptibility to, 1;17357067;142857;{Sarcoidosis, susceptibility to, 1}, 181000 (3);181000
HLA-G;Asthma, susceptibility to;17357067;142871;{Asthma, susceptibility to}, 600807 (2);600807
HLA-H;Alzheimer disease, susceptibility to;17357067;613609;{Alzheimer disease, susceptibility to}, 104300 (3);104300
HLA-H;Hemochromatosis;17357067;613609;Hemochromatosis, 235200 (3);235200
HLA-H;Microvascular complications of diabetes 7;17357067;613609;{Microvascular complications of diabetes 7}, 612635 (3);612635
HLA-H;Porphyria cutanea tarda, susceptibility to;17357067;613609;{Porphyria cutanea tarda, susceptibility to}, 176100 (3);176100
HLA-H;Porphyria variegata, susceptibility to;17357067;613609;{Porphyria variegata, susceptibility to}, 176200 (3);176200
HLA-H;Transferrin serum level QTL2;17357067;613609;[Transferrin serum level QTL2], 614193 (3);614193
HLCS;Holocarboxylase synthetase deficiency;17357067;609018;Holocarboxylase synthetase deficiency, 253270 (3);253270
HMBS;Porphyria, acute intermittent;17357067;609806;Porphyria, acute intermittent, 176000 (3);176000
HMBS;Porphyria, acute intermittent, nonerythroid variant;17357067;609806;Porphyria, acute intermittent, nonerythroid variant, 176000 (3);176000
HMCN1;Macular degeneration, age-related, 1;17357067;608548;{Macular degeneration, age-related, 1}, 603075 (3);603075
HMGA1;Diabetes mellitus, noninsulin-dependent, susceptibility to;17357067;600701;{Diabetes mellitus, noninsulin-dependent, susceptibility to}, 125853 (3);125853
HMGA2;Leiomyoma, uterine, somatic;17357067;600698;Leiomyoma, uterine, somatic, 150699 (2);150699
HMGCL;HMG-CoA lyase deficiency;17357067;613898;HMG-CoA lyase deficiency, 246450 (3);246450
HMGCR;Low density lipoprotein cholesterol level QTL 3;17357067;142910;[Low density lipoprotein cholesterol level QTL 3] (3);0
HMGCR;Statins, attenuated cholesterol lowering by;17357067;142910;[Statins, attenuated cholesterol lowering by] (3);0
HMGCS2;HMG-CoA synthase-2 deficiency;17357067;600234;HMG-CoA synthase-2 deficiency, 605911 (3);605911
HMMR;Breast cancer, susceptibility to;17357067;600936;{Breast cancer, susceptibility to}, 114480 (3);114480
HMOX1;Heme oxygenase-1 deficiency;17357067;141250;Heme oxygenase-1 deficiency, 614034 (3);614034
HMOX1;Pulmonary disease, chronic obstructive, susceptibility to;17357067;141250;{Pulmonary disease, chronic obstructive, susceptibility to}, 606963 (3);606963
HMX1;Oculoauricular syndrome;17357067;142992;Oculoauricular syndrome, 612109 (3);612109
HNF1A;Diabetes mellitus, insulin-dependent;17357067;142410;{Diabetes mellitus, insulin-dependent}, 222100 (3);222100
HNF1A;Diabetes mellitus, insulin-dependent, 20;17357067;142410;Diabetes mellitus, insulin-dependent, 20, 612520 (3);612520
HNF1A;Diabetes mellitus, noninsulin-dependent, 2;17357067;142410;{Diabetes mellitus, noninsulin-dependent, 2}, 125853 (3);125853
HNF1A;Hepatic adenoma, somatic;17357067;142410;Hepatic adenoma, somatic, 142330 (3);142330
HNF1A;MODY, type III;17357067;142410;MODY, type III, 600496 (3);600496
HNF1A;Renal cell carcinoma;17357067;142410;Renal cell carcinoma, 144700 (3);144700
HNF1B;Diabetes mellitus, noninsulin-dependent;17357067;189907;Diabetes mellitus, noninsulin-dependent, 125853 (3);125853
HNF1B;Renal cell carcinoma;17357067;189907;{Renal cell carcinoma}, 144700 (3);144700
HNF1B;Renal cysts and diabetes syndrome;17357067;189907;Renal cysts and diabetes syndrome, 137920 (3);137920
HNF4A;Diabetes mellitus, noninsulin-dependent;17357067;600281;{Diabetes mellitus, noninsulin-dependent}, 125853 (3);125853
HNF4A;Fanconi renotubular syndrome 4, with maturity-onset diabetes of the young;17357067;600281;Fanconi renotubular syndrome 4, with maturity-onset diabetes of the young, 616026 (3);616026
HNF4A;MODY, type I;17357067;600281;MODY, type I, 125850 (3);125850
HNMT;Asthma, susceptibility to;17357067;605238;{Asthma, susceptibility to}, 600807 (3);600807
HNRNPA1;Amyotrophic lateral sclerosis 20;17357067;164017;Amyotrophic lateral sclerosis 20, 615426 (3);615426
HNRNPDL;Limb-girdle muscular dystrophy, type 1G;17357067;607137;Limb-girdle muscular dystrophy, type 1G, 609115 (3);609115
HOGA1;Hyperoxaluria, primary, type III;17357067;613597;Hyperoxaluria, primary, type III, 613616 (3);613616
HOXA1;Athabaskan brainstem dysgenesis syndrome;17357067;142955;Athabaskan brainstem dysgenesis syndrome, 601536 (3);601536
HOXA1;Bosley-Salih-Alorainy syndrome;17357067;142955;Bosley-Salih-Alorainy syndrome, 601536 (3);601536
HOXA11;Radioulnar synostosis with amegakaryocytic thrombocytopenia;17357067;142958;Radioulnar synostosis with amegakaryocytic thrombocytopenia, 605432 (3);605432
HOXA13;Guttmacher syndrome;17357067;142959;Guttmacher syndrome, 176305 (3);176305
HOXA13;Hand-foot-uterus syndrome;17357067;142959;Hand-foot-uterus syndrome, 140000 (3);140000
HOXB1;Facial paresis, hereditary congenital, 3;17357067;142968;Facial paresis, hereditary congenital, 3, 614744 (3);614744
HOXC13;Ectodermal dysplasia 9, hair/nail type;17357067;142976;Ectodermal dysplasia 9, hair/nail type, 614931 (3);614931
HOXD10;Charcot-Marie-Tooth disease, foot deformity of;17357067;142984;Charcot-Marie-Tooth disease, foot deformity of, 192950 (3);192950
HOXD10;Vertical talus, congenital;17357067;142984;Vertical talus, congenital, 192950 (3);192950
HOXD13;Brachydactyly, type D;17357067;142989;Brachydactyly, type D, 113200 (3);113200
HOXD13;Brachydactyly, type E;17357067;142989;Brachydactyly, type E, 113300 (3);113300
HOXD13;Syndactyly, type V;17357067;142989;Syndactyly, type V, 186300 (3);186300
HOXD13;Synpolydactyly with foot anomalies;17357067;142989;Synpolydactyly with foot anomalies, 186000 (3);186000
HOXD13;Synpolydactyly, type II;17357067;142989;Synpolydactyly, type II, 186000 (3);186000
HP;Anhaptoglobinemia;17357067;140100;[Anhaptoglobinemia], 614081 (3);614081
HP;Hypohaptoglobinemia;17357067;140100;[Hypohaptoglobinemia], 614081 (3);614081
HPCA;Dystonia 2, torsion, autosomal recessive;17357067;142622;Dystonia 2, torsion, autosomal recessive, 224500 (3);224500
HPD;Hawkinsinuria;17357067;609695;Hawkinsinuria, 140350 (3);140350
HPD;Tyrosinemia, type III;17357067;609695;Tyrosinemia, type III, 276710 (3);276710
HPGD;Cranioosteoarthropathy;17357067;601688;Cranioosteoarthropathy, 259100 (3);259100
HPGD;Digital clubbing, isolated congenital;17357067;601688;Digital clubbing, isolated congenital, 119900 (3);119900
HPGD;Hypertrophic osteoarthropathy, primary, autosomal recessive 1;17357067;601688;Hypertrophic osteoarthropathy, primary, autosomal recessive 1, 259100 (3);259100
HPRT1;HPRT-related gout;17357067;308000;HPRT-related gout, 300323 (3);300323
HPRT1;Lesch-Nyhan syndrome;17357067;308000;Lesch-Nyhan syndrome, 300322 (3);300322
HPS1;Hermansky-Pudlak syndrome 1;17357067;604982;Hermansky-Pudlak syndrome 1, 203300 (3);203300
HPS3;Hermansky-Pudlak syndrome 3;17357067;606118;Hermansky-Pudlak syndrome 3, 614072 (3);614072
HPS4;Hermansky-Pudlak syndrome 4;17357067;606682;Hermansky-Pudlak syndrome 4, 614073 (3);614073
HPS5;Hermansky-Pudlak syndrome 5;17357067;607521;Hermansky-Pudlak syndrome 5, 614074 (3);614074
HPS6;Hermansky-Pudlak syndrome 6;17357067;607522;Hermansky-Pudlak syndrome 6, 614075 (3);614075
HPSE2;Urofacial syndrome 1;17357067;613469;Urofacial syndrome 1, 236730 (3);236730
HR;Alopecia universalis;17357067;602302;Alopecia universalis, 203655 (3);203655
HR;Atrichia with papular lesions;17357067;602302;Atrichia with papular lesions, 209500 (3);209500
HR;Blood group, Auberger system;17357067;612773;[Blood group, Auberger system], 111200 (3);111200
HR;Blood group, Lutheran null;17357067;612773;[Blood group, Lutheran null], 247420 (3);247420
HR;Blood group, Lutheran system;17357067;612773;[Blood group, Lutheran system], 111200 (3);111200
HR;Hypotrichosis 4;17357067;602302;Hypotrichosis 4, 146550 (3);146550
HRAS;Bladder cancer, somatic;17357067;190020;{Bladder cancer, somatic}, 109800 (3);109800
HRAS;Congenital myopathy with excess of muscle spindles;17357067;190020;Congenital myopathy with excess of muscle spindles, 218040 (3);218040
HRAS;Costello syndrome;17357067;190020;Costello syndrome, 218040 (3);218040
HRAS;Nevus sebaceous or woolly hair nevus, somatic;17357067;190020;{Nevus sebaceous or woolly hair nevus, somatic}, 162900 (3);162900
HRAS;Schimmelpenning-Feuerstein-Mims syndrome, somatic mosaic;17357067;190020;Schimmelpenning-Feuerstein-Mims syndrome, somatic mosaic, 163200 (3);163200
HRAS;Spitz nevus or nevus spilus, somatic;17357067;190020;{Spitz nevus or nevus spilus, somatic}, 137550 (3);137550
HRAS;Thyroid carcinoma, follicular, somatic;17357067;190020;{Thyroid carcinoma, follicular, somatic}, 188470 (3);188470
HRG;Thrombophilia due to HRG deficiency;17357067;142640;Thrombophilia due to HRG deficiency, 613116 (3);613116
HRG;Thrombophilia due to elevated HRG;17357067;142640;Thrombophilia due to elevated HRG, 613116 (1);613116
HS6ST1;Hypogonadotropic hypogonadism 15 with or without anosmia;17357067;604846;{Hypogonadotropic hypogonadism 15 with or without anosmia}, 614880 (3);614880
HSD11B1;Cortisone reductase deficiency 2;17357067;600713;Cortisone reductase deficiency 2, 614662 (3);614662
HSD11B2;Apparent mineralocorticoid excess;17357067;614232;Apparent mineralocorticoid excess, 218030 (3);218030
HSD17B10;17-beta-hydroxysteroid dehydrogenase X deficiency;17357067;300256;17-beta-hydroxysteroid dehydrogenase X deficiency, 300438 (3);300438
HSD17B3;Pseudohermaphroditism, male, with gynecomastia;17357067;605573;Pseudohermaphroditism, male, with gynecomastia, 264300 (3);264300
HSD17B4;D-bifunctional protein deficiency;17357067;601860;D-bifunctional protein deficiency, 261515 (3);261515
HSD17B4;Perrault syndrome 1;17357067;601860;Perrault syndrome 1, 233400 (3);233400
HSD3B2;3-beta-hydroxysteroid dehydrogenase, type II, deficiency;17357067;613890;3-beta-hydroxysteroid dehydrogenase, type II, deficiency, 201810 (3);201810
HSD3B7;Bile acid synthesis defect, congenital, 1;17357067;607764;Bile acid synthesis defect, congenital, 1, 607765 (3);607765
HSF4;Cataract 5, multiple types;17357067;602438;Cataract 5, multiple types, 116800 (3);116800
HSPB1;Charcot-Marie-Tooth disease, axonal, type 2F;17357067;602195;Charcot-Marie-Tooth disease, axonal, type 2F, 606595 (3);606595
HSPB1;Neuropathy, distal hereditary motor, type IIB;17357067;602195;Neuropathy, distal hereditary motor, type IIB, 608634 (3);608634
HSPB8;Charcot-Marie-Tooth disease, axonal, type 2L;17357067;608014;Charcot-Marie-Tooth disease, axonal, type 2L, 608673 (3);608673
HSPB8;Neuropathy, distal hereditary motor, type IIA;17357067;608014;Neuropathy, distal hereditary motor, type IIA, 158590 (3);158590
HSPD1;Leukodystrophy, hypomyelinating, 4;17357067;118190;Leukodystrophy, hypomyelinating, 4, 612233 (3);612233
HSPD1;Spastic paraplegia 13, autosomal dominant;17357067;118190;Spastic paraplegia 13, autosomal dominant, 605280 (3);605280
HSPG2;Dyssegmental dysplasia, Silverman-Handmaker type;17357067;142461;Dyssegmental dysplasia, Silverman-Handmaker type, 224410 (3);224410
HSPG2;Schwartz-Jampel syndrome, type 1;17357067;142461;Schwartz-Jampel syndrome, type 1, 255800 (3);255800
HTR1A;Periodic fever, menstrual cycle dependent;17357067;109760;Periodic fever, menstrual cycle dependent, 614674 (3);614674
HTR2A;Alcohol dependence, susceptibility to;17357067;182135;{Alcohol dependence, susceptibility to}, 103780 (3);103780
HTR2A;Anorexia nervosa, susceptibility to;17357067;182135;{Anorexia nervosa, susceptibility to}, 606788 (3);606788
HTR2A;Major depressive disorder, response to citalopram therapy in;17357067;182135;{Major depressive disorder, response to citalopram therapy in}, 608516 (3);608516
HTR2A;Obsessive-compulsive disorder, susceptibility to;17357067;182135;{Obsessive-compulsive disorder, susceptibility to}, 164230 (3);164230
HTR2A;Schizophrenia, susceptibility to;17357067;182135;{Schizophrenia, susceptibility to}, 181500 (3);181500
HTR2A;Seasonal affective disorder, susceptibility to;17357067;182135;{Seasonal affective disorder, susceptibility to}, 608516 (3);608516
HTRA1;CARASIL syndrome;17357067;602194;CARASIL syndrome, 600142 (3);600142
HTRA1;Macular degeneration, age-related, 7;17357067;602194;{Macular degeneration, age-related, 7}, 610149 (3);610149
HTRA1;Macular degeneration, age-related, neovascular type;17357067;602194;{Macular degeneration, age-related, neovascular type}, 610149 (3);610149
HTRA2;Parkinson disease 13;17357067;606441;{Parkinson disease 13}, 610297 (3);610297
HTRA3;Vitreoretinopathy, neovascular inflammatory;17357067;602537;Vitreoretinopathy, neovascular inflammatory, 193235 (3);193235
HTT;Anxiety-related personality traits;17357067;182138;{Anxiety-related personality traits}, 607834 (3);607834
HTT;Huntington disease;17357067;613004;Huntington disease, 143100 (3);143100
HTT;Obsessive-compulsive disorder;17357067;182138;{Obsessive-compulsive disorder}, 164230 (3);164230
HUWE1;Mental retardation, X-linked syndromic, Turner type;17357067;300697;Mental retardation, X-linked syndromic, Turner type, 300706 (3);300706
HYDIN;Ciliary dyskinesia, primary, 5;17357067;610812;Ciliary dyskinesia, primary, 5, 608647 (3);608647
HYLS1;Hydrolethalus syndrome;17357067;610693;Hydrolethalus syndrome, 236680 (3);236680
ICAM1;Malaria, cerebral, susceptibility to;17357067;147840;{Malaria, cerebral, susceptibility to}, 611162 (3);611162
ICAM4;Blood group, Landsteiner-Wiener;17357067;614088;[Blood group, Landsteiner-Wiener], 111250 (3);111250
ICK;Endocrine-cerebroosteodysplasia;17357067;612325;Endocrine-cerebroosteodysplasia, 612651 (3);612651
ICOS;Immunodeficiency, common variable, 1;17357067;604558;Immunodeficiency, common variable, 1, 607594 (3);607594
IDH1;Glioma, susceptibility to, somatic;17357067;147700;{Glioma, susceptibility to, somatic}, 137800 (3);137800
IDH2;D-2-hydroxyglutaric aciduria 2;17357067;147650;D-2-hydroxyglutaric aciduria 2, 613657 (3);613657
IDH3B;Retinitis pigmentosa 46;17357067;604526;Retinitis pigmentosa 46, 612572 (3);612572
IDS;Mucopolysaccharidosis II;17357067;300823;Mucopolysaccharidosis II, 309900 (3);309900
IDUA;Mucopolysaccharidosis Ih;17357067;252800;Mucopolysaccharidosis Ih, 607014 (3);607014
IDUA;Mucopolysaccharidosis Ih/s;17357067;252800;Mucopolysaccharidosis Ih/s, 607015 (3);607015
IDUA;Mucopolysaccharidosis Is;17357067;252800;Mucopolysaccharidosis Is, 607016 (3);607016
IER3IP1;Microcephaly, epilepsy, and diabetes syndrome;17357067;609382;Microcephaly, epilepsy, and diabetes syndrome, 614231 (3);614231
IFIH1;Aicardi-Goutieres syndrome 7;17357067;606951;Aicardi-Goutieres syndrome 7, 615846 (3);615846
IFIH1;Diabetes mellitus, insulin-dependent, 19;17357067;610155;{Diabetes mellitus, insulin-dependent, 19} (2);0
IFIH1;Singleton-Merten syndrome 1;17357067;606951;Singleton-Merten syndrome 1, 182250 (3);182250
IFITM3;Influenza, severe, susceptibility to;17357067;605579;{Influenza, severe, susceptibility to}, 614680 (3);614680
IFITM5;Osteogenesis imperfecta, type V;17357067;614757;Osteogenesis imperfecta, type V, 610967 (3);610967
IFNA1;Interferon, alpha, deficiency;17357067;147660;Interferon, alpha, deficiency (1);0
IFNAR2;Hepatitis B virus, susceptibility to;17357067;602376;{Hepatitis B virus, susceptibility to}, 610424 (3);610424
IFNG;AIDS, rapid progression to;17357067;147570;{AIDS, rapid progression to}, 609423 (3);609423
IFNG;Aplastic anemia;17357067;147570;{Aplastic anemia}, 609135 (3);609135
IFNG;Hepatitis C virus, response to therapy of;17357067;147570;{Hepatitis C virus, response to therapy of}, 609532 (3);609532
IFNG;TSC2 angiomyolipomas, renal, modifier of;17357067;147570;{TSC2 angiomyolipomas, renal, modifier of}, 613254 (3);613254
IFNG;Tuberculosis, protection against;17357067;147570;{Tuberculosis, protection against}, 607948 (3);607948
IFNGR1;H. pylori infection, susceptibility to;17357067;107470;{H. pylori infection, susceptibility to}, 600263 (3);600263
IFNGR1;Hepatitis B virus infection, susceptibility to;17357067;107470;{Hepatitis B virus infection, susceptibility to}, 610424 (3);610424
IFNGR1;Immunodeficiency 27A, mycobacteriosis, AR;17357067;107470;Immunodeficiency 27A, mycobacteriosis, AR, 209950 (3);209950
IFNGR1;Immunodeficiency 27B, mycobacteriosis, AD;17357067;107470;Immunodeficiency 27B, mycobacteriosis, AD, 615978 (3);615978
IFNGR1;Tuberculosis infection, protection against;17357067;107470;{Tuberculosis infection, protection against}, 607948 (3);607948
IFNGR1;Tuberculosis, susceptibility to;17357067;107470;{Tuberculosis, susceptibility to}, 607948 (3);607948
IFNGR2;Immunodeficiency 28, mycobacteriosis;17357067;147569;Immunodeficiency 28, mycobacteriosis, 614889 (3);614889
IFNL3;Hepatitis C virus infection, response to therapy of;17357067;607402;{Hepatitis C virus infection, response to therapy of}, 609532 (3);609532
IFT122;Cranioectodermal dysplasia 1;17357067;606045;Cranioectodermal dysplasia 1, 218330 (3);218330
IFT140;Short-rib thoracic dysplasia 9 with or without polydactyly;17357067;614620;Short-rib thoracic dysplasia 9 with or without polydactyly, 266920 (3);266920
IFT172;Retinitis pigmentosa 71;17357067;607386;Retinitis pigmentosa 71, 616394 (3);616394
IFT172;Short-rib thoracic dysplasia 10 with or without polydactyly;17357067;607386;Short-rib thoracic dysplasia 10 with or without polydactyly, 615630 (3);615630
IFT43;Cranioectodermal dysplasia 3;17357067;614068;Cranioectodermal dysplasia 3, 614099 (3);614099
IFT80;Short-rib thoracic dysplasia 2 with or without polydactyly;17357067;611177;Short-rib thoracic dysplasia 2 with or without polydactyly, 611263 (3);611263
IGBP1;Corpus callosum, agenesis of, with mental retardation, ocular coloboma and micrognathia;17357067;300139;Corpus callosum, agenesis of, with mental retardation, ocular coloboma and micrognathia, 300472 (3);300472
IGF1;Growth retardation with deafness and mental retardation due to IGF1 deficiency;17357067;147440;Growth retardation with deafness and mental retardation due to IGF1 deficiency, 608747 (3);608747
IGF1R;Insulin-like growth factor I, resistance to;17357067;147370;Insulin-like growth factor I, resistance to, 270450 (3);270450
IGF2BP2;Diabetes mellitus, noninsulin-dependent, susceptibility to;17357067;608289;{Diabetes mellitus, noninsulin-dependent, susceptibility to}, 125853 (3);125853
IGF2R;Hepatocellular carcinoma, somatic;17357067;147280;Hepatocellular carcinoma, somatic, 114550 (3);114550
IGFALS;Acid-labile subunit, deficiency of;17357067;601489;Acid-labile subunit, deficiency of, 615961 (3);615961
IGFBP7;Retinal arterial macroaneurysm with supravalvular pulmonic stenosis;17357067;602867;Retinal arterial macroaneurysm with supravalvular pulmonic stenosis, 614224 (3);614224
IGHG2;IgG2 deficiency, selective;17357067;147110;IgG2 deficiency, selective (3);0
IGHM;Agammaglobulinemia 1;17357067;147020;Agammaglobulinemia 1, 601495 (3);601495
IGHMBP2;Charcot-Marie-Tooth disease, axonal, type 2S;17357067;600502;Charcot-Marie-Tooth disease, axonal, type 2S, 616155 (3);616155
IGHMBP2;Neuronopathy, distal hereditary motor, type VI;17357067;600502;Neuronopathy, distal hereditary motor, type VI, 604320 (3);604320
IGKC;Kappa light chain deficiency;17357067;147200;Kappa light chain deficiency, 614102 (3);614102
IGLL1;Agammaglobulinemia 2;17357067;146770;Agammaglobulinemia 2, 613500 (3);613500
IGSF1;Hypothyroidism, central, and testicular enlargement;17357067;300137;Hypothyroidism, central, and testicular enlargement, 300888 (3);300888
IHH;Acrocapitofemoral dysplasia;17357067;600726;Acrocapitofemoral dysplasia, 607778 (3);607778
IHH;Brachydactyly, type A1;17357067;600726;Brachydactyly, type A1, 112500 (3);112500
IKBKAP;Dysautonomia, familial;17357067;603722;Dysautonomia, familial, 223900 (3);223900
IKBKB;Immunodeficiency 15;17357067;603258;Immunodeficiency 15, 615592 (3);615592
IKBKG;Ectodermal dysplasia, hypohidrotic, with immune deficiency;17357067;300248;Ectodermal dysplasia, hypohidrotic, with immune deficiency, 300291 (3);300291
IKBKG;Ectodermal, dysplasia, anhidrotic, lymphedema and immunodeficiency;17357067;300248;Ectodermal, dysplasia, anhidrotic, lymphedema and immunodeficiency, 300301 (3);300301
IKBKG;Immunodeficiency 33;17357067;300248;Immunodeficiency 33, 300636 (3);300636
IKBKG;Immunodeficiency, isolated;17357067;300248;Immunodeficiency, isolated, 300584 (3);300584
IKBKG;Incontinentia pigmenti;17357067;300248;Incontinentia pigmenti, 308300 (3);308300
IKBKG;Invasive pneumococcal disease, recurrent isolated, 2;17357067;300248;Invasive pneumococcal disease, recurrent isolated, 2, 300640 (3);300640
IKZF1;Leukemia, acute lymphoblastic;17357067;603023;Leukemia, acute lymphoblastic (3);0
IL10;Graft-versus-host disease, protection against;17357067;124092;{Graft-versus-host disease, protection against}, 614395 (3);614395
IL10;HIV-1, susceptibility to;17357067;124092;{HIV-1, susceptibility to}, 609423 (3);609423
IL10;Rheumatoid arthritis, progression of;17357067;124092;{Rheumatoid arthritis, progression of}, 180300 (3);180300
IL10RA;Inflammatory bowel disease 28, early onset, autosomal recessive;17357067;146933;Inflammatory bowel disease 28, early onset, autosomal recessive, 613148 (3);613148
IL10RB;Hepatitis B virus, susceptibility to;17357067;123889;{Hepatitis B virus, susceptibility to}, 610424 (3);610424
IL10RB;Inflammatory bowel disease 25, early onset, autosomal recessive;17357067;123889;Inflammatory bowel disease 25, early onset, autosomal recessive, 612567 (3);612567
IL11RA;Craniosynostosis and dental anomalies;17357067;600939;Craniosynostosis and dental anomalies, 614188 (3);614188
IL12B;Immunodeficiency 29, mycobacteriosis;17357067;161561;Immunodeficiency 29, mycobacteriosis, 614890 (3);614890
IL12RB1;Immunodeficiency 30;17357067;601604;Immunodeficiency 30, 614891 (3);614891
IL13;Allergic rhinitis, susceptibility to;17357067;147683;{Allergic rhinitis, susceptibility to}, 607154 (3);607154
IL13;Asthma, susceptibility to;17357067;147683;{Asthma, susceptibility to}, 600807 (3);600807
IL17RC;Candidiasis, familial, 9;17357067;610925;Candidiasis, familial, 9, 616445 (3);616445
IL17RD;Hypogonadotropic hypogonadism 18 with or without anosmia;17357067;606807;Hypogonadotropic hypogonadism 18 with or without anosmia, 615267 (3);615267
IL1B;Gastric cancer risk after H. pylori infection;17357067;147720;{Gastric cancer risk after H. pylori infection}, 137215 (3);137215
IL1RAPL1;Mental retardation, X-linked 21/34;17357067;300206;Mental retardation, X-linked 21/34, 300143 (3);300143
IL1RN;Gastric cancer risk after H. pylori infection;17357067;147679;{Gastric cancer risk after H. pylori infection}, 137215 (3);137215
IL1RN;Interleukin 1 receptor antagonist deficiency;17357067;147679;Interleukin 1 receptor antagonist deficiency, 612852 (3);612852
IL1RN;Microvascular complications of diabetes 4;17357067;147679;{Microvascular complications of diabetes 4}, 612628 (3);612628
IL2;Severe combined immunodeficiency due to IL2 deficiency;17357067;147680;Severe combined immunodeficiency due to IL2 deficiency (1);0
IL21R;IgE, elevated level of;17357067;605383;[IgE, elevated level of], 147050 (3);147050
IL21R;Immunodeficiency, primary, autosomal recessive, IL21R-related;17357067;605383;Immunodeficiency, primary, autosomal recessive, IL21R-related, 615207 (3);615207
IL23R;Inflammatory bowel disease 17, protection against;17357067;607562;{Inflammatory bowel disease 17, protection against}, 612261 (3);612261
IL23R;Psoriasis, protection against;17357067;607562;{Psoriasis, protection against}, 605606 (3);605606
IL2RA;Diabetes, mellitus, insulin-dependent, susceptibility to, 10;17357067;147730;{Diabetes, mellitus, insulin-dependent, susceptibility to, 10}, 601942 (3);601942
IL2RA;Immunodeficiency 41 with lymphoproliferation and autoimmunity;17357067;147730;Immunodeficiency 41 with lymphoproliferation and autoimmunity, 606367 (3);606367
IL2RG;Combined immunodeficiency, X-linked, moderate;17357067;308380;Combined immunodeficiency, X-linked, moderate, 312863 (3);312863
IL2RG;Severe combined immunodeficiency, X-linked;17357067;308380;Severe combined immunodeficiency, X-linked, 300400 (3);300400
IL31RA;Amyloidosis, primary localized cutaneous, 2;17357067;609510;Amyloidosis, primary localized cutaneous, 2, 613955 (3);613955
IL36RN;Psoriasis 14, pustular;17357067;605507;Psoriasis 14, pustular, 614204 (3);614204
IL4R;AIDS, slow progression to;17357067;147781;{AIDS, slow progression to}, 609423 (3);609423
IL4R;Atopy, susceptibility to;17357067;147781;{Atopy, susceptibility to}, 147050 (3);147050
IL6;Crohn disease-associated growth failure;17357067;147620;{Crohn disease-associated growth failure}, 266600 (3);266600
IL6;Diabetes, susceptibility to, 222100;17357067;147620;{Diabetes, susceptibility to}, 222100, 125853 (3);125853
IL6;Intracranial hemorrhage in brain cerebrovascular malformations, susceptibility to;17357067;147620;{Intracranial hemorrhage in brain cerebrovascular malformations, susceptibility to}, 108010 (3);108010
IL6;Kaposi sarcoma, susceptibility to;17357067;147620;{Kaposi sarcoma, susceptibility to}, 148000 (3);148000
IL6;Rheumatoid arthritis, systemic juvenile;17357067;147620;{Rheumatoid arthritis, systemic juvenile}, 604302 (3);604302
IL6R;Interleukin 6, serum level of, QTL;17357067;147880;[Interleukin 6, serum level of, QTL], 614752 (3);614752
IL6R;Interleukin-6 receptor, soluble, serum level of, QTL;17357067;147880;[Interleukin-6 receptor, soluble, serum level of, QTL], 614689 (3);614689
IL7R;Severe combined immunodeficiency, T-cell negative, B-cell/natural killer cell-positive type;17357067;146661;Severe combined immunodeficiency, T-cell negative, B-cell/natural killer cell-positive type, 608971 (3);608971
ILDR1;Deafness, autosomal recessive 42;17357067;609739;Deafness, autosomal recessive 42, 609646 (3);609646
IMPAD1;Chondrodysplasia with joint dislocations, GRAPP type;17357067;614010;Chondrodysplasia with joint dislocations, GRAPP type, 614078 (3);614078
IMPDH1;Leber congenital amaurosis 11;17357067;146690;Leber congenital amaurosis 11, 613837 (3);613837
IMPDH1;Retinitis pigmentosa 10;17357067;146690;Retinitis pigmentosa 10, 180105 (3);180105
IMPDH2;IMPDH2 enzyme activity, variation in;17357067;146691;[IMPDH2 enzyme activity, variation in] (3);0
IMPG1;Macular dystrophy, vitelliform, 4;17357067;602870;Macular dystrophy, vitelliform, 4, 616151 (3);616151
IMPG2;Macular dystrophy, vitelliform, 5;17357067;607056;Macular dystrophy, vitelliform, 5, 616152 (3);616152
IMPG2;Retinitis pigmentosa 56;17357067;607056;Retinitis pigmentosa 56, 613581 (3);613581
INF2;Charcot-Marie-Tooth disease, dominant intermediate E;17357067;610982;Charcot-Marie-Tooth disease, dominant intermediate E, 614455 (3);614455
INF2;Glomerulosclerosis, focal segmental, 5;17357067;610982;Glomerulosclerosis, focal segmental, 5, 613237 (3);613237
ING1;Squamous cell carcinoma, head and neck, somatic;17357067;601566;Squamous cell carcinoma, head and neck, somatic, 275355 (3);275355
INPP5E;Joubert syndrome 1;17357067;613037;Joubert syndrome 1, 213300 (3);213300
INPP5E;Mental retardation, truncal obesity, retinal dystrophy, and micropenis;17357067;613037;Mental retardation, truncal obesity, retinal dystrophy, and micropenis, 610156 (3);610156
INPPL1;Opsismodysplasia;17357067;600829;Opsismodysplasia, 258480 (3);258480
INS;Diabetes mellitus, insulin-dependent, 2;17357067;176730;Diabetes mellitus, insulin-dependent, 2, 125852 (3);125852
INS;Diabetes mellitus, permanent neonatal;17357067;176730;Diabetes mellitus, permanent neonatal, 606176 (3);606176
INS;Hyperproinsulinemia;17357067;176730;Hyperproinsulinemia, 616214 (3);616214
INS;Maturity-onset diabetes of the young, type 10;17357067;176730;Maturity-onset diabetes of the young, type 10, 613370 (3);613370
INSL3;Cryptorchidism;17357067;146738;Cryptorchidism, 219050 (3);219050
INSR;Diabetes mellitus, insulin-resistant, with acanthosis nigricans;17357067;147670;Diabetes mellitus, insulin-resistant, with acanthosis nigricans, 610549 (3);610549
INSR;Hyperinsulinemic hypoglycemia, familial, 5;17357067;147670;Hyperinsulinemic hypoglycemia, familial, 5, 609968 (3);609968
INSR;Leprechaunism;17357067;147670;Leprechaunism, 246200 (3);246200
INSR;Rabson-Mendenhall syndrome;17357067;147670;Rabson-Mendenhall syndrome, 262190 (3);262190
INVS;Nephronophthisis 2, infantile;17357067;243305;Nephronophthisis 2, infantile, 602088 (3);602088
IQCB1;Senior-Loken syndrome 5;17357067;609237;Senior-Loken syndrome 5, 609254 (3);609254
IQSEC2;Mental retardation, X-linked 1;17357067;300522;Mental retardation, X-linked 1, 309530 (3);309530
IRAK3;Asthma susceptibility 5;17357067;604459;{Asthma susceptibility 5}, 611064 (3);611064
IRAK4;IRAK4 deficiency;17357067;606883;IRAK4 deficiency, 607676 (3);607676
IRAK4;Invasive pneumococcal disease, recurrent isolated, 1;17357067;606883;Invasive pneumococcal disease, recurrent isolated, 1, 610799 (3);610799
IRF1;Gastric cancer, somatic;17357067;147575;Gastric cancer, somatic, 613659 (3);613659
IRF1;Myelodysplastic syndrome, preleukemic;17357067;147575;Myelodysplastic syndrome, preleukemic (3);0
IRF1;Myelogenous leukemia, acute;17357067;147575;Myelogenous leukemia, acute (3);0
IRF1;Nonsmall cell lung cancer, somatic;17357067;147575;Nonsmall cell lung cancer, somatic, 211980 (3);211980
IRF4;Skin/hair/eye pigmentation, variation in, 8;17357067;601900;[Skin/hair/eye pigmentation, variation in, 8], 611724 (3);611724
IRF5;Inflammatory bowel disease 14;17357067;607218;{Inflammatory bowel disease 14}, 612245 (3);612245
IRF5;Systemic lupus erythematosus, susceptibility to, 10;17357067;607218;{Systemic lupus erythematosus, susceptibility to, 10}, 612251 (3);612251
IRF6;Orofacial cleft 6;17357067;607199;Orofacial cleft 6, 608864 (3);608864
IRF6;Popliteal pterygium syndrome 1;17357067;607199;Popliteal pterygium syndrome 1, 119500 (3);119500
IRF6;van der Woude syndrome;17357067;607199;van der Woude syndrome, 119300 (3);119300
IRF8;Immunodeficiency 32A, mycobacteriosis, autosomal dominant;17357067;601565;Immunodeficiency 32A, mycobacteriosis, autosomal dominant, 614893 (3);614893
IRF8;Immunodeficiency 32B, monocyte and dendritic cell deficiency, autosomal recessive;17357067;601565;Immunodeficiency 32B, monocyte and dendritic cell deficiency, autosomal recessive, 614894 (3);614894
IRGM;Inflammatory bowel disease 19;17357067;608212;Inflammatory bowel disease 19, 612278 (3);612278
IRGM;Mycobacterium tuberculosis, protection against;17357067;608212;{Mycobacterium tuberculosis, protection against}, 607948 (3);607948
IRS1;Coronary artery disease, susceptibility to;17357067;147545;{Coronary artery disease, susceptibility to} (3);0
IRS1;Diabetes mellitus, noninsulin-dependent;17357067;147545;{Diabetes mellitus, noninsulin-dependent}, 125853 (3);125853
IRS2;Diabetes mellitus, noninsulin-dependent;17357067;600797;{Diabetes mellitus, noninsulin-dependent}, 125853 (3);125853
IRX5;Hamamy syndrome;17357067;606195;Hamamy syndrome, 611174 (3);611174
ISCA2;Multiple mitochondrial dysfunctions syndrome 4;17357067;615317;Multiple mitochondrial dysfunctions syndrome 4, 616370 (3);616370
ISCU;Myopathy with lactic acidosis, hereditary;17357067;611911;Myopathy with lactic acidosis, hereditary, 255125 (3);255125
ISG15;Immunodeficiency 38;17357067;147571;Immunodeficiency 38, 616126 (3);616126
ISPD;Muscular dystrophy-dystroglycanopathy (congenital with brain and eye anomalies), type A, 7;17357067;614631;Muscular dystrophy-dystroglycanopathy (congenital with brain and eye anomalies), type A, 7, 614643 (3);614643
ISPD;Muscular dystrophy-dystroglycanopathy (limb-girdle), type C, 7;17357067;614631;Muscular dystrophy-dystroglycanopathy (limb-girdle), type C, 7, 616052 (3);616052
ISYNA1;Ichthyosis prematurity syndrome;17357067;604194;Ichthyosis prematurity syndrome, 608649 (3);608649
ITCH;Autoimmune disease, multisystem, with facial dysmorphism;17357067;606409;Autoimmune disease, multisystem, with facial dysmorphism, 613385 (3);613385
ITGA2B;Bleeding disorder, platelet-type, 16, autosomal dominant;17357067;607759;Bleeding disorder, platelet-type, 16, autosomal dominant, 187800 (3);187800
ITGA2B;Glanzmann thrombasthenia;17357067;607759;Glanzmann thrombasthenia, 273800 (3);273800
ITGA2B;Thrombocytopenia, neonatal alloimmune, BAK antigen related;17357067;607759;Thrombocytopenia, neonatal alloimmune, BAK antigen related (3);0
ITGA3;Interstitial lung disease, nephrotic syndrome, and epidermolysis bullosa, congenital;17357067;605025;Interstitial lung disease, nephrotic syndrome, and epidermolysis bullosa, congenital, 614748 (3);614748
ITGA6;Epidermolysis bullosa, junctional, with pyloric stenosis;17357067;147556;Epidermolysis bullosa, junctional, with pyloric stenosis, 226730 (3);226730
ITGA7;Muscular dystrophy, congenital, due to ITGA7 deficiency;17357067;600536;Muscular dystrophy, congenital, due to ITGA7 deficiency, 613204 (3);613204
ITGA8;Renal hypodysplasia/aplasia 1;17357067;604063;Renal hypodysplasia/aplasia 1, 191830 (3);191830
ITGAM;Systemic lupus erythematous, association with susceptibility to, 6;17357067;120980;{Systemic lupus erythematous, association with susceptibility to, 6}, 609939 (3);609939
ITGB2;Leukocyte adhesion deficiency;17357067;600065;Leukocyte adhesion deficiency, 116920 (3);116920
ITGB3;Bleeding disorder, platelet-type, 16, autosomal dominant;17357067;173470;Bleeding disorder, platelet-type, 16, autosomal dominant, 187800 (3);187800
ITGB3;Glanzmann thrombasthenia;17357067;173470;Glanzmann thrombasthenia, 273800 (3);273800
ITGB3;Myocardial infarction, susceptibility to;17357067;173470;{Myocardial infarction, susceptibility to}, 608446 (3);608446
ITGB3;Purpura, posttransfusion;17357067;173470;Purpura, posttransfusion (3);0
ITGB3;Thrombocytopenia, neonatal alloimmune;17357067;173470;Thrombocytopenia, neonatal alloimmune (3);0
ITGB4;Epidermolysis bullosa of hands and feet;17357067;147557;Epidermolysis bullosa of hands and feet, 131800 (3);131800
ITGB4;Epidermolysis bullosa, junctional, non-Herlitz type;17357067;147557;Epidermolysis bullosa, junctional, non-Herlitz type, 226650 (3);226650
ITGB4;Epidermolysis bullosa, junctional, with pyloric atresia;17357067;147557;Epidermolysis bullosa, junctional, with pyloric atresia, 226730 (3);226730
ITGB6;Amelogenesis imperfecta, type IH;17357067;147558;Amelogenesis imperfecta, type IH, 616221 (3);616221
ITIH4;Hypercholesterolemia, susceptibility to;17357067;600564;{Hypercholesterolemia, susceptibility to}, 143890 (3);143890
ITK;Lymphoproliferative syndrome 1;17357067;186973;Lymphoproliferative syndrome 1, 613011 (3);613011
ITM2B;Dementia, familial British;17357067;603904;Dementia, familial British, 176500 (3);176500
ITM2B;Dementia, familial Danish;17357067;603904;Dementia, familial Danish, 117300 (3);117300
ITPA;Inosine triphosphatase deficiency;17357067;147520;[Inosine triphosphatase deficiency], 613850 (3);613850
ITPA;Woodhouse-Sakati syndrome;17357067;612515;Woodhouse-Sakati syndrome, 241080 (3);241080
ITPKC;Kawasaki disease, susceptibility to;17357067;606476;{Kawasaki disease, susceptibility to}, 611775 (3);611775
ITPR1;Spinocerebellar ataxia 15;17357067;147265;Spinocerebellar ataxia 15, 606658 (3);606658
ITPR1;Spinocerebellar ataxia 29, congenital nonprogressive;17357067;147265;Spinocerebellar ataxia 29, congenital nonprogressive, 117360 (3);117360
ITPR3;Diabetes, type 1, susceptibility to;17357067;147267;{Diabetes, type 1, susceptibility to}, 222100 (2);222100
IVD;Isovaleric acidemia;17357067;607036;Isovaleric acidemia, 243500 (3);243500
IYD;Thyroid dyshormonogenesis 4;17357067;612025;Thyroid dyshormonogenesis 4, 274800 (3);274800
JAG1;Alagille syndrome;17357067;601920;Alagille syndrome, 118450 (3);118450
JAG1;Deafness, congenital heart defects, and posterior embryotoxon;17357067;601920;Deafness, congenital heart defects, and posterior embryotoxon (3);0
JAG1;Tetralogy of Fallot;17357067;601920;Tetralogy of Fallot, 187500 (3);187500
JAGN1;Neutropenia, severe congenital, 6, autosomal recessive;17357067;616012;Neutropenia, severe congenital, 6, autosomal recessive, 616022 (3);616022
JAK2;Budd-Chiari syndrome;17357067;147796;{Budd-Chiari syndrome}, 600880 (3);600880
JAK2;Erythrocytosis, somatic;17357067;147796;Erythrocytosis, somatic, 133100 (3);133100
JAK2;Leukemia, acute myelogenous;17357067;147796;Leukemia, acute myelogenous, 601626 (3);601626
JAK2;Myelofibrosis, somatic;17357067;147796;Myelofibrosis, somatic, 254450 (3);254450
JAK2;Polycythemia vera;17357067;147796;Polycythemia vera, 263300 (3);263300
JAK2;Thrombocythemia 3;17357067;147796;Thrombocythemia 3, 614521 (3);614521
JAK3;SCID, autosomal recessive, T-negative/B-positive type;17357067;600173;SCID, autosomal recessive, T-negative/B-positive type, 600802 (3);600802
JAM3;Hemorrhagic destruction of the brain, subependymal calcification, and cataracts;17357067;606871;Hemorrhagic destruction of the brain, subependymal calcification, and cataracts, 613730 (3);613730
JPH2;Cardiomyopathy, hypertrophic, 17;17357067;605267;Cardiomyopathy, hypertrophic, 17, 613873 (3);613873
JPH3;Huntington disease-like 2;17357067;605268;Huntington disease-like 2, 606438 (3);606438
JUP;Arrhythmogenic right ventricular dysplasia 12;17357067;173325;Arrhythmogenic right ventricular dysplasia 12, 611528 (3);611528
JUP;Naxos disease;17357067;173325;Naxos disease, 601214 (3);601214
KAL1;Hypogonadotropic hypogonadism 1 with or without anosmia (Kallmann syndrome 1);17357067;300836;Hypogonadotropic hypogonadism 1 with or without anosmia (Kallmann syndrome 1), 308700 (3);308700
KALRN;Coronary heart disease, susceptibility to, 5;17357067;604605;{Coronary heart disease, susceptibility to, 5}, 608901 (3);608901
KANK1;Cerebral palsy, spastic quadriplegic, 2;17357067;607704;Cerebral palsy, spastic quadriplegic, 2, 612900 (3);612900
KANK2;Palmoplantar keratoderma and woolly hair;17357067;614610;Palmoplantar keratoderma and woolly hair, 616099 (3);616099
KANSL1;Koolen-De Vries syndrome;17357067;612452;Koolen-De Vries syndrome, 610443 (3);610443
KARS;Deafness, autosomal recessive 89;17357067;601421;Deafness, autosomal recessive 89, 613916 (3);613916
KAT6A;Mental retardation, autosomal dominant 32;17357067;601408;Mental retardation, autosomal dominant 32, 616268 (3);616268
KAT6B;Genitopatellar syndrome;17357067;605880;Genitopatellar syndrome, 606170 (3);606170
KAT6B;SBBYSS syndrome;17357067;605880;SBBYSS syndrome, 603736 (3);603736
KATNB1;Lissencephaly 6, with microcephaly;17357067;602703;Lissencephaly 6, with microcephaly, 616212 (3);616212
KBTBD13;Nemaline myopathy 6, autosomal dominant;17357067;613727;Nemaline myopathy 6, autosomal dominant, 609273 (3);609273
KCNA1;Episodic ataxia/myokymia syndrome;17357067;176260;Episodic ataxia/myokymia syndrome, 160120 (3);160120
KCNA2;Epileptic encephalopathy, early infantile, 32;17357067;176262;Epileptic encephalopathy, early infantile, 32, 616366 (3);616366
KCNA5;Atrial fibrillation, familial, 7;17357067;176267;Atrial fibrillation, familial, 7, 612240 (3);612240
KCNB1;Epileptic encephalopathy, early infantile, 26;17357067;600397;Epileptic encephalopathy, early infantile, 26, 616056 (3);616056
KCNC1;Epilepsy, progressive myoclonic 7;17357067;176258;Epilepsy, progressive myoclonic 7, 616187 (3);616187
KCNC3;Spinocerebellar ataxia 13;17357067;176264;Spinocerebellar ataxia 13, 605259 (3);605259
KCND3;Brugada syndrome 9;17357067;605411;Brugada syndrome 9, 616399 (3);616399
KCND3;Spinocerebellar ataxia 19;17357067;605411;Spinocerebellar ataxia 19, 607346 (3);607346
KCNE1;Jervell and Lange-Nielsen syndrome 2;17357067;176261;Jervell and Lange-Nielsen syndrome 2, 612347 (3);612347
KCNE1;Long QT syndrome 5;17357067;176261;Long QT syndrome 5, 613695 (3);613695
KCNE2;Atrial fibrillation, familial, 4;17357067;603796;Atrial fibrillation, familial, 4, 611493 (3);611493
KCNE2;Long QT syndrome 6;17357067;603796;Long QT syndrome 6, 613693 (3);613693
KCNE3;Brugada syndrome 6;17357067;604433;Brugada syndrome 6, 613119 (3);613119
KCNH1;Temple-Baraitser syndrome;17357067;603305;Temple-Baraitser syndrome, 611816 (3);611816
KCNH1;Zimmermann-Laband syndrome 1;17357067;603305;Zimmermann-Laband syndrome 1, 135500 (3);135500
KCNH2;Long QT syndrome 2;17357067;152427;Long QT syndrome 2, 613688 (3);613688
KCNH2;Long QT syndrome 2, acquired, susceptibility to;17357067;152427;{Long QT syndrome 2, acquired, susceptibility to}, 613688 (3);613688
KCNH2;Retinal cone dystrophy 3B;17357067;607604;Retinal cone dystrophy 3B, 610356 (3);610356
KCNH2;Short QT syndrome 1;17357067;152427;Short QT syndrome 1, 609620 (3);609620
KCNH7;Lathosterolosis;17357067;602286;Lathosterolosis, 607330 (3);607330
KCNJ1;Bartter syndrome, type 2;17357067;600359;Bartter syndrome, type 2, 241200 (3);241200
KCNJ10;Enlarged vestibular aqueduct, digenic;17357067;602208;Enlarged vestibular aqueduct, digenic, 600791 (3);600791
KCNJ10;SESAME syndrome;17357067;602208;SESAME syndrome, 612780 (3);612780
KCNJ11;Diabetes mellitus, permanent neonatal, with neurologic features;17357067;600937;Diabetes mellitus, permanent neonatal, with neurologic features, 606176 (3);606176
KCNJ11;Diabetes mellitus, transient neonatal, 3;17357067;600937;Diabetes mellitus, transient neonatal, 3, 610582 (3);610582
KCNJ11;Diabetes mellitus, type 2, susceptibility to;17357067;600937;{Diabetes mellitus, type 2, susceptibility to}, 125853 (3);125853
KCNJ11;Diabetes, permanent neonatal;17357067;600937;Diabetes, permanent neonatal, 606176 (3);606176
KCNJ11;Hyperinsulinemic hypoglycemia, familial, 2;17357067;600937;Hyperinsulinemic hypoglycemia, familial, 2, 601820 (3);601820
KCNJ11;Maturity-onset diabetes of the young, type 13;17357067;600937;Maturity-onset diabetes of the young, type 13, 616329 (3);616329
KCNJ13;Leber congenital amaurosis 16;17357067;603208;Leber congenital amaurosis 16, 614186 (3);614186
KCNJ13;Snowflake vitreoretinal degeneration;17357067;603208;Snowflake vitreoretinal degeneration, 193230 (3);193230
KCNJ18;Thyrotoxic periodic paralysis, susceptibility to, 2;17357067;613236;{Thyrotoxic periodic paralysis, susceptibility to, 2}, 613239 (3);613239
KCNJ2;Andersen syndrome;17357067;600681;Andersen syndrome, 170390 (3);170390
KCNJ2;Atrial fibrillation, familial, 9;17357067;600681;Atrial fibrillation, familial, 9, 613980 (3);613980
KCNJ2;Short QT syndrome 3;17357067;600681;Short QT syndrome 3, 609622 (3);609622
KCNJ5;Hyperaldosteronism, familial, type III;17357067;600734;Hyperaldosteronism, familial, type III, 613677 (3);613677
KCNJ5;Long QT syndrome 13;17357067;600734;Long QT syndrome 13, 613485 (3);613485
KCNJ6;Keppen-Lubinsky syndrome;17357067;600877;Keppen-Lubinsky syndrome, 614098 (3);614098
KCNK18;Migraine, with or without aura, susceptibility to, 13;17357067;613655;{Migraine, with or without aura, susceptibility to, 13}, 613656 (3);613656
KCNK3;Pulmonary hypertension, primary, 4;17357067;603220;Pulmonary hypertension, primary, 4, 615344 (3);615344
KCNK9;Birk-Barel mental retardation dysmorphism syndrome;17357067;605874;Birk-Barel mental retardation dysmorphism syndrome, 612292 (3);612292
KCNMA1;Generalized epilepsy and paroxysmal dyskinesia;17357067;600150;Generalized epilepsy and paroxysmal dyskinesia, 609446 (3);609446
KCNMB1;Hypertension, diastolic, resistance to;17357067;603951;{Hypertension, diastolic, resistance to}, 608622 (3);608622
KCNQ1;Atrial fibrillation, familial, 3;17357067;607542;Atrial fibrillation, familial, 3, 607554 (3);607554
KCNQ1;Jervell and Lange-Nielsen syndrome;17357067;607542;Jervell and Lange-Nielsen syndrome, 220400 (3);220400
KCNQ1;Long QT syndrome 1;17357067;607542;Long QT syndrome 1, 192500 (3);192500
KCNQ1;Long QT syndrome 1, acquired, susceptibility to;17357067;607542;{Long QT syndrome 1, acquired, susceptibility to}, 192500 (3);192500
KCNQ1;Short QT syndrome 2;17357067;607542;Short QT syndrome 2, 609621 (3);609621
KCNQ1OT1;Beckwith-Wiedemann syndrome;17357067;604115;Beckwith-Wiedemann syndrome, 130650 (3);130650
KCNQ2;Epileptic encephalopathy, early infantile, 7;17357067;602235;Epileptic encephalopathy, early infantile, 7, 613720 (3);613720
KCNQ2;Myokymia;17357067;602235;Myokymia, 121200 (3);121200
KCNQ2;Seizures, benign neonatal, 1;17357067;602235;Seizures, benign neonatal, 1, 121200 (3);121200
KCNQ3;Seizures, benign neonatal, type 2;17357067;602232;Seizures, benign neonatal, type 2, 121201 (3);121201
KCNQ4;Deafness, autosomal dominant 2A;17357067;603537;Deafness, autosomal dominant 2A, 600101 (3);600101
KCNT1;Epilepsy, nocturnal frontal lobe, 5;17357067;608167;Epilepsy, nocturnal frontal lobe, 5, 615005 (3);615005
KCNT1;Epileptic encephalopathy, early infantile, 14;17357067;608167;Epileptic encephalopathy, early infantile, 14, 614959 (3);614959
KCNV2;Retinal cone dystrophy 3B;17357067;607604;Retinal cone dystrophy 3B, 610356 (3);610356
KCTD1;Scalp-ear-nipple syndrome;17357067;613420;Scalp-ear-nipple syndrome, 181270 (3);181270
KCTD17;Dystonia 26, myoclonic;17357067;616386;Dystonia 26, myoclonic, 616398 (3);616398
KCTD7;Epilepsy, progressive myoclonic 3, with or without intracellular inclusions;17357067;611725;Epilepsy, progressive myoclonic 3, with or without intracellular inclusions, 611726 (3);611726
KDM5C;Mental retardation, X-linked, syndromic, Claes-Jensen type;17357067;314690;Mental retardation, X-linked, syndromic, Claes-Jensen type, 300534 (3);300534
KDM6A;Kabuki syndrome 2;17357067;300128;Kabuki syndrome 2, 300867 (3);300867
KDR;Hemangioma, capillary infantile, somatic;17357067;191306;Hemangioma, capillary infantile, somatic, 602089 (3);602089
KDR;Hemangioma, capillary infantile, susceptibility to;17357067;191306;{Hemangioma, capillary infantile, susceptibility to}, 602089 (3);602089
KDSR;Lymphoma/leukemia, B-cell, variant;17357067;136440;Lymphoma/leukemia, B-cell, variant (1);0
KEL;Blood group, Kell;17357067;613883;[Blood group, Kell], 110900 (3);110900
KERA;Cornea plana congenita, recessive;17357067;603288;Cornea plana congenita, recessive, 217300 (3);217300
KHDC3L;Hydatidiform mole, recurrent, 2;17357067;611687;Hydatidiform mole, recurrent, 2, 614293 (3);614293
KHK;Fructosuria;17357067;614058;[Fructosuria], 229800 (3);229800
KIAA0196;Ritscher-Schinzel syndrome;17357067;610657;Ritscher-Schinzel syndrome, 220210 (3);220210
KIAA0196;Spastic paraplegia 8, autosomal dominant;17357067;610657;Spastic paraplegia 8, autosomal dominant, 603563 (3);603563
KIAA0319;Dyslexia, susceptibility to, 2;17357067;609269;{Dyslexia, susceptibility to, 2}, 600202 (3);600202
KIAA0586;Joubert syndrome;17357067;610178;Joubert syndrome, 616490 (3);616490
KIAA1279;Goldberg-Shprintzen megacolon syndrome;17357067;609367;Goldberg-Shprintzen megacolon syndrome, 609460 (3);609460
KIAA2022;Mental retardation, X-linked 98;17357067;300524;Mental retardation, X-linked 98, 300912 (3);300912
KIF11;Microcephaly with or without chorioretinopathy, lymphedema, or mental retardation;17357067;148760;Microcephaly with or without chorioretinopathy, lymphedema, or mental retardation, 152950 (3);152950
KIF1A;Mental retardation, autosomal dominant 9;17357067;601255;Mental retardation, autosomal dominant 9, 614255 (3);614255
KIF1A;Neuropathy, hereditary sensory, type IIC;17357067;601255;Neuropathy, hereditary sensory, type IIC, 614213 (3);614213
KIF1A;Spastic paraplegia 30, autosomal recessive;17357067;601255;Spastic paraplegia 30, autosomal recessive, 610357 (3);610357
KIF1B;Neuroblastoma, susceptibility to, 1;17357067;605995;{Neuroblastoma, susceptibility to, 1}, 256700 (3);256700
KIF1B;Pheochromocytoma;17357067;605995;Pheochromocytoma, 171300 (3);171300
KIF1C;Spastic ataxia 2, autosomal recessive;17357067;603060;Spastic ataxia 2, autosomal recessive, 611302 (3);611302
KIF21A;Fibrosis of extraocular muscles, congenital, 1;17357067;608283;Fibrosis of extraocular muscles, congenital, 1, 135700 (3);135700
KIF21A;Fibrosis of extraocular muscles, congenital, 3B;17357067;608283;Fibrosis of extraocular muscles, congenital, 3B, 135700 (3);135700
KIF22;Bart-Pumphrey syndrome;17357067;121011;Bart-Pumphrey syndrome, 149200 (3);149200
KIF22;Deafness, autosomal dominant 3A;17357067;121011;Deafness, autosomal dominant 3A, 601544 (3);601544
KIF22;Deafness, autosomal recessive 1A;17357067;121011;Deafness, autosomal recessive 1A, 220290 (3);220290
KIF22;Hystrix-like ichthyosis with deafness;17357067;121011;Hystrix-like ichthyosis with deafness, 602540 (3);602540
KIF22;Keratitis-ichthyosis-deafness syndrome;17357067;121011;Keratitis-ichthyosis-deafness syndrome, 148210 (3);148210
KIF22;Keratoderma, palmoplantar, with deafness;17357067;121011;Keratoderma, palmoplantar, with deafness, 148350 (3);148350
KIF22;Spondyloepimetaphyseal dysplasia with joint laxity, type 2;17357067;603213;Spondyloepimetaphyseal dysplasia with joint laxity, type 2, 603546 (3);603546
KIF22;Vohwinkel syndrome;17357067;121011;Vohwinkel syndrome, 124500 (3);124500
KIF2A;Cortical dysplasia, complex, with other brain malformations 3;17357067;602591;Cortical dysplasia, complex, with other brain malformations 3, 615411 (3);615411
KIF5A;Spastic paraplegia 10, autosomal dominant;17357067;602821;Spastic paraplegia 10, autosomal dominant, 604187 (3);604187
KIF5C;Cortical dysplasia, complex, with other brain malformations 2;17357067;604593;Cortical dysplasia, complex, with other brain malformations 2, 615282 (3);615282
KIF7;Acrocallosal syndrome;17357067;611254;Acrocallosal syndrome, 200990 (3);200990
KIF7;Hydrolethalus syndrome 2;17357067;611254;Hydrolethalus syndrome 2, 614120 (3);614120
KIF7;Joubert syndrome 12;17357067;611254;Joubert syndrome 12, 200990 (3);200990
KIR3DL1;AIDS, delayed/rapid progression to;17357067;604946;{AIDS, delayed/rapid progression to}, 609423 (3);609423
KIRREL3;Mental retardation, autosomal dominant 4;17357067;607761;Mental retardation, autosomal dominant 4, 612581 (3);612581
KISS1R;Hypogonadotropic hypogonadism 8 with or without anosmia;17357067;604161;Hypogonadotropic hypogonadism 8 with or without anosmia, 614837 (3);614837
KIT;Gastrointestinal stromal tumor, familial;17357067;164920;Gastrointestinal stromal tumor, familial, 606764 (3);606764
KIT;Germ cell tumors;17357067;164920;Germ cell tumors, 273300 (3);273300
KIT;Leukemia, acute myeloid;17357067;164920;Leukemia, acute myeloid, 601626 (3);601626
KIT;Mast cell disease;17357067;164920;Mast cell disease, 154800 (3);154800
KIT;Piebaldism;17357067;164920;Piebaldism, 172800 (3);172800
KITLG;Hyperpigmentation with or without hypopigmentation;17357067;184745;Hyperpigmentation with or without hypopigmentation, 145250 (3);145250
KITLG;Skin/hair/eye pigmentation 7, blond/brown hair;17357067;184745;[Skin/hair/eye pigmentation 7, blond/brown hair], 611664 (3);611664
KIZ;Retinitis pigmentosa 69;17357067;615757;Retinitis pigmentosa 69, 615780 (3);615780
KL;Coronary artery disease, susceptibility to;17357067;604824;{Coronary artery disease, susceptibility to} (3);0
KL;Tumoral calcinosis, hyperphosphatemic;17357067;604824;Tumoral calcinosis, hyperphosphatemic, 211900 (3);211900
KLF1;Blood group--Lutheran inhibitor;17357067;600599;Blood group--Lutheran inhibitor, 111150 (3);111150
KLF1;Dyserythropoietic anemia, congenital, type IV;17357067;600599;Dyserythropoietic anemia, congenital, type IV, 613673 (3);613673
KLF1;Hereditary persistence of fetal hemoglobin;17357067;600599;[Hereditary persistence of fetal hemoglobin], 613566 (3);613566
KLF11;Maturity-onset diabetes of the young, type VII;17357067;603301;Maturity-onset diabetes of the young, type VII, 610508 (3);610508
KLF6;Gastric cancer, somatic;17357067;602053;Gastric cancer, somatic, 613659 (3);613659
KLF6;Prostate adenocarcinoma;17357067;601188;Prostate adenocarcinoma (2);0
KLF6;Prostate cancer, somatic;17357067;602053;Prostate cancer, somatic, 176807 (3);176807
KLHDC8B;Hodgkin lymphoma, susceptibility to;17357067;613169;{Hodgkin lymphoma, susceptibility to}, 246000 (3);246000
KLHL10;Spermatogenic failure 11;17357067;608778;Spermatogenic failure 11, 615081 (3);615081
KLHL3;Pseudohypoaldosteronism, type IID;17357067;605775;Pseudohypoaldosteronism, type IID, 614495 (3);614495
KLHL40;Nemaline myopathy 8, autosomal recessive;17357067;615340;Nemaline myopathy 8, autosomal recessive, 615348 (3);615348
KLHL41;Nemaline myopathy 9;17357067;607701;Nemaline myopathy 9, 615731 (3);615731
KLHL7;Retinitis pigmentosa 42;17357067;611119;Retinitis pigmentosa 42, 612943 (3);612943
KLK1;Kallikrein, decreased urinary activity of;17357067;147910;[Kallikrein, decreased urinary activity of], 615953 (3);615953
KLK3;Fletcher factor (prekallikrein) deficiency;17357067;229000;Fletcher factor (prekallikrein) deficiency, 612423 (3);612423
KLK4;Amelogenesis imperfecta, type IIA1;17357067;603767;Amelogenesis imperfecta, type IIA1, 204700 (3);204700
KLKB1;Fletcher factor (prekallikrein) deficiency;17357067;229000;Fletcher factor (prekallikrein) deficiency, 612423 (3);612423
KLLN;Cowden syndrome 4;17357067;612105;Cowden syndrome 4, 615107 (3);615107
KMT2A;Leukemia, myeloid/lymphoid or mixed-lineage;17357067;159555;Leukemia, myeloid/lymphoid or mixed-lineage (2);0
KMT2A;Wiedemann-Steiner syndrome;17357067;159555;Wiedemann-Steiner syndrome, 605130 (3);605130
KMT2D;Kabuki syndrome 1;17357067;602113;Kabuki syndrome 1, 147920 (3);147920
KNG1;Branched-chain ketoacid dehydrogenase kinase deficiency;17357067;614901;Branched-chain ketoacid dehydrogenase kinase deficiency, 614923 (3);614923
KNG1;High molecular weight kininogen deficiency;17357067;612358;[High molecular weight kininogen deficiency], 228960 (3);228960
KNG1;Kininogen deficiency;17357067;612358;[Kininogen deficiency], 228960 (3);228960
KPTN;Mental retardation, autosomal recessive 41;17357067;615620;Mental retardation, autosomal recessive 41, 615637 (3);615637
KRAS;Bladder cancer, somatic;17357067;190070;Bladder cancer, somatic, 109800 (3);109800
KRAS;Breast cancer, somatic;17357067;190070;Breast cancer, somatic, 114480 (3);114480
KRAS;Cardiofaciocutaneous syndrome 2;17357067;190070;Cardiofaciocutaneous syndrome 2, 615278 (3);615278
KRAS;Gastric cancer, somatic;17357067;190070;Gastric cancer, somatic, 137215 (3);137215
KRAS;Leukemia, acute myelogenous;17357067;190070;Leukemia, acute myelogenous (3);0
KRAS;Lung cancer, somatic;17357067;190070;Lung cancer, somatic, 211980 (3);211980
KRAS;Noonan syndrome 3;17357067;190070;Noonan syndrome 3, 609942 (3);609942
KRAS;Pancreatic carcinoma, somatic;17357067;190070;Pancreatic carcinoma, somatic, 260350 (3);260350
KRAS;SFM syndrome, somatic mosaic;17357067;190070;SFM syndrome, somatic mosaic, 163200 (3);163200
KRIT1;Cavernous malformations of CNS and retina;17357067;604214;Cavernous malformations of CNS and retina, 116860 (3);116860
KRIT1;Cerebral cavernous malformations-1;17357067;604214;Cerebral cavernous malformations-1, 116860 (3);116860
KRIT1;Hyperkeratotic cutaneous capillary-venous malformations associated with cerebral capillary malformations;17357067;604214;Hyperkeratotic cutaneous capillary-venous malformations associated with cerebral capillary malformations, 116860 (3);116860
KRT1;Epidermolytic hyperkeratosis;17357067;139350;Epidermolytic hyperkeratosis, 113800 (3);113800
KRT1;Ichthyosis histrix, Curth-Macklin type;17357067;139350;Ichthyosis histrix, Curth-Macklin type, 146590 (3);146590
KRT1;Ichthyosis, cyclic, with epidermolytic hyperkeratosis;17357067;139350;Ichthyosis, cyclic, with epidermolytic hyperkeratosis, 607602 (3);607602
KRT1;Keratosis palmoplantaris striata III;17357067;139350;Keratosis palmoplantaris striata III, 607654 (3);607654
KRT1;Palmoplantar keratoderma, epidermolytic;17357067;139350;Palmoplantar keratoderma, epidermolytic, 144200 (3);144200
KRT1;Palmoplantar keratoderma, nonepidermolytic;17357067;139350;Palmoplantar keratoderma, nonepidermolytic, 600962 (3);600962
KRT10;Epidermolytic hyperkeratosis;17357067;148080;Epidermolytic hyperkeratosis, 113800 (3);113800
KRT10;Ichthyosis with confetti;17357067;148080;Ichthyosis with confetti, 609165 (3);609165
KRT10;Ichthyosis, cyclic, with epidermolytic hyperkeratosis;17357067;148080;Ichthyosis, cyclic, with epidermolytic hyperkeratosis, 607602 (3);607602
KRT12;Meesmann corneal dystrophy;17357067;601687;Meesmann corneal dystrophy, 122100 (3);122100
KRT13;White sponge nevus 2;17357067;148065;White sponge nevus 2, 615785 (3);615785
KRT14;Dermatopathia pigmentosa reticularis;17357067;148066;Dermatopathia pigmentosa reticularis, 125595 (3);125595
KRT14;Epidermolysis bullosa simplex, Dowling-Meara type;17357067;148066;Epidermolysis bullosa simplex, Dowling-Meara type, 131760 (3);131760
KRT14;Epidermolysis bullosa simplex, Koebner type;17357067;148066;Epidermolysis bullosa simplex, Koebner type, 131900 (3);131900
KRT14;Epidermolysis bullosa simplex, Weber-Cockayne type;17357067;148066;Epidermolysis bullosa simplex, Weber-Cockayne type, 131800 (3);131800
KRT14;Epidermolysis bullosa simplex, recessive 1;17357067;148066;Epidermolysis bullosa simplex, recessive 1, 601001 (3);601001
KRT14;Naegeli-Franceschetti-Jadassohn syndrome;17357067;148066;Naegeli-Franceschetti-Jadassohn syndrome, 161000 (3);161000
KRT16;Epidermolytic hyperkeratosis;17357067;139350;Epidermolytic hyperkeratosis, 113800 (3);113800
KRT16;Ichthyosis histrix, Curth-Macklin type;17357067;139350;Ichthyosis histrix, Curth-Macklin type, 146590 (3);146590
KRT16;Ichthyosis, cyclic, with epidermolytic hyperkeratosis;17357067;139350;Ichthyosis, cyclic, with epidermolytic hyperkeratosis, 607602 (3);607602
KRT16;Keratosis palmoplantaris striata III;17357067;139350;Keratosis palmoplantaris striata III, 607654 (3);607654
KRT16;Pachyonychia congenita 1;17357067;148067;Pachyonychia congenita 1, 167200 (3);167200
KRT16;Palmoplantar keratoderma, epidermolytic;17357067;139350;Palmoplantar keratoderma, epidermolytic, 144200 (3);144200
KRT16;Palmoplantar keratoderma, nonepidermolytic;17357067;139350;Palmoplantar keratoderma, nonepidermolytic, 600962 (3);600962
KRT16;Palmoplantar keratoderma, nonepidermolytic, focal;17357067;148067;Palmoplantar keratoderma, nonepidermolytic, focal, 613000 (3);613000
KRT17;Pachyonychia congenita 2;17357067;148069;Pachyonychia congenita 2, 167210 (3);167210
KRT17;Steatocystoma multiplex;17357067;148069;Steatocystoma multiplex, 184500 (3);184500
KRT18;Cirrhosis, cryptogenic;17357067;148070;Cirrhosis, cryptogenic, 215600 (3);215600
KRT18;Cirrhosis, noncryptogenic, susceptibility to;17357067;148070;{Cirrhosis, noncryptogenic, susceptibility to}, 215600 (3);215600
KRT2;Ichthyosis bullosa of Siemens;17357067;600194;Ichthyosis bullosa of Siemens, 146800 (3);146800
KRT3;Meesmann corneal dystrophy;17357067;148043;Meesmann corneal dystrophy, 122100 (3);122100
KRT4;White sponge nevus 1;17357067;123940;White sponge nevus 1, 193900 (3);193900
KRT5;Dowling-Degos disease 1;17357067;148040;Dowling-Degos disease 1, 179850 (3);179850
KRT5;Epidermolysis bullosa simplex, Dowling-Meara type;17357067;148040;Epidermolysis bullosa simplex, Dowling-Meara type, 131760 (3);131760
KRT5;Epidermolysis bullosa simplex, Koebner type;17357067;148040;Epidermolysis bullosa simplex, Koebner type, 131900 (3);131900
KRT5;Epidermolysis bullosa simplex, Weber-Cockayne type;17357067;148040;Epidermolysis bullosa simplex, Weber-Cockayne type, 131800 (3);131800
KRT5;Epidermolysis bullosa simplex, recessive 1;17357067;148040;Epidermolysis bullosa simplex, recessive 1, 601001 (3);601001
KRT5;Epidermolysis bullosa simplex-MP;17357067;148040;Epidermolysis bullosa simplex-MP, 131960 (3);131960
KRT5;Epidermylysis bullosa simplex-MCR;17357067;148040;Epidermylysis bullosa simplex-MCR, 609352 (3);609352
KRT6A;Pachyonychia congenita 3;17357067;148041;Pachyonychia congenita 3, 615726 (3);615726
KRT6B;Pachyonychia congenita 4;17357067;148042;Pachyonychia congenita 4, 615728 (3);615728
KRT6C;Palmoplantar keratoderma, nonepidermolytic, focal or diffuse;17357067;612315;Palmoplantar keratoderma, nonepidermolytic, focal or diffuse, 615735 (3);615735
KRT74;Woolly hair, autosomal dominant;17357067;608248;Woolly hair, autosomal dominant, 194300 (3);194300
KRT75;Pseudofolliculitis barbae, susceptibility to;17357067;609025;{Pseudofolliculitis barbae, susceptibility to}, 612318 (3);612318
KRT8;Cirrhosis, cryptogenic;17357067;148060;Cirrhosis, cryptogenic, 215600 (3);215600
KRT8;Cirrhosis, noncryptogenic, susceptibility to;17357067;148060;{Cirrhosis, noncryptogenic, susceptibility to}, 215600 (3);215600
KRT81;Monilethrix;17357067;602153;Monilethrix, 158000 (3);158000
KRT85;Ectodermal dysplasia 4, hair/nail type;17357067;602767;Ectodermal dysplasia 4, hair/nail type, 602032 (3);602032
KRT86;Monilethrix;17357067;601928;Monilethrix, 158000 (3);158000
KRT9;Epidermolytic hyperkeratosis;17357067;139350;Epidermolytic hyperkeratosis, 113800 (3);113800
KRT9;Ichthyosis histrix, Curth-Macklin type;17357067;139350;Ichthyosis histrix, Curth-Macklin type, 146590 (3);146590
KRT9;Ichthyosis, cyclic, with epidermolytic hyperkeratosis;17357067;139350;Ichthyosis, cyclic, with epidermolytic hyperkeratosis, 607602 (3);607602
KRT9;Keratosis palmoplantaris striata III;17357067;139350;Keratosis palmoplantaris striata III, 607654 (3);607654
KRT9;Palmoplantar keratoderma, epidermolytic;17357067;139350;Palmoplantar keratoderma, epidermolytic, 144200 (3);144200
KRT9;Palmoplantar keratoderma, nonepidermolytic;17357067;139350;Palmoplantar keratoderma, nonepidermolytic, 600962 (3);600962
L1CAM;CRASH syndrome;17357067;308840;CRASH syndrome, 303350 (3);303350
L1CAM;Corpus callosum, partial agenesis of;17357067;308840;Corpus callosum, partial agenesis of, 304100 (3);304100
L1CAM;Hydrocephalus due to aqueductal stenosis;17357067;308840;Hydrocephalus due to aqueductal stenosis, 307000 (3);307000
L1CAM;Hydrocephalus with Hirschsprung disease;17357067;308840;Hydrocephalus with Hirschsprung disease, 307000 (3);307000
L1CAM;Hydrocephalus with congenital idiopathic intestinal pseudoobstruction;17357067;308840;Hydrocephalus with congenital idiopathic intestinal pseudoobstruction, 307000 (3);307000
L1CAM;MASA syndrome;17357067;308840;MASA syndrome, 303350 (3);303350
L2HGDH;L-2-hydroxyglutaric aciduria;17357067;609584;L-2-hydroxyglutaric aciduria, 236792 (3);236792
LAMA1;Poretti-Boltshauser syndrome;17357067;150320;Poretti-Boltshauser syndrome, 615960 (3);615960
LAMA2;Muscular dystrophy, congenital merosin-deficient;17357067;156225;Muscular dystrophy, congenital merosin-deficient, 607855 (3);607855
LAMA2;Muscular dystrophy, congenital, due to partial LAMA2 deficiency;17357067;156225;Muscular dystrophy, congenital, due to partial LAMA2 deficiency, 607855 (3);607855
LAMA3;Cardiomyopathy, dilated, 1JJ;17357067;600133;Cardiomyopathy, dilated, 1JJ, 615235 (3);615235
LAMA3;Epidermolysis bullosa, generalized atrophic benign;17357067;600805;Epidermolysis bullosa, generalized atrophic benign, 226650 (3);226650
LAMA3;Epidermolysis bullosa, junctional, Herlitz type;17357067;600805;Epidermolysis bullosa, junctional, Herlitz type, 226700 (3);226700
LAMA3;Laryngoonychocutaneous syndrome;17357067;600805;Laryngoonychocutaneous syndrome, 245660 (3);245660
LAMA4;Cardiomyopathy, dilated, 1JJ;17357067;600133;Cardiomyopathy, dilated, 1JJ, 615235 (3);615235
LAMB1;Lissencephaly 5;17357067;150240;Lissencephaly 5, 615191 (3);615191
LAMB2;Nephrotic syndrome, type 5, with or without ocular abnormalities;17357067;150325;Nephrotic syndrome, type 5, with or without ocular abnormalities, 614199 (3);614199
LAMB2;Pierson syndrome;17357067;150325;Pierson syndrome, 609049 (3);609049
LAMB3;Amelogenesis imperfecta, type IA;17357067;150310;Amelogenesis imperfecta, type IA, 104530 (3);104530
LAMB3;Epidermolysis bullosa, junctional, Herlitz type;17357067;150310;Epidermolysis bullosa, junctional, Herlitz type, 226700 (3);226700
LAMB3;Epidermolysis bullosa, junctional, non-Herlitz type;17357067;150310;Epidermolysis bullosa, junctional, non-Herlitz type, 226650 (3);226650
LAMC2;Epidermolysis bullosa, junctional, Herlitz type;17357067;150292;Epidermolysis bullosa, junctional, Herlitz type, 226700 (3);226700
LAMC2;Epidermolysis bullosa, junctional, non-Herlitz type;17357067;150292;Epidermolysis bullosa, junctional, non-Herlitz type, 226650 (3);226650
LAMC3;Cortical malformations, occipital;17357067;604349;Cortical malformations, occipital, 614115 (3);614115
LAMP2;Danon disease;17357067;309060;Danon disease, 300257 (3);300257
LAMTOR2;Immunodeficiency due to defect in MAPBP-interacting protein;17357067;610389;Immunodeficiency due to defect in MAPBP-interacting protein, 610798 (3);610798
LARGE;Muscular dystrophy-dystroglycanopathy (congenital with brain and eye anomalies), type A, 6;17357067;603590;Muscular dystrophy-dystroglycanopathy (congenital with brain and eye anomalies), type A, 6, 613154 (3);613154
LARGE;Muscular dystrophy-dystroglycanopathy (congenital with mental retardation), type B, 6;17357067;603590;Muscular dystrophy-dystroglycanopathy (congenital with mental retardation), type B, 6, 608840 (3);608840
LARP7;Alazami syndrome;17357067;612026;Alazami syndrome, 615071 (3);615071
LARS2;Perrault syndrome 4;17357067;604544;Perrault syndrome 4, 615300 (3);615300
LBR;Greenberg skeletal dysplasia;17357067;600024;Greenberg skeletal dysplasia, 215140 (3);215140
LBR;Pelger-Huet anomaly;17357067;600024;Pelger-Huet anomaly, 169400 (3);169400
LCA5;Leber congenital amaurosis 5;17357067;611408;Leber congenital amaurosis 5, 604537 (3);604537
LCAT;Fish-eye disease;17357067;606967;Fish-eye disease, 136120 (3);136120
LCAT;Norum disease;17357067;606967;Norum disease, 245900 (3);245900
LCT;Lactase deficiency, congenital;17357067;603202;Lactase deficiency, congenital, 223000 (3);223000
LDB3;Cardiomyopathy, dilated, 1C, with or without LVNC;17357067;605906;Cardiomyopathy, dilated, 1C, with or without LVNC, 601493 (3);601493
LDB3;Cardiomyopathy, hypertrophic, 24;17357067;605906;Cardiomyopathy, hypertrophic, 24, 601493 (3);601493
LDB3;Left ventricular noncompaction 3;17357067;605906;Left ventricular noncompaction 3, 601493 (3);601493
LDB3;Myopathy, myofibrillar, 4;17357067;605906;Myopathy, myofibrillar, 4, 609452 (3);609452
LDHA;Glycogen storage disease XI;17357067;150000;Glycogen storage disease XI, 612933 (3);612933
LDHB;Lactate dehydrogenase-B deficiency;17357067;150100;Lactate dehydrogenase-B deficiency, 614128 (3);614128
LDLR;Hypercholesterolemia, familial;17357067;606945;Hypercholesterolemia, familial, 143890 (3);143890
LDLR;LDL cholesterol level QTL2;17357067;606945;LDL cholesterol level QTL2, 143890 (3);143890
LDLRAP1;Hypercholesterolemia, familial, autosomal recessive;17357067;605747;Hypercholesterolemia, familial, autosomal recessive, 603813 (3);603813
LEF1;Sebaceous tumors, somatic;17357067;153245;Sebaceous tumors, somatic (3);0
LEFTY2;Left-right axis malformations;17357067;601877;Left-right axis malformations (3);0
LEMD3;Buschke-Ollendorff syndrome;17357067;607844;Buschke-Ollendorff syndrome, 166700 (3);166700
LEMD3;Melorheostosis with osteopoikilosis;17357067;607844;Melorheostosis with osteopoikilosis, 155950 (3);155950
LEMD3;Osteopoikilosis;17357067;607844;Osteopoikilosis, 166700 (3);166700
LEP;Obesity, morbid, due to leptin deficiency;17357067;164160;Obesity, morbid, due to leptin deficiency, 614962 (3);614962
LEPR;Obesity, morbid, due to leptin receptor deficiency;17357067;601007;Obesity, morbid, due to leptin receptor deficiency, 614963 (3);614963
LEPRE1;Osteogenesis imperfecta, type VIII;17357067;610339;Osteogenesis imperfecta, type VIII, 610915 (3);610915
LEPREL1;Myopia, high, with cataract and vitreoretinal degeneration;17357067;610341;Myopia, high, with cataract and vitreoretinal degeneration, 614292 (3);614292
LGALS2;Myocardial infarction, susceptibility to;17357067;150571;{Myocardial infarction, susceptibility to}, 608446 (3);608446
LGI1;Epilepsy, familial temporal lobe, 1;17357067;604619;Epilepsy, familial temporal lobe, 1, 600512 (3);600512
LGR4;Bone mineral density, low, susceptibility to;17357067;606666;{Bone mineral density, low, susceptibility to}, 615311 (3);615311
LHB;Hypogonadotropic hypogonadism 23 with or without anosmia;17357067;152780;Hypogonadotropic hypogonadism 23 with or without anosmia, 228300 (3);228300
LHCGR;Leydig cell adenoma, somatic, with precocious puberty;17357067;152790;Leydig cell adenoma, somatic, with precocious puberty, 176410 (3);176410
LHCGR;Leydig cell hypoplasia with hypergonadotropic hypogonadism;17357067;152790;Leydig cell hypoplasia with hypergonadotropic hypogonadism, 238320 (3);238320
LHCGR;Leydig cell hypoplasia with pseudohermaphroditism;17357067;152790;Leydig cell hypoplasia with pseudohermaphroditism, 238320 (3);238320
LHCGR;Luteinizing hormone resistance, female;17357067;152790;Luteinizing hormone resistance, female, 238320 (3);238320
LHCGR;Precocious puberty, male;17357067;152790;Precocious puberty, male, 176410 (3);176410
LHFPL5;Deafness, autosomal recessive 67;17357067;609427;Deafness, autosomal recessive 67, 610265 (3);610265
LHX3;Pituitary hormone deficiency, combined, 3;17357067;600577;Pituitary hormone deficiency, combined, 3, 221750 (3);221750
LHX4;Pituitary hormone deficiency, combined, 4;17357067;602146;Pituitary hormone deficiency, combined, 4, 262700 (3);262700
LIAS;Pyruvate dehydrogenase lipoic acid synthetase deficiency;17357067;607031;Pyruvate dehydrogenase lipoic acid synthetase deficiency, 614462 (3);614462
LIFR;Stuve-Wiedemann syndrome/Schwartz-Jampel type 2 syndrome;17357067;151443;Stuve-Wiedemann syndrome/Schwartz-Jampel type 2 syndrome, 601559 (3);601559
LIG1;DNA ligase I deficiency;17357067;126391;DNA ligase I deficiency (3);0
LIG3;Urofacial syndrome 2;17357067;608869;Urofacial syndrome 2, 615112 (3);615112
LIG4;LIG4 syndrome;17357067;601837;LIG4 syndrome, 606593 (3);606593
LIG4;Multiple myeloma, resistance to;17357067;601837;{Multiple myeloma, resistance to}, 254500 (3);254500
LIM2;Cataract 19;17357067;154045;Cataract 19, 615277 (3);615277
LINS;Mental retardation, autosomal recessive 27;17357067;610350;Mental retardation, autosomal recessive 27, 614340 (3);614340
LIPA;Cholesteryl ester storage disease;17357067;613497;Cholesteryl ester storage disease, 278000 (3);278000
LIPA;Wolman disease;17357067;613497;Wolman disease, 278000 (3);278000
LIPC;Diabetes mellitus, noninsulin-dependent;17357067;151670;{Diabetes mellitus, noninsulin-dependent}, 125853 (3);125853
LIPC;Hepatic lipase deficiency;17357067;151670;Hepatic lipase deficiency, 614025 (3);614025
LIPC;High density lipoprotein cholesterol level QTL 12;17357067;151670;[High density lipoprotein cholesterol level QTL 12], 612797 (3);612797
LIPE;Lipodystrophy, familial partial, type 6;17357067;151750;Lipodystrophy, familial partial, type 6, 615980 (3);615980
LIPH;Diabetes mellitus, noninsulin-dependent;17357067;151670;{Diabetes mellitus, noninsulin-dependent}, 125853 (3);125853
LIPH;Hepatic lipase deficiency;17357067;151670;Hepatic lipase deficiency, 614025 (3);614025
LIPH;High density lipoprotein cholesterol level QTL 12;17357067;151670;[High density lipoprotein cholesterol level QTL 12], 612797 (3);612797
LIPH;Hypotrichosis 7;17357067;607365;Hypotrichosis 7, 604379 (3);604379
LIPH;Woolly hair, autosomal recessive 2 with or without hypotrichosis;17357067;607365;Woolly hair, autosomal recessive 2 with or without hypotrichosis, 604379 (3);604379
LIPI;Hypertriglyceridemia, susceptibility to;17357067;609252;{Hypertriglyceridemia, susceptibility to}, 145750 (3);145750
LIPN;Ichthyosis, congenital, autosomal recessive 8;17357067;613924;Ichthyosis, congenital, autosomal recessive 8, 613943 (3);613943
LIPT1;Lipoyltransferase 1 deficiency;17357067;610284;Lipoyltransferase 1 deficiency, 616299 (3);616299
LITAF;Charcot-Marie-Tooth disease, type 1C;17357067;603795;Charcot-Marie-Tooth disease, type 1C, 601098 (3);601098
LMAN1;Combined factor V and VIII deficiency;17357067;601567;Combined factor V and VIII deficiency, 227300 (3);227300
LMBR1;Acheiropody;17357067;605522;Acheiropody, 200500 (3);200500
LMBR1;Hypoplastic or aplastic tibia with polydactyly;17357067;605522;Hypoplastic or aplastic tibia with polydactyly, 188740 (3);188740
LMBR1;Laurin-Sandrow syndrome;17357067;605522;Laurin-Sandrow syndrome, 135750 (3);135750
LMBR1;Polydactyly, preaxial type II;17357067;605522;Polydactyly, preaxial type II, 174500 (3);174500
LMBR1;Syndactyly, type IV;17357067;605522;Syndactyly, type IV, 186200 (3);186200
LMBR1;Triphalangeal thumb, type I;17357067;605522;Triphalangeal thumb, type I, 174500 (3);174500
LMBR1;Triphalangeal thumb-polysyndactyly syndrome;17357067;605522;Triphalangeal thumb-polysyndactyly syndrome, 174500 (3);174500
LMBRD1;Methylmalonic aciduria and homocystinuria, cblF type;17357067;612625;Methylmalonic aciduria and homocystinuria, cblF type, 277380 (3);277380
LMF1;Lipase deficiency, combined;17357067;611761;Lipase deficiency, combined, 246650 (3);246650
LMNA;Cardiomyopathy, dilated, 1A;17357067;150330;Cardiomyopathy, dilated, 1A, 115200 (3);115200
LMNA;Charcot-Marie-Tooth disease, type 2B1;17357067;150330;Charcot-Marie-Tooth disease, type 2B1, 605588 (3);605588
LMNA;Emery-Dreifuss muscular dystrophy 2, AD;17357067;150330;Emery-Dreifuss muscular dystrophy 2, AD, 181350 (3);181350
LMNA;Emery-Dreifuss muscular dystrophy 3, AR;17357067;150330;Emery-Dreifuss muscular dystrophy 3, AR, 181350 (3);181350
LMNA;Heart-hand syndrome, Slovenian type;17357067;150330;Heart-hand syndrome, Slovenian type, 610140 (3);610140
LMNA;Hutchinson-Gilford progeria;17357067;150330;Hutchinson-Gilford progeria, 176670 (3);176670
LMNA;Lipodystrophy, familial partial, 2;17357067;150330;Lipodystrophy, familial partial, 2, 151660 (3);151660
LMNA;Malouf syndrome;17357067;150330;Malouf syndrome, 212112 (3);212112
LMNA;Mandibuloacral dysplasia;17357067;150330;Mandibuloacral dysplasia, 248370 (3);248370
LMNA;Muscular dystrophy, congenital;17357067;150330;Muscular dystrophy, congenital, 613205 (3);613205
LMNA;Muscular dystrophy, limb-girdle, type 1B;17357067;150330;Muscular dystrophy, limb-girdle, type 1B, 159001 (3);159001
LMNA;Restrictive dermopathy, lethal;17357067;150330;Restrictive dermopathy, lethal, 275210 (3);275210
LMNB1;Leukodystrophy, adult-onset, autosomal dominant;17357067;150340;Leukodystrophy, adult-onset, autosomal dominant, 169500 (3);169500
LMNB2;Lipodystrophy, partial, acquired, susceptibility to;17357067;150341;{Lipodystrophy, partial, acquired, susceptibility to}, 608709 (3);608709
LMO1;Leukemia, T-cell acute lymphoblastic;17357067;186921;Leukemia, T-cell acute lymphoblastic (2);0
LMO2;Leukemia, acute T-cell;17357067;180385;Leukemia, acute T-cell (2);0
LMOD3;Nemaline myopathy 10;17357067;616112;Nemaline myopathy 10, 616165 (3);616165
LMX1B;Nail-patella syndrome;17357067;602575;Nail-patella syndrome, 161200 (3);161200
LONP1;CODAS syndrome;17357067;605490;CODAS syndrome, 600373 (3);600373
LOR;Vohwinkel syndrome with ichthyosis;17357067;152445;Vohwinkel syndrome with ichthyosis, 604117 (3);604117
LOXHD1;Deafness, autosomal recessive 77;17357067;613072;Deafness, autosomal recessive 77, 613079 (3);613079
LOXL1;Exfoliation syndrome, susceptibility to;17357067;153456;{Exfoliation syndrome, susceptibility to}, 177650 (3);177650
LPA;Coronary artery disease, susceptibility to;17357067;152200;{Coronary artery disease, susceptibility to} (1);0
LPA;LPA deficiency, congenital;17357067;152200;[LPA deficiency, congenital] (3);0
LPA;Pontocerebellar hypoplasia type 2D;17357067;613009;Pontocerebellar hypoplasia type 2D, 613811 (3);613811
LPAR6;Hypotrichosis 8;17357067;609239;Hypotrichosis 8, 278150 (3);278150
LPAR6;Woolly hair, autosomal recessive 1, with or without hypotrichosis;17357067;609239;Woolly hair, autosomal recessive 1, with or without hypotrichosis, 278150 (3);278150
LPIN1;Myoglobinuria, acute recurrent, autosomal recessive;17357067;605518;Myoglobinuria, acute recurrent, autosomal recessive, 268200 (3);268200
LPIN2;Majeed syndrome;17357067;605519;Majeed syndrome, 609628 (3);609628
LPL;Combined hyperlipidemia, familial;17357067;609708;Combined hyperlipidemia, familial, 144250 (3);144250
LPL;High density lipoprotein cholesterol level QTL 11;17357067;609708;[High density lipoprotein cholesterol level QTL 11] (3);0
LPL;Lipoprotein lipase deficiency;17357067;609708;Lipoprotein lipase deficiency, 238600 (3);238600
LPP;Leukemia, acute myeloid;17357067;600700;Leukemia, acute myeloid, 601626 (3);601626
LPP;Lipoma;17357067;600700;Lipoma (3);0
LRAT;Leber congenital amaurosis 14;17357067;604863;Leber congenital amaurosis 14, 613341 (3);613341
LRAT;Retinal dystrophy, early-onset severe;17357067;604863;Retinal dystrophy, early-onset severe, 613341 (3);613341
LRAT;Retinitis pigmentosa, juvenile;17357067;604863;Retinitis pigmentosa, juvenile, 613341 (3);613341
LRBA;Immunodeficiency, common variable, 8, with autoimmunity;17357067;606453;Immunodeficiency, common variable, 8, with autoimmunity, 614700 (3);614700
LRIG2;Urofacial syndrome 2;17357067;608869;Urofacial syndrome 2, 615112 (3);615112
LRIT3;Night blindness, congenital stationary (complete), 1F, autosomal recessive;17357067;615004;Night blindness, congenital stationary (complete), 1F, autosomal recessive, 615058 (3);615058
LRP2;Donnai-Barrow syndrome;17357067;600073;Donnai-Barrow syndrome, 222448 (3);222448
LRP4;Cenani-Lenz syndactyly syndrome;17357067;604270;Cenani-Lenz syndactyly syndrome, 212780 (3);212780
LRP4;Sclerosteosis 2;17357067;604270;Sclerosteosis 2, 614305 (3);614305
LRP5;Bone mineral density variability 1;17357067;603506;[Bone mineral density variability 1], 601884 (3);601884
LRP5;Exudative vitreoretinopathy 4;17357067;603506;Exudative vitreoretinopathy 4, 601813 (3);601813
LRP5;Hyperostosis, endosteal;17357067;603506;Hyperostosis, endosteal, 144750 (3);144750
LRP5;Osteopetrosis, autosomal dominant 1;17357067;603506;Osteopetrosis, autosomal dominant 1, 607634 (3);607634
LRP5;Osteoporosis;17357067;603506;{Osteoporosis}, 166710 (3);166710
LRP5;Osteoporosis-pseudoglioma syndrome;17357067;603506;Osteoporosis-pseudoglioma syndrome, 259770 (3);259770
LRP5;Osteosclerosis;17357067;603506;Osteosclerosis, 144750 (3);144750
LRP5;van Buchem disease, type 2;17357067;603506;van Buchem disease, type 2, 607636 (3);607636
LRP6;Coronary artery disease, autosomal dominant, 2;17357067;603507;{Coronary artery disease, autosomal dominant, 2}, 610947 (3);610947
LRP8;Myocardial infarction, susceptibility to;17357067;602600;{Myocardial infarction, susceptibility to}, 608446 (3);608446
LRPAP1;Myopia 23, autosomal recessive;17357067;104225;Myopia 23, autosomal recessive, 615431 (3);615431
LRPPRC;Leigh syndrome, French-Canadian type;17357067;607544;Leigh syndrome, French-Canadian type, 220111 (3);220111
LRRC6;Ciliary dyskinesia, primary, 19;17357067;614930;Ciliary dyskinesia, primary, 19, 614935 (3);614935
LRRC8A;Agammaglobulinemia 5;17357067;608360;Agammaglobulinemia 5, 613506 (3);613506
LRRK2;Parkinson disease 8;17357067;609007;{Parkinson disease 8}, 607060 (3);607060
LRSAM1;Charcot-Marie-Toothe disease, axonal, type 2P;17357067;610933;Charcot-Marie-Toothe disease, axonal, type 2P, 614436 (3);614436
LRTOMT;Deafness, autosomal recessive 63;17357067;612414;Deafness, autosomal recessive 63, 611451 (3);611451
LSS;Acheiropody;17357067;605522;Acheiropody, 200500 (3);200500
LSS;Cataract 44;17357067;600909;Cataract 44, 616509 (3);616509
LSS;Hypoplastic or aplastic tibia with polydactyly;17357067;605522;Hypoplastic or aplastic tibia with polydactyly, 188740 (3);188740
LSS;Laurin-Sandrow syndrome;17357067;605522;Laurin-Sandrow syndrome, 135750 (3);135750
LSS;Polydactyly, preaxial type II;17357067;605522;Polydactyly, preaxial type II, 174500 (3);174500
LSS;Syndactyly, type IV;17357067;605522;Syndactyly, type IV, 186200 (3);186200
LSS;Triphalangeal thumb, type I;17357067;605522;Triphalangeal thumb, type I, 174500 (3);174500
LSS;Triphalangeal thumb-polysyndactyly syndrome;17357067;605522;Triphalangeal thumb-polysyndactyly syndrome, 174500 (3);174500
LST1;Hyperbilirubinemia, Rotor type, digenic;17357067;604843;Hyperbilirubinemia, Rotor type, digenic, 237450 (3);237450
LTA;Leprosy, susceptibility to, 4;17357067;153440;{Leprosy, susceptibility to, 4}, 610988 (3);610988
LTA;Myocardial infarction, susceptibility to;17357067;153440;{Myocardial infarction, susceptibility to}, 608446 (3);608446
LTA;Psoriatic arthritis, susceptibility to;17357067;153440;{Psoriatic arthritis, susceptibility to}, 607507 (3);607507
LTBP2;Dental anomalies and short stature;17357067;602090;Dental anomalies and short stature, 601216 (3);601216
LTBP2;Glaucoma 3, primary congenital, D;17357067;602091;Glaucoma 3, primary congenital, D, 613086 (3);613086
LTBP2;Microspherophakia and/or megalocornea, with ectopia lentis and with or without secondary glaucoma;17357067;602091;Microspherophakia and/or megalocornea, with ectopia lentis and with or without secondary glaucoma, 251750 (3);251750
LTBP2;Weill-Marchesani syndrome 3, recessive;17357067;602091;Weill-Marchesani syndrome 3, recessive, 614819 (3);614819
LTBP3;Dental anomalies and short stature;17357067;602090;Dental anomalies and short stature, 601216 (3);601216
LTBP3;Glaucoma 3, primary congenital, D;17357067;602091;Glaucoma 3, primary congenital, D, 613086 (3);613086
LTBP3;Microspherophakia and/or megalocornea, with ectopia lentis and with or without secondary glaucoma;17357067;602091;Microspherophakia and/or megalocornea, with ectopia lentis and with or without secondary glaucoma, 251750 (3);251750
LTBP3;Weill-Marchesani syndrome 3, recessive;17357067;602091;Weill-Marchesani syndrome 3, recessive, 614819 (3);614819
LTBP4;Cutis laxa, autosomal recessive, type IC;17357067;604710;Cutis laxa, autosomal recessive, type IC, 613177 (3);613177
LTC4S;Leukotriene C4 synthase deficiency;17357067;246530;Leukotriene C4 synthase deficiency, 614037 (1);614037
LYL1;Leukemia, T-cell acute lymphoblastoid;17357067;151440;Leukemia, T-cell acute lymphoblastoid (2);0
LYST;Chediak-Higashi syndrome;17357067;606897;Chediak-Higashi syndrome, 214500 (3);214500
LYZ;Amyloidosis, renal;17357067;153450;Amyloidosis, renal, 105200 (3);105200
LZTFL1;Bardet-Biedl syndrome 17;17357067;606568;Bardet-Biedl syndrome 17, 615994 (3);615994
LZTR1;Schwannomatosis-2, susceptibility to;17357067;600574;{Schwannomatosis-2, susceptibility to}, 615670 (3);615670
LZTS1;Esophageal squamous cell carcinoma;17357067;606551;Esophageal squamous cell carcinoma, 133239 (3);133239
MAATS1;Aortic aneurysm, familial thoracic 1;17357067;607086;Aortic aneurysm, familial thoracic 1 (2);0
MAB21L2;Microphthalmia, syndromic 14;17357067;604357;Microphthalmia, syndromic 14, 615877 (3);615877
MAD1L1;Lymphoma, somatic;17357067;602686;Lymphoma, somatic (3);0
MAD1L1;Prostate cancer, somatic;17357067;602686;Prostate cancer, somatic, 176807 (3);176807
MADD;Glutaric acidemia IIA;17357067;608053;Glutaric acidemia IIA, 231680 (3);231680
MADD;Glutaric acidemia IIB;17357067;130410;Glutaric acidemia IIB, 231680 (3);231680
MADD;Glutaric acidemia IIC;17357067;231675;Glutaric acidemia IIC, 231680 (3);231680
MAF;Ayme-Gripp syndrome;17357067;177075;Ayme-Gripp syndrome, 601088 (3);601088
MAF;Cataract 21, multiple types;17357067;177075;Cataract 21, multiple types, 610202 (3);610202
MAFB;Multicentric carpotarsal osteolysis syndrome;17357067;608968;Multicentric carpotarsal osteolysis syndrome, 166300 (3);166300
MAGEL2;Schaaf-Yang syndrome;17357067;605283;Schaaf-Yang syndrome, 615547 (3);615547
MAGT1;Immunodeficiency, X-linked, with magnesium defect, Epstein-Barr virus infection and neoplasia;17357067;300715;Immunodeficiency, X-linked, with magnesium defect, Epstein-Barr virus infection and neoplasia, 300853 (3);300853
MAGT1;Mental retardation, X-linked 95;17357067;300716;Mental retardation, X-linked 95 (2);0
MAK;Retinitis pigmentosa 62;17357067;154235;Retinitis pigmentosa 62, 614181 (3);614181
MAL;Megakaryoblastic leukemia, acute;17357067;606078;Megakaryoblastic leukemia, acute (3);0
MALT1;Immunodeficiency 12;17357067;604860;Immunodeficiency 12, 615468 (3);615468
MAML2;Mucoepidermoid salivary gland carcinoma;17357067;607537;Mucoepidermoid salivary gland carcinoma (3);0
MAMLD1;Hypospadias 2, X-linked;17357067;300120;Hypospadias 2, X-linked, 300758 (3);300758
MAN1B1;Mental retardation, autosomal recessive 15;17357067;604346;Mental retardation, autosomal recessive 15, 614202 (3);614202
MAN2B1;Mannosidosis, alpha-, types I and II;17357067;609458;Mannosidosis, alpha-, types I and II, 248500 (3);248500
MANBA;Mannosidosis, beta;17357067;609489;Mannosidosis, beta, 248510 (3);248510
MAOA;Brunner syndrome;17357067;309850;Brunner syndrome, 300615 (3);300615
MAP2K1;Cardiofaciocutaneous syndrome 3;17357067;176872;Cardiofaciocutaneous syndrome 3, 615279 (3);615279
MAP2K2;Cardiofaciocutaneous syndrome 4;17357067;601263;Cardiofaciocutaneous syndrome 4, 615280 (3);615280
MAP3K1;46XY sex reversal 6;17357067;600982;46XY sex reversal 6, 613762 (3);613762
MAP3K8;Lung cancer, somatic;17357067;191195;Lung cancer, somatic, 211980 (3);211980
MAPK8IP1;Diabetes mellitus, noninsulin-dependent;17357067;604641;{Diabetes mellitus, noninsulin-dependent}, 125853 (3);125853
MAPT;Dementia, frontotemporal, with or without parkinsonism;17357067;157140;Dementia, frontotemporal, with or without parkinsonism, 600274 (3);600274
MAPT;Parkinson disease, susceptibility to;17357067;157140;{Parkinson disease, susceptibility to}, 168600 (3);168600
MAPT;Pick disease;17357067;157140;Pick disease, 172700 (3);172700
MAPT;Supranuclear palsy, progressive;17357067;157140;Supranuclear palsy, progressive, 601104 (3);601104
MAPT;Supranuclear palsy, progressive atypical;17357067;157140;Supranuclear palsy, progressive atypical, 260540 (3);260540
MARCKS;Macrocephaly, alopecia, cutis laxa, and scoliosis;17357067;610222;Macrocephaly, alopecia, cutis laxa, and scoliosis, 613075 (3);613075
MARS;Charcot-Marie-Tooth disease, axonal, type 2U;17357067;156560;Charcot-Marie-Tooth disease, axonal, type 2U, 616280 (3);616280
MARS;Interstitial lung and liver disease;17357067;156560;Interstitial lung and liver disease, 615486 (3);615486
MARS2;Spastic ataxia 3, autosomal recessive;17357067;609728;Spastic ataxia 3, autosomal recessive, 611390 (3);611390
MARVELD2;Deafness, autosomal recessive 49;17357067;610572;Deafness, autosomal recessive 49, 610153 (3);610153
MASP1;3MC syndrome 1;17357067;600521;3MC syndrome 1, 257920 (3);257920
MASP2;MASP2 deficiency;17357067;605102;MASP2 deficiency, 613791 (3);613791
MAT1A;Hypermethioninemia, persistent, autosomal dominant, due to methionine adenosyltransferase I/III deficiency;17357067;610550;Hypermethioninemia, persistent, autosomal dominant, due to methionine adenosyltransferase I/III deficiency, 250850 (3);250850
MAT1A;Methionine adenosyltransferase deficiency, autosomal recessive;17357067;610550;Methionine adenosyltransferase deficiency, autosomal recessive, 250850 (3);250850
MAT1A;Short stature, auditory canal atresia, mandibular hypoplasia, skeletal abnormalities;17357067;138890;Short stature, auditory canal atresia, mandibular hypoplasia, skeletal abnormalities, 602471 (3);602471
MATN3;Epiphyseal dysplasia, multiple, 5;17357067;602109;Epiphyseal dysplasia, multiple, 5, 607078 (3);607078
MATN3;Osteoarthritis susceptibility 2;17357067;602109;{Osteoarthritis susceptibility 2}, 140600 (3);140600
MATN3;Spondyloepimetaphyseal dysplasia;17357067;602109;Spondyloepimetaphyseal dysplasia, 608728 (3);608728
MATR3;Amyotrophic lateral sclerosis 21;17357067;164015;Amyotrophic lateral sclerosis 21, 606070 (3);606070
MAX;Pheochromocytoma, susceptibility to;17357067;154950;{Pheochromocytoma, susceptibility to}, 171300 (3);171300
MBD5;Mental retardation, autosomal dominant 1;17357067;611472;Mental retardation, autosomal dominant 1, 156200 (3);156200
MBL2;Chronic infections, due to MBL deficiency;17357067;154545;{Chronic infections, due to MBL deficiency}, 614372 (3);614372
MBTPS2;IFAP syndrome with or without BRESHECK syndrome;17357067;300294;IFAP syndrome with or without BRESHECK syndrome, 308205 (3);308205
MBTPS2;Keratosis follicularis spinulosa decalvans;17357067;313020;Keratosis follicularis spinulosa decalvans, 308800 (3);308800
MBTPS2;Keratosis follicularis spinulosa decalvans, X-linked;17357067;300294;Keratosis follicularis spinulosa decalvans, X-linked, 308800 (3);308800
MC1R;Albinism, oculocutaneous, type II, modifier of;17357067;155555;{Albinism, oculocutaneous, type II, modifier of}, 203200 (3);203200
MC1R;Analgesia from kappa-opioid receptor agonist, female-specific;17357067;155555;[Analgesia from kappa-opioid receptor agonist, female-specific], 613098 (3);613098
MC1R;Melanoma, cutaneous malignant, 5;17357067;155555;{Melanoma, cutaneous malignant, 5}, 613099 (3);613099
MC1R;Skin/hair/eye pigmentation 2, blond hair/fair skin;17357067;155555;[Skin/hair/eye pigmentation 2, blond hair/fair skin], 266300 (3);266300
MC1R;Skin/hair/eye pigmentation 2, red hair/fair skin;17357067;155555;[Skin/hair/eye pigmentation 2, red hair/fair skin], 266300 (3);266300
MC1R;UV-induced skin damage;17357067;155555;{UV-induced skin damage}, 266300 (3);266300
MC2R;Glucocorticoid deficiency, due to ACTH unresponsiveness;17357067;607397;Glucocorticoid deficiency, due to ACTH unresponsiveness, 202200 (3);202200
MC3R;Mycobacterium tuberculosis, protection against;17357067;155540;{Mycobacterium tuberculosis, protection against}, 607948 (3);607948
MC3R;Obesity, severe, susceptibility to, BMIQ9;17357067;155540;{Obesity, severe, susceptibility to, BMIQ9}, 602025 (3);602025
MC4R;Obesity, autosomal dominant;17357067;155541;Obesity, autosomal dominant, 601665 (3);601665
MCC;Colorectal cancer, somatic;17357067;159350;Colorectal cancer, somatic, 114500 (3);114500
MCCC1;3-Methylcrotonyl-CoA carboxylase 1 deficiency;17357067;609010;3-Methylcrotonyl-CoA carboxylase 1 deficiency, 210200 (3);210200
MCCC2;3-Methylcrotonyl-CoA carboxylase 2 deficiency;17357067;609014;3-Methylcrotonyl-CoA carboxylase 2 deficiency, 210210 (3);210210
MCEE;Methylmalonyl-CoA epimerase deficiency;17357067;608419;Methylmalonyl-CoA epimerase deficiency, 251120 (3);251120
MCFD2;Factor V and factor VIII, combined deficiency of;17357067;607788;Factor V and factor VIII, combined deficiency of, 613625 (3);613625
MCM4;Natural killer cell and glucocorticoid deficiency with DNA repair defect;17357067;602638;Natural killer cell and glucocorticoid deficiency with DNA repair defect, 609981 (3);609981
MCM6;Lactase persistence/nonpersistence;17357067;601806;Lactase persistence/nonpersistence, 223100 (3);223100
MCM9;Ovarian dysgenesis 4;17357067;610098;Ovarian dysgenesis 4, 616185 (3);616185
MCOLN1;Mucolipidosis IV;17357067;605248;Mucolipidosis IV, 252650 (3);252650
MCPH1;Microcephaly 1, primary, autosomal recessive;17357067;607117;Microcephaly 1, primary, autosomal recessive, 251200 (3);251200
MDK;Mesomelic dysplasia, Kantaputra type;17357067;156232;Mesomelic dysplasia, Kantaputra type (2);0
MDM2;Accelerated tumor formation, susceptibility to;17357067;164785;{Accelerated tumor formation, susceptibility to}, 614401 (3);614401
MECOM;3q21q26 syndrome;17357067;165215;3q21q26 syndrome (1);0
MECOM;Myelodysplasia syndrome-1;17357067;600049;Myelodysplasia syndrome-1 (3);0
MECP2;Autism susceptibility, X-linked 3;17357067;300005;{Autism susceptibility, X-linked 3}, 300496 (3);300496
MECP2;Encephalopathy, neonatal severe;17357067;300005;Encephalopathy, neonatal severe, 300673 (3);300673
MECP2;Mental retardation, X-linked syndromic, Lubs type;17357067;300005;Mental retardation, X-linked syndromic, Lubs type, 300260 (3);300260
MECP2;Mental retardation, X-linked, syndromic 13;17357067;300005;Mental retardation, X-linked, syndromic 13, 300055 (3);300055
MECP2;Rett syndrome;17357067;300005;Rett syndrome, 312750 (3);312750
MECP2;Rett syndrome, atypical;17357067;300005;Rett syndrome, atypical, 312750 (3);312750
MECP2;Rett syndrome, preserved speech variant;17357067;300005;Rett syndrome, preserved speech variant, 312750 (3);312750
MED12;Lujan-Fryns syndrome;17357067;300188;Lujan-Fryns syndrome, 309520 (3);309520
MED12;Ohdo syndrome, X-linked;17357067;300188;Ohdo syndrome, X-linked, 300895 (3);300895
MED12;Opitz-Kaveggia syndrome;17357067;300188;Opitz-Kaveggia syndrome, 305450 (3);305450
MED13L;Transposition of the great arteries, dextro-looped 1;17357067;608771;Transposition of the great arteries, dextro-looped 1, 608808 (3);608808
MED17;Microcephaly, postnatal progressive, with seizures and brain atrophy;17357067;603810;Microcephaly, postnatal progressive, with seizures and brain atrophy, 613668 (3);613668
MED23;Mental retardation, autosomal recessive 18;17357067;605042;Mental retardation, autosomal recessive 18, 614249 (3);614249
MED25;Basel-Vanagait-Smirin-Yosef syndrome;17357067;610197;Basel-Vanagait-Smirin-Yosef syndrome, 616449 (3);616449
MEF2A;Coronary artery disease, autosomal dominant, 1;17357067;600660;{Coronary artery disease, autosomal dominant, 1}, 608320 (3);608320
MEF2C;Chromosome 5q14.3 deletion syndrome;17357067;600662;Chromosome 5q14.3 deletion syndrome, 613443 (4);613443
MEF2C;Mental retardation, stereotypic movements, epilepsy, and/or cerebral malformations;17357067;600662;Mental retardation, stereotypic movements, epilepsy, and/or cerebral malformations, 613443 (3);613443
MEFV;Familial Mediterranean fever, AD;17357067;608107;Familial Mediterranean fever, AD, 134610 (3);134610
MEFV;Familial Mediterranean fever, AR;17357067;608107;Familial Mediterranean fever, AR, 249100 (3);249100
MEGF10;Myopathy, areflexia, respiratory distress, and dysphagia, early-onset;17357067;612453;Myopathy, areflexia, respiratory distress, and dysphagia, early-onset, 614399 (3);614399
MEGF10;Myopathy, areflexia, respiratory distress, and dysphagia, early-onset, mild variant;17357067;612453;Myopathy, areflexia, respiratory distress, and dysphagia, early-onset, mild variant, 614399 (3);614399
MEGF8;Carpenter syndrome 2;17357067;604267;Carpenter syndrome 2, 614976 (3);614976
MEN1;Adrenal adenoma, somatic;17357067;613733;Adrenal adenoma, somatic (3);0
MEN1;Angiofibroma, somatic;17357067;613733;Angiofibroma, somatic (3);0
MEN1;Carcinoid tumor of lung;17357067;613733;Carcinoid tumor of lung (3);0
MEN1;Lipoma, somatic;17357067;613733;Lipoma, somatic (3);0
MEN1;Multiple endocrine neoplasia 1;17357067;613733;Multiple endocrine neoplasia 1, 131100 (3);131100
MEN1;Parathyroid adenoma, somatic;17357067;613733;Parathyroid adenoma, somatic (3);0
MEOX1;Klippel-Feil syndrome 2;17357067;600147;Klippel-Feil syndrome 2, 214300 (3);214300
MERTK;Retinitis pigmentosa 38;17357067;604705;Retinitis pigmentosa 38, 613862 (3);613862
MESDC2;Albinism, brown oculocutaneous;17357067;611409;Albinism, brown oculocutaneous, 203200 (3);203200
MESDC2;Albinism, oculocutaneous, type II;17357067;611409;Albinism, oculocutaneous, type II, 203200 (3);203200
MESDC2;Skin/hair/eye pigmentation 1, blond/brown hair;17357067;611409;[Skin/hair/eye pigmentation 1, blond/brown hair], 227220 (3);227220
MESDC2;Skin/hair/eye pigmentation 1, blue/nonblue eyes;17357067;611409;[Skin/hair/eye pigmentation 1, blue/nonblue eyes], 227220 (3);227220
MESP2;Spondylocostal dysostosis 2, autosomal recessive;17357067;605195;Spondylocostal dysostosis 2, autosomal recessive, 608681 (3);608681
MET;Hepatocellular carcinoma, childhood type;17357067;164860;Hepatocellular carcinoma, childhood type, 114550 (3);114550
MET;Renal cell carcinoma, papillary, 1, familial and somatic;17357067;164860;Renal cell carcinoma, papillary, 1, familial and somatic, 605074 (3);605074
METTL23;Mental retardation, autosomal recessive 44;17357067;615262;Mental retardation, autosomal recessive 44, 615942 (3);615942
MFAP5;Aortic aneurysm, familial thoracic 9;17357067;601103;Aortic aneurysm, familial thoracic 9, 616166 (3);616166
MFHAS1;Malignant fibrous histiocytoma;17357067;605352;Malignant fibrous histiocytoma (2);0
MFN2;Charcot-Marie-Tooth disease, type 2A2;17357067;608507;Charcot-Marie-Tooth disease, type 2A2, 609260 (3);609260
MFN2;Hereditary motor and sensory neuropathy VIA;17357067;608507;Hereditary motor and sensory neuropathy VIA, 601152 (3);601152
MFRP;Microphthalmia, isolated 5;17357067;606227;Microphthalmia, isolated 5, 611040 (3);611040
MFRP;Nanophthalmos 2;17357067;606227;Nanophthalmos 2, 609549 (3);609549
MFSD2A;Microcephaly 15, primary, autosomal recessive;17357067;614397;Microcephaly 15, primary, autosomal recessive, 616486 (3);616486
MFSD8;Ceroid lipofuscinosis, neuronal, 7;17357067;611124;Ceroid lipofuscinosis, neuronal, 7, 610951 (3);610951
MFSD8;Macular dystrophy with central cone involvement;17357067;611124;Macular dystrophy with central cone involvement, 616170 (3);616170
MGAT2;Congenital disorder of glycosylation, type IIa;17357067;602616;Congenital disorder of glycosylation, type IIa, 212066 (3);212066
MGME1;Mitochondrial DNA depletion syndrome 11;17357067;615076;Mitochondrial DNA depletion syndrome 11, 615084 (3);615084
MGP;Keutel syndrome;17357067;154870;Keutel syndrome, 245150 (3);245150
MIAT;Myocardial infarction, susceptibility to;17357067;611082;{Myocardial infarction, susceptibility to}, 608446 (3);608446
MIB1;Dehydrated hereditary stomatocytosis with or without pseudohyperkalemia and/or perinatal edema;17357067;611184;Dehydrated hereditary stomatocytosis with or without pseudohyperkalemia and/or perinatal edema, 194380 (3);194380
MIB1;Left ventricular noncompaction 7;17357067;608677;Left ventricular noncompaction 7, 615092 (3);615092
MICU1;Myopathy with extrapyramidal signs;17357067;605084;Myopathy with extrapyramidal signs, 615673 (3);615673
MID1;Opitz GBBB syndrome, type I;17357067;300552;Opitz GBBB syndrome, type I, 300000 (3);300000
MIF;Persistent Mullerian duct syndrome, type I;17357067;600957;Persistent Mullerian duct syndrome, type I, 261550 (3);261550
MIF;Rheumatoid arthritis, systemic juvenile, susceptibility to;17357067;153620;{Rheumatoid arthritis, systemic juvenile, susceptibility to}, 604302 (3);604302
MINPP1;Thyroid carcinoma, follicular;17357067;605391;Thyroid carcinoma, follicular, 188470 (3);188470
MIP;Cataract 15, multiple types;17357067;154050;Cataract 15, multiple types, 615274 (3);615274
MIR17HG;Feingold syndrome 2;17357067;609415;Feingold syndrome 2, 614326 (3);614326
MIR184;EDICT syndrome;17357067;613146;EDICT syndrome, 614303 (3);614303
MIR2861;Bone mineral density QTL 15;17357067;613405;[Bone mineral density QTL 15], 613418 (3);613418
MIR96;Deafness, autosomal dominant 50;17357067;611606;Deafness, autosomal dominant 50, 613074 (3);613074
MITF;Melanoma, cutaneous malignant, susceptibility to, 8;17357067;156845;{Melanoma, cutaneous malignant, susceptibility to, 8}, 614456 (3);614456
MITF;Tietz albinism-deafness syndrome;17357067;156845;Tietz albinism-deafness syndrome, 103500 (3);103500
MITF;Waardenburg syndrome, type 2A;17357067;156845;Waardenburg syndrome, type 2A, 193510 (3);193510
MITF;Waardenburg syndrome/ocular albinism, digenic;17357067;156845;Waardenburg syndrome/ocular albinism, digenic, 103470 (3);103470
MKKS;Bardet-Biedl syndrome 6;17357067;604896;Bardet-Biedl syndrome 6, 605231 (3);605231
MKKS;McKusick-Kaufman syndrome;17357067;604896;McKusick-Kaufman syndrome, 236700 (3);236700
MKL1;Megakaryoblastic leukemia, acute;17357067;606078;Megakaryoblastic leukemia, acute (3);0
MKRN3;Precocious puberty, central, 2;17357067;603856;Precocious puberty, central, 2, 615346 (3);615346
MKS1;Bardet-Biedl syndrome 13;17357067;609883;Bardet-Biedl syndrome 13, 615990 (3);615990
MKS1;Bardet-Biedl syndrome 6;17357067;604896;Bardet-Biedl syndrome 6, 605231 (3);605231
MKS1;McKusick-Kaufman syndrome;17357067;604896;McKusick-Kaufman syndrome, 236700 (3);236700
MKS1;Meckel syndrome 1;17357067;609883;Meckel syndrome 1, 249000 (3);249000
MLC1;Megalencephalic leukoencephalopathy with subcortical cysts;17357067;605908;Megalencephalic leukoencephalopathy with subcortical cysts, 604004 (3);604004
MLF1;Leukemia, acute myeloid;17357067;601402;Leukemia, acute myeloid, 601626 (1);601626
MLH1;Colorectal cancer, hereditary nonpolyposis, type 2;17357067;120436;Colorectal cancer, hereditary nonpolyposis, type 2, 609310 (3);609310
MLH1;Mismatch repair cancer syndrome;17357067;120436;Mismatch repair cancer syndrome, 276300 (3);276300
MLH1;Muir-Torre syndrome;17357067;120436;Muir-Torre syndrome, 158320 (3);158320
MLH3;Colorectal cancer, hereditary nonpolyposis, type 7;17357067;604395;Colorectal cancer, hereditary nonpolyposis, type 7, 614385 (3);614385
MLH3;Colorectal cancer, somatic;17357067;604395;Colorectal cancer, somatic, 114500 (3);114500
MLH3;Endometrial cancer, susceptibility to;17357067;604395;{Endometrial cancer, susceptibility to}, 608089 (3);608089
MLLT10;Leukemia, acute T-cell lymphoblastic;17357067;602409;Leukemia, acute T-cell lymphoblastic (3);0
MLLT10;Leukemia, acute myeloid;17357067;602409;Leukemia, acute myeloid, 601626 (3);601626
MLLT11;Leukemia, acute myelomonocytic;17357067;604684;Leukemia, acute myelomonocytic (3);0
MLPH;Griscelli syndrome, type 3;17357067;606526;Griscelli syndrome, type 3, 609227 (3);609227
MLYCD;Malonyl-CoA decarboxylase deficiency;17357067;606761;Malonyl-CoA decarboxylase deficiency, 248360 (3);248360
MMAA;Methylmalonic aciduria, vitamin B12-responsive;17357067;607481;Methylmalonic aciduria, vitamin B12-responsive, 251100 (3);251100
MMAB;Methylmalonic aciduria, vitamin B12-responsive, due to defect in synthesis of adenosylcobalamin, cblB complementation type;17357067;607568;Methylmalonic aciduria, vitamin B12-responsive, due to defect in synthesis of adenosylcobalamin, cblB complementation type, 251110 (3);251110
MMACHC;Methylmalonic aciduria and homocystinuria, cblC type;17357067;609831;Methylmalonic aciduria and homocystinuria, cblC type, 277400 (3);277400
MMADHC;Homocystinuria, cblD type, variant 1;17357067;611935;Homocystinuria, cblD type, variant 1, 277410 (3);277410
MMADHC;Methylmalonic aciduria and homocystinuria, cblD type;17357067;611935;Methylmalonic aciduria and homocystinuria, cblD type, 277410 (3);277410
MMADHC;Methylmalonic aciduria, cblD type, variant 2;17357067;611935;Methylmalonic aciduria, cblD type, variant 2, 277410 (3);277410
MMD2;Miyoshi muscular dystrophy 2;17357067;613318;Miyoshi muscular dystrophy 2 (2);0
MME;Membranous glomerulonephritis, antenatal;17357067;120520;Membranous glomerulonephritis, antenatal, 614692 (1);614692
MME;Neutral endopeptidase deficiency;17357067;120520;[Neutral endopeptidase deficiency], 614692 (1);614692
MMP1;COPD, rate of decline of lung function in;17357067;120353;COPD, rate of decline of lung function in, 606963 (3);606963
MMP1;Epidermolysis bullosa dystrophica, autosomal recessive, modifier of;17357067;120353;{Epidermolysis bullosa dystrophica, autosomal recessive, modifier of}, 226600 (3);226600
MMP13;Metaphyseal anadysplasia 1;17357067;600108;Metaphyseal anadysplasia 1, 602111 (3);602111
MMP13;Spondyloepimetaphyseal dysplasia, Missouri type;17357067;600108;Spondyloepimetaphyseal dysplasia, Missouri type, 602111 (3);602111
MMP2;Multicentric osteolysis, nodulosis, and arthropathy;17357067;120360;Multicentric osteolysis, nodulosis, and arthropathy, 259600 (3);259600
MMP20;Amelogenesis imperfecta, type IIA2;17357067;604629;Amelogenesis imperfecta, type IIA2, 612529 (3);612529
MMP3;Coronary heart disease, susceptibility to, 6;17357067;185250;{Coronary heart disease, susceptibility to, 6}, 614466 (3);614466
MMP9;Metaphyseal anadysplasia 2;17357067;120361;Metaphyseal anadysplasia 2, 613073 (3);613073
MN1;Meningioma;17357067;156100;Meningioma, 607174 (3);607174
MNX1;Currarino syndrome;17357067;142994;Currarino syndrome, 176450 (3);176450
MOCOS;Bardet-Biedl syndrome 6;17357067;604896;Bardet-Biedl syndrome 6, 605231 (3);605231
MOCOS;McKusick-Kaufman syndrome;17357067;604896;McKusick-Kaufman syndrome, 236700 (3);236700
MOCS1;Molybdenum cofactor deficiency A;17357067;603707;Molybdenum cofactor deficiency A, 252150 (3);252150
MOCS2;Molybdenum cofactor deficiency B;17357067;603708;Molybdenum cofactor deficiency B, 252160 (3);252160
MOGS;Congenital disorder of glycosylation, type IIb;17357067;601336;Congenital disorder of glycosylation, type IIb, 606056 (3);606056
MPC1;Mitochondrial pyruvate carrier deficiency;17357067;614738;Mitochondrial pyruvate carrier deficiency, 614741 (3);614741
MPDU1;Congenital disorder of glycosylation, type If;17357067;604041;Congenital disorder of glycosylation, type If, 609180 (3);609180
MPDZ;Hydrocephalus, nonsyndromic, autosomal recessive 2;17357067;603785;Hydrocephalus, nonsyndromic, autosomal recessive 2, 615219 (3);615219
MPI;Congenital disorder of glycosylation, type Ib;17357067;154550;Congenital disorder of glycosylation, type Ib, 602579 (3);602579
MPL;Myelofibrosis with myeloid metaplasia, somatic;17357067;159530;Myelofibrosis with myeloid metaplasia, somatic, 254450 (3);254450
MPL;Thrombocythemia 2;17357067;159530;Thrombocythemia 2, 601977 (3);601977
MPL;Thrombocytopenia, congenital amegakaryocytic;17357067;159530;Thrombocytopenia, congenital amegakaryocytic, 604498 (3);604498
MPLKIP;Trichothiodystrophy 4, nonphotosensitive;17357067;609188;Trichothiodystrophy 4, nonphotosensitive, 234050 (3);234050
MPO;Alzheimer disease, susceptibility to;17357067;606989;{Alzheimer disease, susceptibility to}, 104300 (3);104300
MPO;Lung cancer, protection against, in smokers;17357067;606989;{Lung cancer, protection against, in smokers} (3);0
MPO;Myeloperoxidase deficiency;17357067;606989;Myeloperoxidase deficiency, 254600 (3);254600
MPST;Tuberculin skin test reactivity QTL;17357067;613637;[Tuberculin skin test reactivity QTL] (2);0
MPV17;Mitochondrial DNA depletion syndrome 6 (hepatocerebral type);17357067;137960;Mitochondrial DNA depletion syndrome 6 (hepatocerebral type), 256810 (3);256810
MPZ;Charcot-Marie-Tooth disease, dominant intermediate D;17357067;159440;Charcot-Marie-Tooth disease, dominant intermediate D, 607791 (3);607791
MPZ;Charcot-Marie-Tooth disease, type 1B;17357067;159440;Charcot-Marie-Tooth disease, type 1B, 118200 (3);118200
MPZ;Charcot-Marie-Tooth disease, type 2I;17357067;159440;Charcot-Marie-Tooth disease, type 2I, 607677 (3);607677
MPZ;Charcot-Marie-Tooth disease, type 2J;17357067;159440;Charcot-Marie-Tooth disease, type 2J, 607736 (3);607736
MPZ;Dejerine-Sottas disease;17357067;159440;Dejerine-Sottas disease, 145900 (3);145900
MPZ;Neuropathy, congenital hypomyelinating;17357067;159440;Neuropathy, congenital hypomyelinating, 605253 (3);605253
MPZ;Roussy-Levy syndrome;17357067;159440;Roussy-Levy syndrome, 180800 (3);180800
MPZL2;Deafness, autosomal recessive 4, with enlarged vestibular aqueduct;17357067;605646;Deafness, autosomal recessive 4, with enlarged vestibular aqueduct, 600791 (3);600791
MPZL2;Pendred syndrome;17357067;605646;Pendred syndrome, 274600 (3);274600
MR1;Paroxysmal nonkinesigenic dyskinesia;17357067;609023;Paroxysmal nonkinesigenic dyskinesia, 118800 (3);118800
MRAP;Glucocorticoid deficiency 2;17357067;609196;Glucocorticoid deficiency 2, 607398 (3);607398
MRAP2;Obesity, susceptibility to, BMIQ18;17357067;615410;{Obesity, susceptibility to, BMIQ18}, 615457 (3);615457
MRE11A;Ataxia-telangiectasia-like disorder;17357067;600814;Ataxia-telangiectasia-like disorder, 604391 (3);604391
MRPL3;Combined oxidative phosphorylation deficiency 9;17357067;607118;Combined oxidative phosphorylation deficiency 9, 614582 (3);614582
MRPS16;Combined oxidative phosphorylation deficiency 2;17357067;609204;Combined oxidative phosphorylation deficiency 2, 610498 (3);610498
MRPS22;Combined oxidative phosphorylation deficiency 5;17357067;605810;Combined oxidative phosphorylation deficiency 5, 611719 (3);611719
MRTO4;Mental retardation, autosomal recessive, 4;17357067;611107;Mental retardation, autosomal recessive, 4 (2);0
MS4A1;Immunodeficiency, common variable, 5;17357067;112210;Immunodeficiency, common variable, 5, 613495 (3);613495
MS4A2;Atopy, susceptibility to;17357067;147138;{Atopy, susceptibility to}, 147050 (3);147050
MSH2;Colorectal cancer, hereditary nonpolyposis, type 1;17357067;609309;Colorectal cancer, hereditary nonpolyposis, type 1, 120435 (3);120435
MSH2;Mismatch repair cancer syndrome;17357067;609309;Mismatch repair cancer syndrome, 276300 (3);276300
MSH2;Muir-Torre syndrome;17357067;609309;Muir-Torre syndrome, 158320 (3);158320
MSH3;Endometrial carcinoma, somatic;17357067;600887;Endometrial carcinoma, somatic, 608089 (3);608089
MSH6;Colorectal cancer, hereditary nonpolyposis, type 5;17357067;600678;Colorectal cancer, hereditary nonpolyposis, type 5, 614350 (3);614350
MSH6;Endometrial cancer, familial;17357067;600678;Endometrial cancer, familial, 608089 (3);608089
MSH6;Mismatch repair cancer syndrome;17357067;600678;Mismatch repair cancer syndrome, 276300 (3);276300
MSMB;Prostate cancer, hereditary, 13;17357067;157145;{Prostate cancer, hereditary, 13}, 611928 (3);611928
MSR1;Barrett esophagus/esophageal adenocarcinoma;17357067;153622;Barrett esophagus/esophageal adenocarcinoma, 614266 (3);614266
MSR1;Prostate cancer, hereditary;17357067;153622;Prostate cancer, hereditary, 176807 (3);176807
MSRB3;Deafness, autosomal recessive 74;17357067;613719;Deafness, autosomal recessive 74, 613718 (3);613718
MST1;T-cell immunodeficiency, recurrent infections, autoimmunity, and cardiac malformations;17357067;604965;T-cell immunodeficiency, recurrent infections, autoimmunity, and cardiac malformations, 614868 (3);614868
MSTN;Muscle hypertrophy;17357067;601788;Muscle hypertrophy, 614160 (3);614160
MSX1;Ectodermal dysplasia 3, Witkop type;17357067;142983;Ectodermal dysplasia 3, Witkop type, 189500 (3);189500
MSX1;Orofacial cleft 5;17357067;142983;Orofacial cleft 5, 608874 (3);608874
MSX1;Tooth agenesis, selective, 1, with or without orofacial cleft;17357067;142983;Tooth agenesis, selective, 1, with or without orofacial cleft, 106600 (3);106600
MSX2;Craniosynostosis, type 2;17357067;123101;Craniosynostosis, type 2, 604757 (3);604757
MSX2;Parietal foramina 1;17357067;123101;Parietal foramina 1, 168500 (3);168500
MSX2;Parietal foramina with cleidocranial dysplasia;17357067;123101;Parietal foramina with cleidocranial dysplasia, 168550 (3);168550
MTA3;Congenital disorder of glycosylation, type Ip;17357067;613666;Congenital disorder of glycosylation, type Ip, 613661 (3);613661
MTAP;Diaphyseal medullary stenosis with malignant fibrous histiocytoma;17357067;156540;Diaphyseal medullary stenosis with malignant fibrous histiocytoma, 112250 (3);112250
MTFMT;Combined oxidative phosphorylation deficiency 15;17357067;611766;Combined oxidative phosphorylation deficiency 15, 614947 (3);614947
MTHFD1;Abruptio placentae, susceptibility to;17357067;172460;{Abruptio placentae, susceptibility to} (3);0
MTHFD1;Spina bifida, folate-sensitive, susceptibility to;17357067;172460;{Spina bifida, folate-sensitive, susceptibility to}, 601634 (3);601634
MTHFR;Homocystinuria due to MTHFR deficiency;17357067;607093;Homocystinuria due to MTHFR deficiency, 236250 (3);236250
MTHFR;Neural tube defects, susceptibility to;17357067;607093;{Neural tube defects, susceptibility to}, 601634 (3);601634
MTHFR;Schizophrenia, susceptibility to;17357067;607093;{Schizophrenia, susceptibility to}, 181500 (3);181500
MTHFR;Thromboembolism, susceptibility to;17357067;607093;{Thromboembolism, susceptibility to}, 188050 (3);188050
MTHFR;Vascular disease, susceptibility to;17357067;607093;{Vascular disease, susceptibility to} (3);0
MTM1;Myotubular myopathy, X-linked;17357067;300415;Myotubular myopathy, X-linked, 310400 (3);310400
MTMR14;Centronuclear myopathy, autosomal, modifier of;17357067;611089;{Centronuclear myopathy, autosomal, modifier of}, 160150 (3);160150
MTMR2;Charcot-Marie-Tooth disease, type 4B1;17357067;603557;Charcot-Marie-Tooth disease, type 4B1, 601382 (3);601382
MTNR1B;Diabetes mellitus, type 2, susceptiblity to;17357067;600804;{Diabetes mellitus, type 2, susceptiblity to}, 125853 (3);125853
MTO1;Combined oxidative phosphorylation deficiency 10;17357067;614667;Combined oxidative phosphorylation deficiency 10, 614702 (3);614702
MTPAP;Ataxia, spastic, 4;17357067;613669;Ataxia, spastic, 4, 613672 (3);613672
MTR;Homocystinuria-megaloblastic anemia, cblG complementation type;17357067;156570;Homocystinuria-megaloblastic anemia, cblG complementation type, 250940 (3);250940
MTR;Neural tube defects, folate-sensitive, susceptibility to;17357067;156570;{Neural tube defects, folate-sensitive, susceptibility to}, 601634 (3);601634
MTRR;Homocystinuria-megaloblastic anemia, cbl E type;17357067;602568;Homocystinuria-megaloblastic anemia, cbl E type, 236270 (3);236270
MTRR;Neural tube defects, folate-sensitive, susceptibility to;17357067;602568;{Neural tube defects, folate-sensitive, susceptibility to}, 601634 (3);601634
MTTP;Abetalipoproteinemia;17357067;157147;Abetalipoproteinemia, 200100 (3);200100
MTTP;Metabolic syndrome, protection against;17357067;157147;{Metabolic syndrome, protection against}, 605552 (3);605552
MUC1;Medullary cystic kidney disease 1;17357067;158340;Medullary cystic kidney disease 1, 174000 (3);174000
MUC5B;Pulmonary fibrosis, idiopathic, susceptibility to;17357067;600770;{Pulmonary fibrosis, idiopathic, susceptibility to}, 178500 (3);178500
MUC7;Asthma, protection against;17357067;158375;{Asthma, protection against}, 600807 (3);600807
MUSK;Fetal akinesia deformation sequence;17357067;601296;Fetal akinesia deformation sequence, 208150 (3);208150
MUSK;Myasthenic syndrome, congenital, 9, associated with acetylcholine receptor deficiency;17357067;601296;Myasthenic syndrome, congenital, 9, associated with acetylcholine receptor deficiency, 616325 (3);616325
MUT;Methylmalonic aciduria, mut(0) type;17357067;609058;Methylmalonic aciduria, mut(0) type, 251000 (3);251000
MUTYH;Adenomas, multiple colorectal;17357067;604933;Adenomas, multiple colorectal, 608456 (3);608456
MUTYH;Colorectal adenomatous polyposis, autosomal recessive, with pilomatricomas;17357067;604933;Colorectal adenomatous polyposis, autosomal recessive, with pilomatricomas, 132600 (3);132600
MUTYH;Gastric cancer, somatic;17357067;604933;Gastric cancer, somatic, 613659 (3);613659
MVK;Hyper-IgD syndrome;17357067;251170;Hyper-IgD syndrome, 260920 (3);260920
MVK;Mevalonic aciduria;17357067;251170;Mevalonic aciduria, 610377 (3);610377
MVK;Porokeratosis 3, disseminated superficial actinic;17357067;251170;Porokeratosis 3, disseminated superficial actinic, 175900 (3);175900
MVP;Mitral valve prolapse, myxomatous 1;17357067;157700;Mitral valve prolapse, myxomatous 1 (2);0
MXI1;Neurofibrosarcoma;17357067;600020;Neurofibrosarcoma (3);0
MXI1;Prostate cancer, susceptibility to;17357067;600020;{Prostate cancer, susceptibility to}, 176807 (3);176807
MYB;T-cell acute lymphoblastic leukemia;17357067;189990;{T-cell acute lymphoblastic leukemia} (3);0
MYBPC1;Arthrogryposis, distal, type 1B;17357067;160794;Arthrogryposis, distal, type 1B, 614335 (3);614335
MYBPC1;Lethal congenital contracture syndrome 4;17357067;160794;Lethal congenital contracture syndrome 4, 614915 (3);614915
MYBPC3;Cardiomyopathy, dilated, 1MM;17357067;600958;Cardiomyopathy, dilated, 1MM, 615396 (3);615396
MYBPC3;Cardiomyopathy, hypertrophic, 4;17357067;600958;Cardiomyopathy, hypertrophic, 4, 115197 (3);115197
MYBPC3;Left ventricular noncompaction 10;17357067;600958;Left ventricular noncompaction 10, 615396 (3);615396
MYC;Burkitt lymphoma;17357067;190080;Burkitt lymphoma, 113970 (3);113970
MYC;Myoclonus, familial cortical;17357067;605235;Myoclonus, familial cortical, 614937 (3);614937
MYCN;Feingold syndrome;17357067;164840;Feingold syndrome, 164280 (3);164280
MYD88;Macroglobulinemia, Waldenstrom, somatic;17357067;602170;Macroglobulinemia, Waldenstrom, somatic, 153600 (3);153600
MYD88;Pyogenic bacterial infections, recurrent, due to MYD88 deficiency;17357067;602170;Pyogenic bacterial infections, recurrent, due to MYD88 deficiency, 612260 (3);612260
MYF6;Myopathy, centronuclear, 3;17357067;159991;Myopathy, centronuclear, 3, 614408 (3);614408
MYH11;Aortic aneurysm, familial thoracic 4;17357067;160745;Aortic aneurysm, familial thoracic 4, 132900 (3);132900
MYH14;Deafness, autosomal dominant 4A;17357067;608568;Deafness, autosomal dominant 4A, 600652 (3);600652
MYH2;Proximal myopathy and ophthalmoplegia;17357067;160740;Proximal myopathy and ophthalmoplegia, 605637 (3);605637
MYH3;Arthrogryposis, distal, type 2A;17357067;160720;Arthrogryposis, distal, type 2A, 193700 (3);193700
MYH3;Arthrogryposis, distal, type 2B;17357067;160720;Arthrogryposis, distal, type 2B, 601680 (3);601680
MYH3;Arthrogryposis, distal, type 8;17357067;160720;Arthrogryposis, distal, type 8, 178110 (3);178110
MYH6;Atrial septal defect 3;17357067;160710;Atrial septal defect 3, 614089 (3);614089
MYH6;Cardiomyopathy, dilated, 1EE;17357067;160710;Cardiomyopathy, dilated, 1EE, 613252 (3);613252
MYH6;Cardiomyopathy, hypertrophic, 14;17357067;160710;Cardiomyopathy, hypertrophic, 14, 613251 (3);613251
MYH6;Sick sinus syndrome 3;17357067;160710;{Sick sinus syndrome 3}, 614090 (3);614090
MYH7;Cardiomyopathy, dilated, 1S;17357067;160760;Cardiomyopathy, dilated, 1S, 613426 (3);613426
MYH7;Cardiomyopathy, hypertrophic, 1;17357067;160760;Cardiomyopathy, hypertrophic, 1, 192600 (3);192600
MYH7;Left ventricular noncompaction 5;17357067;160760;Left ventricular noncompaction 5, 613426 (3);613426
MYH7;Liang distal myopathy;17357067;160760;Liang distal myopathy, 160500 (3);160500
MYH7;Myopathy, myosin storage, autosomal dominant;17357067;160760;Myopathy, myosin storage, autosomal dominant, 608358 (3);608358
MYH7;Myopathy, myosin storage, autosomal recessive;17357067;160760;Myopathy, myosin storage, autosomal recessive, 255160 (3);255160
MYH7;Scapuloperoneal syndrome, myopathic type;17357067;160760;Scapuloperoneal syndrome, myopathic type, 181430 (3);181430
MYH8;Carney complex variant;17357067;160741;Carney complex variant, 608837 (3);608837
MYH8;Trismus-pseudocamptodactyly syndrome;17357067;160741;Trismus-pseudocamptodactyly syndrome, 158300 (3);158300
MYH9;Deafness, autosomal dominant 17;17357067;160775;Deafness, autosomal dominant 17, 603622 (3);603622
MYH9;Epstein syndrome;17357067;160775;Epstein syndrome, 153650 (3);153650
MYH9;Fechtner syndrome;17357067;160775;Fechtner syndrome, 153640 (3);153640
MYH9;Macrothrombocytopenia and progressive sensorineural deafness;17357067;160775;Macrothrombocytopenia and progressive sensorineural deafness, 600208 (3);600208
MYH9;May-Hegglin anomaly;17357067;160775;May-Hegglin anomaly, 155100 (3);155100
MYH9;Sebastian syndrome;17357067;160775;Sebastian syndrome, 605249 (3);605249
MYL2;Cardiomyopathy, hypertrophic, 10;17357067;160781;Cardiomyopathy, hypertrophic, 10, 608758 (3);608758
MYL3;Cardiomyopathy, hypertrophic, 8;17357067;160790;Cardiomyopathy, hypertrophic, 8, 608751 (3);608751
MYL4;Congenital disorder of glycosylation, type IId;17357067;137060;Congenital disorder of glycosylation, type IId, 607091 (3);607091
MYLK;Aortic aneurysm, familial thoracic 7;17357067;600922;Aortic aneurysm, familial thoracic 7, 613780 (3);613780
MYLK2;Cardiomyopathy, hypertrophic, 1, digenic;17357067;606566;Cardiomyopathy, hypertrophic, 1, digenic, 192600 (3);192600
MYO15A;Deafness, autosomal recessive 3;17357067;602666;Deafness, autosomal recessive 3, 600316 (3);600316
MYO1A;Deafness, autosomal dominant 48;17357067;601478;Deafness, autosomal dominant 48, 607841 (3);607841
MYO1C;Glomerulosclerosis, focal segmental, 6;17357067;601479;Glomerulosclerosis, focal segmental, 6, 614131 (3);614131
MYO1E;Glomerulosclerosis, focal segmental, 6;17357067;601479;Glomerulosclerosis, focal segmental, 6, 614131 (3);614131
MYO3A;Deafness, autosomal recessive 30;17357067;606808;Deafness, autosomal recessive 30, 607101 (3);607101
MYO5A;Griscelli syndrome, type 1;17357067;160777;Griscelli syndrome, type 1, 214450 (3);214450
MYO5B;Microvillus inclusion disease;17357067;606540;Microvillus inclusion disease, 251850 (3);251850
MYO6;Deafness, autosomal dominant 22;17357067;600970;Deafness, autosomal dominant 22, 606346 (3);606346
MYO6;Deafness, autosomal dominant 22, with hypertrophic cardiomyopathy;17357067;600970;Deafness, autosomal dominant 22, with hypertrophic cardiomyopathy, 606346 (3);606346
MYO6;Deafness, autosomal recessive 37;17357067;600970;Deafness, autosomal recessive 37, 607821 (3);607821
MYO7A;Deafness, autosomal dominant 11;17357067;276903;Deafness, autosomal dominant 11, 601317 (3);601317
MYO7A;Deafness, autosomal recessive 2;17357067;276903;Deafness, autosomal recessive 2, 600060 (3);600060
MYO7A;Usher syndrome, type 1B;17357067;276903;Usher syndrome, type 1B, 276900 (3);276900
MYO9B;Celiac disease, susceptibility to, 4;17357067;602129;{Celiac disease, susceptibility to, 4}, 609753 (3);609753
MYOC;Glaucoma 1A, primary open angle;17357067;601652;Glaucoma 1A, primary open angle, 137750 (3);137750
MYOT;Muscular dystrophy, limb-girdle, type 1A;17357067;604103;Muscular dystrophy, limb-girdle, type 1A, 159000 (3);159000
MYOT;Myopathy, myofibrillar, 3;17357067;604103;Myopathy, myofibrillar, 3, 609200 (3);609200
MYOT;Myopathy, spheroid body;17357067;604103;Myopathy, spheroid body, 182920 (3);182920
MYOZ2;Cardiomyopathy, hypertrophic, 16;17357067;605602;Cardiomyopathy, hypertrophic, 16, 613838 (3);613838
MYPN;Cardiomyopathy, dilated, 1KK;17357067;608517;Cardiomyopathy, dilated, 1KK, 615248 (3);615248
MYPN;Cardiomyopathy, familial restrictive, 4;17357067;608517;Cardiomyopathy, familial restrictive, 4, 615248 (3);615248
MYPN;Cardiomyopathy, hypertrophic, 22;17357067;608517;Cardiomyopathy, hypertrophic, 22, 615248 (3);615248
MYPOP;Proximal myopathy and ophthalmoplegia;17357067;160740;Proximal myopathy and ophthalmoplegia, 605637 (3);605637
NAA10;N-terminal acetyltransferase deficiency;17357067;300013;N-terminal acetyltransferase deficiency, 300855 (3);300855
NAGA;Kanzaki disease;17357067;104170;Kanzaki disease, 609242 (3);609242
NAGA;Schindler disease, type I;17357067;104170;Schindler disease, type I, 609241 (3);609241
NAGA;Schindler disease, type III;17357067;104170;Schindler disease, type III, 609241 (3);609241
NAGLU;Mucopolysaccharidosis type IIIB (Sanfilippo B);17357067;609701;Mucopolysaccharidosis type IIIB (Sanfilippo B), 252920 (3);252920
NAGS;N-acetylglutamate synthase deficiency;17357067;608300;N-acetylglutamate synthase deficiency, 237310 (3);237310
NALCN;Congenital contractures of the limbs and face, hypotonia, and developmental delay;17357067;611549;Congenital contractures of the limbs and face, hypotonia, and developmental delay, 616266 (3);616266
NALCN;Hypotonia, infantile, with psychomotor retardation and characteristic facies;17357067;611549;Hypotonia, infantile, with psychomotor retardation and characteristic facies, 615419 (3);615419
NANOS1;Spermatogenic failure 12;17357067;608226;Spermatogenic failure 12, 615413 (3);615413
NAPB;Amyotrophy, hereditary neuralgic;17357067;604061;Amyotrophy, hereditary neuralgic, 162100 (3);162100
NAPB;Leukemia, acute myeloid, therapy-related;17357067;604061;Leukemia, acute myeloid, therapy-related (1);0
NAPB;Ovarian carcinoma;17357067;604061;Ovarian carcinoma (1);0
NARS2;Combined oxidative phosphorylation deficiency 24;17357067;612803;Combined oxidative phosphorylation deficiency 24, 616239 (3);616239
NAT1;Orthostatic intolerance;17357067;163970;Orthostatic intolerance, 604715 (3);604715
NAT2;Acetylation, slow;17357067;612182;[Acetylation, slow], 243400 (3);243400
NBAS;Infantile liver failure syndrome 2;17357067;608025;Infantile liver failure syndrome 2, 616483 (3);616483
NBAS;Short stature, optic nerve atrophy, and Pelger-Huet anomaly;17357067;608025;Short stature, optic nerve atrophy, and Pelger-Huet anomaly, 614800 (3);614800
NBEAL2;Gray platelet syndrome;17357067;614169;Gray platelet syndrome, 139090 (3);139090
NBN;Aplastic anemia;17357067;602667;Aplastic anemia, 609135 (3);609135
NBN;Leukemia, acute lymphoblastic;17357067;602667;Leukemia, acute lymphoblastic, 613065 (3);613065
NBN;Nijmegen breakage syndrome;17357067;602667;Nijmegen breakage syndrome, 251260 (3);251260
NCF1;Chronic granulomatous disease due to deficiency of NCF-1;17357067;608512;Chronic granulomatous disease due to deficiency of NCF-1, 233700 (3);233700
NCF2;Chronic granulomatous disease due to deficiency of NCF-2;17357067;608515;Chronic granulomatous disease due to deficiency of NCF-2, 233710 (3);233710
NCF4;Granulomatous disease, chronic, autosomal recessive, cytochrome b-positive, type III;17357067;601488;Granulomatous disease, chronic, autosomal recessive, cytochrome b-positive, type III, 613960 (3);613960
NCOA4;Thyroid carcinoma, papillary;17357067;601984;Thyroid carcinoma, papillary, 188550 (3);188550
NCOR1;Tenorio syndrome;17357067;610432;Tenorio syndrome, 616260 (3);616260
NCR3;Malaria, mild, susceptibility to;17357067;611550;{Malaria, mild, susceptibility to}, 609148 (3);609148
NCSTN;Acne inversa, familial, 1;17357067;605254;Acne inversa, familial, 1, 142690 (3);142690
NDE1;Lissencephaly 4 (with microcephaly);17357067;609449;Lissencephaly 4 (with microcephaly), 614019 (3);614019
NDN;Prader-Willi syndrome;17357067;602117;Prader-Willi syndrome, 176270 (3);176270
NDP;Exudative vitreoretinopathy 2, X-linked;17357067;300658;Exudative vitreoretinopathy 2, X-linked, 305390 (3);305390
NDP;Norrie disease;17357067;300658;Norrie disease, 310600 (3);310600
NDRG1;Charcot-Marie-Tooth disease, type 4D;17357067;605262;Charcot-Marie-Tooth disease, type 4D, 601455 (3);601455
NDST1;Mental retardation, autosomal recessive 46;17357067;600853;Mental retardation, autosomal recessive 46, 616116 (3);616116
NDUFA1;Mitochondrial complex I deficiency;17357067;300078;Mitochondrial complex I deficiency, 252010 (3);252010
NDUFA11;Mitochondrial complex I deficiency;17357067;612638;Mitochondrial complex I deficiency, 252010 (3);252010
NDUFA12;Leigh syndrome due to mitochondrial complex 1 deficiency;17357067;614530;Leigh syndrome due to mitochondrial complex 1 deficiency, 256000 (3);256000
NDUFA13;Thyroid carcinoma, Hurthle cell;17357067;609435;{Thyroid carcinoma, Hurthle cell}, 607464 (3);607464
NDUFA2;Leigh syndrome due to mitochondrial complex I deficiency;17357067;602137;Leigh syndrome due to mitochondrial complex I deficiency, 256000 (3);256000
NDUFA9;Leigh syndrome due to mitochondrial complex I deficiency;17357067;603834;Leigh syndrome due to mitochondrial complex I deficiency, 256000 (3);256000
NDUFAB1;Cerebral palsy, ataxic, autosomal recessive;17357067;605388;Cerebral palsy, ataxic, autosomal recessive (2);0
NDUFAF1;Mitochondrial complex I deficiency;17357067;606934;Mitochondrial complex I deficiency, 252010 (3);252010
NDUFAF2;Leigh syndrome;17357067;609653;Leigh syndrome, 256000 (3);256000
NDUFAF2;Mitochondrial complex I deficiency;17357067;609653;Mitochondrial complex I deficiency, 252010 (3);252010
NDUFAF3;Mitochondrial complex I deficiency;17357067;612911;Mitochondrial complex I deficiency, 252010 (3);252010
NDUFAF4;Mitochondrial complex I deficiency;17357067;611776;Mitochondrial complex I deficiency, 252010 (3);252010
NDUFAF5;Mitochondrial complex 1 deficiency;17357067;612360;Mitochondrial complex 1 deficiency, 252010 (3);252010
NDUFAF6;Leigh syndrome due to mitochondrial complex I deficiency;17357067;612392;Leigh syndrome due to mitochondrial complex I deficiency, 256000 (3);256000
NDUFB11;Linear skin defects with multiple congenital anomalies 3;17357067;300403;Linear skin defects with multiple congenital anomalies 3, 300952 (3);300952
NDUFB3;Mitochondrial complex I deficiency;17357067;603839;Mitochondrial complex I deficiency, 252010 (3);252010
NDUFS1;Mitochondrial complex I deficiency;17357067;157655;Mitochondrial complex I deficiency, 252010 (3);252010
NDUFS2;Mitochondrial complex I deficiency;17357067;602985;Mitochondrial complex I deficiency, 252010 (3);252010
NDUFS3;Leigh syndrome due to mitochondrial complex I deficiency;17357067;603846;Leigh syndrome due to mitochondrial complex I deficiency, 256000 (3);256000
NDUFS3;Mitochondrial complex I deficiency;17357067;603846;Mitochondrial complex I deficiency, 252010 (3);252010
NDUFS4;Leigh syndrome;17357067;602694;Leigh syndrome, 256000 (3);256000
NDUFS4;Mitochondrial complex I deficiency;17357067;602694;Mitochondrial complex I deficiency, 252010 (3);252010
NDUFS6;Mitochondrial complex I deficiency;17357067;603848;Mitochondrial complex I deficiency, 252010 (3);252010
NDUFS7;Leigh syndrome;17357067;601825;Leigh syndrome, 256000 (3);256000
NDUFS8;Leigh syndrome due to mitochondrial complex I deficiency;17357067;602141;Leigh syndrome due to mitochondrial complex I deficiency, 256000 (3);256000
NDUFV1;Mitochondrial complex I deficiency;17357067;161015;Mitochondrial complex I deficiency, 252010 (3);252010
NDUFV2;Mitochondrial complex I deficiency;17357067;600532;Mitochondrial complex I deficiency, 252010 (3);252010
NEB;Nemaline myopathy 2, autosomal recessive;17357067;161650;Nemaline myopathy 2, autosomal recessive, 256030 (3);256030
NEFL;Charcot-Marie-Tooth disease, type 1F;17357067;162280;Charcot-Marie-Tooth disease, type 1F, 607734 (3);607734
NEFL;Charcot-Marie-Tooth disease, type 2E;17357067;162280;Charcot-Marie-Tooth disease, type 2E, 607684 (3);607684
NEK1;Short-rib thoracic dysplasia 6 with or without polydactyly;17357067;604588;Short-rib thoracic dysplasia 6 with or without polydactyly, 263520 (3);263520
NELFE;Alternating hemiplegia of childhood 2;17357067;182350;Alternating hemiplegia of childhood 2, 614820 (3);614820
NELFE;CAPOS syndrome;17357067;182350;CAPOS syndrome, 601338 (3);601338
NELFE;Dystonia-12;17357067;182350;Dystonia-12, 128235 (3);128235
NET1;Orthostatic intolerance;17357067;163970;Orthostatic intolerance, 604715 (3);604715
NEU1;Sialidosis, type I;17357067;608272;Sialidosis, type I, 256550 (3);256550
NEU1;Sialidosis, type II;17357067;608272;Sialidosis, type II, 256550 (3);256550
NEUROD1;Diabetes mellitus, noninsulin-dependent;17357067;601724;{Diabetes mellitus, noninsulin-dependent}, 125853 (3);125853
NEUROD1;Maturity-onset diabetes of the young 6;17357067;601724;Maturity-onset diabetes of the young 6, 606394 (3);606394
NEUROG3;Diarrhea 4, malabsorptive, congenital;17357067;604882;Diarrhea 4, malabsorptive, congenital, 610370 (3);610370
NEXN;Cardiomyopathy, dilated, 1CC;17357067;613121;Cardiomyopathy, dilated, 1CC, 613122 (3);613122
NEXN;Cardiomyopathy, hypertrophic, 20;17357067;613121;Cardiomyopathy, hypertrophic, 20, 613876 (3);613876
NF1;Leukemia, juvenile myelomonocytic;17357067;613113;Leukemia, juvenile myelomonocytic, 607785 (3);607785
NF1;Neurofibromatosis, familial spinal;17357067;613113;Neurofibromatosis, familial spinal, 162210 (3);162210
NF1;Neurofibromatosis, type 1;17357067;613113;Neurofibromatosis, type 1, 162200 (3);162200
NF1;Neurofibromatosis-Noonan syndrome;17357067;613113;Neurofibromatosis-Noonan syndrome, 601321 (3);601321
NF1;Watson syndrome;17357067;613113;Watson syndrome, 193520 (3);193520
NF2;Meningioma, NF2-related, somatic;17357067;607379;Meningioma, NF2-related, somatic, 607174 (3);607174
NF2;Neurofibromatosis, type 2;17357067;607379;Neurofibromatosis, type 2, 101000 (3);101000
NF2;Schwannomatosis;17357067;607379;Schwannomatosis, 162091 (3);162091
NFIX;Marshall-Smith syndrome;17357067;164005;Marshall-Smith syndrome, 602535 (3);602535
NFIX;Sotos syndrome 2;17357067;164005;Sotos syndrome 2, 614753 (3);614753
NFKB2;Immunodeficiency, common variable, 10;17357067;164012;Immunodeficiency, common variable, 10, 615577 (3);615577
NFKBIA;Ectodermal dysplasia, anhidrotic, with T-cell immunodeficiency;17357067;164008;Ectodermal dysplasia, anhidrotic, with T-cell immunodeficiency, 612132 (3);612132
NFKBIL1;Rheumatoid arthritis, susceptibility to;17357067;601022;{Rheumatoid arthritis, susceptibility to}, 180300 (3);180300
NFU1;Multiple mitochondrial dysfunctions syndrome 1;17357067;608100;Multiple mitochondrial dysfunctions syndrome 1, 605711 (3);605711
NGF;Neuropathy, hereditary sensory and autonomic, type V;17357067;162030;Neuropathy, hereditary sensory and autonomic, type V, 608654 (3);608654
NGLY1;Congenital disorder of deglycosylation;17357067;610661;Congenital disorder of deglycosylation, 615273 (3);615273
NHEJ1;Severe combined immunodeficiency with microcephaly, growth retardation, and sensitivity to ionizing radiation;17357067;611290;Severe combined immunodeficiency with microcephaly, growth retardation, and sensitivity to ionizing radiation, 611291 (3);611291
NHLRC1;Epilepsy, progressive myoclonic 2B (Lafora);17357067;608072;Epilepsy, progressive myoclonic 2B (Lafora), 254780 (3);254780
NHP2;Dyskeratosis congenita, autosomal recessive 2;17357067;606470;Dyskeratosis congenita, autosomal recessive 2, 613987 (3);613987
NHS;Cataract 40, X-linked;17357067;300457;Cataract 40, X-linked, 302200 (3);302200
NHS;Nance-Horan syndrome;17357067;300457;Nance-Horan syndrome, 302350 (3);302350
NIN;Seckel syndrome 7;17357067;608684;Seckel syndrome 7, 614851 (3);614851
NIPA1;Spastic paraplegia 6, autosomal dominant;17357067;608145;Spastic paraplegia 6, autosomal dominant, 600363 (3);600363
NIPAL4;Ichthyosis, congenital, autosomal recessive 6;17357067;609383;Ichthyosis, congenital, autosomal recessive 6, 612281 (3);612281
NIPBL;Cornelia de Lange syndrome 1;17357067;608667;Cornelia de Lange syndrome 1, 122470 (3);122470
NKX2-1;Chorea, hereditary benign;17357067;600635;Chorea, hereditary benign, 118700 (3);118700
NKX2-1;Choreoathetosis, hypothyroidism, and neonatal respiratory distress;17357067;600635;Choreoathetosis, hypothyroidism, and neonatal respiratory distress, 610978 (3);610978
NKX2-1;Goiter, familial, due to TTF-1 defect;17357067;600635;Goiter, familial, due to TTF-1 defect (1);0
NKX2-5;Atrial septal defect 7, with or without AV conduction defects;17357067;600584;Atrial septal defect 7, with or without AV conduction defects, 108900 (3);108900
NKX2-5;Conotruncal heart malformations, variable;17357067;600584;Conotruncal heart malformations, variable, 217095 (3);217095
NKX2-5;Hypoplastic left heart syndrome 2;17357067;600584;Hypoplastic left heart syndrome 2, 614435 (3);614435
NKX2-5;Hypothyroidism, congenital nongoitrous, 5;17357067;600584;Hypothyroidism, congenital nongoitrous, 5, 225250 (3);225250
NKX2-5;Tetrology of Fallot;17357067;600584;Tetrology of Fallot, 187500 (3);187500
NKX2-5;Ventricular septal defect 3;17357067;600584;Ventricular septal defect 3, 614432 (3);614432
NKX2-6;Conotruncal heart malformations;17357067;611770;Conotruncal heart malformations, 217095 (3);217095
NKX2-6;Persistent truncus arteriosus;17357067;611770;Persistent truncus arteriosus, 217095 (3);217095
NKX3-2;Spondylo-megaepiphyseal-metaphyseal dysplasia;17357067;602183;Spondylo-megaepiphyseal-metaphyseal dysplasia, 613330 (3);613330
NLGN3;Asperger syndrome susceptibility, X-linked 1;17357067;300336;{Asperger syndrome susceptibility, X-linked 1}, 300494 (3);300494
NLGN3;Autism susceptibility, X-linked 1;17357067;300336;{Autism susceptibility, X-linked 1}, 300425 (3);300425
NLGN4X;Asperger syndrome susceptibility, X-linked 2;17357067;300427;{Asperger syndrome susceptibility, X-linked 2}, 300497 (3);300497
NLGN4X;Autism susceptibility, X-linked 2;17357067;300427;{Autism susceptibility, X-linked 2}, 300495 (3);300495
NLGN4X;Mental retardation, X-linked;17357067;300427;Mental retardation, X-linked, 300495 (3);300495
NLRC4;Autoinflammation with infantile enterocolitis;17357067;606831;Autoinflammation with infantile enterocolitis, 616050 (3);616050
NLRP1;Vitiligo-associated multiple autoimmune disease susceptibility 1;17357067;606636;{Vitiligo-associated multiple autoimmune disease susceptibility 1}, 606579 (3);606579
NLRP12;Familial cold autoinflammatory syndrome 2;17357067;609648;Familial cold autoinflammatory syndrome 2, 611762 (3);611762
NLRP3;CINCA syndrome;17357067;606416;CINCA syndrome, 607115 (3);607115
NLRP3;Familial cold-induced inflammatory syndrome 1;17357067;606416;Familial cold-induced inflammatory syndrome 1, 120100 (3);120100
NLRP3;Muckle-Wells syndrome;17357067;606416;Muckle-Wells syndrome, 191900 (3);191900
NLRP7;Hydatidiform mole, recurrent, 1;17357067;609661;Hydatidiform mole, recurrent, 1, 231090 (3);231090
NME1;Neuroblastoma;17357067;156490;Neuroblastoma, 256700 (3);256700
NME8;Ciliary dyskinesia, primary, 6;17357067;607421;Ciliary dyskinesia, primary, 6, 610852 (3);610852
NMNAT1;Leber congenital amaurosis 9;17357067;608700;Leber congenital amaurosis 9, 608553 (3);608553
NNMT;Homocysteine plasma level;17357067;600008;Homocysteine plasma level (2);0
NNT;Glucocorticoid deficiency 4;17357067;607878;Glucocorticoid deficiency 4, 614736 (3);614736
NOBOX;Premature ovarian failure 5;17357067;610934;Premature ovarian failure 5, 611548 (3);611548
NOD2;Blau syndrome;17357067;605956;Blau syndrome, 186580 (3);186580
NOD2;Inflammatory bowel disease 1;17357067;605956;{Inflammatory bowel disease 1}, 266600 (3);266600
NOD2;Psoriatic arthritis, susceptibility to;17357067;605956;{Psoriatic arthritis, susceptibility to}, 607507 (3);607507
NOD2;Sarcoidosis, early-onset;17357067;605956;Sarcoidosis, early-onset, 609464 (3);609464
NODAL;Heterotaxy, visceral, 5;17357067;601265;Heterotaxy, visceral, 5, 270100 (3);270100
NOG;Brachydactyly, type B2;17357067;602991;Brachydactyly, type B2, 611377 (3);611377
NOG;Multiple synostoses syndrome 1;17357067;602991;Multiple synostoses syndrome 1, 186500 (3);186500
NOG;Stapes ankylosis with broad thumb and toes;17357067;602991;Stapes ankylosis with broad thumb and toes, 184460 (3);184460
NOG;Symphalangism, proximal;17357067;602991;Symphalangism, proximal, 185800 (3);185800
NOG;Tarsal-carpal coalition syndrome;17357067;602991;Tarsal-carpal coalition syndrome, 186570 (3);186570
NOL3;Myoclonus, familial cortical;17357067;605235;Myoclonus, familial cortical, 614937 (3);614937
NOP10;Dyskeratosis congenita, autosomal recessive 1;17357067;606471;Dyskeratosis congenita, autosomal recessive 1, 224230 (3);224230
NOP56;Spinocerebellar ataxia 36;17357067;614154;Spinocerebellar ataxia 36, 614153 (3);614153
NOS1;Spermatogenic failure 12;17357067;608226;Spermatogenic failure 12, 615413 (3);615413
NOS2;Hypertension, susceptibility to;17357067;163730;{Hypertension, susceptibility to}, 145500 (2);145500
NOS2;Malaria, resistance to;17357067;163730;{Malaria, resistance to}, 611162 (3);611162
NOS3;Alzheimer disease, late-onset, susceptibility to;17357067;163729;{Alzheimer disease, late-onset, susceptibility to}, 104300 (3);104300
NOS3;Coronary artery spasm 1, susceptibility to;17357067;163729;{Coronary artery spasm 1, susceptibility to} (3);0
NOS3;Hypertension, pregnancy-induced;17357067;163729;{Hypertension, pregnancy-induced}, 189800 (3);189800
NOS3;Hypertension, susceptibility to;17357067;163729;{Hypertension, susceptibility to}, 145500 (3);145500
NOS3;Ischemic stroke, susceptibility to;17357067;163729;{Ischemic stroke, susceptibility to}, 601367 (3);601367
NOS3;Placental abruption;17357067;163729;{Placental abruption} (3);0
NOTCH1;Adams-Oliver syndrome 5;17357067;190198;Adams-Oliver syndrome 5, 616028 (3);616028
NOTCH1;Aortic valve disease 1;17357067;190198;Aortic valve disease 1, 109730 (3);109730
NOTCH2;Alagille syndrome 2;17357067;600275;Alagille syndrome 2, 610205 (3);610205
NOTCH2;Hajdu-Cheney syndrome;17357067;600275;Hajdu-Cheney syndrome, 102500 (3);102500
NOTCH3;Cerebral arteriopathy with subcortical infarcts and leukoencephalopathy;17357067;600276;Cerebral arteriopathy with subcortical infarcts and leukoencephalopathy, 125310 (3);125310
NOTCH3;Lateral meningocele syndrome;17357067;600276;Lateral meningocele syndrome, 130720 (3);130720
NPC1;Nasopharyngeal carcinoma 1;17357067;607107;{Nasopharyngeal carcinoma 1} (2);0
NPC1;Niemann-Pick disease, type C1;17357067;607623;Niemann-Pick disease, type C1, 257220 (3);257220
NPC1;Niemann-Pick disease, type D;17357067;607623;Niemann-Pick disease, type D, 257220 (3);257220
NPC1L1;Ezetimibe, nonresponse to;17357067;608010;[Ezetimibe, nonresponse to] (3);0
NPC2;Niemann-pick disease, type C2;17357067;601015;Niemann-pick disease, type C2, 607625 (3);607625
NPHP1;Joubert syndrome 4;17357067;607100;Joubert syndrome 4, 609583 (3);609583
NPHP1;Nephronophthisis 1, juvenile;17357067;607100;Nephronophthisis 1, juvenile, 256100 (3);256100
NPHP1;Senior-Loken syndrome-1;17357067;607100;Senior-Loken syndrome-1, 266900 (3);266900
NPHP3;Meckel syndrome 7;17357067;608002;Meckel syndrome 7, 267010 (3);267010
NPHP3;Nephronophthisis 3;17357067;608002;Nephronophthisis 3, 604387 (3);604387
NPHP3;Renal-hepatic-pancreatic dysplasia 1;17357067;608002;Renal-hepatic-pancreatic dysplasia 1, 208540 (3);208540
NPHP3;Senior-Loken syndrome 3;17357067;606995;Senior-Loken syndrome 3 (2);0
NPHP4;Nephronophthisis 4;17357067;607215;Nephronophthisis 4, 606966 (3);606966
NPHP4;Senior-Loken syndrome 4;17357067;607215;Senior-Loken syndrome 4, 606996 (3);606996
NPHS1;Nephrotic syndrome, type 1;17357067;602716;Nephrotic syndrome, type 1, 256300 (3);256300
NPHS2;Nephrotic syndrome, type 2;17357067;604766;Nephrotic syndrome, type 2, 600995 (3);600995
NPM1;Leukemia, acute myeloid;17357067;164040;Leukemia, acute myeloid, 601626 (3);601626
NPM1;Leukemia, acute promyelocytic, NPM/RARA type;17357067;164040;Leukemia, acute promyelocytic, NPM/RARA type (3);0
NPPA;Atrial fibrillation, familial, 6;17357067;108780;Atrial fibrillation, familial, 6, 612201 (3);612201
NPPA;Atrial standstill 2;17357067;108780;Atrial standstill 2, 615745 (3);615745
NPR2;Acromesomelic dysplasia, Maroteaux type;17357067;108961;Acromesomelic dysplasia, Maroteaux type, 602875 (3);602875
NPR2;Epiphyseal chondrodysplasia, Miura type;17357067;108961;Epiphyseal chondrodysplasia, Miura type, 615923 (3);615923
NPSR1;Asthma, susceptibility to, 2;17357067;608595;{Asthma, susceptibility to, 2}, 608584 (3);608584
NPSR1-AS1;Aortic aneurysm, familial abdominal 1;17357067;100070;Aortic aneurysm, familial abdominal 1 (2);0
NQO1;Benzene toxicity, susceptibility to;17357067;125860;{Benzene toxicity, susceptibility to} (3);0
NQO1;Breast cancer, poor survival after chemotherapy for;17357067;125860;{Breast cancer, poor survival after chemotherapy for} (3);0
NQO1;Leukemia, post-chemotherapy, susceptibility to;17357067;125860;{Leukemia, post-chemotherapy, susceptibility to} (3);0
NR0B1;46XY sex reversal 2, dosage-sensitive;17357067;300473;46XY sex reversal 2, dosage-sensitive, 300018 (3);300018
NR0B1;Adrenal hypoplasia, congenital, with hypogonadotropic hypogonadism;17357067;300473;Adrenal hypoplasia, congenital, with hypogonadotropic hypogonadism, 300200 (3);300200
NR0B1;Charcot-Marie-Tooth disease, dominant intermediate D;17357067;159440;Charcot-Marie-Tooth disease, dominant intermediate D, 607791 (3);607791
NR0B1;Charcot-Marie-Tooth disease, type 1A;17357067;601097;Charcot-Marie-Tooth disease, type 1A, 118220 (3);118220
NR0B1;Charcot-Marie-Tooth disease, type 1B;17357067;159440;Charcot-Marie-Tooth disease, type 1B, 118200 (3);118200
NR0B1;Charcot-Marie-Tooth disease, type 1E;17357067;601097;Charcot-Marie-Tooth disease, type 1E, 118300 (3);118300
NR0B1;Charcot-Marie-Tooth disease, type 2I;17357067;159440;Charcot-Marie-Tooth disease, type 2I, 607677 (3);607677
NR0B1;Charcot-Marie-Tooth disease, type 2J;17357067;159440;Charcot-Marie-Tooth disease, type 2J, 607736 (3);607736
NR0B1;Dejerine-Sottas disease;17357067;159440;Dejerine-Sottas disease, 145900 (3);145900
NR0B1;Neuropathy, congenital hypomyelinating;17357067;159440;Neuropathy, congenital hypomyelinating, 605253 (3);605253
NR0B1;Neuropathy, inflammatory demyelinating;17357067;601097;Neuropathy, inflammatory demyelinating, 139393 (3);139393
NR0B1;Neuropathy, recurrent, with pressure palsies;17357067;601097;Neuropathy, recurrent, with pressure palsies, 162500 (3);162500
NR0B1;Roussy-Levy syndrome;17357067;159440;Roussy-Levy syndrome, 180800 (3);180800
NR0B2;Obesity, mild, early-onset;17357067;604630;Obesity, mild, early-onset, 601665 (3);601665
NR2E1;Atrial septal defect 6;17357067;606742;Atrial septal defect 6, 613087 (3);613087
NR2E3;Enhanced S-cone syndrome;17357067;604485;Enhanced S-cone syndrome, 268100 (3);268100
NR2E3;Retinitis pigmentosa 37;17357067;604485;Retinitis pigmentosa 37, 611131 (3);611131
NR2F1;Bosch-Boonstra-Schaaf optic atrophy syndrome;17357067;132890;Bosch-Boonstra-Schaaf optic atrophy syndrome, 615722 (3);615722
NR2F2;Congenital heart defects, multiple types, 4;17357067;107773;Congenital heart defects, multiple types, 4, 615779 (3);615779
NR3C1;Glucocorticoid resistance;17357067;138040;Glucocorticoid resistance, 615962 (3);615962
NR3C2;Hypertension, early-onset, autosomal dominant, with exacerbation in pregnancy;17357067;600983;Hypertension, early-onset, autosomal dominant, with exacerbation in pregnancy, 605115 (3);605115
NR3C2;Pseudohypoaldosteronism type I, autosomal dominant;17357067;600983;Pseudohypoaldosteronism type I, autosomal dominant, 177735 (3);177735
NR4A3;Chondrosarcoma, extraskeletal myxoid;17357067;600542;Chondrosarcoma, extraskeletal myxoid, 612237 (3);612237
NR5A1;46XY sex reversal 3;17357067;184757;46XY sex reversal 3, 612965 (3);612965
NR5A1;Adrenocortical insufficiency;17357067;184757;Adrenocortical insufficiency (3);0
NR5A1;Premature ovarian failure 7;17357067;184757;Premature ovarian failure 7, 612964 (3);612964
NR5A1;Spermatogenic failure 8;17357067;184757;Spermatogenic failure 8, 613957 (3);613957
NRAS;Autoimmune lymphoproliferative syndrome type IV;17357067;164790;Autoimmune lymphoproliferative syndrome type IV, 614470 (3);614470
NRAS;Colorectal cancer, somatic;17357067;164790;Colorectal cancer, somatic, 114500 (3);114500
NRAS;Epidermal nevus, somatic;17357067;164790;Epidermal nevus, somatic, 162900 (3);162900
NRAS;Melanocytic nevus syndrome, congenital, somatic;17357067;164790;Melanocytic nevus syndrome, congenital, somatic, 137550 (3);137550
NRAS;Neurocutaneous melanosis, somatic;17357067;164790;Neurocutaneous melanosis, somatic, 249400 (3);249400
NRAS;Noonan syndrome 6;17357067;164790;Noonan syndrome 6, 613224 (3);613224
NRAS;Schimmelpenning-Feuerstein-Mims syndrome, somatic mosaic;17357067;164790;Schimmelpenning-Feuerstein-Mims syndrome, somatic mosaic, 163200 (3);163200
NRAS;Thyroid carcinoma, follicular, somatic;17357067;164790;Thyroid carcinoma, follicular, somatic, 188470 (3);188470
NRL;Retinal degeneration, autosomal recessive, clumped pigment type;17357067;162080;Retinal degeneration, autosomal recessive, clumped pigment type (3);0
NRL;Retinitis pigmentosa 27;17357067;162080;Retinitis pigmentosa 27, 613750 (3);613750
NRXN1;Pitt-Hopkins-like syndrome 2;17357067;600565;Pitt-Hopkins-like syndrome 2, 614325 (3);614325
NRXN1;Schizophrenia, susceptibility to, 17;17357067;600565;{Schizophrenia, susceptibility to, 17}, 614332 (3);614332
NSD1;Beckwith-Wiedemann syndrome;17357067;606681;Beckwith-Wiedemann syndrome, 130650 (3);130650
NSD1;Leukemia, acute myeloid;17357067;606681;Leukemia, acute myeloid, 601626 (1);601626
NSD1;Sotos syndrome 1;17357067;606681;Sotos syndrome 1, 117550 (3);117550
NSDHL;CHILD syndrome;17357067;300275;CHILD syndrome, 308050 (3);308050
NSDHL;CK syndrome;17357067;300275;CK syndrome, 300831 (3);300831
NSMF;Hypogonadotropic hypogonadism 9 with or without anosmia;17357067;608137;Hypogonadotropic hypogonadism 9 with or without anosmia, 614838 (3);614838
NSUN2;Mental retardation, autosomal recessive 5;17357067;610916;Mental retardation, autosomal recessive 5, 611091 (3);611091
NT3;Low density lipoprotein cholesterol level QTL6;17357067;602458;[Low density lipoprotein cholesterol level QTL6], 613589 (3);613589
NT5C2;Spastic paraplegia 45;17357067;600417;Spastic paraplegia 45, 613162 (3);613162
NT5C3A;Anemia, hemolytic, due to UMPH1 deficiency;17357067;606224;Anemia, hemolytic, due to UMPH1 deficiency, 266120 (3);266120
NT5E;Calcification of joints and arteries;17357067;129190;Calcification of joints and arteries, 211800 (3);211800
NT5E;Glaucoma 1, open angle, 1O;17357067;162662;Glaucoma 1, open angle, 1O, 613100 (3);613100
NTF4;Glaucoma 1, open angle, 1O;17357067;162662;Glaucoma 1, open angle, 1O, 613100 (3);613100
NTHL1;Familial adenomatous polyposis 3;17357067;602656;Familial adenomatous polyposis 3, 616415 (3);616415
NTRK1;Insensitivity to pain, congenital, with anhidrosis;17357067;191315;Insensitivity to pain, congenital, with anhidrosis, 256800 (3);256800
NTRK1;Medullary thyroid carcinoma, familial;17357067;191315;Medullary thyroid carcinoma, familial, 155240 (3);155240
NUBPL;Mitochondrial complex I deficiency;17357067;613621;Mitochondrial complex I deficiency, 252010 (3);252010
NUMA1;Leukemia, acute promyelocytic, NUMA/RARA type;17357067;164009;Leukemia, acute promyelocytic, NUMA/RARA type (3);0
NUP214;Leukemia, T-cell acute lymphoblastic;17357067;114350;Leukemia, T-cell acute lymphoblastic (3);0
NUP214;Leukemia, acute myeloid;17357067;114350;Leukemia, acute myeloid, 601626 (3);601626
NUP62;Striatonigral degeneration, infantile;17357067;605815;Striatonigral degeneration, infantile, 271930 (3);271930
NXPH2;Nephronophthisis 2, infantile;17357067;243305;Nephronophthisis 2, infantile, 602088 (3);602088
NYX;Night blindness, congenital stationary (complete), 1A, X-linked;17357067;300278;Night blindness, congenital stationary (complete), 1A, X-linked, 310500 (3);310500
OAS1;Diabetes mellitus, type 1, susceptibility to;17357067;164350;{Diabetes mellitus, type 1, susceptibility to}, 222100 (3);222100
OAS1;Viral infection, susceptibility to;17357067;164350;{Viral infection, susceptibility to} (3);0
OAT;Gyrate atrophy of choroid and retina with or without ornithinemia;17357067;613349;Gyrate atrophy of choroid and retina with or without ornithinemia, 258870 (3);258870
OBP2A;Spondyloepimetaphyseal dysplasia with joint laxity, type 2;17357067;603213;Spondyloepimetaphyseal dysplasia with joint laxity, type 2, 603546 (3);603546
OBSL1;3-M syndrome 2;17357067;610991;3-M syndrome 2, 612921 (3);612921
OCA2;Albinism, brown oculocutaneous;17357067;611409;Albinism, brown oculocutaneous, 203200 (3);203200
OCA2;Albinism, oculocutaneous, type II;17357067;611409;Albinism, oculocutaneous, type II, 203200 (3);203200
OCA2;Skin/hair/eye pigmentation 1, blond/brown hair;17357067;611409;[Skin/hair/eye pigmentation 1, blond/brown hair], 227220 (3);227220
OCA2;Skin/hair/eye pigmentation 1, blue/nonblue eyes;17357067;611409;[Skin/hair/eye pigmentation 1, blue/nonblue eyes], 227220 (3);227220
OCLN;Band-like calcification with simplified gyration and polymicrogyria;17357067;602876;Band-like calcification with simplified gyration and polymicrogyria, 251290 (3);251290
OCRL;Dent disease 2;17357067;300535;Dent disease 2, 300555 (3);300555
OCRL;Lowe syndrome;17357067;300535;Lowe syndrome, 309000 (3);309000
ODC1;Colonic adenoma recurrence, reduced risk of;17357067;165640;{Colonic adenoma recurrence, reduced risk of}, 114500 (3);114500
OFD1;Joubert syndrome 10;17357067;300170;Joubert syndrome 10, 300804 (3);300804
OFD1;Orofaciodigital syndrome I;17357067;300170;Orofaciodigital syndrome I, 311200 (3);311200
OFD1;Simpson-Golabi-Behmel syndrome, type 2;17357067;300170;Simpson-Golabi-Behmel syndrome, type 2, 300209 (3);300209
OGDH;Alpha-ketoglutarate dehydrogenase deficiency;17357067;613022;Alpha-ketoglutarate dehydrogenase deficiency, 203740 (1);203740
OGG1;Renal cell carcinoma, clear cell, somatic;17357067;601982;Renal cell carcinoma, clear cell, somatic, 144700 (3);144700
OLR1;Myocardial infarction, susceptibility to;17357067;602601;{Myocardial infarction, susceptibility to}, 608446 (3);608446
OPA1;Glaucoma, normal tension, susceptibility to;17357067;605290;{Glaucoma, normal tension, susceptibility to}, 606657 (3);606657
OPA1;Optic atrophy 1;17357067;605290;Optic atrophy 1, 165500 (3);165500
OPA1;Optic atrophy plus syndrome;17357067;605290;Optic atrophy plus syndrome, 125250 (3);125250
OPA3;3-methylglutaconic aciduria, type III;17357067;606580;3-methylglutaconic aciduria, type III, 258501 (3);258501
OPA3;Optic atrophy 3 with cataract;17357067;606580;Optic atrophy 3 with cataract, 165300 (3);165300
OPCML;Ovarian cancer, somatic;17357067;600632;{Ovarian cancer, somatic}, 167000 (3);167000
OPHN1;Mental retardation, X-linked, with cerebellar hypoplasia and distinctive facial appearance;17357067;300127;Mental retardation, X-linked, with cerebellar hypoplasia and distinctive facial appearance, 300486 (3);300486
OPLAH;5-oxoprolinase deficiency;17357067;614243;5-oxoprolinase deficiency, 260005 (3);260005
OPN1LW;Blue cone monochromacy;17357067;300822;Blue cone monochromacy, 303700 (3);303700
OPN1LW;Colorblindness, protan;17357067;300822;Colorblindness, protan, 303900 (3);303900
OPN1MW;Blue cone monochromacy;17357067;300821;Blue cone monochromacy, 303700 (3);303700
OPN1MW;Colorblindness, deutan;17357067;300821;Colorblindness, deutan, 303800 (3);303800
OPN1SW;Colorblindness, tritan;17357067;613522;Colorblindness, tritan, 190900 (3);190900
OPTN;Amyotrophic lateral sclerosis 12;17357067;602432;Amyotrophic lateral sclerosis 12, 613435 (3);613435
OPTN;Glaucoma 1, open angle, E;17357067;602432;Glaucoma 1, open angle, E, 137760 (3);137760
OPTN;Glaucoma, normal tension, susceptibility to;17357067;602432;{Glaucoma, normal tension, susceptibility to}, 606657 (3);606657
OR2J3;C3HEX, ability to smell;17357067;615016;[C3HEX, ability to smell], 615082 (3);615082
ORAI1;Immunodeficiency 9;17357067;610277;Immunodeficiency 9, 612782 (3);612782
ORAI1;Myopathy, tubular aggregate, 2;17357067;610277;Myopathy, tubular aggregate, 2, 615883 (3);615883
ORC1;Meier-Gorlin syndrome 1;17357067;601902;Meier-Gorlin syndrome 1, 224690 (3);224690
ORC4;Meier-Gorlin syndrome 2;17357067;603056;Meier-Gorlin syndrome 2, 613800 (3);613800
ORC6;Meier-Gorlin syndrome 3;17357067;607213;Meier-Gorlin syndrome 3, 613803 (3);613803
OSBPL1A;Retinitis pigmentosa 1;17357067;603937;Retinitis pigmentosa 1, 180100 (3);180100
OSBPL2;Deafness, autosomal dominant 67;17357067;606731;Deafness, autosomal dominant 67, 616340 (3);616340
OSMR;Amyloidosis, primary localized cutaneous, 1;17357067;601743;Amyloidosis, primary localized cutaneous, 1, 105250 (3);105250
OSTM1;Osteopetrosis, autosomal recessive 5;17357067;607649;Osteopetrosis, autosomal recessive 5, 259720 (3);259720
OTC;Ornithine transcarbamylase deficiency;17357067;300461;Ornithine transcarbamylase deficiency, 311250 (3);311250
OTOA;Deafness, autosomal recessive 22;17357067;607038;Deafness, autosomal recessive 22, 607039 (3);607039
OTOF;Auditory neuropathy, autosomal recessive, 1;17357067;603681;Auditory neuropathy, autosomal recessive, 1, 601071 (3);601071
OTOF;Deafness, autosomal recessive 9;17357067;603681;Deafness, autosomal recessive 9, 601071 (3);601071
OTOG;Deafness, autosomal recessive 18B;17357067;604487;Deafness, autosomal recessive 18B, 614945 (3);614945
OTOGL;Deafness, autosomal recessive 84B;17357067;614925;Deafness, autosomal recessive 84B, 614944 (3);614944
OTX2;Microphthalmia, syndromic 5;17357067;600037;Microphthalmia, syndromic 5, 610125 (3);610125
OTX2;Pituitary hormone deficiency, combined, 6;17357067;600037;Pituitary hormone deficiency, combined, 6, 613986 (3);613986
OTX2;Retinal dystrophy, early-onset, with or without pituitary dysfunction;17357067;600037;Retinal dystrophy, early-onset, with or without pituitary dysfunction, 610125 (3);610125
OXCT1;Succinyl CoA:3-oxoacid CoA transferase deficiency;17357067;601424;Succinyl CoA:3-oxoacid CoA transferase deficiency, 245050 (3);245050
P2RX1;Bleeding disorder due to P2RX1 defect, somatic;17357067;600845;Bleeding disorder due to P2RX1 defect, somatic, 609821 (3);609821
P2RX2;Deafness, autosomal dominant 41;17357067;600844;Deafness, autosomal dominant 41, 608224 (3);608224
P2RY12;Bleeding disorder, platelet-type, 8;17357067;600515;Bleeding disorder, platelet-type, 8, 609821 (3);609821
P4HB;Cole-Carpenter syndrome 1;17357067;176790;Cole-Carpenter syndrome 1, 112240 (3);112240
PABPN1;Oculopharyngeal muscular dystrophy;17357067;602279;Oculopharyngeal muscular dystrophy, 164300 (3);164300
PACS1;Mental retardation, autosomal dominant 17;17357067;607492;Mental retardation, autosomal dominant 17, 615009 (3);615009
PADI4;Rheumatoid arthritis, susceptibility to;17357067;605347;{Rheumatoid arthritis, susceptibility to}, 180300 (3);180300
PAEP;Diabetes, type 1, susceptibility to;17357067;600716;{Diabetes, type 1, susceptibility to}, 222100 (3);222100
PAEP;Rheumatoid arthritis, susceptibility to;17357067;600716;{Rheumatoid arthritis, susceptibility to}, 180300 (3);180300
PAEP;Systemic lupus erythematosus susceptibility to;17357067;600716;{Systemic lupus erythematosus susceptibility to}, 152700 (3);152700
PAF1;Peroxisome biogenesis disorder 5A (Zellweger);17357067;170993;Peroxisome biogenesis disorder 5A (Zellweger), 614866 (3);614866
PAF1;Peroxisome biogenesis disorder 5B;17357067;170993;Peroxisome biogenesis disorder 5B, 614867 (3);614867
PAFAH1B1;Bohring-Opitz syndrome;17357067;612990;Bohring-Opitz syndrome, 605039 (3);605039
PAFAH1B1;Lissencephaly 1;17357067;601545;Lissencephaly 1, 607432 (3);607432
PAFAH1B1;Miller-Dieker lissencephaly syndrome;17357067;247200;Miller-Dieker lissencephaly syndrome (4);0
PAFAH1B1;Myelodysplastic syndrome, somatic;17357067;605590;Myelodysplastic syndrome, somatic, 614286 (3);614286
PAFAH1B1;Subcortical laminar heterotopia;17357067;601545;Subcortical laminar heterotopia, 607432 (3);607432
PAFAH1B1P1;Epilepsy, familial temporal lobe, 7;17357067;600514;{Epilepsy, familial temporal lobe, 7}, 616436 (3);616436
PAFAH1B1P1;Lissencephaly 2 (Norman-Roberts type);17357067;600514;Lissencephaly 2 (Norman-Roberts type), 257320 (3);257320
PAH;Hyperphenylalaninemia, non-PKU mild;17357067;612349;[Hyperphenylalaninemia, non-PKU mild], 261600 (3);261600
PAH;Phenylketonuria;17357067;612349;Phenylketonuria, 261600 (3);261600
PAK3;Mental retardation, X-linked 30/47;17357067;300142;Mental retardation, X-linked 30/47, 300558 (3);300558
PALB2;Breast cancer, susceptibility to;17357067;610355;{Breast cancer, susceptibility to}, 114480 (3);114480
PALB2;Fanconi anemia, complementation group N;17357067;610355;Fanconi anemia, complementation group N, 610832 (3);610832
PALB2;Pancreatic cancer, susceptibility to, 3;17357067;610355;{Pancreatic cancer, susceptibility to, 3}, 613348 (3);613348
PALLD;Pancreatic cancer, susceptibility to, 1;17357067;608092;{Pancreatic cancer, susceptibility to, 1}, 606856 (3);606856
PAM16;Spondylometaphyseal dysplasia, Megarbane-Dagher-Melike type;17357067;614336;Spondylometaphyseal dysplasia, Megarbane-Dagher-Melike type, 613320 (3);613320
PANK2;HARP syndrome;17357067;606157;HARP syndrome, 607236 (3);607236
PANK2;Neurodegeneration with brain iron accumulation 1;17357067;606157;Neurodegeneration with brain iron accumulation 1, 234200 (3);234200
PAPSS2;Brachyolmia 4 with mild epiphyseal and metaphyseal changes;17357067;603005;Brachyolmia 4 with mild epiphyseal and metaphyseal changes, 612847 (3);612847
PARK2;Adenocarcinoma of lung, somatic;17357067;602544;Adenocarcinoma of lung, somatic, 211980 (3);211980
PARK2;Adenocarcinoma, ovarian, somatic;17357067;602544;Adenocarcinoma, ovarian, somatic, 167000 (3);167000
PARK2;Leprosy, susceptibility to;17357067;602544;{Leprosy, susceptibility to}, 607572 (3);607572
PARK2;Parkinson disease, juvenile, type 2;17357067;602544;Parkinson disease, juvenile, type 2, 600116 (3);600116
PARK7;Parkinson disease 7, autosomal recessive early-onset;17357067;602533;Parkinson disease 7, autosomal recessive early-onset, 606324 (3);606324
PARN;Dyskeratosis congenita, autosomal recessive, 6;17357067;604212;Dyskeratosis congenita, autosomal recessive, 6, 616353 (3);616353
PARN;Pulmonary fibrosis and/or bone marrow failure, telomere-related, 4;17357067;604212;Pulmonary fibrosis and/or bone marrow failure, telomere-related, 4, 616371 (3);616371
PAX2;Glomerulosclerosis, focal segmental, 7;17357067;167409;Glomerulosclerosis, focal segmental, 7, 616002 (3);616002
PAX2;Papillorenal syndrome;17357067;167409;Papillorenal syndrome, 120330 (3);120330
PAX2;Renal hypoplasia, isolated;17357067;167409;Renal hypoplasia, isolated, 191830 (3);191830
PAX3;Craniofacial-deafness-hand syndrome;17357067;606597;Craniofacial-deafness-hand syndrome, 122880 (3);122880
PAX3;Rhabdomyosarcoma 2, alveolar;17357067;606597;Rhabdomyosarcoma 2, alveolar, 268220 (3);268220
PAX3;Waardenburg syndrome, type 1;17357067;606597;Waardenburg syndrome, type 1, 193500 (3);193500
PAX3;Waardenburg syndrome, type 3;17357067;606597;Waardenburg syndrome, type 3, 148820 (3);148820
PAX4;Diabetes mellitus, ketosis-prone, susceptibility to;17357067;167413;{Diabetes mellitus, ketosis-prone, susceptibility to}, 612227 (3);612227
PAX4;Diabetes mellitus, type 2;17357067;167413;Diabetes mellitus, type 2, 125853 (3);125853
PAX4;Maturity-onset diabetes of the young, type IX;17357067;167413;Maturity-onset diabetes of the young, type IX, 612225 (3);612225
PAX5;Leukemia, acute lymphoblastic, susceptibility to, 3;17357067;167414;{Leukemia, acute lymphoblastic, susceptibility to, 3}, 615545 (3);615545
PAX6;Aniridia;17357067;607108;Aniridia, 106210 (3);106210
PAX6;Cataract with late-onset corneal dystrophy;17357067;607108;Cataract with late-onset corneal dystrophy, 106210 (3);106210
PAX6;Coloboma of optic nerve;17357067;607108;Coloboma of optic nerve, 120430 (3);120430
PAX6;Coloboma, ocular;17357067;607108;Coloboma, ocular, 120200 (3);120200
PAX6;Foveal hypoplasia 1;17357067;607108;Foveal hypoplasia 1, 136520 (3);136520
PAX6;Gillespie syndrome;17357067;607108;Gillespie syndrome, 206700 (3);206700
PAX6;Keratitis;17357067;607108;Keratitis, 148190 (3);148190
PAX6;Optic nerve hypoplasia;17357067;607108;Optic nerve hypoplasia, 165550 (3);165550
PAX6;Peters anomaly;17357067;607108;Peters anomaly, 604229 (3);604229
PAX7;Rhabdomyosarcoma 2, alveolar;17357067;167410;Rhabdomyosarcoma 2, alveolar, 268220 (3);268220
PAX8;Hypothyroidism, congenital, due to thyroid dysgenesis or hypoplasia;17357067;167415;Hypothyroidism, congenital, due to thyroid dysgenesis or hypoplasia, 218700 (3);218700
PAX9;Tooth agenesis, selective, 3;17357067;167416;Tooth agenesis, selective, 3, 604625 (3);604625
PAXIP1;Alzheimer disease, susceptibility to;17357067;608254;{Alzheimer disease, susceptibility to}, 104300 (3);104300
PBX1;Leukemia, acute pre-B-cell;17357067;176310;Leukemia, acute pre-B-cell (2);0
PC;Pyruvate carboxylase deficiency;17357067;608786;Pyruvate carboxylase deficiency, 266150 (3);266150
PC;Thrombophilia due to protein C deficiency, autosomal dominant;17357067;612283;Thrombophilia due to protein C deficiency, autosomal dominant, 176860 (3);176860
PC;Thrombophilia due to protein C deficiency, autosomal recessive;17357067;612283;Thrombophilia due to protein C deficiency, autosomal recessive, 612304 (3);612304
PCBD1;Hyperphenylalaninemia, BH4-deficient, D;17357067;126090;Hyperphenylalaninemia, BH4-deficient, D, 264070 (3);264070
PCCA;Propionicacidemia;17357067;232000;Propionicacidemia, 606054 (3);606054
PCCB;Propionicacidemia;17357067;232050;Propionicacidemia, 606054 (3);606054
PCDH15;Deafness, autosomal recessive 23;17357067;605514;Deafness, autosomal recessive 23, 609533 (3);609533
PCDH15;Usher syndrome, type 1D/F digenic;17357067;605514;Usher syndrome, type 1D/F digenic, 601067 (3);601067
PCDH15;Usher syndrome, type 1F;17357067;605514;Usher syndrome, type 1F, 602083 (3);602083
PCDH19;Epileptic encephalopathy, early infantile, 9;17357067;300460;Epileptic encephalopathy, early infantile, 9, 300088 (3);300088
PCK2;PEPCK deficiency, mitochondrial;17357067;614095;PEPCK deficiency, mitochondrial, 261650 (1);261650
PCM1;Thyroid carcinoma, papillary;17357067;600299;Thyroid carcinoma, papillary, 188550 (3);188550
PCNT;Microcephalic osteodysplastic primordial dwarfism, type II;17357067;605925;Microcephalic osteodysplastic primordial dwarfism, type II, 210720 (3);210720
PCSK1;Obesity with impaired prohormone processing;17357067;162150;Obesity with impaired prohormone processing, 600955 (3);600955
PCSK1;Obesity, susceptibility to, BMIQ12;17357067;162150;{Obesity, susceptibility to, BMIQ12}, 612362 (3);612362
PCSK1;Pachyonychia congenita 1;17357067;148067;Pachyonychia congenita 1, 167200 (3);167200
PCSK1;Palmoplantar keratoderma, nonepidermolytic, focal;17357067;148067;Palmoplantar keratoderma, nonepidermolytic, focal, 613000 (3);613000
PCSK9;Hypercholesterolemia, familial, 3;17357067;607786;Hypercholesterolemia, familial, 3, 603776 (3);603776
PCSK9;Low density lipoprotein cholesterol level QTL 1;17357067;607786;{Low density lipoprotein cholesterol level QTL 1}, 603776 (3);603776
PCYT1A;Spondylometaphyseal dysplasia with cone-rod dystrophy;17357067;123695;Spondylometaphyseal dysplasia with cone-rod dystrophy, 608940 (3);608940
PDC;Paroxysmal nonkinesigenic dyskinesia;17357067;609023;Paroxysmal nonkinesigenic dyskinesia, 118800 (3);118800
PDCD1;Multiple sclerosis, disease progression, modifier of;17357067;600244;{Multiple sclerosis, disease progression, modifier of}, 126200 (3);126200
PDCD1;Systemic lupus erythematosus, susceptibility to, 2;17357067;600244;{Systemic lupus erythematosus, susceptibility to, 2}, 605218 (3);605218
PDCD10;Cerebral cavernous malformations 3;17357067;609118;Cerebral cavernous malformations 3, 603285 (3);603285
PDE11A;Pigmented nodular adrenocortical disease, primary, 2;17357067;604961;Pigmented nodular adrenocortical disease, primary, 2, 610475 (3);610475
PDE3A;Hypertension and brachydactyly syndrome;17357067;123805;Hypertension and brachydactyly syndrome, 112410 (3);112410
PDE4D;Acrodysostosis 2, with or without hormone resistance;17357067;600129;Acrodysostosis 2, with or without hormone resistance, 614613 (3);614613
PDE4D;Stroke, susceptibility to, 1;17357067;600129;{Stroke, susceptibility to, 1}, 606799 (3);606799
PDE6A;Retinitis pigmentosa 43;17357067;180071;Retinitis pigmentosa 43, 613810 (3);613810
PDE6B;Night blindness, congenital stationary, autosomal dominant 2;17357067;180072;Night blindness, congenital stationary, autosomal dominant 2, 163500 (3);163500
PDE6B;Retinitis pigmentosa-40;17357067;180072;Retinitis pigmentosa-40, 613801 (3);613801
PDE6C;Cone dystrophy 4;17357067;600827;Cone dystrophy 4, 613093 (3);613093
PDE6G;Retinitis pigmentosa 57;17357067;180073;Retinitis pigmentosa 57, 613582 (3);613582
PDE6H;Achromatopsia 6;17357067;601190;Achromatopsia 6, 610024 (3);610024
PDE6H;Retinal cone dystrophy 3;17357067;601190;Retinal cone dystrophy 3, 610024 (3);610024
PDE8B;Pigmented nodular adrenocortical disease, primary, 3;17357067;603390;Pigmented nodular adrenocortical disease, primary, 3, 614190 (3);614190
PDE8B;Striatal degeneration, autosomal dominant;17357067;603390;Striatal degeneration, autosomal dominant, 609161 (3);609161
PDGFB;Basal ganglia calcification, idiopathic, 5;17357067;190040;Basal ganglia calcification, idiopathic, 5, 615483 (3);615483
PDGFB;Dermatofibrosarcoma protuberans;17357067;190040;Dermatofibrosarcoma protuberans, 607907 (3);607907
PDGFB;Meningioma, SIS-related;17357067;190040;Meningioma, SIS-related, 607174 (3);607174
PDGFRA;Gastrointestinal stromal tumor, somatic;17357067;173490;Gastrointestinal stromal tumor, somatic, 606764 (3);606764
PDGFRA;Hypereosinophilic syndrome, idiopathic, resistant to imatinib;17357067;173490;Hypereosinophilic syndrome, idiopathic, resistant to imatinib, 607685 (3);607685
PDGFRB;Basal ganglia calcification, idiopathic, 4;17357067;173410;Basal ganglia calcification, idiopathic, 4, 615007 (3);615007
PDGFRB;Myeloproliferative disorder with eosinophilia;17357067;173410;Myeloproliferative disorder with eosinophilia, 131440 (4);131440
PDGFRB;Myofibromatosis, infantile, 1;17357067;173410;Myofibromatosis, infantile, 1, 228550 (3);228550
PDGFRL;Colorectal cancer, somatic;17357067;604584;Colorectal cancer, somatic, 114500 (3);114500
PDGFRL;Hepatocellular cancer, somatic;17357067;604584;Hepatocellular cancer, somatic, 114550 (3);114550
PDHA1;Pyruvate dehydrogenase E1-alpha deficiency;17357067;300502;Pyruvate dehydrogenase E1-alpha deficiency, 312170 (3);312170
PDHB;Pyruvate dehydrogenase E1-beta deficiency;17357067;179060;Pyruvate dehydrogenase E1-beta deficiency, 614111 (3);614111
PDLIM4;Osteoporosis, susceptibility to;17357067;603422;{Osteoporosis, susceptibility to}, 166710 (3);166710
PDP1;Pyruvate dehydrogenase phosphatase deficiency;17357067;605993;Pyruvate dehydrogenase phosphatase deficiency, 608782 (3);608782
PDSS1;Coenzyme Q10 deficiency, primary, 2;17357067;607429;Coenzyme Q10 deficiency, primary, 2, 614651 (3);614651
PDSS2;Coenzyme Q10 deficiency, primary, 3;17357067;610564;Coenzyme Q10 deficiency, primary, 3, 614652 (3);614652
PDX1;Diabetes mellitus, type II, susceptibility to;17357067;600733;{Diabetes mellitus, type II, susceptibility to}, 125853 (3);125853
PDX1;Lacticacidemia due to PDX1 deficiency;17357067;608769;Lacticacidemia due to PDX1 deficiency, 245349 (3);245349
PDX1;MODY, type IV;17357067;600733;MODY, type IV, 606392 (3);606392
PDX1;Pancreatic agenesis 1;17357067;600733;Pancreatic agenesis 1, 260370 (3);260370
PDYN;Spinocerebellar ataxia 23;17357067;131340;Spinocerebellar ataxia 23, 610245 (3);610245
PDZD7;Retinal disease in Usher syndrome type IIA, modifier of;17357067;612971;{Retinal disease in Usher syndrome type IIA, modifier of}, 276901 (3);276901
PDZD7;Usher syndrome, type IIC, GPR98/PDZD7 digenic;17357067;612971;Usher syndrome, type IIC, GPR98/PDZD7 digenic, 605472 (3);605472
PEA15;Albinism, brown oculocutaneous;17357067;611409;Albinism, brown oculocutaneous, 203200 (3);203200
PEA15;Albinism, oculocutaneous, type II;17357067;611409;Albinism, oculocutaneous, type II, 203200 (3);203200
PEA15;Dystonia 9;17357067;138140;Dystonia 9, 601042 (3);601042
PEA15;Epilepsy, idiopathic generalized, suscpetibility to, 12;17357067;138140;{Epilepsy, idiopathic generalized, suscpetibility to, 12}, 614847 (3);614847
PEA15;GLUT1 deficiency syndrome 1;17357067;138140;GLUT1 deficiency syndrome 1, 606777 (3);606777
PEA15;GLUT1 deficiency syndrome 2;17357067;138140;GLUT1 deficiency syndrome 2, 612126 (3);612126
PEA15;Skin/hair/eye pigmentation 1, blond/brown hair;17357067;611409;[Skin/hair/eye pigmentation 1, blond/brown hair], 227220 (3);227220
PEA15;Skin/hair/eye pigmentation 1, blue/nonblue eyes;17357067;611409;[Skin/hair/eye pigmentation 1, blue/nonblue eyes], 227220 (3);227220
PEPD;Prolidase deficiency;17357067;613230;Prolidase deficiency, 170100 (3);170100
PER2;Advanced sleep phase syndrome, familial, 1;17357067;603426;Advanced sleep phase syndrome, familial, 1, 604348 (3);604348
PET100;Mitochondrial complex IV deficiency;17357067;614770;Mitochondrial complex IV deficiency, 220110 (3);220110
PEX1;Peroxisome biogenesis disorder 11A (Zellweger);17357067;601789;Peroxisome biogenesis disorder 11A (Zellweger), 614883 (3);614883
PEX1;Peroxisome biogenesis disorder 11B;17357067;601789;Peroxisome biogenesis disorder 11B, 614885 (3);614885
PEX1;Peroxisome biogenesis disorder 1A (Zellweger);17357067;602136;Peroxisome biogenesis disorder 1A (Zellweger), 214100 (3);214100
PEX1;Peroxisome biogenesis disorder 1B (NALD/IRD);17357067;602136;Peroxisome biogenesis disorder 1B (NALD/IRD), 601539 (3);601539
PEX10;Peroxisome biogenesis disorder 6A (Zellweger);17357067;602859;Peroxisome biogenesis disorder 6A (Zellweger), 614870 (3);614870
PEX10;Peroxisome biogenesis disorder 6B;17357067;602859;Peroxisome biogenesis disorder 6B, 614871 (3);614871
PEX11B;Peroxisome biogenesis disorder 14B;17357067;603867;Peroxisome biogenesis disorder 14B, 614920 (3);614920
PEX12;Peroxisome biogenesis disorder 3A (Zellweger);17357067;601758;Peroxisome biogenesis disorder 3A (Zellweger), 614859 (3);614859
PEX12;Peroxisome biogenesis disorder 3B;17357067;601758;Peroxisome biogenesis disorder 3B, 266510 (3);266510
PEX13;Peroxisome biogenesis disorder 11A (Zellweger);17357067;601789;Peroxisome biogenesis disorder 11A (Zellweger), 614883 (3);614883
PEX13;Peroxisome biogenesis disorder 11B;17357067;601789;Peroxisome biogenesis disorder 11B, 614885 (3);614885
PEX14;Peroxisome biogenesis disorder 13A (Zellweger);17357067;601791;Peroxisome biogenesis disorder 13A (Zellweger), 614887 (3);614887
PEX16;Peroxisome biogenesis disorder 8A, (Zellweger);17357067;603360;Peroxisome biogenesis disorder 8A, (Zellweger), 614876 (3);614876
PEX16;Peroxisome biogenesis disorder 8B;17357067;603360;Peroxisome biogenesis disorder 8B, 614877 (3);614877
PEX19;Peroxisome biogenesis disorder 12A (Zellweger);17357067;600279;Peroxisome biogenesis disorder 12A (Zellweger), 614886 (3);614886
PEX2;Peroxisome biogenesis disorder 5A (Zellweger);17357067;170993;Peroxisome biogenesis disorder 5A (Zellweger), 614866 (3);614866
PEX2;Peroxisome biogenesis disorder 5B;17357067;170993;Peroxisome biogenesis disorder 5B, 614867 (3);614867
PEX26;Peroxisome biogenesis disorder 7A (Zellweger);17357067;608666;Peroxisome biogenesis disorder 7A (Zellweger), 614872 (3);614872
PEX26;Peroxisome biogenesis disorder 7B;17357067;608666;Peroxisome biogenesis disorder 7B, 614873 (3);614873
PEX3;Peroxisome biogenesis disorder 10A (Zellweger);17357067;603164;Peroxisome biogenesis disorder 10A (Zellweger), 614882 (3);614882
PEX5;Peroxisome biogenesis disorder 2A (Zellweger);17357067;600414;Peroxisome biogenesis disorder 2A (Zellweger), 214110 (3);214110
PEX5;Peroxisome biogenesis disorder 2B;17357067;600414;Peroxisome biogenesis disorder 2B, 202370 (3);202370
PEX6;Peroxisome biogenesis disorder 4A (Zellweger);17357067;601498;Peroxisome biogenesis disorder 4A (Zellweger), 614862 (3);614862
PEX6;Peroxisome biogenesis disorder 4B;17357067;601498;Peroxisome biogenesis disorder 4B, 614863 (3);614863
PEX7;Chondrodysplasia punctata, rhizomelic, type 1;17357067;601757;Chondrodysplasia punctata, rhizomelic, type 1, 215100 (3);215100
PEX7;Peroxisome biogenesis disorder 9B;17357067;601757;Peroxisome biogenesis disorder 9B, 614879 (3);614879
PFKL;Hemolytic anemia due to phosphofructokinase deficiency;17357067;171860;Hemolytic anemia due to phosphofructokinase deficiency (1);0
PFKM;Glycogen storage disease VII;17357067;610681;Glycogen storage disease VII, 232800 (3);232800
PFN1;Amyotrophic lateral sclerosis 18;17357067;176610;Amyotrophic lateral sclerosis 18, 614808 (3);614808
PGAM2;Glycogen storage disease X;17357067;612931;Glycogen storage disease X, 261670 (3);261670
PGAP2;Hyperphosphatasia with mental retardation syndrome 3;17357067;615187;Hyperphosphatasia with mental retardation syndrome 3, 614207 (3);614207
PGAP3;Hyperphosphatasia with mental retardation syndrome 4;17357067;611801;Hyperphosphatasia with mental retardation syndrome 4, 615716 (3);615716
PGK1;Phosphoglycerate kinase 1 deficiency;17357067;311800;Phosphoglycerate kinase 1 deficiency, 300653 (3);300653
PGM1;Congenital disorder of glycosylation, type It;17357067;171900;Congenital disorder of glycosylation, type It, 614921 (3);614921
PGM3;Agammaglobulinemia 1;17357067;147020;Agammaglobulinemia 1, 601495 (3);601495
PGM3;Immunodeficiency 23;17357067;172100;Immunodeficiency 23, 615816 (3);615816
PHB;Breast cancer, susceptibility to;17357067;176705;{Breast cancer, susceptibility to}, 114480 (3);114480
PHEX;Hypophosphatemic rickets, X-linked dominant;17357067;300550;Hypophosphatemic rickets, X-linked dominant, 307800 (3);307800
PHF11;Asthma;17357067;607796;{Asthma}, 600807 (3);600807
PHF11;IgE levels QTL;17357067;607796;[IgE levels QTL], 147050 (3);147050
PHF6;Borjeson-Forssman-Lehmann syndrome;17357067;300414;Borjeson-Forssman-Lehmann syndrome, 301900 (3);301900
PHF8;Mental retardation syndrome, X-linked, Siderius type;17357067;300560;Mental retardation syndrome, X-linked, Siderius type, 300263 (3);300263
PHGDH;Neu-Laxova syndrome1;17357067;606879;Neu-Laxova syndrome1, 256520 (3);256520
PHGDH;Phosphoglycerate dehydrogenase deficiency;17357067;606879;Phosphoglycerate dehydrogenase deficiency, 601815 (3);601815
PHKA1;Muscle glycogenosis;17357067;311870;Muscle glycogenosis, 300559 (3);300559
PHKA2;Glycogen storage disease, type IXa1;17357067;300798;Glycogen storage disease, type IXa1, 306000 (3);306000
PHKA2;Glycogen storage disease, type IXa2;17357067;300798;Glycogen storage disease, type IXa2, 306000 (3);306000
PHKB;Phosphorylase kinase deficiency of liver and muscle, autosomal recessive;17357067;172490;Phosphorylase kinase deficiency of liver and muscle, autosomal recessive, 261750 (3);261750
PHKG2;Cirrhosis due to liver phosphorylase kinase deficiency;17357067;172471;Cirrhosis due to liver phosphorylase kinase deficiency (3);0
PHKG2;Glycogen storage disease IXc;17357067;172471;Glycogen storage disease IXc, 613027 (3);613027
PHOX2A;Fibrosis of extraocular muscles, congenital, 2;17357067;602753;Fibrosis of extraocular muscles, congenital, 2, 602078 (3);602078
PHOX2B;Central hypoventilation syndrome, congenital, with or without Hirschsprung disease;17357067;603851;Central hypoventilation syndrome, congenital, with or without Hirschsprung disease, 209880 (3);209880
PHOX2B;Neuroblastoma with Hirschsprung disease;17357067;603851;Neuroblastoma with Hirschsprung disease, 613013 (3);613013
PHOX2B;Neuroblastoma, susceptibility to, 2;17357067;603851;{Neuroblastoma, susceptibility to, 2}, 613013 (3);613013
PHYH;Refsum disease;17357067;602026;Refsum disease, 266500 (3);266500
PICALM;Leukemia, acute T-cell lymphoblastic;17357067;603025;Leukemia, acute T-cell lymphoblastic (3);0
PICALM;Leukemia, acute myeloid;17357067;603025;Leukemia, acute myeloid, 601626 (3);601626
PIEZO1;Dehydrated hereditary stomatocytosis with or without pseudohyperkalemia and/or perinatal edema;17357067;611184;Dehydrated hereditary stomatocytosis with or without pseudohyperkalemia and/or perinatal edema, 194380 (3);194380
PIEZO2;Arthrogryposis, distal, type 3;17357067;613629;Arthrogryposis, distal, type 3, 114300 (3);114300
PIEZO2;Arthrogryposis, distal, type 5;17357067;613629;Arthrogryposis, distal, type 5, 108145 (3);108145
PIGA;Multiple congenital anomalies-hypotonia-seizures syndrome 2;17357067;311770;Multiple congenital anomalies-hypotonia-seizures syndrome 2, 300868 (3);300868
PIGA;Paroxysmal nocturnal hemoglobinuria, somatic;17357067;311770;Paroxysmal nocturnal hemoglobinuria, somatic, 300818 (3);300818
PIGL;CHIME syndrome;17357067;605947;CHIME syndrome, 280000 (3);280000
PIGM;Glycosylphosphatidylinositol deficiency;17357067;610273;Glycosylphosphatidylinositol deficiency, 610293 (3);610293
PIGN;Multiple congenital anomalies-hypotonia-seizures syndrome 1;17357067;606097;Multiple congenital anomalies-hypotonia-seizures syndrome 1, 614080 (3);614080
PIGO;Hyperphosphatasia with mental retardation syndrome 2;17357067;614730;Hyperphosphatasia with mental retardation syndrome 2, 614749 (3);614749
PIGV;Hyperphosphatasia with mental retardation syndrome 1;17357067;610274;Hyperphosphatasia with mental retardation syndrome 1, 239300 (3);239300
PIK3CA;Breast cancer, somatic;17357067;171834;Breast cancer, somatic, 114480 (3);114480
PIK3CA;CLOVE syndrome, somatic;17357067;171834;CLOVE syndrome, somatic, 612918 (3);612918
PIK3CA;Colorectal cancer, somatic;17357067;171834;Colorectal cancer, somatic, 114500 (3);114500
PIK3CA;Cowden syndrome 5;17357067;171834;Cowden syndrome 5, 615108 (3);615108
PIK3CA;Gastric cancer, somatic;17357067;171834;Gastric cancer, somatic, 613659 (3);613659
PIK3CA;Hepatocellular carcinoma, somatic;17357067;171834;Hepatocellular carcinoma, somatic, 114550 (3);114550
PIK3CA;Keratosis, seborrheic, somatic;17357067;171834;Keratosis, seborrheic, somatic, 182000 (3);182000
PIK3CA;Megalencephaly-capillary malformation-polymicrogyria syndrome, somatic;17357067;171834;Megalencephaly-capillary malformation-polymicrogyria syndrome, somatic, 602501 (3);602501
PIK3CA;Nevus, epidermal, somatic;17357067;171834;Nevus, epidermal, somatic, 162900 (3);162900
PIK3CA;Nonsmall cell lung cancer, somatic;17357067;171834;Nonsmall cell lung cancer, somatic, 211980 (3);211980
PIK3CA;Ovarian cancer, somatic;17357067;171834;Ovarian cancer, somatic, 167000 (3);167000
PIK3CD;Immunodeficiency 14;17357067;602839;Immunodeficiency 14, 615513 (3);615513
PIK3R1;Immunodeficiency 36;17357067;171833;Immunodeficiency 36, 616005 (3);616005
PIK3R1;SHORT syndrome;17357067;171833;SHORT syndrome, 269880 (3);269880
PIK3R2;Megalencephaly-polymicrogyria-polydactyly-hydrocephalus syndrome 1;17357067;603157;Megalencephaly-polymicrogyria-polydactyly-hydrocephalus syndrome 1, 603387 (3);603387
PIK3R5;Ataxia-oculomotor apraxia 3;17357067;611317;Ataxia-oculomotor apraxia 3, 615217 (3);615217
PIKFYVE;Corneal fleck dystrophy;17357067;609414;Corneal fleck dystrophy, 121850 (3);121850
PINK1;Parkinson disease 6, early onset;17357067;608309;Parkinson disease 6, early onset, 605909 (3);605909
PIP5K1C;Lethal congenital contractural syndrome 3;17357067;606102;Lethal congenital contractural syndrome 3, 611369 (3);611369
PITPNM3;Cone-rod dystrophy 5;17357067;608921;Cone-rod dystrophy 5, 600977 (3);600977
PITX1;Clubfoot, congenital, with or without deficiency of long bones and/or mirror-image polydactyly;17357067;602149;Clubfoot, congenital, with or without deficiency of long bones and/or mirror-image polydactyly, 119800 (3);119800
PITX1;Liebenberg syndrome;17357067;602149;Liebenberg syndrome, 186550 (4);186550
PITX2;Axenfeld-Rieger syndrome, type 1;17357067;601542;Axenfeld-Rieger syndrome, type 1, 180500 (3);180500
PITX2;Iridogoniodysgenesis, type 2;17357067;601542;Iridogoniodysgenesis, type 2, 137600 (3);137600
PITX2;Peters anomaly;17357067;601542;Peters anomaly, 604229 (3);604229
PITX2;Ring dermoid of cornea;17357067;601542;Ring dermoid of cornea, 180550 (3);180550
PITX3;Anterior segment mesenchymal dysgenesis;17357067;601094;Anterior segment mesenchymal dysgenesis, 107250 (3);107250
PITX3;Aphakia, congenital primary;17357067;601094;Aphakia, congenital primary, 610256 (3);610256
PITX3;Cataract 11, multiple types;17357067;602669;Cataract 11, multiple types, 610623 (3);610623
PITX3;Cataract 11, syndromic;17357067;602669;Cataract 11, syndromic, 610623 (3);610623
PKD1;Polycystic kidney disease, adult type I;17357067;601313;Polycystic kidney disease, adult type I, 173900 (3);173900
PKD2;Polycystic kidney disease 2;17357067;173910;Polycystic kidney disease 2, 613095 (3);613095
PKHD1;Polycystic kidney and hepatic disease;17357067;606702;Polycystic kidney and hepatic disease, 263200 (3);263200
PKLR;Adenosine triphosphate, elevated, of erythrocytes;17357067;609712;Adenosine triphosphate, elevated, of erythrocytes, 102900 (3);102900
PKLR;Pyruvate kinase deficiency;17357067;609712;Pyruvate kinase deficiency, 266200 (3);266200
PKP1;Ectodermal dysplasia/skin fragility syndrome;17357067;601975;Ectodermal dysplasia/skin fragility syndrome, 604536 (3);604536
PKP2;Arrhythmogenic right ventricular dysplasia 9;17357067;602861;Arrhythmogenic right ventricular dysplasia 9, 609040 (3);609040
PLA2G2A;Colorectal cancer;17357067;172411;{Colorectal cancer}, 114500 (3);114500
PLA2G4A;Phospholipase A2, group IV A, deficiency of;17357067;600522;Phospholipase A2, group IV A, deficiency of (3);0
PLA2G5;Fleck retina, familial benign;17357067;601192;[Fleck retina, familial benign], 228980 (3);228980
PLA2G6;Infantile neuroaxonal dystrophy 1;17357067;603604;Infantile neuroaxonal dystrophy 1, 256600 (3);256600
PLA2G6;Neurodegeneration with brain iron accumulation 2B;17357067;603604;Neurodegeneration with brain iron accumulation 2B, 610217 (3);610217
PLA2G6;Parkinson disease 14, autosomal recessive;17357067;603604;Parkinson disease 14, autosomal recessive, 612953 (3);612953
PLA2G7;Asthma, susceptibility to;17357067;601690;{Asthma, susceptibility to}, 600807 (3);600807
PLA2G7;Atopy, susceptibility to;17357067;601690;{Atopy, susceptibility to}, 147050 (3);147050
PLA2G7;Platelet-activating factor acetylhydrolase deficiency;17357067;601690;Platelet-activating factor acetylhydrolase deficiency, 614278 (3);614278
PLAG1;Adenomas, salivary gland pleomorphic;17357067;603026;Adenomas, salivary gland pleomorphic, 181030 (3);181030
PLAGL1;Diabetes mellitus, transient neonatal;17357067;603044;{Diabetes mellitus, transient neonatal}, 601410 (1);601410
PLAT;Hyperfibrinolysis, familial, due to increased release of PLAT;17357067;173370;Hyperfibrinolysis, familial, due to increased release of PLAT, 612348 (1);612348
PLAT;Thrombophilia, familial, due to decreased release of PLAT;17357067;173370;Thrombophilia, familial, due to decreased release of PLAT, 612348 (1);612348
PLAU;Alzheimer disease, late-onset, susceptibility to;17357067;191840;{Alzheimer disease, late-onset, susceptibility to}, 104300 (3);104300
PLAU;Quebec platelet disorder;17357067;191840;Quebec platelet disorder, 601709 (3);601709
PLCB1;Epileptic encephalopathy, early infantile, 12;17357067;607120;Epileptic encephalopathy, early infantile, 12, 613722 (3);613722
PLCB2;Platelet PLC beta-2 deficiency;17357067;604114;Platelet PLC beta-2 deficiency (1);0
PLCB4;Auriculocondylar syndrome 2;17357067;600810;Auriculocondylar syndrome 2, 614669 (3);614669
PLCD1;Nail disorder, nonsyndromic congenital, 3, (leukonychia);17357067;602142;Nail disorder, nonsyndromic congenital, 3, (leukonychia), 151600 (3);151600
PLCE1;Nephrotic syndrome, type 3;17357067;608414;Nephrotic syndrome, type 3, 610725 (3);610725
PLCG2;Autoinflammation, antibody deficiency, and immune dysregulation syndrome;17357067;600220;Autoinflammation, antibody deficiency, and immune dysregulation syndrome, 614878 (3);614878
PLCG2;Familial cold autoinflammatory syndrome 3;17357067;600220;Familial cold autoinflammatory syndrome 3, 614468 (3);614468
PLD3;Alzheimer disease 19, late onset, susceptibility to;17357067;615698;{Alzheimer disease 19, late onset, susceptibility to}, 615711 (3);615711
PLEC;Epidermolysis bullosa simplex with muscular dystrophy;17357067;601282;Epidermolysis bullosa simplex with muscular dystrophy, 226670 (3);226670
PLEC;Epidermolysis bullosa simplex with pyloric atresia;17357067;601282;Epidermolysis bullosa simplex with pyloric atresia, 612138 (3);612138
PLEC;Epidermolysis bullosa simplex, Ogna type;17357067;601282;Epidermolysis bullosa simplex, Ogna type, 131950 (3);131950
PLEC;Muscular dystrophy, limb-girdle, type 2Q;17357067;601282;Muscular dystrophy, limb-girdle, type 2Q, 613723 (3);613723
PLEKHA1;Age-related maculopathy, susceptibility to;17357067;607772;{Age-related maculopathy, susceptibility to}, 603075 (2);603075
PLEKHG4;Spinocerebellar ataxia 4;17357067;600223;Spinocerebellar ataxia 4 (2);0
PLEKHG5;Charcot-Marie-Tooth disease, recessive intermediate C;17357067;611101;Charcot-Marie-Tooth disease, recessive intermediate C, 615376 (3);615376
PLEKHG5;Spinal muscular atrophy, distal, autosomal recessive, 4;17357067;611101;Spinal muscular atrophy, distal, autosomal recessive, 4, 611067 (3);611067
PLEKHM1;Osteopetrosis, autosomal recessive 6;17357067;611466;Osteopetrosis, autosomal recessive 6, 611497 (3);611497
PLG;Dysplasminogenemia;17357067;173350;Dysplasminogenemia, 217090 (3);217090
PLG;Plasminogen deficiency, type I;17357067;173350;Plasminogen deficiency, type I, 217090 (3);217090
PLIN1;Lipodystrophy, familial partial, type 4;17357067;170290;Lipodystrophy, familial partial, type 4, 613877 (3);613877
PLK4;Microcephaly and chorioretinopathy, autosomal recessive, 2;17357067;605031;Microcephaly and chorioretinopathy, autosomal recessive, 2, 616171 (3);616171
PLN;Cardiomyopathy, dilated, 1P;17357067;172405;Cardiomyopathy, dilated, 1P, 609909 (3);609909
PLN;Cardiomyopathy, hypertrophic, 18;17357067;172405;Cardiomyopathy, hypertrophic, 18, 613874 (3);613874
PLOD1;Ehlers-Danlos syndrome, type VI;17357067;153454;Ehlers-Danlos syndrome, type VI, 225400 (3);225400
PLOD2;Bruck syndrome 2;17357067;601865;Bruck syndrome 2, 609220 (3);609220
PLOD3;Lysyl hydroxylase 3 deficiency;17357067;603066;Lysyl hydroxylase 3 deficiency, 612394 (3);612394
PLP1;Pelizaeus-Merzbacher disease;17357067;300401;Pelizaeus-Merzbacher disease, 312080 (3);312080
PLP1;Spastic paraplegia 2, X-linked;17357067;300401;Spastic paraplegia 2, X-linked, 312920 (3);312920
PLS3;Bone mineral density QTL18, osteoporosis;17357067;300131;Bone mineral density QTL18, osteoporosis, 300910 (3);300910
PLTP;High density lipoprotein cholesterol level QTL 9;17357067;172425;[High density lipoprotein cholesterol level QTL 9] (3);0
PML;Leukemia, acute promyelocytic, PML/RARA type;17357067;102578;Leukemia, acute promyelocytic, PML/RARA type (3);0
PMM2;Congenital disorder of glycosylation, type Ia;17357067;601785;Congenital disorder of glycosylation, type Ia, 212065 (3);212065
PMM2;Congenital disorder of glycosylation, type Ib;17357067;154550;Congenital disorder of glycosylation, type Ib, 602579 (3);602579
PMP22;Charcot-Marie-Tooth disease, type 1A;17357067;601097;Charcot-Marie-Tooth disease, type 1A, 118220 (3);118220
PMP22;Charcot-Marie-Tooth disease, type 1E;17357067;601097;Charcot-Marie-Tooth disease, type 1E, 118300 (3);118300
PMP22;Dejerine-Sottas disease;17357067;601097;Dejerine-Sottas disease, 145900 (3);145900
PMP22;Neuropathy, inflammatory demyelinating;17357067;601097;Neuropathy, inflammatory demyelinating, 139393 (3);139393
PMP22;Neuropathy, recurrent, with pressure palsies;17357067;601097;Neuropathy, recurrent, with pressure palsies, 162500 (3);162500
PMP22;Roussy-Levy syndrome;17357067;601097;Roussy-Levy syndrome, 180800 (3);180800
PMS2;Colorectal cancer, hereditary nonpolyposis, type 4;17357067;600259;Colorectal cancer, hereditary nonpolyposis, type 4, 614337 (3);614337
PMS2;Mismatch repair cancer syndrome;17357067;600259;Mismatch repair cancer syndrome, 276300 (3);276300
PNKD;Paroxysmal nonkinesigenic dyskinesia;17357067;609023;Paroxysmal nonkinesigenic dyskinesia, 118800 (3);118800
PNKP;Ataxia-oculomotor apraxia 4;17357067;605610;Ataxia-oculomotor apraxia 4, 616267 (3);616267
PNKP;Microcephaly, seizures, and developmental delay;17357067;605610;Microcephaly, seizures, and developmental delay, 613402 (3);613402
PNLIP;Pancreatic lipase deficiency;17357067;246600;Pancreatic lipase deficiency, 614338 (1);614338
PNP;Immunodeficiency due to purine nucleoside phosphorylase deficiency;17357067;164050;Immunodeficiency due to purine nucleoside phosphorylase deficiency, 613179 (3);613179
PNPLA1;Ichthyosis, congenital, autosomal recessive 10;17357067;612121;Ichthyosis, congenital, autosomal recessive 10, 615024 (3);615024
PNPLA2;Neutral lipid storage disease with myopathy;17357067;609059;Neutral lipid storage disease with myopathy, 610717 (3);610717
PNPLA6;Boucher-Neuhauser syndrome;17357067;603197;Boucher-Neuhauser syndrome, 215470 (3);215470
PNPLA6;Capillary malformations, congenital, 1, somatic, mosaic;17357067;600998;Capillary malformations, congenital, 1, somatic, mosaic, 163000 (3);163000
PNPLA6;Oliver-McFarlane syndrome;17357067;603197;Oliver-McFarlane syndrome, 275400 (3);275400
PNPLA6;Spastic paraplegia 39, autosomal recessive;17357067;603197;Spastic paraplegia 39, autosomal recessive, 612020 (3);612020
PNPLA6;Sturge-Weber syndrome, somatic, mosaic;17357067;600998;Sturge-Weber syndrome, somatic, mosaic, 185300 (3);185300
PNPLA6;Stuve-Wiedemann syndrome/Schwartz-Jampel type 2 syndrome;17357067;151443;Stuve-Wiedemann syndrome/Schwartz-Jampel type 2 syndrome, 601559 (3);601559
PNPO;Pyridoxamine 5'-phosphate oxidase deficiency;17357067;603287;Pyridoxamine 5'-phosphate oxidase deficiency, 610090 (3);610090
PNPT1;Combined oxidative phosphorylation deficiency 13;17357067;610316;Combined oxidative phosphorylation deficiency 13, 614932 (3);614932
PNPT1;Deafness, autosomal recessive 70;17357067;610316;Deafness, autosomal recessive 70, 614934 (3);614934
POC1A;Short stature, onychodysplasia, facial dysmorphism, and hypotrichosis;17357067;614783;Short stature, onychodysplasia, facial dysmorphism, and hypotrichosis, 614813 (3);614813
POC1B;Cone-rod dystrophy 20;17357067;614784;Cone-rod dystrophy 20, 615973 (3);615973
POF1B;Premature ovarian failure 2B;17357067;300603;Premature ovarian failure 2B, 300604 (3);300604
POFUT1;Dowling-Degos disease 2;17357067;607491;Dowling-Degos disease 2, 615327 (3);615327
POGLUT1;Dowling-Degos disease 4;17357067;615618;Dowling-Degos disease 4, 615696 (3);615696
POGZ;Mental retardation, autosomal dominant 37;17357067;614787;Mental retardation, autosomal dominant 37, 616364 (3);616364
POLD1;Colorectal cancer, susceptibility to, 10;17357067;174761;{Colorectal cancer, susceptibility to, 10}, 612591 (3);612591
POLD1;Mandibular hypoplasia, deafness, progeroid features, and lipodystrophy syndrome;17357067;174761;Mandibular hypoplasia, deafness, progeroid features, and lipodystrophy syndrome, 615381 (3);615381
POLE;Colorectal cancer, susceptibility to, 12;17357067;174762;{Colorectal cancer, susceptibility to, 12}, 615083 (3);615083
POLE;FILS syndrome;17357067;174762;FILS syndrome, 615139 (3);615139
POLG;Mitochondrial DNA depletion syndrome 4A (Alpers type);17357067;174763;Mitochondrial DNA depletion syndrome 4A (Alpers type), 203700 (3);203700
POLG;Mitochondrial DNA depletion syndrome 4B (MNGIE type);17357067;174763;Mitochondrial DNA depletion syndrome 4B (MNGIE type), 613662 (3);613662
POLG;Mitochondrial recessive ataxia syndrome (includes SANDO and SCAE);17357067;174763;Mitochondrial recessive ataxia syndrome (includes SANDO and SCAE), 607459 (3);607459
POLG;Progressive external ophthalmoplegia, autosomal dominant;17357067;174763;Progressive external ophthalmoplegia, autosomal dominant, 157640 (3);157640
POLG;Progressive external ophthalmoplegia, autosomal recessive;17357067;174763;Progressive external ophthalmoplegia, autosomal recessive, 258450 (3);258450
POLG2;Progressive external ophthalmoplegia with mitochondrial DNA deletions, autosomal dominant 4;17357067;604983;Progressive external ophthalmoplegia with mitochondrial DNA deletions, autosomal dominant 4, 610131 (3);610131
POLH;Xeroderma pigmentosum, variant type;17357067;603968;Xeroderma pigmentosum, variant type, 278750 (3);278750
POLR1A;Acrofacial dysostosis, Cincinnati type;17357067;616404;Acrofacial dysostosis, Cincinnati type, 616462 (3);616462
POLR1C;Leukodystrophy, hypomyelinating, 11;17357067;610060;Leukodystrophy, hypomyelinating, 11, 616494 (3);616494
POLR1C;Treacher Collins syndrome 3;17357067;610060;Treacher Collins syndrome 3, 248390 (3);248390
POLR1D;Treacher Collins syndrome 2;17357067;613715;Treacher Collins syndrome 2, 613717 (3);613717
POLR3A;Leukodystrophy, hypomyelinating, 7, with or without oligodontia and/or hypogonadotropic hypogonadism;17357067;614258;Leukodystrophy, hypomyelinating, 7, with or without oligodontia and/or hypogonadotropic hypogonadism, 607694 (3);607694
POLR3B;Leukodystrophy, hypomyelinating, 8, with or without oligodontia and/or hypogonadotropic hypogonadism;17357067;614366;Leukodystrophy, hypomyelinating, 8, with or without oligodontia and/or hypogonadotropic hypogonadism, 614381 (3);614381
POMC;Lactase deficiency, congenital;17357067;603202;Lactase deficiency, congenital, 223000 (3);223000
POMC;Obesity, adrenal insufficiency, and red hair due to POMC deficiency;17357067;176830;Obesity, adrenal insufficiency, and red hair due to POMC deficiency, 609734 (3);609734
POMC;Obesity, early-onset, susceptibility to;17357067;176830;{Obesity, early-onset, susceptibility to}, 601665 (3);601665
POMGNT1;Muscular dystrophy-dystroglycanopathy (congenital with brain and eye anomalies), type A, 3;17357067;606822;Muscular dystrophy-dystroglycanopathy (congenital with brain and eye anomalies), type A, 3, 253280 (3);253280
POMGNT1;Muscular dystrophy-dystroglycanopathy (congenital with mental retardation), type B, 3;17357067;606822;Muscular dystrophy-dystroglycanopathy (congenital with mental retardation), type B, 3, 613151 (3);613151
POMGNT1;Muscular dystrophy-dystroglycanopathy (limb-girdle), type C, 3;17357067;606822;Muscular dystrophy-dystroglycanopathy (limb-girdle), type C, 3, 613157 (3);613157
POMGNT2;Muscular dystrophy-dystroglycanopathy (congenital with brain and eye anomalies, type A, 8;17357067;614828;Muscular dystrophy-dystroglycanopathy (congenital with brain and eye anomalies, type A, 8, 614830 (3);614830
POMK;Muscular dystrophy-dystroglycanopathy (congenital with brain and eye anomalies), type A, 12;17357067;615247;Muscular dystrophy-dystroglycanopathy (congenital with brain and eye anomalies), type A, 12, 615249 (3);615249
POMP;Keratosis linearis with ichthyosis congenita and sclerosing keratoderma;17357067;613386;Keratosis linearis with ichthyosis congenita and sclerosing keratoderma, 601952 (3);601952
POMT1;Muscular dystrophy-dystroglycanopathy (congenital with brain and eye anomalies), type A, 1;17357067;607423;Muscular dystrophy-dystroglycanopathy (congenital with brain and eye anomalies), type A, 1, 236670 (3);236670
POMT1;Muscular dystrophy-dystroglycanopathy (congenital with mental retardation), type B, 1;17357067;607423;Muscular dystrophy-dystroglycanopathy (congenital with mental retardation), type B, 1, 613155 (3);613155
POMT1;Muscular dystrophy-dystroglycanopathy (limb-girdle), type C, 1;17357067;607423;Muscular dystrophy-dystroglycanopathy (limb-girdle), type C, 1, 609308 (3);609308
POMT2;Muscular dystrophy-dystroglycanopathy (congenital with brain and eye anomalies), type A, 2;17357067;607439;Muscular dystrophy-dystroglycanopathy (congenital with brain and eye anomalies), type A, 2, 613150 (3);613150
POMT2;Muscular dystrophy-dystroglycanopathy (congenital with mental retardation), type B, 2;17357067;607439;Muscular dystrophy-dystroglycanopathy (congenital with mental retardation), type B, 2, 613156 (3);613156
POMT2;Muscular dystrophy-dystroglycanopathy (limb-girdle), type C, 2;17357067;607439;Muscular dystrophy-dystroglycanopathy (limb-girdle), type C, 2, 613158 (3);613158
PON1;Coronary artery disease, susceptibility to;17357067;168820;{Coronary artery disease, susceptibility to} (3);0
PON1;Coronary artery spasm 2, susceptibility to;17357067;168820;{Coronary artery spasm 2, susceptibility to (3);0
PON1;Microvascular complications of diabetes 5;17357067;168820;{Microvascular complications of diabetes 5}, 612633 (3);612633
PON1;Organophosphate poisoning, sensitivity to;17357067;168820;{Organophosphate poisoning, sensitivity to} (3);0
PON2;Coronary artery disease, susceptibility to;17357067;602447;{Coronary artery disease, susceptibility to} (3);0
POR;Antley-Bixler syndrome with genital anomalies and disordered steroidogenesis;17357067;124015;Antley-Bixler syndrome with genital anomalies and disordered steroidogenesis, 201750 (3);201750
POR;Disordered steroidogenesis due to cytochrome P450 oxidoreductase;17357067;124015;Disordered steroidogenesis due to cytochrome P450 oxidoreductase, 613571 (3);613571
PORCN;Focal dermal hypoplasia;17357067;300651;Focal dermal hypoplasia, 305600 (3);305600
POSTN;Poikiloderma with neutropenia;17357067;613276;Poikiloderma with neutropenia, 604173 (3);604173
POT1;Melanoma, cutaneous malignant, susceptibility to, 10;17357067;606478;{Melanoma, cutaneous malignant, susceptibility to, 10}, 615848 (3);615848
POU1F1;Pituitary hormone deficiency, combined, 1;17357067;173110;Pituitary hormone deficiency, combined, 1, 613038 (3);613038
POU3F4;Deafness, X-linked 2;17357067;300039;Deafness, X-linked 2, 304400 (3);304400
POU4F3;Deafness, autosomal dominant 15;17357067;602460;Deafness, autosomal dominant 15, 602459 (3);602459
POU6F2;Wilms tumor susceptibility-5;17357067;609062;{Wilms tumor susceptibility-5}, 601583 (3);601583
PPARA;Hyperapobetalipoproteinemia, susceptibility to;17357067;170998;{Hyperapobetalipoproteinemia, susceptibility to} (3);0
PPARG;Carotid intimal medial thickness 1;17357067;601487;Carotid intimal medial thickness 1, 609338 (3);609338
PPARG;Diabetes, type 2;17357067;601487;{Diabetes, type 2}, 125853 (3);125853
PPARG;Insulin resistance, severe, digenic;17357067;601487;Insulin resistance, severe, digenic, 604367 (3);604367
PPARG;Lipodystrophy, familial partial, type 3;17357067;601487;Lipodystrophy, familial partial, type 3, 604367 (3);604367
PPARG;Obesity, resistance to;17357067;601487;[Obesity, resistance to] (3);0
PPARG;Obesity, severe;17357067;601487;Obesity, severe, 601665 (3);601665
PPARGC1B;Obesity, variation in;17357067;608886;{Obesity, variation in}, 601665 (3);601665
PPIB;Osteogenesis imperfecta, type IX;17357067;123841;Osteogenesis imperfecta, type IX, 259440 (3);259440
PPM1D;Breast cancer;17357067;605100;Breast cancer, 114480 (3);114480
PPOX;Diabetes insipidus, neurohypophyseal;17357067;192340;Diabetes insipidus, neurohypophyseal, 125700 (3);125700
PPOX;Porphyria variegata;17357067;600923;Porphyria variegata, 176200 (3);176200
PPP1R17;Hypercholesterolemia, susceptibility to;17357067;604088;{Hypercholesterolemia, susceptibility to}, 143890 (3);143890
PPP1R3A;Insulin resistance, severe, digenic;17357067;600917;Insulin resistance, severe, digenic, 604367 (3);604367
PPP2R1A;Mental retardation, autosomal dominant 36;17357067;605983;Mental retardation, autosomal dominant 36, 616362 (3);616362
PPP2R1B;Lung cancer;17357067;603113;Lung cancer, 211980 (3);211980
PPP2R2B;Spinocerebellar ataxia 12;17357067;604325;Spinocerebellar ataxia 12, 604326 (3);604326
PPP2R5D;Mental retardation, autosomal dominant 35;17357067;601646;Mental retardation, autosomal dominant 35, 616355 (3);616355
PPT1;Ceroid lipofuscinosis, neuronal, 1;17357067;600722;Ceroid lipofuscinosis, neuronal, 1, 256730 (3);256730
PQBP1;Alpha-thalassemia myelodysplasia syndrome, somatic;17357067;300032;Alpha-thalassemia myelodysplasia syndrome, somatic, 300448 (3);300448
PQBP1;Alpha-thalassemia/mental retardation syndrome;17357067;300032;Alpha-thalassemia/mental retardation syndrome, 301040 (3);301040
PQBP1;Mental retardation, X-linked 2;17357067;300428;Mental retardation, X-linked 2 (2);0
PQBP1;Mental retardation, X-linked, FRAXE type;17357067;300806;Mental retardation, X-linked, FRAXE type, 309548 (3);309548
PQBP1;Mental retardation-hypotonic facies syndrome, X-linked;17357067;300032;Mental retardation-hypotonic facies syndrome, X-linked, 309580 (3);309580
PQBP1;Renpenning syndrome;17357067;300463;Renpenning syndrome, 309500 (3);309500
PRCC;Renal cell carcinoma, papillary;17357067;179755;Renal cell carcinoma, papillary, 605074 (3);605074
PRCD;Retinitis pigmentosa 36;17357067;610598;Retinitis pigmentosa 36, 610599 (3);610599
PRDM12;Neuropathy, hereditary sensory and autonomic, type VIII;17357067;616458;Neuropathy, hereditary sensory and autonomic, type VIII, 616488 (3);616488
PRDM16;Cardiomyopathy, dilated, 1LL;17357067;605557;Cardiomyopathy, dilated, 1LL, 615373 (3);615373
PRDM16;Left ventricular noncompaction 8;17357067;605557;Left ventricular noncompaction 8, 615373 (3);615373
PRDM5;Brittle cornea syndrome 2;17357067;614161;Brittle cornea syndrome 2, 614170 (3);614170
PRF1;Aplastic anemia;17357067;170280;Aplastic anemia, 609135 (3);609135
PRF1;Hemophagocytic lymphohistiocytosis, familial, 2;17357067;170280;Hemophagocytic lymphohistiocytosis, familial, 2, 603553 (3);603553
PRF1;Lymphoma, non-Hodgkin;17357067;170280;Lymphoma, non-Hodgkin, 605027 (3);605027
PRG2;Corneal opacification and other ocular anomalies;17357067;605158;Corneal opacification and other ocular anomalies, 269400 (3);269400
PRG4;Camptodactyly-arthropathy-coxa vara-pericarditis syndrome;17357067;604283;Camptodactyly-arthropathy-coxa vara-pericarditis syndrome, 208250 (3);208250
PRICKLE1;Epilepsy, progressive myoclonic 1B;17357067;608500;Epilepsy, progressive myoclonic 1B, 612437 (3);612437
PRICKLE2;Epilepsy, progressive myoclonic 5;17357067;608501;Epilepsy, progressive myoclonic 5, 613832 (3);613832
PRIMPOL;Myopia 22, autosomal dominant;17357067;615421;Myopia 22, autosomal dominant, 615420 (3);615420
PRKACA;Cushing syndrome, ACTH-independent adrenal, somatic;17357067;601639;Cushing syndrome, ACTH-independent adrenal, somatic, 615830 (3);615830
PRKAG2;Cardiomyopathy, hypertrophic 6;17357067;602743;Cardiomyopathy, hypertrophic 6, 600858 (3);600858
PRKAG2;Glycogen storage disease of heart, lethal congenital;17357067;602743;Glycogen storage disease of heart, lethal congenital, 261740 (3);261740
PRKAG2;Wolff-Parkinson-White syndrome;17357067;602743;Wolff-Parkinson-White syndrome, 194200 (3);194200
PRKAR1A;Acrodysostosis 1, with or without hormone resistance;17357067;188830;Acrodysostosis 1, with or without hormone resistance, 101800 (3);101800
PRKAR1A;Adrenocortical tumor, somatic;17357067;188830;Adrenocortical tumor, somatic, (3);0
PRKAR1A;Carney complex, type 1;17357067;188830;Carney complex, type 1, 160980 (3);160980
PRKAR1A;Myxoma, intracardiac;17357067;188830;Myxoma, intracardiac, 255960 (3);255960
PRKAR1A;Pigmented nodular adrenocortical disease, primary, 1;17357067;188830;Pigmented nodular adrenocortical disease, primary, 1, 610489 (3);610489
PRKAR1A;Thyroid carcinoma, papillary, somatic;17357067;188830;Thyroid carcinoma, papillary, somatic, 188550 (3);188550
PRKCA;Pituitary tumor, invasive;17357067;176960;Pituitary tumor, invasive (3);0
PRKCD;Autoimmune lymphoproliferative syndrome, type III;17357067;176977;Autoimmune lymphoproliferative syndrome, type III, 615559 (3);615559
PRKCG;Spinocerebellar ataxia 14;17357067;176980;Spinocerebellar ataxia 14, 605361 (3);605361
PRKCH;Cerebral infarction, susceptibility to;17357067;605437;{Cerebral infarction, susceptibility to}, 601367 (3);601367
PRKCSH;Polycystic liver disease;17357067;177060;Polycystic liver disease, 174050 (3);174050
PRKDC;Immunodeficiency 16, with or without neurologic abnormalities;17357067;600899;Immunodeficiency 16, with or without neurologic abnormalities, 615966 (3);615966
PRKG1;Aortic aneurysm, familial thoracic 8;17357067;176894;Aortic aneurysm, familial thoracic 8, 615436 (3);615436
PRKRA;Dystonia 16;17357067;603424;Dystonia 16, 612067 (3);612067
PRLR;Multiple fibroadenomas of the breast;17357067;176761;Multiple fibroadenomas of the breast, 615554 (3);615554
PRNP;Cerebral amyloid angiopathy, PRNP-related;17357067;176640;Cerebral amyloid angiopathy, PRNP-related, 137440 (3);137440
PRNP;Creutzfeldt-Jakob disease;17357067;176640;Creutzfeldt-Jakob disease, 123400 (3);123400
PRNP;Gerstmann-Straussler disease;17357067;176640;Gerstmann-Straussler disease, 137440 (3);137440
PRNP;Huntington disease-like 1;17357067;176640;Huntington disease-like 1, 603218 (3);603218
PRNP;Insomnia, fatal familial;17357067;176640;Insomnia, fatal familial, 600072 (3);600072
PRNP;Kuru, susceptibility to;17357067;176640;{Kuru, susceptibility to}, 245300 (3);245300
PRNP;Prion disease with protracted course;17357067;176640;Prion disease with protracted course, 606688 (3);606688
PROC;Thrombophilia due to protein C deficiency, autosomal dominant;17357067;612283;Thrombophilia due to protein C deficiency, autosomal dominant, 176860 (3);176860
PROC;Thrombophilia due to protein C deficiency, autosomal recessive;17357067;612283;Thrombophilia due to protein C deficiency, autosomal recessive, 612304 (3);612304
PRODH;Hyperprolinemia, type I;17357067;606810;Hyperprolinemia, type I, 239500 (3);239500
PRODH;Schizophrenia, susceptibility to, 4;17357067;606810;{Schizophrenia, susceptibility to, 4}, 600850 (3);600850
PRODH2;Hyperprolinemia, type I;17357067;606810;Hyperprolinemia, type I, 239500 (3);239500
PRODH2;Schizophrenia, susceptibility to, 4;17357067;606810;{Schizophrenia, susceptibility to, 4}, 600850 (3);600850
PROK1;Adenosine triphosphate, elevated, of erythrocytes;17357067;609712;Adenosine triphosphate, elevated, of erythrocytes, 102900 (3);102900
PROK1;Pyruvate kinase deficiency;17357067;609712;Pyruvate kinase deficiency, 266200 (3);266200
PROK2;Hypogonadotropic hypogonadism 4 with or without anosmia;17357067;607002;Hypogonadotropic hypogonadism 4 with or without anosmia, 610628 (3);610628
PROKR2;Hypogonadotropic hypogonadism 3 with or without anosmia;17357067;607123;Hypogonadotropic hypogonadism 3 with or without anosmia, 244200 (3);244200
PROM1;Cone-rod dystrophy 12;17357067;604365;Cone-rod dystrophy 12, 612657 (3);612657
PROM1;Macular dystrophy, retinal, 2;17357067;604365;Macular dystrophy, retinal, 2, 608051 (3);608051
PROM1;Retinitis pigmentosa 41;17357067;604365;Retinitis pigmentosa 41, 612095 (3);612095
PROM1;Stargardt disease 4;17357067;603786;Stargardt disease 4 (2);0
PROP1;Pituitary hormone deficiency, combined, 2;17357067;601538;Pituitary hormone deficiency, combined, 2, 262600 (3);262600
PROS1;Thrombophilia due to protein S deficiency, autosomal dominant;17357067;176880;Thrombophilia due to protein S deficiency, autosomal dominant, 612336 (3);612336
PROS1;Thrombophilia due to protein S deficiency, autosomal recessive;17357067;176880;Thrombophilia due to protein S deficiency, autosomal recessive, 614514 (3);614514
PROZ;Protein Z deficiency;17357067;176895;[Protein Z deficiency], 614024 (3);614024
PRPF3;Retinitis pigmentosa 18;17357067;607301;Retinitis pigmentosa 18, 601414 (3);601414
PRPF31;Retinitis pigmentosa 11;17357067;606419;Retinitis pigmentosa 11, 600138 (3);600138
PRPF4;Retinitis pigmentosa 70;17357067;607795;Retinitis pigmentosa 70, 615922 (3);615922
PRPF6;Retinitis pigmentosa 60;17357067;613979;Retinitis pigmentosa 60, 613983 (3);613983
PRPF8;Retinitis pigmentosa 13;17357067;607300;Retinitis pigmentosa 13, 600059 (3);600059
PRPH;Amyotrophic lateral sclerosis, susceptibility to;17357067;170710;{Amyotrophic lateral sclerosis, susceptibility to}, 105400 (3);105400
PRPH;Choriodal dystrophy, central areolar 2;17357067;179605;Choriodal dystrophy, central areolar 2, 613105 (3);613105
PRPH;Leber congenital amaurosis 18;17357067;179605;Leber congenital amaurosis 18, 608133 (3);608133
PRPH;Macular dystrophy, patterned, 1;17357067;179605;Macular dystrophy, patterned, 1, 169150 (3);169150
PRPH;Macular dystrophy, vitelliform, 3;17357067;179605;Macular dystrophy, vitelliform, 3, 608161 (3);608161
PRPH;Retinitis pigmentosa 7 and digenic;17357067;179605;Retinitis pigmentosa 7 and digenic, 608133 (3);608133
PRPH;Retinitis punctata albescens;17357067;179605;Retinitis punctata albescens, 136880 (3);136880
PRPH2;Choriodal dystrophy, central areolar 2;17357067;179605;Choriodal dystrophy, central areolar 2, 613105 (3);613105
PRPH2;Leber congenital amaurosis 18;17357067;179605;Leber congenital amaurosis 18, 608133 (3);608133
PRPH2;Macular dystrophy, patterned, 1;17357067;179605;Macular dystrophy, patterned, 1, 169150 (3);169150
PRPH2;Macular dystrophy, vitelliform, 3;17357067;179605;Macular dystrophy, vitelliform, 3, 608161 (3);608161
PRPH2;Retinitis pigmentosa 7 and digenic;17357067;179605;Retinitis pigmentosa 7 and digenic, 608133 (3);608133
PRPH2;Retinitis pigmentosa 7, digenic;17357067;180721;Retinitis pigmentosa 7, digenic, 608133 (3);608133
PRPH2;Retinitis punctata albescens;17357067;179605;Retinitis punctata albescens, 136880 (3);136880
PRPS1;Arts syndrome;17357067;311850;Arts syndrome, 301835 (3);301835
PRPS1;Charcot-Marie-Tooth disease, X-linked recessive, 5;17357067;311850;Charcot-Marie-Tooth disease, X-linked recessive, 5, 311070 (3);311070
PRPS1;Deafness, X-linked 1;17357067;311850;Deafness, X-linked 1, 304500 (3);304500
PRPS1;Gout, PRPS-related;17357067;311850;Gout, PRPS-related, 300661 (3);300661
PRPS1;Phosphoribosylpyrophosphate synthetase superactivity;17357067;311850;Phosphoribosylpyrophosphate synthetase superactivity, 300661 (3);300661
PRR4;Ectodermal dysplasia-syndactyly syndrome 1;17357067;609607;Ectodermal dysplasia-syndactyly syndrome 1, 613573 (3);613573
PRRT2;Convulsions, familial infantile, with paroxysmal choreoathetosis;17357067;614386;Convulsions, familial infantile, with paroxysmal choreoathetosis, 602066 (3);602066
PRRT2;Episodic kinesigenic dyskinesia 1;17357067;614386;Episodic kinesigenic dyskinesia 1, 128200 (3);128200
PRRT2;Seizures, benign familial infantile, 2;17357067;614386;Seizures, benign familial infantile, 2, 605751 (3);605751
PRRX1;Agnathia-otocephaly complex;17357067;167420;Agnathia-otocephaly complex, 202650 (3);202650
PRSS1;Pancreatitis, hereditary;17357067;276000;Pancreatitis, hereditary, 167800 (3);167800
PRSS1;Trypsinogen deficiency;17357067;276000;Trypsinogen deficiency, 614044 (1);614044
PRSS12;Mental retardation, autosomal recessive 1;17357067;606709;Mental retardation, autosomal recessive 1, 249500 (3);249500
PRSS2;Pancreatitis, chronic, protection against;17357067;601564;{Pancreatitis, chronic, protection against}, 167800 (3);167800
PRSS56;Microphthalmia, isolated 6;17357067;613858;Microphthalmia, isolated 6, 613517 (3);613517
PRX;Charcot-Marie-Tooth disease, type 4F;17357067;605725;Charcot-Marie-Tooth disease, type 4F, 614895 (3);614895
PRX;Dejerine-Sottas disease;17357067;605725;Dejerine-Sottas disease, 145900 (3);145900
PSAP;Combined SAP deficiency;17357067;176801;Combined SAP deficiency, 611721 (3);611721
PSAP;Gaucher disease, atypical;17357067;176801;Gaucher disease, atypical, 610539 (3);610539
PSAP;Krabbe disease, atypical;17357067;176801;Krabbe disease, atypical, 611722 (3);611722
PSAP;Metachromatic leukodystrophy due to SAP-b deficiency;17357067;176801;Metachromatic leukodystrophy due to SAP-b deficiency, 249900 (3);249900
PSAT1;Neu-Laxova syndrome 2;17357067;610936;Neu-Laxova syndrome 2, 616038 (3);616038
PSEN1;Acne inversa, familial, 3;17357067;104311;Acne inversa, familial, 3, 613737 (3);613737
PSEN1;Alzheimer disease, type 3;17357067;104311;Alzheimer disease, type 3, 607822 (3);607822
PSEN1;Alzheimer disease, type 3, with spastic paraparesis and apraxia;17357067;104311;Alzheimer disease, type 3, with spastic paraparesis and apraxia, 607822 (3);607822
PSEN1;Alzheimer disease, type 3, with spastic paraparesis and unusual plaques;17357067;104311;Alzheimer disease, type 3, with spastic paraparesis and unusual plaques, 607822 (3);607822
PSEN1;Cardiomyopathy, dilated, 1U;17357067;104311;Cardiomyopathy, dilated, 1U, 613694 (3);613694
PSEN1;Dementia, frontotemporal;17357067;104311;Dementia, frontotemporal, 600274 (3);600274
PSEN1;Pick disease;17357067;104311;Pick disease, 172700 (3);172700
PSEN2;Alzheimer disease-4;17357067;600759;Alzheimer disease-4, 606889 (3);606889
PSEN2;Cardiomyopathy, dilated, 1V;17357067;600759;Cardiomyopathy, dilated, 1V, 613697 (3);613697
PSENEN;Acne inversa, familial, 2;17357067;607632;Acne inversa, familial, 2, 613736 (3);613736
PSMA6;Myocardial infarcation, susceptibility to;17357067;602855;{Myocardial infarcation, susceptibility to}, 608446 (3);608446
PSMB8;Autoinflammation, lipodystrophy, and dermatosis syndrome;17357067;177046;Autoinflammation, lipodystrophy, and dermatosis syndrome, 256040 (3);256040
PSMC3IP;Ovarian dysgenesis 3;17357067;608665;Ovarian dysgenesis 3, 614324 (3);614324
PSPH;Phosphoserine phosphatase deficiency;17357067;172480;Phosphoserine phosphatase deficiency, 614023 (3);614023
PSTPIP1;Pyogenic sterile arthritis, pyoderma gangrenosum, and acne;17357067;606347;Pyogenic sterile arthritis, pyoderma gangrenosum, and acne, 604416 (3);604416
PTCH1;Basal cell carcinoma, somatic;17357067;601309;Basal cell carcinoma, somatic, 605462 (3);605462
PTCH1;Basal cell nevus syndrome;17357067;601309;Basal cell nevus syndrome, 109400 (3);109400
PTCH1;Holoprosencephaly-7;17357067;601309;Holoprosencephaly-7, 610828 (3);610828
PTCH2;Basal cell carcinoma, somatic;17357067;603673;Basal cell carcinoma, somatic, 605462 (3);605462
PTCH2;Basal cell nevus syndrome;17357067;603673;Basal cell nevus syndrome, 109400 (3);109400
PTCH2;Medulloblastoma;17357067;603673;Medulloblastoma, 155255 (3);155255
PTDSS1;Hypotrichosis 2;17357067;602593;Hypotrichosis 2, 146520 (3);146520
PTDSS1;Lenz-Majewski hyperostotic dwarfism;17357067;612792;Lenz-Majewski hyperostotic dwarfism, 151050 (3);151050
PTDSS1;Peeling skin syndrome 1;17357067;602593;Peeling skin syndrome 1, 270300 (3);270300
PTDSS1;Pityriasis rubra pilaris;17357067;607211;Pityriasis rubra pilaris, 173200 (3);173200
PTDSS1;Psoriasis 2;17357067;607211;Psoriasis 2, 602723 (3);602723
PTDSS2;Peeling skin syndrome 2;17357067;603805;Peeling skin syndrome 2, 609796 (3);609796
PTEN;Bannayan-Riley-Ruvalcaba syndrome;17357067;601728;Bannayan-Riley-Ruvalcaba syndrome, 153480 (3);153480
PTEN;Cowden syndrome 1;17357067;601728;Cowden syndrome 1, 158350 (3);158350
PTEN;Endometrial carcinoma, somatic;17357067;601728;Endometrial carcinoma, somatic, 608089 (3);608089
PTEN;Glioma susceptibility 2;17357067;601728;{Glioma susceptibility 2}, 613028 (3);613028
PTEN;Lhermitte-Duclos syndrome;17357067;601728;Lhermitte-Duclos syndrome, 158350 (3);158350
PTEN;Macrocephaly/autism syndrome;17357067;601728;Macrocephaly/autism syndrome, 605309 (3);605309
PTEN;Malignant melanoma, somatic;17357067;601728;Malignant melanoma, somatic, 155600 (3);155600
PTEN;Meningioma;17357067;601728;{Meningioma}, 607174 (3);607174
PTEN;PTEN hamartoma tumor syndrome;17357067;601728;PTEN hamartoma tumor syndrome (3);0
PTEN;Prostate cancer, somatic;17357067;601728;{Prostate cancer, somatic}, 176807 (3);176807
PTEN;Squamous cell carcinoma, head and neck, somatic;17357067;601728;Squamous cell carcinoma, head and neck, somatic, 275355 (3);275355
PTEN;Thyroid carcinoma, follicular, somatic;17357067;601728;Thyroid carcinoma, follicular, somatic, 188470 (3);188470
PTEN;VATER association with macrocephaly and ventriculomegaly;17357067;601728;VATER association with macrocephaly and ventriculomegaly, 276950 (3);276950
PTF1A;Pancreatic agenesis 2;17357067;607194;Pancreatic agenesis 2, 615935 (3);615935
PTF1A;Pancreatic and cerebellar agenesis;17357067;607194;Pancreatic and cerebellar agenesis, 609069 (3);609069
PTGDR;Asthma, susceptibility to, 1;17357067;604687;{Asthma, susceptibility to, 1}, 607277 (3);607277
PTGER2;Asthma, aspirin-induced, susceptibility to;17357067;176804;{Asthma, aspirin-induced, susceptibility to}, 208550 (3);208550
PTGIS;Hypertension, essential;17357067;601699;Hypertension, essential, 145500 (3);145500
PTH;Hypoparathyroidism, autosomal dominant;17357067;168450;Hypoparathyroidism, autosomal dominant, 146200 (3);146200
PTH;Hypoparathyroidism, autosomal recessive;17357067;168450;Hypoparathyroidism, autosomal recessive, 146200 (3);146200
PTH1R;Chondrodysplasia, Blomstrand type;17357067;168468;Chondrodysplasia, Blomstrand type, 215045 (3);215045
PTH1R;Eiken syndrome;17357067;168468;Eiken syndrome, 600002 (3);600002
PTH1R;Failure of tooth eruption, primary;17357067;168468;Failure of tooth eruption, primary, 125350 (3);125350
PTH1R;Metaphyseal chondrodysplasia, Murk Jansen type;17357067;168468;Metaphyseal chondrodysplasia, Murk Jansen type, 156400 (3);156400
PTHLH;Brachydactyly, type E2;17357067;168470;Brachydactyly, type E2, 613382 (3);613382
PTHLH;Humoral hypercalcemia of malignancy;17357067;168470;Humoral hypercalcemia of malignancy (1);0
PTPN1;Insulin resistance, susceptibility to;17357067;176885;{Insulin resistance, susceptibility to}, 125853 (3);125853
PTPN11;LEOPARD syndrome 1;17357067;176876;LEOPARD syndrome 1, 151100 (3);151100
PTPN11;Leukemia, juvenile myelomonocytic;17357067;176876;Leukemia, juvenile myelomonocytic, 607785 (3);607785
PTPN11;Metachondromatosis;17357067;176876;Metachondromatosis, 156250 (3);156250
PTPN11;Noonan syndrome 1;17357067;176876;Noonan syndrome 1, 163950 (3);163950
PTPN12;Colon cancer, somatic;17357067;600079;Colon cancer, somatic, 114500 (3);114500
PTPN14;Choanal atresia and lymphedema;17357067;603155;Choanal atresia and lymphedema, 613611 (3);613611
PTPN22;Diabetes, type 1, susceptibility to;17357067;600716;{Diabetes, type 1, susceptibility to}, 222100 (3);222100
PTPN22;Rheumatoid arthritis, susceptibility to;17357067;600716;{Rheumatoid arthritis, susceptibility to}, 180300 (3);180300
PTPN22;Systemic lupus erythematosus susceptibility to;17357067;600716;{Systemic lupus erythematosus susceptibility to}, 152700 (3);152700
PTPRC;Hepatitic C virus, susceptibility to;17357067;151460;{Hepatitic C virus, susceptibility to}, 609532 (3);609532
PTPRC;Severe combined immunodeficiency, T cell-negative, B-cell/natural killer-cell positive;17357067;151460;Severe combined immunodeficiency, T cell-negative, B-cell/natural killer-cell positive, 608971 (3);608971
PTPRJ;Colon cancer, somatic;17357067;600925;Colon cancer, somatic, 114500 (3);114500
PTPRO;Nephrotic syndrome, type 6;17357067;600579;Nephrotic syndrome, type 6, 614196 (3);614196
PTPRQ;Deafness, autosomal recessive 84A;17357067;603317;Deafness, autosomal recessive 84A, 613391 (3);613391
PTPRZ1;H. pylori infection, susceptibility to;17357067;176891;{H. pylori infection, susceptibility to}, 600263 (1);600263
PTRF;Lipodystrophy, congenital generalized, type 4;17357067;603198;Lipodystrophy, congenital generalized, type 4, 613327 (3);613327
PTRH2;Infantile-onset multisystem neurologic, endocrine, and pancreatic disease;17357067;608625;Infantile-onset multisystem neurologic, endocrine, and pancreatic disease, 616263 (3);616263
PTS;Hyperphenylalaninemia, BH4-deficient, A;17357067;612719;Hyperphenylalaninemia, BH4-deficient, A, 261640 (3);261640
PUF60;Verheij syndrome;17357067;604819;Verheij syndrome, 615583 (3);615583
PURA;Mental retardation, autosomal dominant 31;17357067;600473;Mental retardation, autosomal dominant 31, 616158 (3);616158
PUS1;Mitochondrial myopathy and sideroblastic anemia 1;17357067;608109;Mitochondrial myopathy and sideroblastic anemia 1, 600462 (3);600462
PVRL1;Cleft lip/palate-ectodermal dysplasia syndrome;17357067;600644;Cleft lip/palate-ectodermal dysplasia syndrome, 225060 (3);225060
PVRL1;Orofacial cleft 7;17357067;600644;Orofacial cleft 7, 225060 (3);225060
PVRL3;Photoparoxysmal response 3;17357067;609573;Photoparoxysmal response 3 (2);0
PVRL4;Ectodermal dysplasia-syndactyly syndrome 1;17357067;609607;Ectodermal dysplasia-syndactyly syndrome 1, 613573 (3);613573
PXDN;Corneal opacification and other ocular anomalies;17357067;605158;Corneal opacification and other ocular anomalies, 269400 (3);269400
PXN;Corneal opacification and other ocular anomalies;17357067;605158;Corneal opacification and other ocular anomalies, 269400 (3);269400
PYCR1;Cutis laxa, autosomal recessive, type IIB;17357067;179035;Cutis laxa, autosomal recessive, type IIB, 612940 (3);612940
PYCR1;Cutis laxa, autosomal recessive, type IIIB;17357067;179035;Cutis laxa, autosomal recessive, type IIIB, 614438 (3);614438
PYCR2;Leukodystrophy, hypomyelinating, 10;17357067;616406;Leukodystrophy, hypomyelinating, 10, 616420 (3);616420
PYGL;Glycogen storage disease VI;17357067;613741;Glycogen storage disease VI, 232700 (3);232700
PYGM;McArdle disease;17357067;608455;McArdle disease, 232600 (3);232600
QARS;Microcephaly, progressive, seizures, and cerebral and cerebellar atrophy;17357067;603727;Microcephaly, progressive, seizures, and cerebral and cerebellar atrophy, 615760 (3);615760
QDPR;Hyperphenylalaninemia, BH4-deficient, C;17357067;612676;Hyperphenylalaninemia, BH4-deficient, C, 261630 (3);261630
RAB18;Warburg micro syndrome 3;17357067;602207;Warburg micro syndrome 3, 614222 (3);614222
RAB23;Carpenter syndrome;17357067;606144;Carpenter syndrome, 201000 (3);201000
RAB27A;Griscelli syndrome, type 2;17357067;603868;Griscelli syndrome, type 2, 607624 (3);607624
RAB28;Cone-rod dystrophy 18;17357067;612994;Cone-rod dystrophy 18, 615374 (3);615374
RAB33B;Smith-McCort dysplasia 2;17357067;605950;Smith-McCort dysplasia 2, 615222 (3);615222
RAB39B;Mental retardation, X-linked 72;17357067;300774;Mental retardation, X-linked 72, 300271 (3);300271
RAB3GAP1;Warburg micro syndrome 1;17357067;602536;Warburg micro syndrome 1, 600118 (3);600118
RAB3GAP2;Martsolf syndrome;17357067;609275;Martsolf syndrome, 212720 (3);212720
RAB3GAP2;Warburg micro syndrome 2;17357067;609275;Warburg micro syndrome 2, 614225 (3);614225
RAB7A;Charcot-Marie-Tooth disease, type 2B;17357067;602298;Charcot-Marie-Tooth disease, type 2B, 600882 (3);600882
RAC2;Neutrophil immunodeficiency syndrome;17357067;602049;Neutrophil immunodeficiency syndrome, 608203 (3);608203
RAD21;Cornelia de Lange syndrome 4;17357067;606462;Cornelia de Lange syndrome 4, 614701 (3);614701
RAD50;Nijmegen breakage syndrome-like disorder;17357067;604040;Nijmegen breakage syndrome-like disorder, 613078 (3);613078
RAD51;Breast cancer, susceptibility to;17357067;179617;{Breast cancer, susceptibility to}, 114480 (3);114480
RAD51;Mirror movements 2;17357067;179617;Mirror movements 2, 614508 (3);614508
RAD51C;Breast-ovarian cancer, familial, susceptibility to, 3;17357067;602774;{Breast-ovarian cancer, familial, susceptibility to, 3}, 613399 (3);613399
RAD51C;Fanconi anemia, complementation group O;17357067;602774;Fanconi anemia, complementation group O, 613390 (3);613390
RAD51D;Breast-ovarian cancer, familial, susceptibility to, 4;17357067;602954;{Breast-ovarian cancer, familial, susceptibility to, 4}, 614291 (3);614291
RAD54B;Colon cancer, somatic;17357067;604289;Colon cancer, somatic, 114500 (3);114500
RAD54B;Lymphoma, non-Hodgkin, somatic;17357067;604289;Lymphoma, non-Hodgkin, somatic, 605027 (3);605027
RAD54L;Adenocarcinoma, colonic, somatic;17357067;603615;Adenocarcinoma, colonic, somatic (3);0
RAD54L;Breast cancer, invasive ductal;17357067;603615;{Breast cancer, invasive ductal}, 114480 (3);114480
RAD54L;Lymphoma, non-Hodgkin, somatic;17357067;603615;Lymphoma, non-Hodgkin, somatic, 605027 (3);605027
RAF1;Cardiomyopathy, dilated, 1NN;17357067;164760;Cardiomyopathy, dilated, 1NN, 615916 (3);615916
RAF1;LEOPARD syndrome 2;17357067;164760;LEOPARD syndrome 2, 611554 (3);611554
RAF1;Noonan syndrome 5;17357067;164760;Noonan syndrome 5, 611553 (3);611553
RAG1;Alpha/beta T-cell lymphopenia with gamma/delta T-cell expansion, severe cytomegalovirus infection, and autoimmunity;17357067;179615;Alpha/beta T-cell lymphopenia with gamma/delta T-cell expansion, severe cytomegalovirus infection, and autoimmunity, 609889 (3);609889
RAG1;Combined cellular and humoral immune defects with granulomas;17357067;179615;Combined cellular and humoral immune defects with granulomas, 233650 (3);233650
RAG1;Omenn syndrome;17357067;179615;Omenn syndrome, 603554 (3);603554
RAG1;Severe combined immunodeficiency, B cell-negative;17357067;179615;Severe combined immunodeficiency, B cell-negative, 601457 (3);601457
RAG2;Combined cellular and humoral immune defects with granulomas;17357067;179616;Combined cellular and humoral immune defects with granulomas, 233650 (3);233650
RAG2;Omenn syndrome;17357067;179616;Omenn syndrome, 603554 (3);603554
RAG2;Severe combined immunodeficiency, B cell-negative;17357067;179616;Severe combined immunodeficiency, B cell-negative, 601457 (3);601457
RAI1;Smith-Magenis syndrome;17357067;607642;Smith-Magenis syndrome, 182290 (3);182290
RANBP2;Encephalopathy, acute, infection-induced, 3, susceptibility to;17357067;601181;{Encephalopathy, acute, infection-induced, 3, susceptibility to}, 608033 (3);608033
RAP1GDS1;Lymphocytic leukemia, acute T-cell;17357067;179502;Lymphocytic leukemia, acute T-cell (3);0
RAPSN;Fetal akinesia deformation sequence;17357067;601592;Fetal akinesia deformation sequence, 208150 (3);208150
RAPSN;Myasthenic syndrome, congenital, 11, associated with acetylcholine receptor deficiency;17357067;601592;Myasthenic syndrome, congenital, 11, associated with acetylcholine receptor deficiency, 616326 (3);616326
RARA;Leukemia, acute promyelocytic;17357067;180240;Leukemia, acute promyelocytic, 612376 (1);612376
RARB;Microphthalmia, syndromic 12;17357067;180220;Microphthalmia, syndromic 12, 615524 (3);615524
RARS;Leukodystrophy, hypomyelinating, 9;17357067;107820;Leukodystrophy, hypomyelinating, 9, 616140 (3);616140
RARS2;Pontocerebellar hypoplasia, type 6;17357067;611524;Pontocerebellar hypoplasia, type 6, 611523 (3);611523
RASA1;Basal cell carcinoma, somatic;17357067;139150;Basal cell carcinoma, somatic, 605462 (3);605462
RASA1;Capillary malformation-arteriovenous malformation;17357067;139150;Capillary malformation-arteriovenous malformation, 608354 (3);608354
RASA1;Parkes Weber syndrome;17357067;139150;Parkes Weber syndrome, 608355 (3);608355
RASSF1;Lung cancer;17357067;605082;Lung cancer, 211980 (2);211980
RAX;Dystonia 16;17357067;603424;Dystonia 16, 612067 (3);612067
RAX;Microphthalmia, isolated 3;17357067;601881;Microphthalmia, isolated 3, 611038 (3);611038
RAX2;Cone-rod dystrophy 11;17357067;610362;Cone-rod dystrophy 11, 610381 (3);610381
RB1;Bladder cancer, somatic;17357067;614041;Bladder cancer, somatic, 109800 (3);109800
RB1;Osteosarcoma, somatic;17357067;614041;Osteosarcoma, somatic, 259500 (3);259500
RB1;Retinoblastoma;17357067;614041;Retinoblastoma, 180200 (3);180200
RB1;Retinoblastoma, trilateral;17357067;614041;Retinoblastoma, trilateral, 180200 (3);180200
RB1;Small cell cancer of the lung, somatic;17357067;614041;Small cell cancer of the lung, somatic, 182280 (3);182280
RB1CC1;Breast cancer, somatic;17357067;606837;Breast cancer, somatic, 114480 (3);114480
RBBP8;Jawad syndrome;17357067;604124;Jawad syndrome, 251255 (3);251255
RBBP8;Pancreatic carcinoma, somatic;17357067;604124;Pancreatic carcinoma, somatic (3);0
RBBP8;Seckel syndrome 2;17357067;604124;Seckel syndrome 2, 606744 (3);606744
RBCK1;Polyglucosan body myopathy 1 with or without immunodeficiency;17357067;610924;Polyglucosan body myopathy 1 with or without immunodeficiency, 615895 (3);615895
RBM10;TARP syndrome;17357067;300080;TARP syndrome, 311900 (3);311900
RBM15;Megakaryoblastic leukemia, acute;17357067;606077;Megakaryoblastic leukemia, acute (2);0
RBM20;Cardiomyopathy, dilated, 1DD;17357067;613171;Cardiomyopathy, dilated, 1DD, 613172 (3);613172
RBM8A;Thrombocytopenia-absent radius syndrome;17357067;605313;Thrombocytopenia-absent radius syndrome, 274000 (3);274000
RBM8B;Thrombocytopenia-absent radius syndrome;17357067;605313;Thrombocytopenia-absent radius syndrome, 274000 (3);274000
RBP4;Microphthalmia, isolated, with coloboma 10;17357067;180250;Microphthalmia, isolated, with coloboma 10, 616428 (3);616428
RBP4;Retinal dystrophy, iris coloboma, and comedogenic acne syndrome;17357067;180250;Retinal dystrophy, iris coloboma, and comedogenic acne syndrome, 615147 (3);615147
RBPJ;Adams-Oliver syndrome 3;17357067;147183;Adams-Oliver syndrome 3, 614814 (3);614814
RCBTB1;Alcohol dependence, susceptibility to;17357067;607867;{Alcohol dependence, susceptibility to}, 103780 (3);103780
RCBTB1;Beta-glycopyranoside tasting;17357067;607867;[Beta-glycopyranoside tasting] (3);0
RD3;Leber congenital amaurosis 12;17357067;180040;Leber congenital amaurosis 12, 610612 (3);610612
RDH12;Leber congenital amaurosis 13;17357067;608830;Leber congenital amaurosis 13, 612712 (3);612712
RDH5;Fundus albipunctatus;17357067;601617;Fundus albipunctatus, 136880 (3);136880
RDX;Deafness, autosomal recessive 24;17357067;179410;Deafness, autosomal recessive 24, 611022 (3);611022
RECQL4;Baller-Gerold syndrome;17357067;603780;Baller-Gerold syndrome, 218600 (3);218600
RECQL4;RAPADILINO syndrome;17357067;603780;RAPADILINO syndrome, 266280 (3);266280
RECQL4;Rothmund-Thomson syndrome;17357067;603780;Rothmund-Thomson syndrome, 268400 (3);268400
REEP1;Spastic paraplegia 31, autosomal dominant;17357067;609139;Spastic paraplegia 31, autosomal dominant, 610250 (3);610250
RELN;Epilepsy, familial temporal lobe, 7;17357067;600514;{Epilepsy, familial temporal lobe, 7}, 616436 (3);616436
RELN;Lissencephaly 2 (Norman-Roberts type);17357067;600514;Lissencephaly 2 (Norman-Roberts type), 257320 (3);257320
REN;Hyperproreninemia;17357067;179820;[Hyperproreninemia] (3);0
REN;Hyperuricemic nephropathy, familial juvenile 2;17357067;179820;Hyperuricemic nephropathy, familial juvenile 2, 613092 (3);613092
REN;Renal tubular dysgenesis;17357067;179820;Renal tubular dysgenesis, 267430 (3);267430
RET;Central hypoventilation syndrome, congenital;17357067;164761;Central hypoventilation syndrome, congenital, 209880 (3);209880
RET;Hirschsprung disease, susceptibility to, 1;17357067;164761;{Hirschsprung disease, susceptibility to, 1}, 142623 (3);142623
RET;Medullary thyroid carcinoma;17357067;164761;Medullary thyroid carcinoma, 155240 (3);155240
RET;Multiple endocrine neoplasia IIA;17357067;164761;Multiple endocrine neoplasia IIA, 171400 (3);171400
RET;Multiple endocrine neoplasia IIB;17357067;164761;Multiple endocrine neoplasia IIB, 162300 (3);162300
RET;Pheochromocytoma;17357067;164761;Pheochromocytoma, 171300 (3);171300
RET;Renal agenesis;17357067;164761;Renal agenesis, 191830 (3);191830
RETN;Diabetes mellitus, noninsulin-dependent, susceptibility to;17357067;605565;{Diabetes mellitus, noninsulin-dependent, susceptibility to}, 125853 (3);125853
RETN;Hypertension, insulin resistance-related, susceptibility to;17357067;605565;{Hypertension, insulin resistance-related, susceptibility to}, 125853 (3);125853
RFT1;Congenital disorder of glycosylation, type In;17357067;611908;Congenital disorder of glycosylation, type In, 612015 (3);612015
RFX5;Bare lymphocyte syndrome, type II, complementation group C;17357067;601863;Bare lymphocyte syndrome, type II, complementation group C, 209920 (3);209920
RFX5;Bare lymphocyte syndrome, type II, complementation group E;17357067;601863;Bare lymphocyte syndrome, type II, complementation group E, 209920 (3);209920
RFX6;Mitchell-Riley syndrome;17357067;612659;Mitchell-Riley syndrome, 615710 (3);615710
RFXANK;MHC class II deficiency, complementation group B;17357067;603200;MHC class II deficiency, complementation group B, 209920 (3);209920
RFXAP;Bare lymphocyte syndrome, type II, complementation group D;17357067;601861;Bare lymphocyte syndrome, type II, complementation group D, 209920 (3);209920
RGR;Retinitis pigmentosa 44;17357067;600342;Retinitis pigmentosa 44, 613769 (3);613769
RGS2;Rieger syndrome, type 2;17357067;601499;Rieger syndrome, type 2 (2);0
RGS4;Schizoaffective disorder, susceptibility to;17357067;605210;{Schizoaffective disorder, susceptibility to}, 181500 (3);181500
RGS4;Schizophrenia, susceptibility to;17357067;605210;{Schizophrenia, susceptibility to}, 604906 (3);604906
RGS5;Blood pressure regulation QTL;17357067;603276;[Blood pressure regulation QTL], 145500 (2);145500
RGS9;Bradyopsia;17357067;604067;Bradyopsia, 608415 (3);608415
RGS9BP;Bradyopsia;17357067;607814;Bradyopsia, 608415 (3);608415
RHAG;Anemia, hemolytic, Rh-null, regulator type;17357067;180297;Anemia, hemolytic, Rh-null, regulator type, 268150 (3);268150
RHAG;Rh-mod syndrome;17357067;180297;Rh-mod syndrome (3);0
RHBDF2;Tylosis with esophageal cancer;17357067;614404;Tylosis with esophageal cancer, 148500 (3);148500
RHCE;Blood group, Rhesus;17357067;111700;[Blood group, Rhesus], 111690 (3);111690
RHCE;Rh-null disease, amorph type;17357067;111700;Rh-null disease, amorph type (3);0
RHD;Rh-negative blood type;17357067;111680;[Rh-negative blood type] (3);0
RHO;Night blindness, congenital stationary, autosomal dominant 1;17357067;180380;Night blindness, congenital stationary, autosomal dominant 1, 610445 (3);610445
RHO;Retinitis pigmentosa 4, autosomal dominant or recessive;17357067;180380;Retinitis pigmentosa 4, autosomal dominant or recessive, 613731 (3);613731
RHO;Retinitis punctata albescens;17357067;180380;Retinitis punctata albescens, 136880 (3);136880
RILP;Epilepsy, progressive myoclonic 1B;17357067;608500;Epilepsy, progressive myoclonic 1B, 612437 (3);612437
RIMS1;Cone-rod dystrophy 7;17357067;606629;Cone-rod dystrophy 7, 603649 (3);603649
RIN2;Macrocephaly, alopecia, cutis laxa, and scoliosis;17357067;610222;Macrocephaly, alopecia, cutis laxa, and scoliosis, 613075 (3);613075
RIPK4;Popliteal pterygium syndrome 2, lethal type;17357067;605706;Popliteal pterygium syndrome 2, lethal type, 263650 (3);263650
RIT1;Noonan syndrome 8;17357067;609591;Noonan syndrome 8, 615355 (3);615355
RLBP1;Bothnia retinal dystrophy;17357067;180090;Bothnia retinal dystrophy, 607475 (3);607475
RLBP1;Fundus albipunctatus;17357067;180090;Fundus albipunctatus, 136880 (3);136880
RLBP1;Newfoundland rod-cone dystrophy;17357067;180090;Newfoundland rod-cone dystrophy, 607476 (3);607476
RLBP1;Retinitis punctata albescens;17357067;180090;Retinitis punctata albescens, 136880 (3);136880
RMND1;Combined oxidative phosphorylation deficiency 11;17357067;614917;Combined oxidative phosphorylation deficiency 11, 614922 (3);614922
RMRP;Anauxetic dysplasia;17357067;157660;Anauxetic dysplasia, 607095 (3);607095
RMRP;Cartilage-hair hypoplasia;17357067;157660;Cartilage-hair hypoplasia, 250250 (3);250250
RMRP;Metaphyseal dysplasia without hypotrichosis;17357067;157660;Metaphyseal dysplasia without hypotrichosis, 250460 (3);250460
RNASEH1;Progressive external ophthalmoplegia with mitochondrial DNA deletions, autosomal recessive 2;17357067;604123;Progressive external ophthalmoplegia with mitochondrial DNA deletions, autosomal recessive 2, 616479 (3);616479
RNASEH2A;Aicardi-Goutieres syndrome 4;17357067;606034;Aicardi-Goutieres syndrome 4, 610333 (3);610333
RNASEH2B;Aicardi-Goutieres syndrome 2;17357067;610326;Aicardi-Goutieres syndrome 2, 610181 (3);610181
RNASEH2B;Alagille syndrome 2;17357067;600275;Alagille syndrome 2, 610205 (3);610205
RNASEH2B;Hajdu-Cheney syndrome;17357067;600275;Hajdu-Cheney syndrome, 102500 (3);102500
RNASEH2C;Aicardi-Goutieres syndrome 3;17357067;610330;Aicardi-Goutieres syndrome 3, 610329 (3);610329
RNASEL;Prostate cancer 1;17357067;180435;Prostate cancer 1, 601518 (3);601518
RNASET2;Leukoencephalopathy, cystic, without megalencephaly;17357067;612944;Leukoencephalopathy, cystic, without megalencephaly, 612951 (3);612951
RNF114;Psoriasis susceptibility 12;17357067;612950;{Psoriasis susceptibility 12} (2);0
RNF125;Tenorio syndrome;17357067;610432;Tenorio syndrome, 616260 (3);616260
RNF135;Macrocephaly, macrosomia, facial dysmorphism syndrome;17357067;611358;Macrocephaly, macrosomia, facial dysmorphism syndrome, 614192 (3);614192
RNF139;Renal cell carcinoma;17357067;603046;Renal cell carcinoma, 144700 (3);144700
RNF168;RIDDLE syndrome;17357067;612688;RIDDLE syndrome, 611943 (3);611943
RNF170;Ataxia, sensory, 1, autosomal dominant;17357067;614649;Ataxia, sensory, 1, autosomal dominant, 608984 (3);608984
RNF212;Recombination rate QTL 1;17357067;612041;Recombination rate QTL 1, 612042 (3);612042
RNF213;Moyamoya disease 2, susceptibility to;17357067;613768;{Moyamoya disease 2, susceptibility to}, 607151 (3);607151
RNF216;Cerebellar ataxia and hypogonadotropic hypogonadism;17357067;609948;Cerebellar ataxia and hypogonadotropic hypogonadism, 212840 (3);212840
RNF6;Esophageal carcinoma, somatic;17357067;604242;Esophageal carcinoma, somatic, 133239 (3);133239
RNU4ATAC;Microcephalic osteodysplastic primordial dwarfism, type I;17357067;601428;Microcephalic osteodysplastic primordial dwarfism, type I, 210710 (3);210710
ROBO1;Vesicoureteral reflux 2;17357067;602431;Vesicoureteral reflux 2, 610878 (3);610878
ROBO2;Vesicoureteral reflux 2;17357067;602431;Vesicoureteral reflux 2, 610878 (3);610878
ROBO3;Gaze palsy, horizontal, with progressive scoliosis;17357067;608630;Gaze palsy, horizontal, with progressive scoliosis, 607313 (3);607313
ROGDI;Kohlschutter-Tonz syndrome;17357067;614574;Kohlschutter-Tonz syndrome, 226750 (3);226750
ROM1;Retinitis pigmentosa 7, digenic;17357067;180721;Retinitis pigmentosa 7, digenic, 608133 (3);608133
ROR2;Brachydactyly, type B1;17357067;602337;Brachydactyly, type B1, 113000 (3);113000
ROR2;Robinow syndrome, autosomal recessive;17357067;602337;Robinow syndrome, autosomal recessive, 268310 (3);268310
RP1;Retinitis pigmentosa 1;17357067;603937;Retinitis pigmentosa 1, 180100 (3);180100
RP1L1;Occult macular dystrophy;17357067;608581;Occult macular dystrophy, 613587 (3);613587
RP2;Retinitis pigmentosa 2;17357067;300757;Retinitis pigmentosa 2, 312600 (3);312600
RPE65;Leber congenital amaurosis 2;17357067;180069;Leber congenital amaurosis 2, 204100 (3);204100
RPE65;Retinitis pigmentosa 20;17357067;180069;Retinitis pigmentosa 20, 613794 (3);613794
RPGR;Cone-rod dystrophy, X-linked, 1;17357067;312610;Cone-rod dystrophy, X-linked, 1, 304020 (3);304020
RPGR;Macular degeneration, X-linked atrophic;17357067;312610;Macular degeneration, X-linked atrophic, 300834 (3);300834
RPGR;Retinitis pigmentosa 3;17357067;312610;Retinitis pigmentosa 3, 300029 (3);300029
RPGR;Retinitis pigmentosa, X-linked, and sinorespiratory infections, with or without deafness;17357067;312610;Retinitis pigmentosa, X-linked, and sinorespiratory infections, with or without deafness, 300455 (3);300455
RPGRIP1;Cone-rod dystrophy 13;17357067;605446;Cone-rod dystrophy 13, 608194 (3);608194
RPGRIP1;Leber congenital amaurosis 6;17357067;605446;Leber congenital amaurosis 6, 613826 (3);613826
RPGRIP1L;COACH syndrome;17357067;610937;COACH syndrome, 216360 (3);216360
RPGRIP1L;Joubert syndrome 7;17357067;610937;Joubert syndrome 7, 611560 (3);611560
RPGRIP1L;Meckel syndrome 5;17357067;610937;Meckel syndrome 5, 611561 (3);611561
RPL10;Autism, susceptibility to, X-linked 5;17357067;312173;{Autism, susceptibility to, X-linked 5}, 300847 (3);300847
RPL11;Diamond-Blackfan anemia 7;17357067;604175;Diamond-Blackfan anemia 7, 612562 (3);612562
RPL21;Hypotrichosis 12;17357067;603636;Hypotrichosis 12, 615885 (3);615885
RPL35A;Diamond-Blackfan anemia 5;17357067;180468;Diamond-Blackfan anemia 5, 612528 (3);612528
RPL5;Diamond-Blackfan anemia 6;17357067;603634;Diamond-Blackfan anemia 6, 612561 (3);612561
RPS10;Diamond-Blackfan anemia 9;17357067;603632;Diamond-Blackfan anemia 9, 613308 (3);613308
RPS14;Macrocytic anemia, refractory, due to 5q deletion, somatic;17357067;130620;Macrocytic anemia, refractory, due to 5q deletion, somatic, 153550 (3);153550
RPS17;Diamond-Blackfan anemia 4;17357067;180472;Diamond-Blackfan anemia 4, 612527 (3);612527
RPS19;Diamond-Blackfan anemia 1;17357067;603474;Diamond-Blackfan anemia 1, 105650 (3);105650
RPS24;Diamond-blackfan anemia 3;17357067;602412;Diamond-blackfan anemia 3, 610629 (3);610629
RPS26;Diamond-Blackfan anemia 10;17357067;603701;Diamond-Blackfan anemia 10, 613309 (3);613309
RPS28;Diamond Blackfan anemia 15 with mandibulofacial dysostosis;17357067;603685;Diamond Blackfan anemia 15 with mandibulofacial dysostosis, 606164 (3);606164
RPS29;Diamond-Blackfan anemia 13;17357067;603633;Diamond-Blackfan anemia 13, 615909 (3);615909
RPS6KA3;Coffin-Lowry syndrome;17357067;300075;Coffin-Lowry syndrome, 303600 (3);303600
RPS6KA3;Mental retardation, X-linked 19;17357067;300075;Mental retardation, X-linked 19, 300844 (3);300844
RPS7;Diamond-Blackfan anemia 8;17357067;603658;Diamond-Blackfan anemia 8, 612563 (3);612563
RPSA;Asplenia, isolated congenital;17357067;150370;Asplenia, isolated congenital, 271400 (3);271400
RRAS2;Ovarian carcinoma;17357067;600098;Ovarian carcinoma (3);0
RRM2B;Mitochondrial DNA depletion syndrome 8A (encephalomyopathic type with renal tubulopathy);17357067;604712;Mitochondrial DNA depletion syndrome 8A (encephalomyopathic type with renal tubulopathy), 612075 (3);612075
RRM2B;Mitochondrial DNA depletion syndrome 8B (MNGIE type);17357067;604712;Mitochondrial DNA depletion syndrome 8B (MNGIE type), 612075 (3);612075
RRM2B;Progressive external ophthalmoplegia with mitochondrial DNA deletions, autosomal dominant, 5;17357067;604712;Progressive external ophthalmoplegia with mitochondrial DNA deletions, autosomal dominant, 5, 613077 (3);613077
RS1;Retinoschisis;17357067;300839;Retinoschisis, 312700 (3);312700
RSPH1;Ciliary dyskinesia, primary, 24;17357067;609314;Ciliary dyskinesia, primary, 24, 615481 (3);615481
RSPH3;Ciliary dyskinesia, primary, 32;17357067;615876;Ciliary dyskinesia, primary, 32, 616481 (3);616481
RSPH4A;Ciliary dyskinesia, primary, 11;17357067;612647;Ciliary dyskinesia, primary, 11, 612649 (3);612649
RSPH9;Ciliary dyskinesia, primary, 12;17357067;612648;Ciliary dyskinesia, primary, 12, 612650 (3);612650
RSPO1;Palmoplantar hyperkeratosis and true hermaphroditism;17357067;609595;Palmoplantar hyperkeratosis and true hermaphroditism, 610644 (3);610644
RSPO1;Palmoplantar hyperkeratosis with squamous cell carcinoma of skin and sex reversal;17357067;609595;Palmoplantar hyperkeratosis with squamous cell carcinoma of skin and sex reversal, 610644 (3);610644
RSPO4;Anonychia congenita;17357067;610573;Anonychia congenita, 206800 (3);206800
RTEL1;Dyskeratosis congenita, autosomal dominant 4;17357067;608833;Dyskeratosis congenita, autosomal dominant 4, 615190 (3);615190
RTEL1;Dyskeratosis congenita, autosomal recessive 5;17357067;608833;Dyskeratosis congenita, autosomal recessive 5, 615190 (3);615190
RTEL1;Pulmonary fibrosis and/or bone marrow failure, telomere-related, 3;17357067;608833;Pulmonary fibrosis and/or bone marrow failure, telomere-related, 3, 616373 (3);616373
RTN2;Spastic paraplegia 12, autosomal dominant;17357067;603183;Spastic paraplegia 12, autosomal dominant, 604805 (3);604805
RTN4R;Schizophrenia, susceptibility to;17357067;605566;{Schizophrenia, susceptibility to}, 181500 (3);181500
RTTN;Polymicrogyria with seizures;17357067;610436;Polymicrogyria with seizures, 614833 (3);614833
RUNX1;Leukemia, acute myeloid;17357067;151385;Leukemia, acute myeloid, 601626 (3);601626
RUNX1;Platelet disorder, familial, with associated myeloid malignancy;17357067;151385;Platelet disorder, familial, with associated myeloid malignancy, 601399 (3);601399
RUNX2;Cleidocranial dysplasia;17357067;600211;Cleidocranial dysplasia, 119600 (3);119600
RUNX2;Cleidocranial dysplasia, forme fruste, dental anomalies only;17357067;600211;Cleidocranial dysplasia, forme fruste, dental anomalies only, 119600 (3);119600
RUNX2;Cleidocranial dysplasia, forme fruste, with brachydactyly;17357067;600211;Cleidocranial dysplasia, forme fruste, with brachydactyly, 119600 (3);119600
RUNX2;Metaphyseal dysplasia with maxillary hypoplasia with or without brachydactyly;17357067;600211;Metaphyseal dysplasia with maxillary hypoplasia with or without brachydactyly, 156510 (3);156510
RYR1;Central core disease;17357067;180901;Central core disease, 117000 (3);117000
RYR1;King-Denborough syndrome;17357067;180901;King-Denborough syndrome, 145600 (3);145600
RYR1;Malignant hyperthermia susceptibility 1;17357067;180901;{Malignant hyperthermia susceptibility 1}, 145600 (3);145600
RYR1;Minicore myopathy with external ophthalmoplegia;17357067;180901;Minicore myopathy with external ophthalmoplegia, 255320 (3);255320
RYR1;Neuromuscular disease, congenital, with uniform type 1 fiber;17357067;180901;Neuromuscular disease, congenital, with uniform type 1 fiber, 117000 (3);117000
RYR2;Arrhythmogenic right ventricular dysplasia 2;17357067;180902;Arrhythmogenic right ventricular dysplasia 2, 600996 (3);600996
RYR2;Ventricular tachycardia, catecholaminergic polymorphic, 1;17357067;180902;Ventricular tachycardia, catecholaminergic polymorphic, 1, 604772 (3);604772
SACS;Spastic ataxia, Charlevoix-Saguenay type;17357067;604490;Spastic ataxia, Charlevoix-Saguenay type, 270550 (3);270550
SAE1;Adams-Oliver syndrome 1;17357067;610911;Adams-Oliver syndrome 1, 100300 (3);100300
SAG;Oguchi disease-1;17357067;181031;Oguchi disease-1, 258100 (3);258100
SAG;Retinitis pigmentosa 47;17357067;181031;Retinitis pigmentosa 47, 613758 (3);613758
SALL1;Townes-Brocks branchiootorenal-like syndrome;17357067;602218;Townes-Brocks branchiootorenal-like syndrome, 107480 (3);107480
SALL1;Townes-Brocks syndrome;17357067;602218;Townes-Brocks syndrome, 107480 (3);107480
SALL4;Duane-radial ray syndrome;17357067;607343;Duane-radial ray syndrome, 607323 (3);607323
SALL4;IVIC syndrome;17357067;607343;IVIC syndrome, 147750 (3);147750
SAMD9;Tumoral calcinosis, familial, normophosphatemic;17357067;610456;Tumoral calcinosis, familial, normophosphatemic, 610455 (3);610455
SAMHD1;Aicardi-Goutieres syndrome 5;17357067;606754;Aicardi-Goutieres syndrome 5, 612952 (3);612952
SAMHD1;Chilblain lupus 2;17357067;606754;Chilblain lupus 2, 614415 (3);614415
SAR1B;Chylomicron retention disease;17357067;607690;Chylomicron retention disease, 246700 (3);246700
SARDH;Sarcosinemia;17357067;604455;[Sarcosinemia], 268900 (3);268900
SARS2;Hyperuricemia, pulmonary hypertension, renal failure, and alkalosis;17357067;612804;Hyperuricemia, pulmonary hypertension, renal failure, and alkalosis, 613845 (3);613845
SAT1;Keratosis follicularis spinulosa decalvans;17357067;313020;Keratosis follicularis spinulosa decalvans, 308800 (3);308800
SATB2;Glass syndrome;17357067;608148;Glass syndrome, 612313 (3);612313
SBDS;Aplastic anemia, susceptibility to;17357067;607444;{Aplastic anemia, susceptibility to}, 609135 (3);609135
SBDS;Shwachman-Diamond syndrome;17357067;607444;Shwachman-Diamond syndrome, 260400 (3);260400
SBF1;Charcot-Marie-Tooth disease, type 4B3;17357067;603560;Charcot-Marie-Tooth disease, type 4B3, 615284 (3);615284
SBF2;Charcot-Marie-Tooth disease, type 4B2;17357067;607697;Charcot-Marie-Tooth disease, type 4B2, 604563 (3);604563
SC5D;Lathosterolosis;17357067;602286;Lathosterolosis, 607330 (3);607330
SCARB1;High density lipoprotein cholesterol level QTL6;17357067;601040;[High density lipoprotein cholesterol level QTL6], 610762 (3);610762
SCARB2;Epilepsy, progressive myoclonic 4, with or without renal failure;17357067;602257;Epilepsy, progressive myoclonic 4, with or without renal failure, 254900 (3);254900
SCARF2;Van den Ende-Gupta syndrome;17357067;613619;Van den Ende-Gupta syndrome, 600920 (3);600920
SCD;Carnitine deficiency, systemic primary;17357067;603377;Carnitine deficiency, systemic primary, 212140 (3);212140
SCG3;Muscular dystrophy, limb-girdle, type 2C;17357067;608896;Muscular dystrophy, limb-girdle, type 2C, 253700 (3);253700
SCGB3A2;Asthma, susceptibility to;17357067;606531;{Asthma, susceptibility to}, 600807 (3);600807
SCN10A;Episodic pain syndrome, familial, 2;17357067;604427;Episodic pain syndrome, familial, 2, 615551 (3);615551
SCN11A;Episodic pain syndrome, familial, 3;17357067;604385;Episodic pain syndrome, familial, 3, 615552 (3);615552
SCN11A;Neuropathy, hereditary sensory and autonomic, type VII;17357067;604385;Neuropathy, hereditary sensory and autonomic, type VII, 615548 (3);615548
SCN1A;Dravet syndrome;17357067;182389;Dravet syndrome, 607208 (3);607208
SCN1A;Epilepsy, generalized, with febrile seizures plus, type 2;17357067;182389;Epilepsy, generalized, with febrile seizures plus, type 2, 604403 (3);604403
SCN1A;Febrile seizures, familial, 3A;17357067;182389;Febrile seizures, familial, 3A, 604403 (3);604403
SCN1A;Migraine, familial hemiplegic, 3;17357067;182389;Migraine, familial hemiplegic, 3, 609634 (3);609634
SCN1A;Neutropenia, cyclic;17357067;130130;Neutropenia, cyclic, 162800 (3);162800
SCN1A;Neutropenia, severe congenital 1, autosomal dominant;17357067;130130;Neutropenia, severe congenital 1, autosomal dominant, 202700 (3);202700
SCN1B;Atrial fibrillation, familial, 13;17357067;600235;Atrial fibrillation, familial, 13, 615377 (3);615377
SCN1B;Brugada syndrome 5;17357067;600235;Brugada syndrome 5, 612838 (3);612838
SCN1B;Cardiac conduction defect, nonspecific;17357067;600235;Cardiac conduction defect, nonspecific, 612838 (3);612838
SCN1B;Epilepsy, generalized, with febrile seizures plus, type 1;17357067;600235;Epilepsy, generalized, with febrile seizures plus, type 1, 604233 (3);604233
SCN2A;Epileptic encephalopathy, early infantile, 11;17357067;182390;Epileptic encephalopathy, early infantile, 11, 613721 (3);613721
SCN2A;Seizures, benign familial infantile, 3;17357067;182390;Seizures, benign familial infantile, 3, 607745 (3);607745
SCN2B;Atrial fibrillation, familial, 14;17357067;601327;Atrial fibrillation, familial, 14, 615378 (3);615378
SCN3B;Atrial fibrillation, familial, 16;17357067;608214;Atrial fibrillation, familial, 16, 613120 (3);613120
SCN3B;Brugada syndrome 7;17357067;608214;Brugada syndrome 7, 613120 (3);613120
SCN4A;Brugada syndrome 6;17357067;604433;Brugada syndrome 6, 613119 (3);613119
SCN4A;Hyperkalemic periodic paralysis, type 2;17357067;603967;Hyperkalemic periodic paralysis, type 2, 170500 (3);170500
SCN4A;Hypokalemic periodic paralysis, type 2;17357067;603967;Hypokalemic periodic paralysis, type 2, 613345 (3);613345
SCN4A;Myasthenic syndrome, congenital, 16;17357067;603967;Myasthenic syndrome, congenital, 16, 614198 (3);614198
SCN4A;Myotonia congenita, atypical, acetazolamide-responsive;17357067;603967;Myotonia congenita, atypical, acetazolamide-responsive, 608390 (3);608390
SCN4A;Paramyotonia congenita;17357067;603967;Paramyotonia congenita, 168300 (3);168300
SCN4B;Atrial fibrillation, familial, 17;17357067;608256;Atrial fibrillation, familial, 17, 611819 (3);611819
SCN4B;Long QT syndrome-10;17357067;608256;Long QT syndrome-10, 611819 (3);611819
SCN5A;Atrial fibrillation, familial, 10;17357067;600163;Atrial fibrillation, familial, 10, 614022 (3);614022
SCN5A;Brugada syndrome 1;17357067;600163;Brugada syndrome 1, 601144 (3);601144
SCN5A;Cardiomyopathy, dilated, 1E;17357067;600163;Cardiomyopathy, dilated, 1E, 601154 (3);601154
SCN5A;Heart block, nonprogressive;17357067;600163;Heart block, nonprogressive, 113900 (3);113900
SCN5A;Heart block, progressive, type IA;17357067;600163;Heart block, progressive, type IA, 113900 (3);113900
SCN5A;Hypogonadotropic hypogonadism 1 with or without anosmia (Kallmann syndrome 1);17357067;300836;Hypogonadotropic hypogonadism 1 with or without anosmia (Kallmann syndrome 1), 308700 (3);308700
SCN5A;Long QT syndrome-3;17357067;600163;Long QT syndrome-3, 603830 (3);603830
SCN5A;Monilethrix;17357067;602153;Monilethrix, 158000 (3);158000
SCN5A;Sick sinus syndrome 1;17357067;600163;Sick sinus syndrome 1, 608567 (3);608567
SCN5A;Sudden infant death syndrome, susceptibility to;17357067;600163;{Sudden infant death syndrome, susceptibility to}, 272120 (3);272120
SCN5A;Ventricular fibrillation, familial, 1;17357067;600163;Ventricular fibrillation, familial, 1, 603829 (3);603829
SCN8A;Epileptic encephalopathy, early infantile, 13;17357067;600702;Epileptic encephalopathy, early infantile, 13, 614558 (3);614558
SCN9A;Dravet syndrome, modifier of;17357067;603415;{Dravet syndrome, modifier of}, 607208 (3);607208
SCN9A;Epilepsy, generalized, with febrile seizures plus, type 7;17357067;603415;Epilepsy, generalized, with febrile seizures plus, type 7, 613863 (3);613863
SCN9A;Erythermalgia, primary;17357067;603415;Erythermalgia, primary, 133020 (3);133020
SCN9A;Febrile seizures, familial, 3B;17357067;603415;Febrile seizures, familial, 3B, 613863 (3);613863
SCN9A;HSAN2D, autosomal recessive;17357067;603415;HSAN2D, autosomal recessive, 243000 (3);243000
SCN9A;Insensitivity to pain, congenital;17357067;603415;Insensitivity to pain, congenital, 243000 (3);243000
SCN9A;Paroxysmal extreme pain disorder, 1;17357067;603415;Paroxysmal extreme pain disorder, 167400, (3);167400
SCN9A;Small fiber neuropathy;17357067;603415;Small fiber neuropathy, 133020 (3);133020
SCNN1A;Bronchiectasis with or without elevated sweat chloride 2;17357067;600228;Bronchiectasis with or without elevated sweat chloride 2, 613021 (3);613021
SCNN1A;Pseudohypoaldosteronism, type I;17357067;600228;Pseudohypoaldosteronism, type I, 264350 (3);264350
SCNN1B;Bronchiectasis with or without elevated sweat chloride 1;17357067;600760;Bronchiectasis with or without elevated sweat chloride 1, 211400 (3);211400
SCNN1B;Liddle syndrome;17357067;600760;Liddle syndrome, 177200 (3);177200
SCNN1B;Pseudohypoaldosteronism, type I;17357067;600760;Pseudohypoaldosteronism, type I, 264350 (3);264350
SCNN1G;Bronchiectasis with or without elevated sweat chloride 3;17357067;600761;Bronchiectasis with or without elevated sweat chloride 3, 613071 (3);613071
SCNN1G;Liddle syndrome;17357067;600761;Liddle syndrome, 177200 (3);177200
SCNN1G;Pseudohypoaldosteronism, type I;17357067;600761;Pseudohypoaldosteronism, type I, 264350 (3);264350
SCO1;Hepatic failure, early onset, and neurologic disorder;17357067;603644;Hepatic failure, early onset, and neurologic disorder (3);0
SCO2;Cardioencephalomyopathy, fatal infantile, due to cytochrome c oxidase deficiency 1;17357067;604272;Cardioencephalomyopathy, fatal infantile, due to cytochrome c oxidase deficiency 1, 604377 (3);604377
SCO2;Myopia 6;17357067;604272;Myopia 6, 608908 (3);608908
SCP2;Leukoencephalopathy with dystonia and motor neuropathy;17357067;184755;Leukoencephalopathy with dystonia and motor neuropathy, 613724 (3);613724
SCT;Atelosteogenesis, type I;17357067;603381;Atelosteogenesis, type I, 108720 (3);108720
SCT;Atelosteogenesis, type III;17357067;603381;Atelosteogenesis, type III, 108721 (3);108721
SCT;Boomerang dysplasia;17357067;603381;Boomerang dysplasia, 112310 (3);112310
SCT;Larsen syndrome;17357067;603381;Larsen syndrome, 150250 (3);150250
SCT;Spondylocarpotarsal synostosis syndrome;17357067;603381;Spondylocarpotarsal synostosis syndrome, 272460 (3);272460
SDC3;Obesity, association with;17357067;186357;{Obesity, association with}, 601665 (3);601665
SDCCAG8;Bardet-Biedl syndrome 16;17357067;613524;Bardet-Biedl syndrome 16, 615993 (3);615993
SDCCAG8;Senior-Loken syndrome 7;17357067;613524;Senior-Loken syndrome 7, 613615 (3);613615
SDHA;Cardiomyopathy, dilated, 1GG;17357067;600857;Cardiomyopathy, dilated, 1GG, 613642 (3);613642
SDHA;Cowden syndrome 2;17357067;185470;Cowden syndrome 2, 612359 (3);612359
SDHA;Gastrointestinal stromal tumor;17357067;185470;Gastrointestinal stromal tumor, 606764 (3);606764
SDHA;Leigh syndrome;17357067;600857;Leigh syndrome, 256000 (3);256000
SDHA;Mitochondrial respiratory chain complex II deficiency;17357067;600857;Mitochondrial respiratory chain complex II deficiency, 252011 (3);252011
SDHA;Paraganglioma and gastric stromal sarcoma;17357067;185470;Paraganglioma and gastric stromal sarcoma, 606864 (3);606864
SDHA;Paragangliomas 4;17357067;185470;Paragangliomas 4, 115310 (3);115310
SDHA;Paragangliomas 5;17357067;600857;Paragangliomas 5, 614165 (3);614165
SDHA;Pheochromocytoma;17357067;185470;Pheochromocytoma, 171300 (3);171300
SDHAF1;Mitochondrial complex II deficiency;17357067;612848;Mitochondrial complex II deficiency, 252011 (3);252011
SDHAF2;Paragangliomas 2;17357067;613019;Paragangliomas 2, 601650 (3);601650
SDHB;Cardiomyopathy, dilated, 1GG;17357067;600857;Cardiomyopathy, dilated, 1GG, 613642 (3);613642
SDHB;Cowden syndrome 2;17357067;185470;Cowden syndrome 2, 612359 (3);612359
SDHB;Gastrointestinal stromal tumor;17357067;185470;Gastrointestinal stromal tumor, 606764 (3);606764
SDHB;Leigh syndrome;17357067;600857;Leigh syndrome, 256000 (3);256000
SDHB;Mitochondrial respiratory chain complex II deficiency;17357067;600857;Mitochondrial respiratory chain complex II deficiency, 252011 (3);252011
SDHB;Paraganglioma and gastric stromal sarcoma;17357067;185470;Paraganglioma and gastric stromal sarcoma, 606864 (3);606864
SDHB;Paragangliomas 4;17357067;185470;Paragangliomas 4, 115310 (3);115310
SDHB;Paragangliomas 5;17357067;600857;Paragangliomas 5, 614165 (3);614165
SDHB;Pheochromocytoma;17357067;185470;Pheochromocytoma, 171300 (3);171300
SDHC;Gastrointestinal stromal tumor;17357067;602413;Gastrointestinal stromal tumor, 606764 (3);606764
SDHC;Paraganglioma and gastric stromal sarcoma;17357067;602413;Paraganglioma and gastric stromal sarcoma, 606864 (3);606864
SDHC;Paragangliomas 3;17357067;602413;Paragangliomas 3, 605373 (3);605373
SDHD;Carcinoid tumors, intestinal;17357067;602690;Carcinoid tumors, intestinal, 114900 (3);114900
SDHD;Cowden syndrome 3;17357067;602690;Cowden syndrome 3, 615106 (3);615106
SDHD;Merkel cell carcinoma, somatic;17357067;602690;Merkel cell carcinoma, somatic (3);0
SDHD;Mitochondrial complex II deficiency;17357067;602690;Mitochondrial complex II deficiency, 252011 (3);252011
SDHD;Paraganglioma and gastric stromal sarcoma;17357067;602690;Paraganglioma and gastric stromal sarcoma, 606864 (3);606864
SDHD;Paragangliomas 1, with or without deafness;17357067;602690;Paragangliomas 1, with or without deafness, 168000 (3);168000
SDHD;Pheochromocytoma;17357067;602690;Pheochromocytoma, 171300 (3);171300
SDS;Aplastic anemia, susceptibility to;17357067;607444;{Aplastic anemia, susceptibility to}, 609135 (3);609135
SDS;Shwachman-Diamond syndrome;17357067;607444;Shwachman-Diamond syndrome, 260400 (3);260400
SEC23A;Craniolenticulosutural dysplasia;17357067;610511;Craniolenticulosutural dysplasia, 607812 (3);607812
SEC23B;Dyserythropoietic anemia, congenital, type II;17357067;610512;Dyserythropoietic anemia, congenital, type II, 224100 (3);224100
SEC24D;Cole-Carpenter syndrome 2;17357067;607186;Cole-Carpenter syndrome 2, 616294 (3);616294
SEC63;Polycystic liver disease;17357067;608648;Polycystic liver disease, 174050 (3);174050
SECISBP2;Thyroid hormone metabolism, abnormal;17357067;607693;Thyroid hormone metabolism, abnormal, 609698 (3);609698
SEL1L;Inflammatory bowel disease 2;17357067;601458;{Inflammatory bowel disease 2} (2);0
SELE;Blood pressure regulation QTL;17357067;131210;[Blood pressure regulation QTL], 145500 (2);145500
SELP;Atopy, susceptibility to;17357067;173610;{Atopy, susceptibility to}, 147050 (3);147050
SEMA3A;Hypogonadotropic hypogonadism 16 with or without anosmia;17357067;603961;{Hypogonadotropic hypogonadism 16 with or without anosmia}, 614897 (3);614897
SEMA3E;CHARGE syndrome;17357067;608166;CHARGE syndrome, 214800 (3);214800
SEMA4A;Cone-rod dystrophy 10;17357067;607292;Cone-rod dystrophy 10, 610283 (3);610283
SEMA4A;Retinitis pigmentosa 35;17357067;607292;Retinitis pigmentosa 35, 610282 (3);610282
SEMA7A;Blood group, John-Milton-Hagen system;17357067;607961;[Blood group, John-Milton-Hagen system], 614745 (3);614745
SEPN1;Muscular dystrophy, rigid spine, 1;17357067;606210;Muscular dystrophy, rigid spine, 1, 602771 (3);602771
SEPN1;Myopathy, congenital, with fiber-type disproportion;17357067;606210;Myopathy, congenital, with fiber-type disproportion, 255310 (3);255310
SEPN1;Silver-Russell syndrome;17357067;180860;Silver-Russell syndrome (4);0
SEPSECS;Pontocerebellar hypoplasia type 2D;17357067;613009;Pontocerebellar hypoplasia type 2D, 613811 (3);613811
SEPT12;Spermatogenic failure 10;17357067;611562;Spermatogenic failure 10, 614822 (3);614822
SEPT9;Amyotrophy, hereditary neuralgic;17357067;604061;Amyotrophy, hereditary neuralgic, 162100 (3);162100
SEPT9;Leukemia, acute myeloid, therapy-related;17357067;604061;Leukemia, acute myeloid, therapy-related (1);0
SEPT9;Ovarian carcinoma;17357067;604061;Ovarian carcinoma (1);0
SERAC1;3-methylglutaconic aciduria with deafness, encephalopathy, and Leigh-like syndrome;17357067;614725;3-methylglutaconic aciduria with deafness, encephalopathy, and Leigh-like syndrome, 614739 (3);614739
SERPINA1;Emphysema due to AAT deficiency;17357067;107400;Emphysema due to AAT deficiency, 613490 (3);613490
SERPINA1;Emphysema-cirrhosis, due to AAT deficiency;17357067;107400;Emphysema-cirrhosis, due to AAT deficiency, 613490 (3);613490
SERPINA1;Hemorrhagic diathesis due to \'antithrombin\' Pittsburgh;17357067;107400;Hemorrhagic diathesis due to \'antithrombin\' Pittsburgh, 613490 (3);613490
SERPINA1;Pulmonary disease, chronic obstructive, susceptibility to;17357067;107400;{Pulmonary disease, chronic obstructive, susceptibility to}, 606963 (1);606963
SERPINA3;Alpha-1-antichymotrypsin deficiency;17357067;107280;Alpha-1-antichymotrypsin deficiency (3);0
SERPINA3;Cerebrovascular disease, occlusive;17357067;107280;Cerebrovascular disease, occlusive (3);0
SERPINA6;Corticosteroid-binding globulin deficiency;17357067;122500;Corticosteroid-binding globulin deficiency, 611489 (3);611489
SERPINA7;Thyroxine-binding globulin deficiency;17357067;314200;Thyroxine-binding globulin deficiency (3);0
SERPINB7;Palmoplantar keratoderma, Nagashima type;17357067;603357;Palmoplantar keratoderma, Nagashima type, 615598 (3);615598
SERPINC1;Thrombophilia due to antithrombin III deficiency;17357067;107300;Thrombophilia due to antithrombin III deficiency, 613118 (3);613118
SERPIND1;Acrocallosal syndrome;17357067;611254;Acrocallosal syndrome, 200990 (3);200990
SERPIND1;Hydrolethalus syndrome 2;17357067;611254;Hydrolethalus syndrome 2, 614120 (3);614120
SERPIND1;Joubert syndrome 12;17357067;611254;Joubert syndrome 12, 200990 (3);200990
SERPIND1;Thrombophilia due to heparin cofactor II deficiency;17357067;142360;Thrombophilia due to heparin cofactor II deficiency, 612356 (3);612356
SERPINE1;Plasminogen activator inhibitor-1 deficiency;17357067;173360;Plasminogen activator inhibitor-1 deficiency, 613329 (3);613329
SERPINE1;Transcription of plasminogen activator inhibitor, modulator of;17357067;173360;{Transcription of plasminogen activator inhibitor, modulator of} (3);0
SERPINF1;Osteogenesis imperfecta, type VI;17357067;172860;Osteogenesis imperfecta, type VI, 613982 (3);613982
SERPINF2;Alpha-2-plasmin inhibitor deficiency;17357067;613168;Alpha-2-plasmin inhibitor deficiency, 262850 (3);262850
SERPING1;Angioedema, hereditary, types I and II;17357067;606860;Angioedema, hereditary, types I and II, 106100 (3);106100
SERPING1;Complement component 4, partial deficiency of;17357067;606860;Complement component 4, partial deficiency of, 120790 (3);120790
SERPINH1;Osteogenesis imperfecta, type X;17357067;600943;Osteogenesis imperfecta, type X, 613848 (3);613848
SERPINH1;Preterm premature rupture of the membranes, susceptibility to;17357067;600943;{Preterm premature rupture of the membranes, susceptibility to}, 610504 (3);610504
SERPINI1;Encephalopathy, familial, with neuroserpin inclusion bodies;17357067;602445;Encephalopathy, familial, with neuroserpin inclusion bodies, 604218 (3);604218
SETBP1;Mental retardation, autosomal dominant 29;17357067;611060;Mental retardation, autosomal dominant 29, 616078 (3);616078
SETBP1;Schinzel-Giedion midface retraction syndrome;17357067;611060;Schinzel-Giedion midface retraction syndrome, 269150 (3);269150
SETD5;Mental retardation, autosomal dominant 23;17357067;615743;Mental retardation, autosomal dominant 23, 615761 (3);615761
SETX;Amyotrophic lateral sclerosis 4, juvenile;17357067;608465;Amyotrophic lateral sclerosis 4, juvenile, 602433 (3);602433
SETX;Spinocerebellar ataxia, autosomal recessive 1;17357067;608465;Spinocerebellar ataxia, autosomal recessive 1, 606002 (3);606002
SF1;46XY sex reversal 3;17357067;184757;46XY sex reversal 3, 612965 (3);612965
SF1;Adrenocortical insufficiency;17357067;184757;Adrenocortical insufficiency (3);0
SF1;Premature ovarian failure 7;17357067;184757;Premature ovarian failure 7, 612964 (3);612964
SF1;Spermatogenic failure 8;17357067;184757;Spermatogenic failure 8, 613957 (3);613957
SF3B1;Myelodysplastic syndrome, somatic;17357067;605590;Myelodysplastic syndrome, somatic, 614286 (3);614286
SF3B4;Acrofacial dysostosis 1, Nager type;17357067;605593;Acrofacial dysostosis 1, Nager type, 154400 (3);154400
SFTPA1;Pulmonary fibrosis, idiopathic, susceptibility to;17357067;178630;{Pulmonary fibrosis, idiopathic, susceptibility to}, 178500 (3);178500
SFTPA2;Pulmonary fibrosis, idiopathic;17357067;178642;Pulmonary fibrosis, idiopathic, 178500 (3);178500
SFTPB;Surfactant metabolism dysfunction, pulmonary, 1;17357067;178640;Surfactant metabolism dysfunction, pulmonary, 1, 265120 (3);265120
SFTPC;Surfactant metabolism dysfunction, pulmonary, 2;17357067;178620;Surfactant metabolism dysfunction, pulmonary, 2, 610913 (3);610913
SFXN4;Combined oxidative phosphorylation deficiency 18;17357067;615564;Combined oxidative phosphorylation deficiency 18, 615578 (3);615578
SGCA;Muscular dystrophy, limb-girdle, type 2D;17357067;600119;Muscular dystrophy, limb-girdle, type 2D, 608099 (3);608099
SGCB;Muscular dystrophy, limb-girdle, type 2E;17357067;600900;Muscular dystrophy, limb-girdle, type 2E, 604286 (3);604286
SGCD;Cardiomyopathy, dilated, 1L;17357067;601411;Cardiomyopathy, dilated, 1L, 606685 (3);606685
SGCD;Muscular dystrophy, limb-girdle, type 2F;17357067;601411;Muscular dystrophy, limb-girdle, type 2F, 601287 (3);601287
SGCE;Dystonia-11, myoclonic;17357067;604149;Dystonia-11, myoclonic, 159900 (3);159900
SGCG;Muscular dystrophy, limb-girdle, type 2C;17357067;608896;Muscular dystrophy, limb-girdle, type 2C, 253700 (3);253700
SGOL1;Chronic atrial and intestinal dysrhythmia;17357067;609168;Chronic atrial and intestinal dysrhythmia, 616201 (3);616201
SGSH;Mucopolysaccharidisis type IIIA (Sanfilippo A);17357067;605270;Mucopolysaccharidisis type IIIA (Sanfilippo A), 252900 (3);252900
SH2B3;Diabetes mellitus, insulin-dependent;17357067;142410;{Diabetes mellitus, insulin-dependent}, 222100 (3);222100
SH2B3;Diabetes mellitus, insulin-dependent, 20;17357067;142410;Diabetes mellitus, insulin-dependent, 20, 612520 (3);612520
SH2B3;Diabetes mellitus, noninsulin-dependent, 2;17357067;142410;{Diabetes mellitus, noninsulin-dependent, 2}, 125853 (3);125853
SH2B3;Erythrocytosis, somatic;17357067;605093;Erythrocytosis, somatic, 133100 (3);133100
SH2B3;Hepatic adenoma, somatic;17357067;142410;Hepatic adenoma, somatic, 142330 (3);142330
SH2B3;MODY, type III;17357067;142410;MODY, type III, 600496 (3);600496
SH2B3;Myelofibrosis, somatic;17357067;605093;Myelofibrosis, somatic, 254450 (3);254450
SH2B3;Renal cell carcinoma;17357067;142410;Renal cell carcinoma, 144700 (3);144700
SH2B3;Thrombocythemia, somatic;17357067;605093;Thrombocythemia, somatic, 187950 (3);187950
SH2D1A;Lymphoproliferative syndrome, X-linked, 1;17357067;300490;Lymphoproliferative syndrome, X-linked, 1, 308240 (3);308240
SH3BP2;Cherubism;17357067;602104;Cherubism, 118400 (3);118400
SH3GL1;Leukemia, acute myeloid;17357067;601768;Leukemia, acute myeloid, 601626 (1);601626
SH3PXD2B;Frank-ter Haar syndrome;17357067;613293;Frank-ter Haar syndrome, 249420 (3);249420
SH3TC2;Charcot-Marie-Tooth disease, type 4C;17357067;608206;Charcot-Marie-Tooth disease, type 4C, 601596 (3);601596
SH3TC2;Mononeuropathy of the median nerve, mild;17357067;608206;Mononeuropathy of the median nerve, mild, 613353 (3);613353
SHANK2;Autism susceptibility 17;17357067;603290;{Autism susceptibility 17}, 613436 (3);613436
SHANK3;Phelan-McDermid syndrome;17357067;606230;Phelan-McDermid syndrome, 606232 (3);606232
SHANK3;Schizophrenia 15;17357067;606230;{Schizophrenia 15}, 613950 (3);613950
SHFM1;Split hand/foot malformation 1;17357067;183600;Split hand/foot malformation 1 (4);0
SHH;Holoprosencephaly-3;17357067;600725;Holoprosencephaly-3, 142945 (3);142945
SHH;Microphthalmia with coloboma 5;17357067;600725;Microphthalmia with coloboma 5, 611638 (3);611638
SHH;Schizencephaly;17357067;600725;Schizencephaly, 269160 (3);269160
SHH;Single median maxillary central incisor;17357067;600725;Single median maxillary central incisor, 147250 (3);147250
SHOC2;Noonan-like syndrome with loose anagen hair;17357067;602775;Noonan-like syndrome with loose anagen hair, 607721 (3);607721
SHOX;Langer mesomelic dysplasia;17357067;312865;Langer mesomelic dysplasia, 249700 (3);249700
SHOX;Leri-Weill dyschondrosteosis;17357067;312865;Leri-Weill dyschondrosteosis, 127300 (3);127300
SHOX;Short stature, idiopathic familial;17357067;312865;Short stature, idiopathic familial, 300582 (3);300582
SI;Sucrase-isomaltase deficiency, congenital;17357067;609845;Sucrase-isomaltase deficiency, congenital, 222900 (3);222900
SIAE;Autoimmune disease, susceptibility to, 6;17357067;610079;{Autoimmune disease, susceptibility to, 6}, 613551 (3);613551
SIGMAR1;Amyotrophic lateral sclerosis 16, juvenile;17357067;601978;Amyotrophic lateral sclerosis 16, juvenile, 614373 (3);614373
SIK1;Epileptic encephalopathy, early infantile, 30;17357067;605705;Epileptic encephalopathy, early infantile, 30, 616341 (3);616341
SIL1;Marinesco-Sjogren syndrome;17357067;608005;Marinesco-Sjogren syndrome, 248800 (3);248800
SIM1;Obesity, severe;17357067;603128;Obesity, severe, 601665 (3);601665
SIX1;Brachiootic syndrome 3;17357067;601205;Brachiootic syndrome 3, 608389 (3);608389
SIX1;Deafness, autosomal dominant 23;17357067;601205;Deafness, autosomal dominant 23, 605192 (3);605192
SIX3;Holoprosencephaly-2;17357067;603714;Holoprosencephaly-2, 157170 (3);157170
SIX3;Schizencephaly;17357067;603714;Schizencephaly, 269160 (3);269160
SIX5;Branchiootorenal syndrome 2;17357067;600963;Branchiootorenal syndrome 2, 610896 (3);610896
SIX6;Optic disc anomalies with retinal and/or macular dystrophy;17357067;606326;Optic disc anomalies with retinal and/or macular dystrophy, 212550 (3);212550
SKI;Shprintzen-Goldberg syndrome;17357067;164780;Shprintzen-Goldberg syndrome, 182212 (3);182212
SKIV2L;Trichohepatoenteric syndrome 2;17357067;600478;Trichohepatoenteric syndrome 2, 614602 (3);614602
SLA;Pontocerebellar hypoplasia type 2D;17357067;613009;Pontocerebellar hypoplasia type 2D, 613811 (3);613811
SLC10A2;Bile acid malabsorption, primary;17357067;601295;Bile acid malabsorption, primary, 613291 (3);613291
SLC11A1;Buruli ulcer, susceptibility to;17357067;600266;{Buruli ulcer, susceptibility to}, 610446 (3);610446
SLC11A1;Mycobacterium tuberculosis, susceptibility to infection by;17357067;600266;{Mycobacterium tuberculosis, susceptibility to infection by}, 607948 (3);607948
SLC11A2;Anemia, hypochromic microcytic;17357067;600523;Anemia, hypochromic microcytic, 206100 (3);206100
SLC12A1;Bartter syndrome, type 1;17357067;600839;Bartter syndrome, type 1, 601678 (3);601678
SLC12A3;Gitelman syndrome;17357067;600968;Gitelman syndrome, 263800 (3);263800
SLC12A6;Agenesis of the corpus callosum with peripheral neuropathy;17357067;604878;Agenesis of the corpus callosum with peripheral neuropathy, 218000 (3);218000
SLC13A5;Epileptic encephalopathy, early infantile, 25;17357067;608305;Epileptic encephalopathy, early infantile, 25, 615905 (3);615905
SLC14A1;Blood group, Kidd;17357067;613868;[Blood group, Kidd], 111000 (3);111000
SLC16A1;Erythrocyte lactate transporter defect;17357067;600682;Erythrocyte lactate transporter defect, 245340 (3);245340
SLC16A1;Hyperinsulinemic hypoglycemia, familial, 7;17357067;600682;Hyperinsulinemic hypoglycemia, familial, 7, 610021 (3);610021
SLC16A1;Monocarboxylate transporter 1 deficiency;17357067;600682;Monocarboxylate transporter 1 deficiency, 616095 (3);616095
SLC16A10;Spermatogenic failure 3;17357067;608480;Spermatogenic failure 3, 606766 (3);606766
SLC16A12;Cataract, juvenile, with microcornea and glucosuria;17357067;611910;Cataract, juvenile, with microcornea and glucosuria, 612018 (3);612018
SLC16A2;Allan-Herndon-Dudley syndrome;17357067;300095;Allan-Herndon-Dudley syndrome, 300523 (3);300523
SLC17A2;Fanconi renotubular syndrome 2;17357067;182309;Fanconi renotubular syndrome 2, 613388 (3);613388
SLC17A2;Nephrolithiasis/osteoporosis, hypophosphatemic, 1;17357067;182309;Nephrolithiasis/osteoporosis, hypophosphatemic, 1, 612286 (3);612286
SLC17A3;Gout susceptibility 4;17357067;611034;{Gout susceptibility 4}, 612671 (3);612671
SLC17A3;Uric acid concentration, serum, QTL4;17357067;611034;[Uric acid concentration, serum, QTL4], 612671 (3);612671
SLC17A5;Salla disease;17357067;604322;Salla disease, 604369 (3);604369
SLC17A5;Sialic acid storage disorder, infantile;17357067;604322;Sialic acid storage disorder, infantile, 269920 (3);269920
SLC17A8;Deafness, autosomal dominant 25;17357067;607557;Deafness, autosomal dominant 25, 605583 (3);605583
SLC17A9;Porokeratosis 8, disseminated superficial actinic type;17357067;612107;Porokeratosis 8, disseminated superficial actinic type, 616063 (3);616063
SLC19A2;Thiamine-responsive megaloblastic anemia syndrome;17357067;603941;Thiamine-responsive megaloblastic anemia syndrome, 249270 (3);249270
SLC19A3;Thiamine metabolism dysfunction syndrome 2 (biotin- or thiamine-responsive encephalopathy type 2);17357067;606152;Thiamine metabolism dysfunction syndrome 2 (biotin- or thiamine-responsive encephalopathy type 2), 607483 (3);607483
SLC1A1;Dicarboxylic aminoaciduria;17357067;133550;Dicarboxylic aminoaciduria, 222730 (3);222730
SLC1A3;Episodic ataxia, type 6;17357067;600111;Episodic ataxia, type 6, 612656 (3);612656
SLC20A2;Basal ganglia calcification, idiopathic, 1;17357067;158378;Basal ganglia calcification, idiopathic, 1, 213600 (3);213600
SLC22A12;Hypouricemia, renal;17357067;607096;Hypouricemia, renal, 220150 (3);220150
SLC22A18;Breast cancer, somatic;17357067;602631;Breast cancer, somatic, 114480 (3);114480
SLC22A18;Lung cancer, somatic;17357067;602631;Lung cancer, somatic, 211980 (3);211980
SLC22A18;Rhabdomyosarcoma, somatic;17357067;602631;Rhabdomyosarcoma, somatic, 268210 (3);268210
SLC22A4;Rheumatoid arthritis, susceptibility to;17357067;604190;{Rheumatoid arthritis, susceptibility to}, 180300 (3);180300
SLC22A5;Carnitine deficiency, systemic primary;17357067;603377;Carnitine deficiency, systemic primary, 212140 (3);212140
SLC24A1;Night blindness, congenital stationary (complete), 1D, autosomal recessive;17357067;603617;Night blindness, congenital stationary (complete), 1D, autosomal recessive, 613830 (3);613830
SLC24A4;Amelogenesis imperfecta, type IIA5;17357067;609840;Amelogenesis imperfecta, type IIA5, 615887 (3);615887
SLC24A4;Skin/hair/eye pigmentation 6, blond/brown hair;17357067;609840;[Skin/hair/eye pigmentation 6, blond/brown hair], 210750 (3);210750
SLC24A4;Skin/hair/eye pigmentation 6, blue/green eyes;17357067;609840;[Skin/hair/eye pigmentation 6, blue/green eyes], 210750 (3);210750
SLC24A5;Albinism, oculocutaneous, type VI;17357067;609802;Albinism, oculocutaneous, type VI, 113750 (3);113750
SLC24A5;Skin/hair/eye pigmentation 4, fair/dark skin;17357067;609802;[Skin/hair/eye pigmentation 4, fair/dark skin], 113750 (3);113750
SLC25A1;Combined D-2- and L-2-hydroxyglutaric aciduria;17357067;190315;Combined D-2- and L-2-hydroxyglutaric aciduria, 615182 (3);615182
SLC25A12;Hypomyelination, global cerebral;17357067;603667;Hypomyelination, global cerebral, 612949 (3);612949
SLC25A13;Citrullinemia, adult-onset type II;17357067;603859;Citrullinemia, adult-onset type II, 603471 (3);603471
SLC25A13;Citrullinemia, type II, neonatal-onset;17357067;603859;Citrullinemia, type II, neonatal-onset, 605814 (3);605814
SLC25A15;Hyperornithinemia-hyperammonemia-homocitrullinemia syndrome;17357067;603861;Hyperornithinemia-hyperammonemia-homocitrullinemia syndrome, 238970 (3);238970
SLC25A19;Microcephaly, Amish type;17357067;606521;Microcephaly, Amish type, 607196 (3);607196
SLC25A19;Thiamine metabolism dysfunction syndrome 4 (progressive polyneuropathy type);17357067;606521;Thiamine metabolism dysfunction syndrome 4 (progressive polyneuropathy type), 613710 (3);613710
SLC25A20;Carnitine-acylcarnitine translocase deficiency;17357067;613698;Carnitine-acylcarnitine translocase deficiency, 212138 (3);212138
SLC25A22;Epileptic encephalopathy, early infantile, 3;17357067;609302;Epileptic encephalopathy, early infantile, 3, 609304 (3);609304
SLC25A3;Mitochondrial phosphate carrier deficiency;17357067;600370;Mitochondrial phosphate carrier deficiency, 610773 (3);610773
SLC25A38;Anemia, sideroblastic, pyridoxine-refractory, autosomal recessive;17357067;610819;Anemia, sideroblastic, pyridoxine-refractory, autosomal recessive, 205950 (3);205950
SLC25A4;Mitochondrial DNA depletion syndrome 12 (cardiomyopathic type);17357067;103220;Mitochondrial DNA depletion syndrome 12 (cardiomyopathic type), 615418 (3);615418
SLC25A4;Progressive external ophthalmoplegia with mitochondrial DNA deletions 2;17357067;103220;Progressive external ophthalmoplegia with mitochondrial DNA deletions 2, 609283 (3);609283
SLC25A4;Retinitis pigmentosa 60;17357067;613979;Retinitis pigmentosa 60, 613983 (3);613983
SLC25A46;Neuropathy, hereditary motor and sensory, type VIB;17357067;610826;Neuropathy, hereditary motor and sensory, type VIB, 616505 (3);616505
SLC26A1;Achondrogenesis Ib;17357067;606718;Achondrogenesis Ib, 600972 (3);600972
SLC26A1;Atelosteogenesis II;17357067;606718;Atelosteogenesis II, 256050 (3);256050
SLC26A1;De la Chapelle dysplasia;17357067;606718;De la Chapelle dysplasia, 256050 (3);256050
SLC26A1;Diastrophic dysplasia;17357067;606718;Diastrophic dysplasia, 222600 (3);222600
SLC26A1;Diastrophic dysplasia, broad bone-platyspondylic variant;17357067;606718;Diastrophic dysplasia, broad bone-platyspondylic variant, 222600 (3);222600
SLC26A1;Epiphyseal dysplasia, multiple, 4;17357067;606718;Epiphyseal dysplasia, multiple, 4, 226900 (3);226900
SLC26A2;Achondrogenesis Ib;17357067;606718;Achondrogenesis Ib, 600972 (3);600972
SLC26A2;Atelosteogenesis II;17357067;606718;Atelosteogenesis II, 256050 (3);256050
SLC26A2;De la Chapelle dysplasia;17357067;606718;De la Chapelle dysplasia, 256050 (3);256050
SLC26A2;Diastrophic dysplasia;17357067;606718;Diastrophic dysplasia, 222600 (3);222600
SLC26A2;Diastrophic dysplasia, broad bone-platyspondylic variant;17357067;606718;Diastrophic dysplasia, broad bone-platyspondylic variant, 222600 (3);222600
SLC26A2;Epiphyseal dysplasia, multiple, 4;17357067;606718;Epiphyseal dysplasia, multiple, 4, 226900 (3);226900
SLC26A3;Diarrhea 1, secretory chloride, congenital;17357067;126650;Diarrhea 1, secretory chloride, congenital, 214700 (3);214700
SLC26A4;Deafness, autosomal recessive 4, with enlarged vestibular aqueduct;17357067;605646;Deafness, autosomal recessive 4, with enlarged vestibular aqueduct, 600791 (3);600791
SLC26A4;Pendred syndrome;17357067;605646;Pendred syndrome, 274600 (3);274600
SLC26A8;Spermatogenic failure 3;17357067;608480;Spermatogenic failure 3, 606766 (3);606766
SLC27A4;Ichthyosis prematurity syndrome;17357067;604194;Ichthyosis prematurity syndrome, 608649 (3);608649
SLC29A3;Histiocytosis-lymphadenopathy plus syndrome;17357067;612373;Histiocytosis-lymphadenopathy plus syndrome, 602782 (3);602782
SLC2A1;Dystonia 9;17357067;138140;Dystonia 9, 601042 (3);601042
SLC2A1;Epilepsy, idiopathic generalized, suscpetibility to, 12;17357067;138140;{Epilepsy, idiopathic generalized, suscpetibility to, 12}, 614847 (3);614847
SLC2A1;GLUT1 deficiency syndrome 1;17357067;138140;GLUT1 deficiency syndrome 1, 606777 (3);606777
SLC2A1;GLUT1 deficiency syndrome 2;17357067;138140;GLUT1 deficiency syndrome 2, 612126 (3);612126
SLC2A10;Arterial tortuosity syndrome;17357067;606145;Arterial tortuosity syndrome, 208050 (3);208050
SLC2A2;Diabetes mellitus, noninsulin-dependent;17357067;138160;{Diabetes mellitus, noninsulin-dependent}, 125853 (3);125853
SLC2A2;Fanconi-Bickel syndrome;17357067;138160;Fanconi-Bickel syndrome, 227810 (3);227810
SLC2A9;Hypouricemia, renal, 2;17357067;606142;Hypouricemia, renal, 2, 612076 (3);612076
SLC2A9;Uric acid concentration, serum, QTL 2;17357067;606142;{Uric acid concentration, serum, QTL 2}, 612076 (3);612076
SLC30A10;Diabetes mellitus, noninsulin-dependent, susceptibility to;17357067;611145;{Diabetes mellitus, noninsulin-dependent, susceptibility to}, 125853 (3);125853
SLC30A10;Hypermanganesemia with dystonia, polycythemia, and cirrhosis;17357067;611146;Hypermanganesemia with dystonia, polycythemia, and cirrhosis, 613280 (3);613280
SLC30A2;Zinc deficiency, transient neonatal;17357067;609617;Zinc deficiency, transient neonatal, 608118 (3);608118
SLC30A8;Diabetes mellitus, noninsulin-dependent, susceptibility to;17357067;611145;{Diabetes mellitus, noninsulin-dependent, susceptibility to}, 125853 (3);125853
SLC33A1;Congenital cataracts, hearing loss, and neurodegeneration;17357067;603690;Congenital cataracts, hearing loss, and neurodegeneration, 614482 (3);614482
SLC33A1;Spastic paraplegia 42, autosomal dominant;17357067;603690;Spastic paraplegia 42, autosomal dominant, 612539 (3);612539
SLC34A1;Fanconi renotubular syndrome 2;17357067;182309;Fanconi renotubular syndrome 2, 613388 (3);613388
SLC34A1;Nephrolithiasis/osteoporosis, hypophosphatemic, 1;17357067;182309;Nephrolithiasis/osteoporosis, hypophosphatemic, 1, 612286 (3);612286
SLC34A2;Pulmonary alveolar microlithiasis;17357067;604217;Pulmonary alveolar microlithiasis, 265100 (3);265100
SLC34A3;Hypophosphatemic rickets with hypercalciuria;17357067;609826;Hypophosphatemic rickets with hypercalciuria, 241530 (3);241530
SLC35A1;Congenital disorder of glycosylation, type IIf;17357067;605634;Congenital disorder of glycosylation, type IIf, 603585 (3);603585
SLC35A2;Congenital disorder of glycosylation, type IIm;17357067;314375;Congenital disorder of glycosylation, type IIm, 300896 (3);300896
SLC35C1;Congenital disorder of glycosylation, type IIc;17357067;605881;Congenital disorder of glycosylation, type IIc, 266265 (3);266265
SLC35D1;Schneckenbecken dysplasia;17357067;610804;Schneckenbecken dysplasia, 269250 (3);269250
SLC36A2;Hyperglycinuria;17357067;608331;Hyperglycinuria, 138500 (3);138500
SLC36A2;Iminoglycinuria, digenic;17357067;608331;Iminoglycinuria, digenic, 242600 (3);242600
SLC37A4;Glycogen storage disease Ib;17357067;602671;Glycogen storage disease Ib, 232220 (3);232220
SLC37A4;Glycogen storage disease Ic;17357067;602671;Glycogen storage disease Ic, 232240 (3);232240
SLC38A8;Foveal hypoplasia 2, with or without optic nerve misrouting and/or anterior segment dysgenesis;17357067;615585;Foveal hypoplasia 2, with or without optic nerve misrouting and/or anterior segment dysgenesis, 609218 (3);609218
SLC39A13;Spondylocheirodysplasia, Ehlers-Danlos syndrome-like;17357067;608735;Spondylocheirodysplasia, Ehlers-Danlos syndrome-like, 612350 (3);612350
SLC39A4;Acrodermatitis enteropathica;17357067;607059;Acrodermatitis enteropathica, 201100 (3);201100
SLC39A5;Myopia 24, autosomal dominant;17357067;608730;Myopia 24, autosomal dominant, 615946 (3);615946
SLC3A1;Alpha-thalassemia/mental retardation syndrome, type 1;17357067;141750;Alpha-thalassemia/mental retardation syndrome, type 1 (4);0
SLC3A1;Cystinuria;17357067;104614;Cystinuria, 220100 (3);220100
SLC40A1;Hemochromatosis, type 4;17357067;604653;Hemochromatosis, type 4, 606069 (3);606069
SLC45A2;Albinism, oculocutaneous, type IV;17357067;606202;Albinism, oculocutaneous, type IV, 606574 (3);606574
SLC45A2;Skin/hair/eye pigmentation 5, black/nonblack hair;17357067;606202;[Skin/hair/eye pigmentation 5, black/nonblack hair], 227240 (3);227240
SLC45A2;Skin/hair/eye pigmentation 5, dark/fair skin;17357067;606202;[Skin/hair/eye pigmentation 5, dark/fair skin], 227240 (3);227240
SLC45A2;Skin/hair/eye pigmentation 5, dark/light eyes;17357067;606202;[Skin/hair/eye pigmentation 5, dark/light eyes], 227240 (3);227240
SLC46A1;Folate malabsorption, hereditary;17357067;611672;Folate malabsorption, hereditary, 229050 (3);229050
SLC4A1;Blood group, Diego;17357067;109270;[Blood group, Diego], 110500 (3);110500
SLC4A1;Blood group, Froese;17357067;109270;[Blood group, Froese], 601551 (3);601551
SLC4A1;Blood group, Swann;17357067;109270;[Blood group, Swann], 601550 (3);601550
SLC4A1;Blood group, Waldner;17357067;109270;[Blood group, Waldner], 112010 (3);112010
SLC4A1;Blood group, Wright;17357067;109270;[Blood group, Wright], 112050 (3);112050
SLC4A1;Malaria, resistance to;17357067;109270;[Malaria, resistance to], 611162 (3);611162
SLC4A1;Ovalocytosis;17357067;109270;Ovalocytosis (3);0
SLC4A1;Renal tubular acidosis, distal, AD;17357067;109270;Renal tubular acidosis, distal, AD, 179800 (3);179800
SLC4A1;Renal tubular acidosis, distal, AR;17357067;109270;Renal tubular acidosis, distal, AR, 611590 (3);611590
SLC4A1;Spherocytosis, type 4;17357067;109270;Spherocytosis, type 4, 612653 (3);612653
SLC4A11;Corneal dystrophy, Fuchs endothelial, 4;17357067;610206;Corneal dystrophy, Fuchs endothelial, 4, 613268 (3);613268
SLC4A11;Corneal endothelial dystrophy 2, autosomal recessive;17357067;610206;Corneal endothelial dystrophy 2, autosomal recessive, 217700 (3);217700
SLC4A11;Corneal endothelial dystrophy and perceptive deafness;17357067;610206;Corneal endothelial dystrophy and perceptive deafness, 217400 (3);217400
SLC4A4;Renal tubular acidosis, proximal, with ocular abnormalities;17357067;603345;Renal tubular acidosis, proximal, with ocular abnormalities, 604278 (3);604278
SLC50A1;Cerebral palsy, spastic quadriplegic, 1;17357067;605363;Cerebral palsy, spastic quadriplegic, 1, 603513 (3);603513
SLC52A1;Riboflavin deficiency;17357067;607883;Riboflavin deficiency, 615026 (3);615026
SLC52A2;Brown-Vialetto-Van Laere syndrome 2;17357067;607882;Brown-Vialetto-Van Laere syndrome 2, 614707 (3);614707
SLC52A3;Brown-Vialetto-Van Laere syndrome 1;17357067;613350;Brown-Vialetto-Van Laere syndrome 1, 211530 (3);211530
SLC52A3;Fazio-Londe disease;17357067;613350;Fazio-Londe disease, 211500 (3);211500
SLC5A1;Glucose/galactose malabsorption;17357067;182380;Glucose/galactose malabsorption, 606824 (3);606824
SLC5A2;Renal glucosuria;17357067;182381;Renal glucosuria, 233100 (3);233100
SLC5A5;Thyroid dyshormonogenesis 1;17357067;601843;Thyroid dyshormonogenesis 1, 274400 (3);274400
SLC5A7;Neuronopathy, distal hereditary motor, type VIIA;17357067;608761;Neuronopathy, distal hereditary motor, type VIIA, 158580 (3);158580
SLC6A1;Myoclonic-atonic epilepsy;17357067;137165;Myoclonic-atonic epilepsy, 616421 (3);616421
SLC6A14;Obesity, susceptibility to, BMIQ11;17357067;300444;{Obesity, susceptibility to, BMIQ11}, 300306 (3);300306
SLC6A17;Mental retardation, autosomal recessive 48;17357067;610299;Mental retardation, autosomal recessive 48, 616269 (3);616269
SLC6A19;Hartnup disorder;17357067;608893;Hartnup disorder, 234500 (3);234500
SLC6A19;Hyperglycinuria;17357067;608893;Hyperglycinuria, 138500 (3);138500
SLC6A19;Iminoglycinuria, digenic;17357067;608893;Iminoglycinuria, digenic, 242600 (3);242600
SLC6A2;Orthostatic intolerance;17357067;163970;Orthostatic intolerance, 604715 (3);604715
SLC6A20;Hyperglycinuria;17357067;605616;Hyperglycinuria, 138500 (3);138500
SLC6A20;Iminoglycinuria, digenic;17357067;605616;Iminoglycinuria, digenic, 242600 (3);242600
SLC6A3;Nicotine dependence, protection against;17357067;126455;{Nicotine dependence, protection against}, 188890 (3);188890
SLC6A3;Parkinsonism-dystonia, infantile;17357067;126455;Parkinsonism-dystonia, infantile, 613135 (3);613135
SLC6A4;Anxiety-related personality traits;17357067;182138;{Anxiety-related personality traits}, 607834 (3);607834
SLC6A4;Obsessive-compulsive disorder;17357067;182138;{Obsessive-compulsive disorder}, 164230 (3);164230
SLC6A5;Hyperekplexia 3;17357067;604159;Hyperekplexia 3, 614618 (3);614618
SLC6A8;Cerebral creatine deficiency syndrome 1;17357067;300036;Cerebral creatine deficiency syndrome 1, 300352 (3);300352
SLC7A14;Retinitis pigmentosa 68;17357067;615720;Retinitis pigmentosa 68, 615725 (3);615725
SLC7A7;Lysinuric protein intolerance;17357067;603593;Lysinuric protein intolerance, 222700 (3);222700
SLC7A9;Cystinuria;17357067;604144;Cystinuria, 220100 (3);220100
SLC9A3R1;Nephrolithiasis/osteoporosis, hypophosphatemic, 2;17357067;604990;Nephrolithiasis/osteoporosis, hypophosphatemic, 2, 612287 (3);612287
SLC9A6;Mental retardation, X-linked syndromic, Christianson type;17357067;300231;Mental retardation, X-linked syndromic, Christianson type, 300243 (3);300243
SLCO1B1;Hyperbilirubinemia, Rotor type, digenic;17357067;604843;Hyperbilirubinemia, Rotor type, digenic, 237450 (3);237450
SLCO1B3;Hyperbilirubinemia, Rotor type, digenic;17357067;605495;Hyperbilirubinemia, Rotor type, digenic, 237450 (3);237450
SLCO2A1;Hypertrophic osteoarthropathy, primary, autosomal recessive 2;17357067;601460;Hypertrophic osteoarthropathy, primary, autosomal recessive 2, 614441 (3);614441
SLITRK1;Tourette syndrome;17357067;609678;Tourette syndrome, 137580 (3);137580
SLITRK6;Deafness and myopia;17357067;609681;Deafness and myopia, 221200 (3);221200
SLURP1;Al-Raqad syndrome;17357067;610534;Al-Raqad syndrome, 616459 (3);616459
SLURP1;Meleda disease;17357067;606119;Meleda disease, 248300 (3);248300
SLX4;Fanconi anemia, complementation group P;17357067;613278;Fanconi anemia, complementation group P, 613951 (3);613951
SMAD1;Charcot-Marie-Tooth disease, type 2D;17357067;600287;Charcot-Marie-Tooth disease, type 2D, 601472 (3);601472
SMAD1;Neuropathy, distal hereditary motor, type VA;17357067;600287;Neuropathy, distal hereditary motor, type VA, 600794 (3);600794
SMAD3;Loeys-Dietz syndrome, type 3;17357067;603109;Loeys-Dietz syndrome, type 3, 613795 (3);613795
SMAD4;Juvenile polyposis/hereditary hemorrhagic telangiectasia syndrome;17357067;600993;Juvenile polyposis/hereditary hemorrhagic telangiectasia syndrome, 175050 (3);175050
SMAD4;Myhre syndrome;17357067;600993;Myhre syndrome, 139210 (3);139210
SMAD4;Pancreatic cancer, somatic;17357067;600993;Pancreatic cancer, somatic, 260350 (3);260350
SMAD4;Polyposis, juvenile intestinal;17357067;600993;Polyposis, juvenile intestinal, 174900 (3);174900
SMAD6;Aortic valve disease 2;17357067;602931;Aortic valve disease 2, 614823 (3);614823
SMAD7;Colorectal cancer, susceptibility to, 3;17357067;602932;{Colorectal cancer, susceptibility to, 3}, 612229 (3);612229
SMAD9;Pulmonary hypertension, primary, 2;17357067;603295;Pulmonary hypertension, primary, 2, 615342 (3);615342
SMAP2;Dentin dysplasia, type I, with microdontia and misshapen teeth;17357067;607223;Dentin dysplasia, type I, with microdontia and misshapen teeth, 125400 (3);125400
SMARCA2;Nicolaides-Baraitser syndrome;17357067;600014;Nicolaides-Baraitser syndrome, 601358 (3);601358
SMARCA4;Mental retardation, autosomal dominant 16;17357067;603254;Mental retardation, autosomal dominant 16, 614609 (3);614609
SMARCA4;Rhabdoid tumor predisposition syndrome 2;17357067;603254;{Rhabdoid tumor predisposition syndrome 2}, 613325 (3);613325
SMARCAD1;Adermatoglyphia;17357067;612761;Adermatoglyphia, 136000 (3);136000
SMARCAL1;Schimke immunoosseous dysplasia;17357067;606622;Schimke immunoosseous dysplasia, 242900 (3);242900
SMARCB1;Mental retardation, autosomal dominant 15;17357067;601607;Mental retardation, autosomal dominant 15, 614608 (3);614608
SMARCB1;Rhabdoid predisposition syndrome 1;17357067;601607;{Rhabdoid predisposition syndrome 1}, 609322 (3);609322
SMARCB1;Rhabdoid tumors, somatic;17357067;601607;Rhabdoid tumors, somatic, 609322 (3);609322
SMARCB1;Schwannomatosis-1, susceptibility to;17357067;601607;{Schwannomatosis-1, susceptibility to}, 162091 (3);162091
SMARCE1;Meningioma, familial, susceptibility to;17357067;603111;{Meningioma, familial, susceptibility to}, 607174 (3);607174
SMC1A;Cornelia de Lange syndrome 2;17357067;300040;Cornelia de Lange syndrome 2, 300590 (3);300590
SMC2;Smith-McCort dysplasia 2;17357067;605950;Smith-McCort dysplasia 2, 615222 (3);615222
SMC3;Cornelia de Lange syndrome 3;17357067;606062;Cornelia de Lange syndrome 3, 610759 (3);610759
SMCHD1;Fascioscapulohumeral muscular dystrophy 2, digenic;17357067;614982;Fascioscapulohumeral muscular dystrophy 2, digenic, 158901 (3);158901
SMIM1;Blood group, Vel system;17357067;615242;[Blood group, Vel system], 615264 (3);615264
SMN1;Spinal muscular atrophy-1;17357067;600354;Spinal muscular atrophy-1, 253300 (3);253300
SMN1;Spinal muscular atrophy-2;17357067;600354;Spinal muscular atrophy-2, 253550 (3);253550
SMN1;Spinal muscular atrophy-3;17357067;600354;Spinal muscular atrophy-3, 253400 (3);253400
SMN1;Spinal muscular atrophy-4;17357067;600354;Spinal muscular atrophy-4, 271150 (3);271150
SMN2;Spinal muscular atrophy, type III, modifier of;17357067;601627;{Spinal muscular atrophy, type III, modifier of}, 253400 (3);253400
SMO;Basal cell carcinoma, somatic;17357067;601500;Basal cell carcinoma, somatic (3);0
SMOC1;Microphthalmia with limb anomalies;17357067;608488;Microphthalmia with limb anomalies, 206920 (3);206920
SMOC2;Dentin dysplasia, type I, with microdontia and misshapen teeth;17357067;607223;Dentin dysplasia, type I, with microdontia and misshapen teeth, 125400 (3);125400
SMPD1;Niemann-Pick disease, type A;17357067;607608;Niemann-Pick disease, type A, 257200 (3);257200
SMPD1;Niemann-Pick disease, type B;17357067;607608;Niemann-Pick disease, type B, 607616 (3);607616
SMPX;Deafness, X-linked 4;17357067;300226;Deafness, X-linked 4, 300066 (3);300066
SMS;Mental retardation, X-linked, Snyder-Robinson type;17357067;300105;Mental retardation, X-linked, Snyder-Robinson type, 309583 (3);309583
SMS;Silver-Russell syndrome;17357067;180860;Silver-Russell syndrome (4);0
SMS;Smith-Magenis syndrome;17357067;607642;Smith-Magenis syndrome, 182290 (3);182290
SNAI2;Piebaldism;17357067;602150;Piebaldism, 172800 (3);172800
SNAI2;Waardenburg syndrome, type 2D;17357067;602150;Waardenburg syndrome, type 2D, 608890 (3);608890
SNAP29;Cerebral dysgenesis, neuropathy, ichthyosis, and palmoplantar keratoderma syndrome;17357067;604202;Cerebral dysgenesis, neuropathy, ichthyosis, and palmoplantar keratoderma syndrome, 609528 (3);609528
SNCA;Dementia, Lewy body;17357067;163890;Dementia, Lewy body, 127750 (3);127750
SNCA;Parkinson disease 1;17357067;163890;Parkinson disease 1, 168601 (3);168601
SNCA;Parkinson disease 4;17357067;163890;Parkinson disease 4, 605543 (3);605543
SNCB;Dementia, Lewy body;17357067;602569;Dementia, Lewy body, 127750 (3);127750
SNIP1;Psychomotor retardation, epilepsy, and craniofacial dysmorphism;17357067;608241;Psychomotor retardation, epilepsy, and craniofacial dysmorphism, 614501 (3);614501
SNORA73A;Maple syrup urine disease, type Ib;17357067;248611;Maple syrup urine disease, type Ib, 248600 (3);248600
SNRNP200;Retinitis pigmentosa 33;17357067;601664;Retinitis pigmentosa 33, 610359 (3);610359
SNRPB;Cerebrocostomandibular syndrome;17357067;182282;Cerebrocostomandibular syndrome, 117650 (3);117650
SNRPE;Hypotrichosis 11;17357067;128260;Hypotrichosis 11, 615059 (3);615059
SNRPN;Prader-Willi syndrome;17357067;182279;Prader-Willi syndrome, 176270 (3);176270
SNTA1;Long QT syndrome 12;17357067;601017;Long QT syndrome 12, 612955 (3);612955
SNX10;Osteopetrosis, autosomal recessive 8;17357067;614780;Osteopetrosis, autosomal recessive 8, 615085 (3);615085
SNX14;Spinocerebellar ataxia, autosomal recessive 20;17357067;616105;Spinocerebellar ataxia, autosomal recessive 20, 616354 (3);616354
SOBP;Mental retardation, anterior maxillary protrusion, and strabismus;17357067;613667;Mental retardation, anterior maxillary protrusion, and strabismus, 613671 (3);613671
SOD1;Amyotrophic lateral sclerosis 1;17357067;147450;Amyotrophic lateral sclerosis 1, 105400 (3);105400
SOD2;Microvascular complications of diabetes 6;17357067;147460;{Microvascular complications of diabetes 6}, 612634 (3);612634
SOD3;Superoxide dismutase, elevated extracellular;17357067;185490;[Superoxide dismutase, elevated extracellular] (3);0
SORL1;Alzheimer disease, pathogenesis, association with;17357067;602005;{Alzheimer disease, pathogenesis, association with}, 104300 (3);104300
SORT1;Low density lipoprotein cholesterol level QTL6;17357067;602458;[Low density lipoprotein cholesterol level QTL6], 613589 (3);613589
SOS1;Fibromatosis, gingival;17357067;182530;Fibromatosis, gingival, 135300 (3);135300
SOS1;Noonan syndrome 4;17357067;182530;Noonan syndrome 4, 610733 (3);610733
SOST;Craniodiaphyseal dysplasia, autosomal dominant;17357067;605740;Craniodiaphyseal dysplasia, autosomal dominant, 122860 (3);122860
SOST;Sclerosteosis 1;17357067;605740;Sclerosteosis 1, 269500 (3);269500
SOST;Van Buchem disease;17357067;605740;Van Buchem disease, 239100 (3);239100
SOX10;PCWH syndrome;17357067;602229;PCWH syndrome, 609136 (3);609136
SOX10;Waardenburg syndrome, type 2E, with or without neurologic involvement;17357067;602229;Waardenburg syndrome, type 2E, with or without neurologic involvement, 611584 (3);611584
SOX10;Waardenburg syndrome, type 4C;17357067;602229;Waardenburg syndrome, type 4C, 613266 (3);613266
SOX11;Mental retardation, autosomal dominant, 27;17357067;600898;Mental retardation, autosomal dominant, 27, 615866 (3);615866
SOX17;Vesicoureteral reflux 3;17357067;610928;Vesicoureteral reflux 3, 613674 (3);613674
SOX18;Hypotrichosis-lymphedema-telangiectasia syndrome;17357067;601618;Hypotrichosis-lymphedema-telangiectasia syndrome, 607823 (3);607823
SOX18;Hypotrichosis-lymphedema-telangiectasia-renal defect syndrome;17357067;601618;Hypotrichosis-lymphedema-telangiectasia-renal defect syndrome, 137940 (3);137940
SOX2;Microphthalmia, syndromic 3;17357067;184429;Microphthalmia, syndromic 3, 206900 (3);206900
SOX2;Optic nerve hypoplasia and abnormalities of the central nervous system;17357067;184429;Optic nerve hypoplasia and abnormalities of the central nervous system, 206900 (3);206900
SOX3;Mental retardation, X-linked, with isolated growth hormone deficiency;17357067;313430;Mental retardation, X-linked, with isolated growth hormone deficiency, 300123 (3);300123
SOX3;Panhypopituitarism, X-linked;17357067;313430;Panhypopituitarism, X-linked, 312000 (3);312000
SOX9;Acampomelic campomelic dysplasia;17357067;608160;Acampomelic campomelic dysplasia, 114290 (3);114290
SOX9;Campomelic dysplasia;17357067;608160;Campomelic dysplasia, 114290 (3);114290
SOX9;Campomelic dysplasia with autosomal sex reversal;17357067;608160;Campomelic dysplasia with autosomal sex reversal, 114290 (3);114290
SOX9;Cardiomyopathy, dilated 1B;17357067;600884;Cardiomyopathy, dilated 1B (2);0
SP110;Hepatic venoocclusive disease with immunodeficiency;17357067;604457;Hepatic venoocclusive disease with immunodeficiency, 235550 (3);235550
SP110;Mycobacterium tuberculosis, susceptibility to;17357067;604457;{Mycobacterium tuberculosis, susceptibility to}, 607948 (3);607948
SP7;Opitz GBBB syndrome, type I;17357067;300552;Opitz GBBB syndrome, type I, 300000 (3);300000
SPAG1;Ciliary dyskinesia, primary, 28;17357067;603395;Ciliary dyskinesia, primary, 28, 615505 (3);615505
SPAG8;Ciliary dyskinesia, primary, 28;17357067;603395;Ciliary dyskinesia, primary, 28, 615505 (3);615505
SPARC;Osteogenesis imperfecta, type XVII;17357067;182120;Osteogenesis imperfecta, type XVII, 616507 (3);616507
SPAST;Spastic paraplegia 4, autosomal dominant;17357067;604277;Spastic paraplegia 4, autosomal dominant, 182601 (3);182601
SPATA7;Leber congenital amaurosis 3;17357067;609868;Leber congenital amaurosis 3, 604232 (3);604232
SPATA7;Retinitis pigmentosa, juvenile, autosomal recessive;17357067;609868;Retinitis pigmentosa, juvenile, autosomal recessive, 604232 (3);604232
SPECC1L;Opitz GBBB syndrome, type II;17357067;614140;Opitz GBBB syndrome, type II, 145410 (3);145410
SPEG;Centronuclear myopathy 5;17357067;615950;Centronuclear myopathy 5, 615959 (3);615959
SPEN;Megakaryoblastic leukemia, acute;17357067;606077;Megakaryoblastic leukemia, acute (2);0
SPG11;Spastic paraplegia 11, autosomal recessive;17357067;610844;Spastic paraplegia 11, autosomal recessive, 604360 (3);604360
SPG20;Troyer syndrome;17357067;607111;Troyer syndrome, 275900 (3);275900
SPG21;Mast syndrome;17357067;608181;Mast syndrome, 248900 (3);248900
SPG7;Spastic paraplegia 7, autosomal recessive;17357067;602783;Spastic paraplegia 7, autosomal recessive, 607259 (3);607259
SPINK1;Fibrocalculous pancreatic diabetes, susceptibility to;17357067;167790;{Fibrocalculous pancreatic diabetes, susceptibility to}, 608189 (3);608189
SPINK1;Pancreatitis, hereditary;17357067;167790;Pancreatitis, hereditary, 167800 (3);167800
SPINK1;Tropical calcific pancreatitis;17357067;167790;Tropical calcific pancreatitis, 608189 (3);608189
SPINK5;Atopy;17357067;605010;Atopy, 147050 (3);147050
SPINK5;Netherton syndrome;17357067;605010;Netherton syndrome, 256500 (3);256500
SPINT2;Diarrhea 3, secretory sodium, congenital, syndromic;17357067;605124;Diarrhea 3, secretory sodium, congenital, syndromic, 270420 (3);270420
SPN;Mental retardation, autosomal dominant 24;17357067;602635;Mental retardation, autosomal dominant 24, 615828 (3);615828
SPR;Dystonia, dopa-responsive, due to sepiapterin reductase deficiency;17357067;182125;Dystonia, dopa-responsive, due to sepiapterin reductase deficiency, 612716 (3);612716
SPRED1;Legius syndrome;17357067;609291;Legius syndrome, 611431 (3);611431
SPRTN;Ruijs-Aalfs syndrome;17357067;616086;Ruijs-Aalfs syndrome, 616200 (3);616200
SPRY4;Hypogonadotropic hypogonadism 17 with or without anosmia;17357067;607984;Hypogonadotropic hypogonadism 17 with or without anosmia, 615266 (3);615266
SPTA1;Elliptocytosis-2;17357067;182860;Elliptocytosis-2, 130600 (3);130600
SPTA1;Pyropoikilocytosis;17357067;182860;Pyropoikilocytosis, 266140 (3);266140
SPTA1;Spherocytosis, type 3;17357067;182860;Spherocytosis, type 3, 270970 (3);270970
SPTAN1;Epileptic encephalopathy, early infantile, 5;17357067;182810;Epileptic encephalopathy, early infantile, 5, 613477 (3);613477
SPTB;Anemia, neonatal hemolytic, fatal and near-fatal;17357067;182870;Anemia, neonatal hemolytic, fatal and near-fatal (3);0
SPTB;Elliptocytosis-3;17357067;182870;Elliptocytosis-3 (3);0
SPTB;Spherocytosis, type 2;17357067;182870;Spherocytosis, type 2 (3);0
SPTBN2;Spinocerebellar ataxia 5;17357067;604985;Spinocerebellar ataxia 5, 600224 (3);600224
SPTBN2;Spinocerebellar ataxia, autosomal recessive 14;17357067;604985;Spinocerebellar ataxia, autosomal recessive 14, 615386 (3);615386
SPTLC1;Neuropathy, hereditary sensory and autonomic, type IA;17357067;605712;Neuropathy, hereditary sensory and autonomic, type IA, 162400 (3);162400
SPTLC2;Neuropathy, hereditary sensory and autonomic, type IC;17357067;605713;Neuropathy, hereditary sensory and autonomic, type IC, 613640 (3);613640
SQSTM1;Frontotemporal dementia and/or amyotrophic lateral sclerosis 3;17357067;601530;Frontotemporal dementia and/or amyotrophic lateral sclerosis 3, 616437 (3);616437
SQSTM1;Paget disease of bone 3;17357067;601530;Paget disease of bone 3, 167250 (3);167250
SRA1;Acampomelic campomelic dysplasia;17357067;608160;Acampomelic campomelic dysplasia, 114290 (3);114290
SRA1;Barrett esophagus/esophageal adenocarcinoma;17357067;153622;Barrett esophagus/esophageal adenocarcinoma, 614266 (3);614266
SRA1;Campomelic dysplasia;17357067;608160;Campomelic dysplasia, 114290 (3);114290
SRA1;Campomelic dysplasia with autosomal sex reversal;17357067;608160;Campomelic dysplasia with autosomal sex reversal, 114290 (3);114290
SRA1;Prostate cancer, hereditary;17357067;153622;Prostate cancer, hereditary, 176807 (3);176807
SRC;Colon cancer, advanced, somatic;17357067;190090;Colon cancer, advanced, somatic (3);0
SRCAP;Floating-Harbor syndrome;17357067;611421;Floating-Harbor syndrome, 136140 (3);136140
SRD5A2;Pseudovaginal perineoscrotal hypospadias;17357067;607306;Pseudovaginal perineoscrotal hypospadias, 264600 (3);264600
SRD5A3;Congenital disorder of glycosylation, type Iq;17357067;611715;Congenital disorder of glycosylation, type Iq, 612379 (3);612379
SRD5A3;Kahrizi syndrome;17357067;611715;Kahrizi syndrome, 612713 (3);612713
SRP72;Bone marrow failure syndrome 1;17357067;602122;Bone marrow failure syndrome 1, 614675 (3);614675
SRSF11;Exudative vitreoretinopathy 5;17357067;613138;Exudative vitreoretinopathy 5, 613310 (3);613310
SRY;46XX sex reversal 1;17357067;480000;46XX sex reversal 1, 400045 (3);400045
SRY;46XY sex reversal 1;17357067;480000;46XY sex reversal 1, 400044 (3);400044
SS18;Sarcoma, synovial;17357067;600192;Sarcoma, synovial (1);0
SSTR5;Somatostatin analog, resistance to;17357067;182455;Somatostatin analog, resistance to (3);0
ST14;Ichthyosis, congenital, autosomal recessive 11;17357067;606797;Ichthyosis, congenital, autosomal recessive 11, 602400 (3);602400
ST3GAL2;Epileptic encephalopathy, early infantile, 15;17357067;606494;Epileptic encephalopathy, early infantile, 15, 615006 (3);615006
ST3GAL2;Mental retardation, autosomal recessive 12;17357067;606494;Mental retardation, autosomal recessive 12, 611090 (3);611090
ST3GAL3;Epileptic encephalopathy, early infantile, 15;17357067;606494;Epileptic encephalopathy, early infantile, 15, 615006 (3);615006
ST3GAL3;Mental retardation, autosomal recessive 12;17357067;606494;Mental retardation, autosomal recessive 12, 611090 (3);611090
ST3GAL5;Amish infantile epilepsy syndrome;17357067;604402;Amish infantile epilepsy syndrome, 609056 (3);609056
STAC3;Native American myopathy;17357067;615521;Native American myopathy, 255995 (3);255995
STAMBP;Microcephaly-capillary malformation syndrome;17357067;606247;Microcephaly-capillary malformation syndrome, 614261 (3);614261
STAR;Lipoid adrenal hyperplasia;17357067;600617;Lipoid adrenal hyperplasia, 201710 (3);201710
STAR;STAR syndrome;17357067;300708;STAR syndrome, 300707 (3);300707
STAT1;Immunodeficiency 31A, mycobacteriosis, autosomal dominant;17357067;600555;Immunodeficiency 31A, mycobacteriosis, autosomal dominant, 614892 (3);614892
STAT1;Immunodeficiency 31B, mycobacterial and viral infections, autosomal recessive;17357067;600555;Immunodeficiency 31B, mycobacterial and viral infections, autosomal recessive, 613796 (3);613796
STAT1;Immunodeficiency 31C, autosomal dominant;17357067;600555;Immunodeficiency 31C, autosomal dominant, 614162 (3);614162
STAT3;Autoimmune disease, multisystem, infantile-onset;17357067;102582;Autoimmune disease, multisystem, infantile-onset, 615952 (3);615952
STAT3;Hyper-IgE recurrent infection syndrome;17357067;102582;Hyper-IgE recurrent infection syndrome, 147060 (3);147060
STAT4;Systemic lupus erythematosus, susceptibility to, 11;17357067;600558;{Systemic lupus erythematosus, susceptibility to, 11}, 612253 (3);612253
STAT5B;Growth hormone insensitivity with immunodeficiency;17357067;604260;Growth hormone insensitivity with immunodeficiency, 245590 (3);245590
STAT5B;Leukemia, acute promyelocytic, STAT5B/RARA type;17357067;604260;Leukemia, acute promyelocytic, STAT5B/RARA type (3);0
STIL;Microcephaly 7, primary, autosomal recessive;17357067;181590;Microcephaly 7, primary, autosomal recessive, 612703 (3);612703
STIM1;Immunodeficiency 10;17357067;605921;Immunodeficiency 10, 612783 (3);612783
STIM1;Myopathy, tubular aggregate, 1;17357067;605921;Myopathy, tubular aggregate, 1 160565 (3);160565
STIM1;Stormorken syndrome;17357067;605921;Stormorken syndrome, 185070 (3);185070
STK11;Melanoma, malignant, somatic;17357067;602216;Melanoma, malignant, somatic (3);0
STK11;Pancreatic cancer;17357067;602216;Pancreatic cancer, 260350 (3);260350
STK11;Peutz-Jeghers syndrome;17357067;602216;Peutz-Jeghers syndrome, 175200 (3);175200
STK11;Testicular tumor, somatic;17357067;602216;Testicular tumor, somatic, 273300 (3);273300
STK4;T-cell immunodeficiency, recurrent infections, autoimmunity, and cardiac malformations;17357067;604965;T-cell immunodeficiency, recurrent infections, autoimmunity, and cardiac malformations, 614868 (3);614868
STOX1;Preeclampsia/eclampsia 4;17357067;609397;Preeclampsia/eclampsia 4, 609404 (3);609404
STRA6;Microphthalmia, isolated, with coloboma 8;17357067;610745;Microphthalmia, isolated, with coloboma 8, 601186 (3);601186
STRA6;Microphthalmia, syndromic 9;17357067;610745;Microphthalmia, syndromic 9, 601186 (3);601186
STRADA;Polyhydramnios, megalencephaly, and symptomatic epilepsy;17357067;608626;Polyhydramnios, megalencephaly, and symptomatic epilepsy, 611087 (3);611087
STRC;Deafness, autosomal recessive 16;17357067;606440;Deafness, autosomal recessive 16, 603720 (3);603720
STS;Ichthyosis, X-linked;17357067;300747;Ichthyosis, X-linked, 308100 (3);308100
STUB1;Spinocerebellar ataxia, autosomal recessive 16;17357067;607207;Spinocerebellar ataxia, autosomal recessive 16, 615768 (3);615768
STX11;Hemophagocytic lymphohistiocytosis, familial, 4;17357067;605014;Hemophagocytic lymphohistiocytosis, familial, 4, 603552 (3);603552
STX16;Pseudohypoparathyroidism, type IB;17357067;603666;Pseudohypoparathyroidism, type IB, 603233 (3);603233
STX1B;Generalized epilepsy with febrile seizures plus, type 9;17357067;601485;Generalized epilepsy with febrile seizures plus, type 9, 616172 (3);616172
STXBP1;Epileptic encephalopathy, early infantile, 4;17357067;602926;Epileptic encephalopathy, early infantile, 4, 612164 (3);612164
STXBP2;Hemophagocytic lymphohistiocytosis, familial, 5;17357067;601717;Hemophagocytic lymphohistiocytosis, familial, 5, 613101 (3);613101
SUCLA2;Mitochondrial DNA depletion syndrome 5 (encephalomyopathic with or without methylmalonic aciduria);17357067;603921;Mitochondrial DNA depletion syndrome 5 (encephalomyopathic with or without methylmalonic aciduria), 612073 (3);612073
SUCLG1;Mitochondrial DNA depletion syndrome 9 (encephalomyopathic type with methylmalonic aciduria);17357067;611224;Mitochondrial DNA depletion syndrome 9 (encephalomyopathic type with methylmalonic aciduria), 245400 (3);245400
SUFU;Basal cell nevus syndrome;17357067;607035;Basal cell nevus syndrome, 109400 (3);109400
SUFU;Medulloblastoma, desmoplastic;17357067;607035;Medulloblastoma, desmoplastic, 155255 (3);155255
SUFU;Meningioma, familial, susceptibility to;17357067;607035;{Meningioma, familial, susceptibility to}, 607174 (3);607174
SUGCT;Glutaric aciduria III;17357067;609187;Glutaric aciduria III, 231690 (3);231690
SUMF1;Multiple sulfatase deficiency;17357067;607939;Multiple sulfatase deficiency, 272200 (3);272200
SUMO1;Orofacial cleft 10;17357067;601912;Orofacial cleft 10, 613705 (3);613705
SUMO4;Diabetes mellitus, insulin-dependent, 5;17357067;608829;{Diabetes mellitus, insulin-dependent, 5}, 600320 (3);600320
SUOX;Sulfite oxidase deficiency;17357067;606887;Sulfite oxidase deficiency, 272300 (3);272300
SURF1;Leigh syndrome, due to COX deficiency;17357067;185620;Leigh syndrome, due to COX deficiency, 256000 (3);256000
SYCP3;Pregnancy loss, susceptibility to;17357067;604759;{Pregnancy loss, susceptibility to} (3);0
SYCP3;Spermatogenic failure 4;17357067;604759;Spermatogenic failure 4, 270960 (3);270960
SYN1;Epilepsy, X-linked, with variable learning disabilities and behavior disorders;17357067;313440;Epilepsy, X-linked, with variable learning disabilities and behavior disorders, 300491 (3);300491
SYN2;Schizophrenia, susceptibility to;17357067;600755;{Schizophrenia, susceptibility to}, 181500 (3);181500
SYNE1;Emery-Dreifuss muscular dystrophy 4, autosomal dominant;17357067;608441;Emery-Dreifuss muscular dystrophy 4, autosomal dominant, 612998 (3);612998
SYNE1;Spinocerebellar ataxia, autosomal recessive 8;17357067;608441;Spinocerebellar ataxia, autosomal recessive 8, 610743 (3);610743
SYNE2;Emery-Dreifuss muscular dystrophy 5, autosomal dominant;17357067;608442;Emery-Dreifuss muscular dystrophy 5, autosomal dominant, 612999 (3);612999
SYNE4;Deafness, autosomal recessive 76;17357067;615535;Deafness, autosomal recessive 76, 615540 (3);615540
SYNGAP1;Mental retardation, autosomal dominant 5;17357067;603384;Mental retardation, autosomal dominant 5, 612621 (3);612621
SYNJ1;Parkinson disease 20, early-onset;17357067;604297;Parkinson disease 20, early-onset, 615530 (3);615530
SYP;Mental retardation, X-linked 96;17357067;313475;Mental retardation, X-linked 96, 300802 (3);300802
SYT14;Spinocerebellar ataxia, autosomal recessive 11;17357067;610949;Spinocerebellar ataxia, autosomal recessive 11, 614229 (3);614229
SYT2;Myasthenic syndrome, congenital, 7, presynaptic;17357067;600104;Myasthenic syndrome, congenital, 7, presynaptic, 616040 (3);616040
SZT2;Epileptic encephalopathy, early infantile, 18;17357067;615463;Epileptic encephalopathy, early infantile, 18, 615476 (3);615476
T;Neural tube defects, susceptibility to;17357067;601397;{Neural tube defects, susceptibility to}, 182940 (3);182940
T;Sacral agenesis with vertebral anomalies;17357067;601397;Sacral agenesis with vertebral anomalies, 615709 (3);615709
TAB2;Congenital heart defects, nonsyndromic, 2;17357067;605101;Congenital heart defects, nonsyndromic, 2, 614980 (3);614980
TAC3;Hypogonadotropic hypogonadism 10 with or without anosmia;17357067;162330;Hypogonadotropic hypogonadism 10 with or without anosmia, 614839 (3);614839
TACO1;Mitochondrial complex IV deficiency;17357067;612958;Mitochondrial complex IV deficiency, 220110 (3);220110
TACR3;Hypogonadotropic hypogonadism 11 with or without anosmia;17357067;162332;Hypogonadotropic hypogonadism 11 with or without anosmia, 614840 (3);614840
TACSTD2;Corneal dystrophy, gelatinous drop-like;17357067;137290;Corneal dystrophy, gelatinous drop-like, 204870 (3);204870
TAF1;Dystonia-Parkinsonism, X-linked;17357067;313650;Dystonia-Parkinsonism, X-linked, 314250 (3);314250
TAF15;Chondrosarcoma, extraskeletal myxoid;17357067;601574;Chondrosarcoma, extraskeletal myxoid, 612237 (1);612237
TAF2;Mental retardation, autosomal recessive 40;17357067;604912;Mental retardation, autosomal recessive 40, 615599 (3);615599
TAGAP;Diabetes mellitus, insulin-dependent, 21;17357067;612521;{Diabetes mellitus, insulin-dependent, 21} (2);0
TAL1;Leukemia-1, T-cell acute lymphocytic;17357067;187040;Leukemia-1, T-cell acute lymphocytic (3);0
TAL2;Leukemia-2, T-cell acute lymphoblastic;17357067;186855;Leukemia-2, T-cell acute lymphoblastic (3);0
TALDO1;Transaldolase deficiency;17357067;602063;Transaldolase deficiency, 606003 (3);606003
TAP1;Bare lymphocyte syndrome, type I;17357067;170260;Bare lymphocyte syndrome, type I, 604571 (3);604571
TAP2;Bare lymphocyte syndrome, type I, due to TAP2 deficiency;17357067;170261;Bare lymphocyte syndrome, type I, due to TAP2 deficiency, 604571 (3);604571
TAP2;Wegener-like granulomatosis;17357067;170261;Wegener-like granulomatosis (3);0
TAPBP;Bare lymphocyte syndrome, type I;17357067;601962;Bare lymphocyte syndrome, type I, 604571 (3);604571
TARDBP;Amyotrophic lateral sclerosis 10, with or without FTD;17357067;605078;Amyotrophic lateral sclerosis 10, with or without FTD, 612069 (3);612069
TARDBP;Frontotemporal lobar degeneration, TARDBP-related;17357067;605078;Frontotemporal lobar degeneration, TARDBP-related, 612069 (3);612069
TAS2R16;Alcohol dependence;17357067;604867;{Alcohol dependence}, 103780 (3);103780
TAS2R38;Phenylthiocarbamide tasting;17357067;607751;[Phenylthiocarbamide tasting], 171200 (3);171200
TAT;Tyrosinemia, type II;17357067;613018;Tyrosinemia, type II, 276600 (3);276600
TAZ;Barth syndrome;17357067;300394;Barth syndrome, 302060 (3);302060
TBC1D20;Warburg micro syndrome 4;17357067;611663;Warburg micro syndrome 4, 615663 (3);615663
TBC1D24;DOOR syndrome;17357067;613577;DOOR syndrome, 220500 (3);220500
TBC1D24;Deafness , autosomal recessive 86;17357067;613577;Deafness , autosomal recessive 86, 614617 (3);614617
TBC1D24;Deafness, autosomal dominant 65;17357067;613577;Deafness, autosomal dominant 65, 616044 (3);616044
TBC1D24;Epileptic encephalopathy, early infantile, 16;17357067;613577;Epileptic encephalopathy, early infantile, 16, 615338 (3);615338
TBC1D24;Myoclonic epilepsy, infantile, familial;17357067;613577;Myoclonic epilepsy, infantile, familial, 605021 (3);605021
TBC1D4;Diabetes mellitus, noninsulin-dependent, 5;17357067;612465;{Diabetes mellitus, noninsulin-dependent, 5}, 616087 (3);616087
TBC1D7;Macrocephaly/megalencephaly syndrome, autosomal recessive;17357067;612655;Macrocephaly/megalencephaly syndrome, autosomal recessive, 248000 (3);248000
TBCE;Hypoparathyroidism-retardation-dysmorphism syndrome;17357067;604934;Hypoparathyroidism-retardation-dysmorphism syndrome, 241410 (3);241410
TBCE;Kenny-Caffey syndrome-1;17357067;604934;Kenny-Caffey syndrome-1, 244460 (3);244460
TBK1;Frontotemporal dementia and/or amyotrophic lateral sclerosis 4;17357067;604834;Frontotemporal dementia and/or amyotrophic lateral sclerosis 4, 616439 (3);616439
TBP;Parkinson disease, susceptibility to;17357067;600075;{Parkinson disease, susceptibility to}, 168600 (3);168600
TBP;Spinocerebellar ataxia 17;17357067;600075;Spinocerebellar ataxia 17, 607136 (3);607136
TBX1;Conotruncal anomaly face syndrome;17357067;602054;Conotruncal anomaly face syndrome, 217095 (3);217095
TBX1;DiGeorge syndrome;17357067;602054;DiGeorge syndrome, 188400 (3);188400
TBX1;Tetralogy of Fallot;17357067;602054;Tetralogy of Fallot, 187500 (3);187500
TBX1;Velocardiofacial syndrome;17357067;602054;Velocardiofacial syndrome, 192430 (3);192430
TBX15;Cousin syndrome;17357067;604127;Cousin syndrome, 260660 (3);260660
TBX19;Adrenocorticotropic hormone deficiency;17357067;604614;Adrenocorticotropic hormone deficiency, 201400 (3);201400
TBX20;Atrial septal defect 4;17357067;606061;Atrial septal defect 4, 611363 (3);611363
TBX21;Asthma and nasal polyps;17357067;604895;Asthma and nasal polyps, 208550 (3);208550
TBX21;Asthma, aspirin-induced, susceptibility to;17357067;604895;{Asthma, aspirin-induced, susceptibility to}, 208550 (3);208550
TBX22;Cleft palate with ankyloglossia;17357067;300307;Cleft palate with ankyloglossia, 303400 (3);303400
TBX3;Ulnar-mammary syndrome;17357067;601621;Ulnar-mammary syndrome, 181450 (3);181450
TBX4;Small patella syndrome;17357067;601719;Small patella syndrome, 147891 (3);147891
TBX5;Holt-Oram syndrome;17357067;601620;Holt-Oram syndrome, 142900 (3);142900
TBX6;Spondylocostal dysostosis 5, autosomal dominant;17357067;602427;Spondylocostal dysostosis 5, autosomal dominant, 122600 (3);122600
TBXA2R;Bleeding disorder, platelet-type, 13, susceptibility to;17357067;188070;{Bleeding disorder, platelet-type, 13, susceptibility to}, 614009 (3);614009
TBXAS1;Ghosal hematodiaphyseal syndrome;17357067;274180;Ghosal hematodiaphyseal syndrome, 231095 (3);231095
TBXAS1;Thoracoabdominal syndrome;17357067;313850;Thoracoabdominal syndrome (2);0
TCAP;Cardiomyopathy, hypertrophic, 25;17357067;604488;Cardiomyopathy, hypertrophic, 25, 607487 (3);607487
TCAP;Muscular dystrophy, limb-girdle, type 2G;17357067;604488;Muscular dystrophy, limb-girdle, type 2G, 601954 (3);601954
TCF12;Craniosynostosis 3;17357067;600480;Craniosynostosis 3, 615314 (3);615314
TCF3;Leukemia, acute lymphoblastic;17357067;147141;Leukemia, acute lymphoblastic (1);0
TCF4;Corneal dystrophy, Fuchs endothelial, 3;17357067;602272;Corneal dystrophy, Fuchs endothelial, 3, 613267 (3);613267
TCF4;Diabetes mellitus, type 2, susceptibility to;17357067;602228;{Diabetes mellitus, type 2, susceptibility to}, 125853 (3);125853
TCF4;Pitt-Hopkins syndrome;17357067;602272;Pitt-Hopkins syndrome, 610954 (3);610954
TCF7L2;Diabetes mellitus, type 2, susceptibility to;17357067;602228;{Diabetes mellitus, type 2, susceptibility to}, 125853 (3);125853
TCIRG1;Osteopetrosis, autosomal recessive 1;17357067;604592;Osteopetrosis, autosomal recessive 1, 259700 (3);259700
TCL1A;Leukemia/lymphoma, T-cell;17357067;186960;Leukemia/lymphoma, T-cell (2);0
TCL1B;Leukemia/lymphoma, T-cell;17357067;603769;Leukemia/lymphoma, T-cell (2);0
TCL4;Leukemia/lymphoma, T-cell;17357067;186860;Leukemia/lymphoma, T-cell (2);0
TCN2;Transcobalamin II deficiency;17357067;613441;Transcobalamin II deficiency, 275350 (3);275350
TCOF1;Treacher Collins syndrome 1;17357067;606847;Treacher Collins syndrome 1, 154500 (3);154500
TCTN1;Joubert syndrome 13;17357067;609863;Joubert syndrome 13, 614173 (3);614173
TCTN3;Joubert syndrome 18;17357067;613847;Joubert syndrome 18, 614815 (3);614815
TCTN3;Orofaciodigital syndrome IV;17357067;613847;Orofaciodigital syndrome IV, 258860 (3);258860
TDGF1;Forebrain defects;17357067;187395;Forebrain defects (3);0
TDO2;Amelogenesis imperfecta, type IV;17357067;600525;Amelogenesis imperfecta, type IV, 104510 (3);104510
TDO2;Trichodontoosseous syndrome;17357067;600525;Trichodontoosseous syndrome, 190320 (3);190320
TDP1;Desbuquois dysplasia;17357067;613165;Desbuquois dysplasia, 251450 (3);251450
TDP1;Spinocerebellar ataxia, autosomal recessive with axonal neuropathy;17357067;607198;Spinocerebellar ataxia, autosomal recessive with axonal neuropathy, 607250 (3);607250
TDRD7;Cataract 36;17357067;611258;Cataract 36, 613887 (3);613887
TEAD1;Sveinsson choreoretinal atrophy;17357067;189967;Sveinsson choreoretinal atrophy, 108985 (3);108985
TEC;Transient erythroblastopenia of childhood;17357067;227050;Transient erythroblastopenia of childhood (2);0
TECPR2;Spastic paraplegia 49, autosomal recessive;17357067;615000;Spastic paraplegia 49, autosomal recessive, 615031 (3);615031
TECR;Mental retardation, autosomal recessive 14;17357067;610057;Mental retardation, autosomal recessive 14, 614020 (3);614020
TECTA;Deafness, autosomal dominant 8/12;17357067;602574;Deafness, autosomal dominant 8/12, 601543 (3);601543
TECTA;Deafness, autosomal recessive 21;17357067;602574;Deafness, autosomal recessive 21, 603629 (3);603629
TEK;Venous malformations, multiple cutaneous and mucosal;17357067;600221;Venous malformations, multiple cutaneous and mucosal, 600195 (3);600195
TERC;Aplastic anemia;17357067;602322;{Aplastic anemia}, 614743 (3);614743
TERC;Dyskeratosis congenita, autosomal dominant 1;17357067;602322;Dyskeratosis congenita, autosomal dominant 1, 127550 (3);127550
TERC;Pulmonary fibrosis, idiopathic, susceptibility to;17357067;602322;{Pulmonary fibrosis, idiopathic, susceptibility to}, 614743 (3);614743
TERT;Dyskeratosis congenita, autosomal recessive 4;17357067;187270;{Dyskeratosis congenita, autosomal recessive 4}, 613989 (3);613989
TERT;Dyskeratosis congenita, autosomal, autosomal dominant 2;17357067;187270;{Dyskeratosis congenita, autosomal, autosomal dominant 2}, 613979 (3);613979
TERT;Leukemia, acute myeloid;17357067;187270;{Leukemia, acute myeloid}, 601626 (3);601626
TERT;Melanoma, cutaneous malignant, 9;17357067;187270;{Melanoma, cutaneous malignant, 9}, 615134 (3);615134
TERT;Pulmonary fibrosis and/or bone marrow failure, telomere-related, 1;17357067;187270;{Pulmonary fibrosis and/or bone marrow failure, telomere-related, 1}, 614742 (3);614742
TERT;Treacher Collins syndrome 1;17357067;606847;Treacher Collins syndrome 1, 154500 (3);154500
TET2;Myelodysplastic syndrome, somatic;17357067;612839;Myelodysplastic syndrome, somatic, 614286 (3);614286
TEX11;Spermatogenic failure, X-linked, 2;17357067;300311;Spermatogenic failure, X-linked, 2, 309120 (3);309120
TF;Atransferrinemia;17357067;190000;Atransferrinemia, 209300 (3);209300
TFAP2A;Branchiooculofacial syndrome;17357067;107580;Branchiooculofacial syndrome, 113620 (3);113620
TFAP2B;Char syndrome;17357067;601601;Char syndrome, 169100 (3);169100
TFE3;Renal cell carcinoma, papillary, 1;17357067;314310;Renal cell carcinoma, papillary, 1, 300854 (3);300854
TFG;Hereditary motor and sensory neuropathy, Okinawa type;17357067;602498;Hereditary motor and sensory neuropathy, Okinawa type, 604484 (3);604484
TFR2;Hemochromatosis, type 3;17357067;604720;Hemochromatosis, type 3, 604250 (3);604250
TG;Autoimmune thyroid disease, susceptibility to, 3;17357067;188450;{Autoimmune thyroid disease, susceptibility to, 3}, 608175 (3);608175
TG;Thyroid dyshormonogenesis 3;17357067;188450;Thyroid dyshormonogenesis 3, 274700 (3);274700
TGDS;Catel-Manzke syndrome;17357067;616146;Catel-Manzke syndrome, 616145 (3);616145
TGFB1;Camurati-Engelmann disease;17357067;190180;Camurati-Engelmann disease, 131300 (3);131300
TGFB1;Cystic fibrosis lung disease, modifier of;17357067;190180;{Cystic fibrosis lung disease, modifier of}, 219700 (3);219700
TGFB2;Loeys-Dietz syndrome, type 4;17357067;190220;Loeys-Dietz syndrome, type 4, 614816 (3);614816
TGFB3;Arrhythmogenic right ventricular dysplasia 1;17357067;190230;Arrhythmogenic right ventricular dysplasia 1, 107970 (3);107970
TGFB3;Loeys-Dietz syndrome 5;17357067;190230;Loeys-Dietz syndrome 5, 615582 (3);615582
TGFBI;Corneal dystrophy, Avellino type;17357067;601692;Corneal dystrophy, Avellino type, 607541 (3);607541
TGFBI;Corneal dystrophy, Groenouw type I;17357067;601692;Corneal dystrophy, Groenouw type I, 121900 (3);121900
TGFBI;Corneal dystrophy, Reis-Bucklers type;17357067;601692;Corneal dystrophy, Reis-Bucklers type, 608470 (3);608470
TGFBI;Corneal dystrophy, Thiel-Behnke type;17357067;601692;Corneal dystrophy, Thiel-Behnke type, 602082 (3);602082
TGFBI;Corneal dystrophy, epithelial basement membrane;17357067;601692;Corneal dystrophy, epithelial basement membrane, 121820 (3);121820
TGFBI;Corneal dystrophy, lattice type I;17357067;601692;Corneal dystrophy, lattice type I, 122200 (3);122200
TGFBI;Corneal dystrophy, lattice type IIIA;17357067;601692;Corneal dystrophy, lattice type IIIA, 608471 (3);608471
TGFBR1;Loeys-Dietz syndrome, type 1;17357067;190181;Loeys-Dietz syndrome, type 1, 609192 (3);609192
TGFBR1;Multiple self-healing squamous epithelioma, susceptiblity to;17357067;190181;{Multiple self-healing squamous epithelioma, susceptiblity to}, 132800 (3);132800
TGFBR2;Colorectal cancer, hereditary nonpolyposis, type 6;17357067;190182;Colorectal cancer, hereditary nonpolyposis, type 6, 614331 (3);614331
TGFBR2;Esophageal cancer, somatic;17357067;190182;Esophageal cancer, somatic, 133239 (3);133239
TGFBR2;Loeys-Dietz syndrome, type 2;17357067;190182;Loeys-Dietz syndrome, type 2, 610168 (3);610168
TGIF1;Holoprosencephaly-4;17357067;602630;Holoprosencephaly-4, 142946 (3);142946
TGM1;Ichthyosis, congenital, autosomal recessive 1;17357067;190195;Ichthyosis, congenital, autosomal recessive 1, 242300 (3);242300
TGM5;Peeling skin syndrome 2;17357067;603805;Peeling skin syndrome 2, 609796 (3);609796
TGM6;Spinocerebellar ataxia 35;17357067;613900;Spinocerebellar ataxia 35, 613908 (3);613908
TH;Segawa syndrome, recessive;17357067;191290;Segawa syndrome, recessive, 605407 (3);605407
THAP1;Dystonia 6, torsion;17357067;609520;Dystonia 6, torsion, 602629 (3);602629
THBD;Hemolytic uremic syndrome, atypical, susceptibility to, 6;17357067;188040;{Hemolytic uremic syndrome, atypical, susceptibility to, 6}, 612926 (3);612926
THBD;Thrombophilia due to thrombomodulin defect;17357067;188040;Thrombophilia due to thrombomodulin defect, 614486 (3);614486
THBS2;Lumbar disc herniation, susceptibility to;17357067;188061;{Lumbar disc herniation, susceptibility to}, 603932 (3);603932
THOC6;Beaulieu-Boycott-Innes syndrome;17357067;615403;Beaulieu-Boycott-Innes syndrome, 613680 (3);613680
THPO;Thrombocythemia 1;17357067;600044;Thrombocythemia 1, 187950 (3);187950
THRA;Hypothyroidism, congenital, nongoitrous, 6;17357067;190120;Hypothyroidism, congenital, nongoitrous, 6, 614450 (3);614450
THRB;Thyroid hormone resistance;17357067;190160;Thyroid hormone resistance, 188570 (3);188570
THRB;Thyroid hormone resistance, autosomal recessive;17357067;190160;Thyroid hormone resistance, autosomal recessive, 274300 (3);274300
THRB;Thyroid hormone resistance, selective pituitary;17357067;190160;Thyroid hormone resistance, selective pituitary, 145650 (3);145650
TIA1;Welander distal myopathy;17357067;603518;Welander distal myopathy, 604454 (3);604454
TICAM1;Encephalopathy, acute, infection-induced, susceptibility to, 6;17357067;607601;{Encephalopathy, acute, infection-induced, susceptibility to, 6}, 614850 (3);614850
TIMM8A;Deafness, X-linked 1, progressive;17357067;300356;Deafness, X-linked 1, progressive (3);0
TIMM8A;Jensen syndrome;17357067;300356;Jensen syndrome, 311150 (3);311150
TIMM8A;Mohr-Tranebjaerg syndrome;17357067;300356;Mohr-Tranebjaerg syndrome, 304700 (3);304700
TIMP3;Sorsby fundus dystrophy;17357067;188826;Sorsby fundus dystrophy, 136900 (3);136900
TINF2;Dyskeratosis congenita, autosomal dominant 3;17357067;604319;Dyskeratosis congenita, autosomal dominant 3, 613990 (3);613990
TINF2;Revesz syndrome;17357067;604319;Revesz syndrome, 268130 (3);268130
TIRAP;Bacteremia, protection against;17357067;606252;{Bacteremia, protection against}, 614382 (3);614382
TIRAP;Malaria, protection against;17357067;606252;{Malaria, protection against}, 611162 (3);611162
TIRAP;Pneumococcal disease, invasive, protection against;17357067;606252;{Pneumococcal disease, invasive, protection against}, 610799 (3);610799
TIRAP;Tuberculosis, protection against;17357067;606252;{Tuberculosis, protection against}, 607948 (3);607948
TJP2;Cholestasis, progressive familial intrahepatic 4;17357067;607709;Cholestasis, progressive familial intrahepatic 4, 615878 (3);615878
TJP2;Deafness, autosomal dominant 51;17357067;613558;Deafness, autosomal dominant 51 (4);0
TJP2;Hypercholanemia, familial;17357067;607709;Hypercholanemia, familial, 607748 (3);607748
TK2;Mitochondrial DNA depletion syndrome 2 (myopathic type);17357067;188250;Mitochondrial DNA depletion syndrome 2 (myopathic type), 609560 (3);609560
TKT;Spondylometaepiphyseal dysplasia, short limb-hand type;17357067;191311;Spondylometaepiphyseal dysplasia, short limb-hand type, 271665 (3);271665
TLL1;Atrial septal defect 6;17357067;606742;Atrial septal defect 6, 613087 (3);613087
TLR1;Leprosy, protection against;17357067;601194;{Leprosy, protection against}, 613223 (3);613223
TLR1;Leprosy, susceptibility to, 5;17357067;601194;{Leprosy, susceptibility to, 5}, 613223 (3);613223
TLR2;Colorectal cancer, susceptibility to;17357067;603028;{Colorectal cancer, susceptibility to}, 114500 (3);114500
TLR2;Leprosy, susceptibility to;17357067;603028;{Leprosy, susceptibility to}, 246300 (3);246300
TLR2;Mycobacterium tuberculosis, susceptibility to;17357067;603028;{Mycobacterium tuberculosis, susceptibility to}, 607948 (3);607948
TLR3;HIV1 infection, resistance to;17357067;603029;{HIV1 infection, resistance to}, 609423 (3);609423
TLR3;Herpes simplex encephalitis, susceptibility to, 2;17357067;603029;{Herpes simplex encephalitis, susceptibility to, 2} 613002 (3);613002
TLR4;Colorectal cancer, susceptibility to;17357067;603030;{Colorectal cancer, susceptibility to}, 114500 (3);114500
TLR4;Endotoxin hyporesponsiveness;17357067;603030;Endotoxin hyporesponsiveness (3);0
TLR4;Macular degeneration, age-related, 10;17357067;603030;{Macular degeneration, age-related, 10}, 611488 (3);611488
TLR5;Legionaire disease, susceptibility to;17357067;603031;{Legionaire disease, susceptibility to}, 608556 (3);608556
TLR5;Melioidosis, susceptibility to;17357067;603031;{Melioidosis, susceptibility to}, 615557 (3);615557
TLR5;Systemic lupus erythematosus, resistance to;17357067;603031;{Systemic lupus erythematosus, resistance to}, 601744 (3);601744
TLR5;Systemic lupus erythematosus, susceptibility to, 1;17357067;603031;{Systemic lupus erythematosus, susceptibility to, 1}, 601744 (2);601744
TM4SF20;Specific language impairment 5;17357067;615404;{Specific language impairment 5}, 615432 (3);615432
TMC1;Deafness, autosomal dominant 36;17357067;606706;Deafness, autosomal dominant 36, 606705 (3);606705
TMC1;Deafness, autosomal recessive 7;17357067;606706;Deafness, autosomal recessive 7, 600974 (3);600974
TMC6;Epidermodysplasia verruciformis;17357067;605828;Epidermodysplasia verruciformis, 226400 (3);226400
TMC8;Epidermodysplasia verruciformis;17357067;605829;Epidermodysplasia verruciformis, 226400 (3);226400
TMCO1;Craniofacial dysmorphism, skeletal anomalies, and mental retardation syndrome;17357067;614123;Craniofacial dysmorphism, skeletal anomalies, and mental retardation syndrome, 213980 (3);213980
TMEM126A;Optic atrophy 7;17357067;612988;Optic atrophy 7, 612989 (3);612989
TMEM127;Pheochromocytoma, susceptibility to;17357067;613403;{Pheochromocytoma, susceptibility to}, 171300 (3);171300
TMEM138;Joubert syndrome 16;17357067;614459;Joubert syndrome 16, 614465 (3);614465
TMEM165;Congenital disorder of glycosylation, type IIk;17357067;614726;Congenital disorder of glycosylation, type IIk, 614727 (3);614727
TMEM173;STING-associated vasculopathy, infantile-onset;17357067;612374;STING-associated vasculopathy, infantile-onset, 615934 (3);615934
TMEM216;Joubert syndrome 2;17357067;613277;Joubert syndrome 2, 608091 (3);608091
TMEM216;Meckel syndrome 2;17357067;613277;Meckel syndrome 2, 603194 (3);603194
TMEM231;Joubert syndrome 20;17357067;614949;Joubert syndrome 20, 614970 (3);614970
TMEM231;Meckel syndrome 11;17357067;614949;Meckel syndrome 11, 615397 (3);615397
TMEM237;Joubert syndrome 14;17357067;614423;Joubert syndrome 14, 614424 (3);614424
TMEM240;Spinocerebellar ataxia 21;17357067;616101;Spinocerebellar ataxia 21, 607454 (3);607454
TMEM38B;Osteogenesis imperfecta, type XIV;17357067;611236;Osteogenesis imperfecta, type XIV, 615066 (3);615066
TMEM43;Arrhythmogenic right ventricular dysplasia 5;17357067;612048;Arrhythmogenic right ventricular dysplasia 5, 604400 (3);604400
TMEM43;Emery-Dreifuss muscular dystrophy 7, AD;17357067;612048;Emery-Dreifuss muscular dystrophy 7, AD, 614302 (3);614302
TMEM5;Muscular dystrophy-dystroglycanopathy (congenital with brain and eye anomalies), type A, 10;17357067;605862;Muscular dystrophy-dystroglycanopathy (congenital with brain and eye anomalies), type A, 10, 615041 (3);615041
TMEM67;Bardet-Biedl syndrome 14, modifier of;17357067;609884;{Bardet-Biedl syndrome 14, modifier of}, 209900 (3);209900
TMEM67;COACH syndrome;17357067;609884;COACH syndrome, 216360 (3);216360
TMEM67;Joubert syndrome 6;17357067;609884;Joubert syndrome 6, 610688 (3);610688
TMEM67;Meckel syndrome 3;17357067;609884;Meckel syndrome 3, 607361 (3);607361
TMEM67;Nephronophthisis 11;17357067;609884;Nephronophthisis 11, 613550 (3);613550
TMEM70;Mitochondrial complex V (ATP synthase) deficiency, nuclear type 2;17357067;612418;Mitochondrial complex V (ATP synthase) deficiency, nuclear type 2, 614052 (3);614052
TMIE;Deafness, autosomal recessive 6;17357067;607237;Deafness, autosomal recessive 6, 600971 (3);600971
TMLHE;Epsilon-trimethyllysine hydroxylase deficiency;17357067;300777;Epsilon-trimethyllysine hydroxylase deficiency, 300872 (3);300872
TMPRSS15;Enterokinase deficiency;17357067;606635;Enterokinase deficiency, 226200 (3);226200
TMPRSS3;Deafness, autosomal recessive 8/10;17357067;605511;Deafness, autosomal recessive 8/10, 601072 (3);601072
TMPRSS6;Iron-refractory iron deficiency anemia;17357067;609862;Iron-refractory iron deficiency anemia, 206200 (3);206200
TNC;Deafness, autosomal dominant 56;17357067;187380;Deafness, autosomal dominant 56, 615629 (3);615629
TNF;Asthma, susceptibility to;17357067;191160;{Asthma, susceptibility to}, 600807 (3);600807
TNF;Dementia, vascular, susceptibility to;17357067;191160;{Dementia, vascular, susceptibility to} (3);0
TNF;Malaria, cerebral, susceptibility to;17357067;191160;{Malaria, cerebral, susceptibility to}, 611162 (3);611162
TNF;Migraine without aura, susceptibility to;17357067;191160;{Migraine without aura, susceptibility to}, 157300 (3);157300
TNF;Septic shock, susceptibility to;17357067;191160;{Septic shock, susceptibility to} (3);0
TNFRSF10B;Squamous cell carcinoma, head and neck;17357067;603612;Squamous cell carcinoma, head and neck, 275355 (3);275355
TNFRSF11A;Osteolysis, familial expansile;17357067;603499;Osteolysis, familial expansile, 174810 (3);174810
TNFRSF11A;Osteopetrosis, autosomal recessive 7;17357067;603499;Osteopetrosis, autosomal recessive 7, 612301 (3);612301
TNFRSF11A;Paget disease of bone 2, early-onset;17357067;603499;{Paget disease of bone 2, early-onset}, 602080 (3);602080
TNFRSF11B;Paget disease of bone 5, juvenile-onset;17357067;602643;Paget disease of bone 5, juvenile-onset, 239000 (3);239000
TNFRSF13B;Immunodeficiency, common variable, 2;17357067;604907;Immunodeficiency, common variable, 2, 240500 (3);240500
TNFRSF13B;Immunoglobulin A deficiency 2;17357067;604907;Immunoglobulin A deficiency 2, 609529 (3);609529
TNFRSF13C;Immunodeficiency, common variable, 4;17357067;606269;Immunodeficiency, common variable, 4, 613494 (3);613494
TNFRSF1A;Multiple sclerosis, susceptibility to, 5;17357067;191190;{Multiple sclerosis, susceptibility to, 5}, 614810 (3);614810
TNFRSF1A;Periodic fever, familial;17357067;191190;Periodic fever, familial, 142680 (3);142680
TNFSF11;Osteopetrosis, autosomal recessive 2;17357067;602642;Osteopetrosis, autosomal recessive 2, 259710 (3);259710
TNFSF4;Myocardial infarction, susceptibility to;17357067;603594;{Myocardial infarction, susceptibility to}, 608446 (3);608446
TNMD;Trichoepithelioma, multiple familial, 2;17357067;612099;Trichoepithelioma, multiple familial, 2 (2);0
TNNC1;Cardiomyopathy, dilated, 1Z;17357067;191040;Cardiomyopathy, dilated, 1Z, 611879 (3);611879
TNNC1;Cardiomyopathy, hypertrophic, 13;17357067;191040;Cardiomyopathy, hypertrophic, 13, 613243 (3);613243
TNNI2;Arthrogryposis multiplex congenita, distal, type 2B;17357067;191043;Arthrogryposis multiplex congenita, distal, type 2B, 601680 (3);601680
TNNI3;Cardiomyopathy, dilated, 1FF;17357067;191044;Cardiomyopathy, dilated, 1FF, 613286 (3);613286
TNNI3;Cardiomyopathy, familial restrictive, 1;17357067;191044;Cardiomyopathy, familial restrictive, 1, 115210 (3);115210
TNNI3;Cardiomyopathy, hypertrophic, 7;17357067;191044;Cardiomyopathy, hypertrophic, 7, 613690 (3);613690
TNNT1;Nemaline myopathy 5, Amish type;17357067;191041;Nemaline myopathy 5, Amish type, 605355 (3);605355
TNNT2;Cardiomyopathy, dilated, 1D;17357067;191045;Cardiomyopathy, dilated, 1D, 601494 (3);601494
TNNT2;Cardiomyopathy, familial restrictive, 3;17357067;191045;Cardiomyopathy, familial restrictive, 3, 612422 (3);612422
TNNT2;Cardiomyopathy, hypertrophic, 2;17357067;191045;Cardiomyopathy, hypertrophic, 2, 115195 (3);115195
TNNT2;Left ventricular noncompaction 6;17357067;191045;Left ventricular noncompaction 6, 601494 (3);601494
TNNT3;Arthyrgryposis, distal, type 2B;17357067;600692;Arthyrgryposis, distal, type 2B, 601680 (3);601680
TNPO3;Muscular dystrophy, limb-girdle, type 1F;17357067;610032;Muscular dystrophy, limb-girdle, type 1F, 608423 (3);608423
TNXA;Ehlers-Danlos syndrome due to tenascin X deficiency;17357067;600985;Ehlers-Danlos syndrome due to tenascin X deficiency, 606408 (3);606408
TNXA;Vesicoureteral reflux 8;17357067;600985;Vesicoureteral reflux 8, 615963 (3);615963
TNXB;Ehlers-Danlos syndrome due to tenascin X deficiency;17357067;600985;Ehlers-Danlos syndrome due to tenascin X deficiency, 606408 (3);606408
TNXB;Vesicoureteral reflux 8;17357067;600985;Vesicoureteral reflux 8, 615963 (3);615963
TOP1;DNA topoisomerase I, camptothecin-resistant;17357067;126420;DNA topoisomerase I, camptothecin-resistant (3);0
TOP2A;DNA topoisomerase II, resistance to inhibition of, by amsacrine;17357067;126430;DNA topoisomerase II, resistance to inhibition of, by amsacrine (3);0
TOPORS;Retinitis pigmentosa 31;17357067;609507;Retinitis pigmentosa 31, 609923 (3);609923
TOR1A;Dystonia, early-onset atypical, with myoclonic features;17357067;605204;Dystonia, early-onset atypical, with myoclonic features (3);0
TOR1A;Dystonia-1, modifier of;17357067;605204;{Dystonia-1, modifier of} (3);0
TOR1A;Dystonia-1, torsion;17357067;605204;Dystonia-1, torsion, 128100 (3);128100
TP53;Adrenal cortical carcinoma;17357067;191170;Adrenal cortical carcinoma, 202300 (3);202300
TP53;Basal cell carcinoma 7;17357067;191170;{Basal cell carcinoma 7}, 614740 (3);614740
TP53;Breast cancer;17357067;191170;Breast cancer, 114480 (3);114480
TP53;Choroid plexus papilloma;17357067;191170;Choroid plexus papilloma, 260500 (3);260500
TP53;Colorectal cancer;17357067;191170;Colorectal cancer, 114500 (3);114500
TP53;Glioma susceptibility 1;17357067;191170;{Glioma susceptibility 1}, 137800 (3);137800
TP53;Hepatocellular carcinoma;17357067;191170;Hepatocellular carcinoma, 114550 (3);114550
TP53;Li-Fraumeni syndrome;17357067;191170;Li-Fraumeni syndrome, 151623 (3);151623
TP53;Nasopharyngeal carcinoma;17357067;191170;Nasopharyngeal carcinoma, 607107 (3);607107
TP53;Osteosarcoma;17357067;191170;Osteosarcoma, 259500 (3);259500
TP53;Pancreatic cancer;17357067;191170;Pancreatic cancer, 260350 (3);260350
TP63;ADULT syndrome;17357067;603273;ADULT syndrome, 103285 (3);103285
TP63;Ectrodactyly, ectodermal dysplasia, and cleft lip/palate syndrome 3;17357067;603273;Ectrodactyly, ectodermal dysplasia, and cleft lip/palate syndrome 3, 604292 (3);604292
TP63;Hay-Wells syndrome;17357067;603273;Hay-Wells syndrome, 106260 (3);106260
TP63;Limb-mammary syndrome;17357067;603273;Limb-mammary syndrome, 603543 (3);603543
TP63;Orofacial cleft 8;17357067;603273;Orofacial cleft 8, 129400 (3);129400
TP63;Rapp-Hodgkin syndrome;17357067;603273;Rapp-Hodgkin syndrome, 129400 (3);129400
TP63;Split-hand/foot malformation 4;17357067;603273;Split-hand/foot malformation 4, 605289 (3);605289
TPCN2;Skin/hair/eye pigmentation 10, blond/brown hair;17357067;612163;[Skin/hair/eye pigmentation 10, blond/brown hair], 612267 (3);612267
TPH2;Attention deficit-hyperactivity disorder, susceptibility to, 7;17357067;607478;{Attention deficit-hyperactivity disorder, susceptibility to, 7}, 613003 (3);613003
TPH2;Unipolar depression, susceptibility to;17357067;607478;{Unipolar depression, susceptibility to}, 608516 (3);608516
TPI1;Hemolytic anemia due to triosephosphate isomerase deficiency;17357067;190450;Hemolytic anemia due to triosephosphate isomerase deficiency, 615512 (3);615512
TPK1;Thiamine metabolism dysfunction syndrome 5 (episodic encephalopathy type);17357067;606370;Thiamine metabolism dysfunction syndrome 5 (episodic encephalopathy type), 614458 (3);614458
TPM1;Cardiomyopathy, dilated, 1Y;17357067;191010;Cardiomyopathy, dilated, 1Y, 611878 (3);611878
TPM1;Cardiomyopathy, hypertrophic, 3;17357067;191010;Cardiomyopathy, hypertrophic, 3, 115196 (3);115196
TPM1;Left ventricular noncompaction 9;17357067;191010;Left ventricular noncompaction 9, 611878 (3);611878
TPM2;Arthrogryposis multiplex congenita, distal, type 1;17357067;190990;Arthrogryposis multiplex congenita, distal, type 1, 108120 (3);108120
TPM2;Arthrogryposis, distal, type 2B;17357067;190990;Arthrogryposis, distal, type 2B, 601680 (3);601680
TPM2;CAP myopathy 2;17357067;190990;CAP myopathy 2, 609285 (3);609285
TPM2;Nemaline myopathy 4, autosomal dominant;17357067;190990;Nemaline myopathy 4, autosomal dominant, 609285 (3);609285
TPM3;CAP myopathy 1;17357067;191030;CAP myopathy 1, 609284 (3);609284
TPM3;Myopathy, congenital, with fiber-type disproportion;17357067;191030;Myopathy, congenital, with fiber-type disproportion, 255310 (3);255310
TPM3;Nemaline myopathy 1, autosomal dominant or recessive;17357067;191030;Nemaline myopathy 1, autosomal dominant or recessive, 609284 (3);609284
TPMT;6-mercaptopurine sensitivity;17357067;187680;6-mercaptopurine sensitivity, 610460 (3);610460
TPO;Thrombocythemia 1;17357067;600044;Thrombocythemia 1, 187950 (3);187950
TPO;Thyroid dyshormonogenesis 2A;17357067;606765;Thyroid dyshormonogenesis 2A, 274500 (3);274500
TPP1;Ceroid lipofuscinosis, neuronal, 2;17357067;607998;Ceroid lipofuscinosis, neuronal, 2, 204500 (3);204500
TPP1;Spinocerebellar ataxia, autosomal recessive 7;17357067;607998;Spinocerebellar ataxia, autosomal recessive 7, 609270 (3);609270
TPRN;Deafness, autosomal recessive 79;17357067;613354;Deafness, autosomal recessive 79, 613307 (3);613307
TRA;Immunodeficiency 7, TCR-alpha/beta deficient;17357067;186880;Immunodeficiency 7, TCR-alpha/beta deficient, 615387 (3);615387
TRAC;Immunodeficiency 7, TCR-alpha/beta deficient;17357067;186880;Immunodeficiency 7, TCR-alpha/beta deficient, 615387 (3);615387
TRAF3;Herpes simplex encephalitis, susceptibility to, 3;17357067;601896;{Herpes simplex encephalitis, susceptibility to, 3}, 614849 (3);614849
TRAF3IP2;Psoriasis susceptibility 13;17357067;607043;{Psoriasis susceptibility 13}, 614070 (3);614070
TRAPPC11;Muscular dystrophy, limb-girdle, type 2S;17357067;614138;Muscular dystrophy, limb-girdle, type 2S, 615356 (3);615356
TRAPPC2;Spondyloepiphyseal dysplasia tarda;17357067;300202;Spondyloepiphyseal dysplasia tarda, 313400 (3);313400
TRAPPC9;Mental retardation, autosomal recessive 13;17357067;611966;Mental retardation, autosomal recessive 13, 613192 (3);613192
TRDN;Ventricular tachycardia, catecholaminergic polymorphic, 5, with or without muscle weakness;17357067;603283;Ventricular tachycardia, catecholaminergic polymorphic, 5, with or without muscle weakness, 615441 (3);615441
TREH;Trehalase deficiency;17357067;275360;Trehalase deficiency, 612119 (1);612119
TREM2;Nasu-Hakola disease;17357067;605086;Nasu-Hakola disease, 221770 (3);221770
TREX1;Aicardi-Goutieres syndrome 1, dominant and recessive;17357067;606609;Aicardi-Goutieres syndrome 1, dominant and recessive, 225750 (3);225750
TREX1;Chilblain lupus;17357067;606609;Chilblain lupus, 610448 (3);610448
TREX1;Systemic lupus erythematosus, susceptibility to;17357067;606609;{Systemic lupus erythematosus, susceptibility to}, 152700 (3);152700
TREX1;Vasculopathy, retinal, with cerebral leukodystrophy;17357067;606609;Vasculopathy, retinal, with cerebral leukodystrophy, 192315 (3);192315
TRGJP2;Cardiomyopathy, hypertrophic, 17;17357067;605267;Cardiomyopathy, hypertrophic, 17, 613873 (3);613873
TRH;Thyrotropin-releasing hormone deficiency;17357067;613879;Thyrotropin-releasing hormone deficiency, 275120 (1);275120
TRHR;Thyrotropin-releasing hormone resistance, generalized;17357067;188545;Thyrotropin-releasing hormone resistance, generalized (3);0
TRIM2;Charcot-Marie-Tooth disease, type 2R;17357067;614141;Charcot-Marie-Tooth disease, type 2R, 615490 (3);615490
TRIM24;Thyroid carcinoma, papillary;17357067;603406;Thyroid carcinoma, papillary, 188550 (3);188550
TRIM32;Muscular dystrophy, limb-girdle, type 2H;17357067;602290;Muscular dystrophy, limb-girdle, type 2H, 254110 (3);254110
TRIM33;Thyroid carcinoma, papillary;17357067;605769;Thyroid carcinoma, papillary, 188550 (3);188550
TRIM37;Mulibrey nanism;17357067;605073;Mulibrey nanism, 253250 (3);253250
TRIOBP;Deafness, autosomal recessive 28;17357067;609761;Deafness, autosomal recessive 28, 609823 (3);609823
TRIP11;Achondrogenesis, type IA;17357067;604505;Achondrogenesis, type IA, 200600 (3);200600
TRMT10A;Microcephaly, short stature, and impaired glucose metabolism;17357067;616013;Microcephaly, short stature, and impaired glucose metabolism, 616033 (3);616033
TRMU;Deafness, mitochondrial, modifier of;17357067;610230;{Deafness, mitochondrial, modifier of}, 580000 (3);580000
TRMU;Liver failure, transient infantile;17357067;610230;Liver failure, transient infantile, 613070 (3);613070
TRNT1;Cataract 7;17357067;115660;Cataract 7 (2);0
TRNT1;Sideroblastic anemia with B-cell immunodeficiency, periodic fevers, and developmental delay;17357067;612907;Sideroblastic anemia with B-cell immunodeficiency, periodic fevers, and developmental delay, 616084 (3);616084
TRPA1;Episodic pain syndrome, familial;17357067;604775;Episodic pain syndrome, familial, 615040 (3);615040
TRPC6;Glomerulosclerosis, focal segmental, 2;17357067;603652;Glomerulosclerosis, focal segmental, 2, 603965 (3);603965
TRPM1;Night blindness, congenital stationary (complete), 1C, autosomal recessive;17357067;603576;Night blindness, congenital stationary (complete), 1C, autosomal recessive, 613216 (3);613216
TRPM4;Progressive familial heart block, type IB;17357067;606936;Progressive familial heart block, type IB, 604559 (3);604559
TRPM6;Hypomagnesemia 1, intestinal;17357067;607009;Hypomagnesemia 1, intestinal, 602014 (3);602014
TRPM7;Amyotrophic lateral sclerosis-parkinsonism/dementia complex, susceptibility to;17357067;605692;{Amyotrophic lateral sclerosis-parkinsonism/dementia complex, susceptibility to}, 105500 (3);105500
TRPS1;Trichorhinophalangeal syndrome, type I;17357067;604386;Trichorhinophalangeal syndrome, type I, 190350 (3);190350
TRPS1;Trichorhinophalangeal syndrome, type III;17357067;604386;Trichorhinophalangeal syndrome, type III, 190351 (3);190351
TRPV3;Olmsted syndrome;17357067;607066;Olmsted syndrome, 614594 (3);614594
TRPV4;Brachyolmia type 3;17357067;605427;Brachyolmia type 3, 113500 (3);113500
TRPV4;Digital arthropathy-brachydactyly, familial;17357067;605427;Digital arthropathy-brachydactyly, familial, 606835 (3);606835
TRPV4;Hereditary motor and sensory neuropathy, type IIc;17357067;605427;Hereditary motor and sensory neuropathy, type IIc, 606071 (3);606071
TRPV4;Metatropic dysplasia;17357067;605427;Metatropic dysplasia, 156530 (3);156530
TRPV4;Parastremmatic dwarfism;17357067;605427;Parastremmatic dwarfism, 168400 (3);168400
TRPV4;SED, Maroteaux type;17357067;605427;SED, Maroteaux type, 184095 (3);184095
TRPV4;Scapuloperoneal spinal muscular atrophy;17357067;605427;Scapuloperoneal spinal muscular atrophy, 181405 (3);181405
TRPV4;Sodium serum level QTL 1;17357067;605427;[Sodium serum level QTL 1], 613508 (3);613508
TRPV4;Spinal muscular atrophy, distal, congenital nonprogressive;17357067;605427;Spinal muscular atrophy, distal, congenital nonprogressive, 600175 (3);600175
TRPV4;Spondylometaphyseal dysplasia, Kozlowski type;17357067;605427;Spondylometaphyseal dysplasia, Kozlowski type, 184252 (3);184252
TSC1;Focal cortical dysplasia, Taylor balloon cell type;17357067;605284;Focal cortical dysplasia, Taylor balloon cell type, 607341 (3);607341
TSC1;Lymphangioleiomyomatosis;17357067;605284;Lymphangioleiomyomatosis, 606690 (3);606690
TSC1;Tuberous sclerosis-1;17357067;605284;Tuberous sclerosis-1, 191100 (3);191100
TSC2;Lymphangioleiomyomatosis, somatic;17357067;191092;Lymphangioleiomyomatosis, somatic, 606690 (3);606690
TSC2;Tuberous sclerosis-2;17357067;191092;Tuberous sclerosis-2, 613254 (3);613254
TSEN2;Pontocerebellar hypoplasia type 2B;17357067;608753;Pontocerebellar hypoplasia type 2B, 612389 (3);612389
TSEN34;Pontocerebellar hypoplasia type 2C;17357067;608754;Pontocerebellar hypoplasia type 2C, 612390 (3);612390
TSEN54;Pontocerebellar hypoplasia type 2A;17357067;608755;Pontocerebellar hypoplasia type 2A, 277470 (3);277470
TSEN54;Pontocerebellar hypoplasia type 4;17357067;608755;Pontocerebellar hypoplasia type 4, 225753 (3);225753
TSFM;Combined oxidative phosphorylation deficiency 3;17357067;604723;Combined oxidative phosphorylation deficiency 3, 610505 (3);610505
TSG101;Breast cancer, somatic;17357067;601387;Breast cancer, somatic, 114480 (3);114480
TSHB;Hypothryoidism, congenital, nongoitrous 4;17357067;188540;Hypothryoidism, congenital, nongoitrous 4, 275100 (3);275100
TSHR;Hyperthyroidism, familial gestational;17357067;603372;Hyperthyroidism, familial gestational, 603373 (3);603373
TSHR;Hyperthyroidism, nonautoimmune;17357067;603372;Hyperthyroidism, nonautoimmune, 609152 (3);609152
TSHR;Hypothyroidism, congenital, nongoitrous, 1;17357067;603372;Hypothyroidism, congenital, nongoitrous, 1 275200 (3);275200
TSHR;Thyroid adenoma, hyperfunctioning, somatic;17357067;603372;Thyroid adenoma, hyperfunctioning, somatic (3);0
TSHR;Thyroid carcinoma with thyrotoxicosis;17357067;603372;Thyroid carcinoma with thyrotoxicosis (3);0
TSHZ1;Aural atresia, congenital;17357067;614427;Aural atresia, congenital, 607842 (3);607842
TSPAN12;Exudative vitreoretinopathy 5;17357067;613138;Exudative vitreoretinopathy 5, 613310 (3);613310
TSPAN7;Mental retardation, X-linked 58;17357067;300096;Mental retardation, X-linked 58, 300210 (3);300210
TSPEAR;Deafness, autosomal recessive 98;17357067;612920;Deafness, autosomal recessive 98, 614861 (3);614861
TSPYL1;Sudden infant death with dysgenesis of the testes syndrome;17357067;604714;Sudden infant death with dysgenesis of the testes syndrome, 608800 (3);608800
TSPYL2;Dyserythropoietic anemia, congenital, type Ia;17357067;607465;Dyserythropoietic anemia, congenital, type Ia, 224120 (3);224120
TTBK2;Spinocerebellar ataxia 11;17357067;611695;Spinocerebellar ataxia 11, 604432 (3);604432
TTC19;Mitochondrial complex III deficiency, nuclear type 2;17357067;613814;Mitochondrial complex III deficiency, nuclear type 2, 615157 (3);615157
TTC21B;Nephronophthisis 12;17357067;612014;Nephronophthisis 12, 613820 (3);613820
TTC21B;Short-rib thoracic dysplasia 4 with or without polydactyly;17357067;612014;Short-rib thoracic dysplasia 4 with or without polydactyly, 613819 (3);613819
TTC37;Trichohepatoenteric syndrome 1;17357067;614589;Trichohepatoenteric syndrome 1, 222470 (3);222470
TTC7A;Gastrointestinal defects and immunodeficiency syndrome;17357067;609332;Gastrointestinal defects and immunodeficiency syndrome, 243150 (3);243150
TTC8;Bardet-Biedl syndrome 8;17357067;608132;Bardet-Biedl syndrome 8, 615985 (3);615985
TTF1;Chorea, hereditary benign;17357067;600635;Chorea, hereditary benign, 118700 (3);118700
TTF1;Choreoathetosis, hypothyroidism, and neonatal respiratory distress;17357067;600635;Choreoathetosis, hypothyroidism, and neonatal respiratory distress, 610978 (3);610978
TTF1;Goiter, familial, due to TTF-1 defect;17357067;600635;Goiter, familial, due to TTF-1 defect (1);0
TTF2;Bamforth-Lazarus syndrome;17357067;602617;Bamforth-Lazarus syndrome, 241850 (3);241850
TTI2;Mental retardation, autosomal recessive 39;17357067;614426;Mental retardation, autosomal recessive 39, 615541 (3);615541
TTLL5;Cone-rod dystrophy 19;17357067;612268;Cone-rod dystrophy 19, 615860 (3);615860
TTN;Cardiomyopathy, dilated, 1G;17357067;188840;Cardiomyopathy, dilated, 1G, 604145 (3);604145
TTN;Cardiomyopathy, familial hypertrophic, 9;17357067;188840;Cardiomyopathy, familial hypertrophic, 9, 613765 (3);613765
TTN;Muscular dystrophy, limb-girdle, type 2J;17357067;188840;Muscular dystrophy, limb-girdle, type 2J, 608807 (3);608807
TTN;Myopathy, early-onset, with fatal cardiomyopathy;17357067;188840;Myopathy, early-onset, with fatal cardiomyopathy, 611705 (3);611705
TTN;Myopathy, proximal, with early respiratory muscle involvement;17357067;188840;Myopathy, proximal, with early respiratory muscle involvement, 603689 (3);603689
TTN;Tibial muscular dystrophy, tardive;17357067;188840;Tibial muscular dystrophy, tardive, 600334 (3);600334
TTPA;Ataxia with isolated vitamin E deficiency;17357067;600415;Ataxia with isolated vitamin E deficiency, 277460 (3);277460
TTR;Amyloidosis, hereditary, transthyretin-related;17357067;176300;Amyloidosis, hereditary, transthyretin-related, 105210 (3);105210
TTR;Carpal tunnel syndrome, familial;17357067;176300;Carpal tunnel syndrome, familial, 115430 (3);115430
TTR;Dystransthyretinemic hyperthyroxinemia;17357067;176300;[Dystransthyretinemic hyperthyroxinemia], 145680 (3);145680
TUBA1A;Lissencephaly 3;17357067;602529;Lissencephaly 3, 611603 (3);611603
TUBA4A;Amyotrophic lateral sclerosis 22 with or without frontotemoral dementia;17357067;191110;Amyotrophic lateral sclerosis 22 with or without frontotemoral dementia, 616208 (3);616208
TUBA8;Polymicrogyria with optic nerve hypoplasia;17357067;605742;Polymicrogyria with optic nerve hypoplasia, 613180 (3);613180
TUBB;Cortical dysplasia, complex, with other brain malformations 6;17357067;191130;Cortical dysplasia, complex, with other brain malformations 6, 615771 (3);615771
TUBB1;Macrothrombocytopenia, autosomal dominant, TUBB1-related;17357067;612901;Macrothrombocytopenia, autosomal dominant, TUBB1-related, 613112 (3);613112
TUBB2A;Cortical dysplasia, complex, with other brain malformations 5;17357067;615101;Cortical dysplasia, complex, with other brain malformations 5, 615763 (3);615763
TUBB2B;Polymicrogyria, symmetric or asymmetric;17357067;612850;Polymicrogyria, symmetric or asymmetric, 610031 (3);610031
TUBB3;Cortical dysplasia, complex, with other brain malformations 1;17357067;602661;Cortical dysplasia, complex, with other brain malformations 1, 614039 (3);614039
TUBB3;Fibrosis of extraocular muscles, congenital, 3A;17357067;602661;Fibrosis of extraocular muscles, congenital, 3A, 600638 (3);600638
TUBB4A;Cortical dysplasia, complex, with other brain malformations 1;17357067;602661;Cortical dysplasia, complex, with other brain malformations 1, 614039 (3);614039
TUBB4A;Dystonia 4, torsion, autosomal dominant;17357067;602662;Dystonia 4, torsion, autosomal dominant, 128101 (3);128101
TUBB4A;Fibrosis of extraocular muscles, congenital, 3A;17357067;602661;Fibrosis of extraocular muscles, congenital, 3A, 600638 (3);600638
TUBB4A;Leukodystrophy, hypomyelinating, 6;17357067;602662;Leukodystrophy, hypomyelinating, 6, 612438 (3);612438
TUBG1;Cortical dysplasia, complex, with other brain malformations 4;17357067;191135;Cortical dysplasia, complex, with other brain malformations 4, 615412 (3);615412
TUBGCP4;Microcephaly and chorioretinopathy, autosomal recessive, 3;17357067;609610;Microcephaly and chorioretinopathy, autosomal recessive, 3, 616335 (3);616335
TUBGCP6;Microcephaly and chorioretinopathy, autosomal recessive, 1;17357067;610053;Microcephaly and chorioretinopathy, autosomal recessive, 1, 251270 (3);251270
TUFM;Combined oxidative phosphorylation deficiency 4;17357067;602389;Combined oxidative phosphorylation deficiency 4, 610678 (3);610678
TULP1;Leber congenital amaurosis 15;17357067;602280;Leber congenital amaurosis 15, 613843 (3);613843
TULP1;Retinitis pigmentosa 14;17357067;602280;Retinitis pigmentosa 14, 600132 (3);600132
TUSC3;Mental retardation, autosomal recessive 7;17357067;601385;Mental retardation, autosomal recessive 7, 611093 (3);611093
TWIST1;Craniosynostosis, type 1;17357067;601622;Craniosynostosis, type 1, 123100 (3);123100
TWIST1;Robinow-Sorauf syndrome;17357067;601622;Robinow-Sorauf syndrome, 180750 (3);180750
TWIST1;Saethre-Chotzen syndrome;17357067;601622;Saethre-Chotzen syndrome, 101400 (3);101400
TWIST1;Saethre-Chotzen syndrome with eyelid anomalies;17357067;601622;Saethre-Chotzen syndrome with eyelid anomalies, 101400 (3);101400
TWIST2;Ablepharon-macrostomia syndrome;17357067;607556;Ablepharon-macrostomia syndrome, 200110 (3);200110
TWIST2;Barber-Say syndrome;17357067;607556;Barber-Say syndrome, 209885 (3);209885
TWIST2;Focal facial dermal dysplasia 3, Setleis type;17357067;607556;Focal facial dermal dysplasia 3, Setleis type, 227260 (3);227260
TXNL4A;Burn-McKeown syndrome;17357067;611595;Burn-McKeown syndrome, 608572 (3);608572
TYK2;Immunodeficiency 35;17357067;176941;Immunodeficiency 35, 611521 (3);611521
TYMP;Mitochondrial DNA depletion syndrome 1 (MNGIE type);17357067;131222;Mitochondrial DNA depletion syndrome 1 (MNGIE type), 603041 (3);603041
TYR;Albinism, oculocutaneous, type IA;17357067;606933;Albinism, oculocutaneous, type IA, 203100 (3);203100
TYR;Albinism, oculocutaneous, type IB;17357067;606933;Albinism, oculocutaneous, type IB, 606952 (3);606952
TYR;Melanoma, cutaneous malignant, susceptibility to, 8;17357067;606933;{Melanoma, cutaneous malignant, susceptibility to, 8}, 601800 (3);601800
TYR;Skin/hair/eye pigmentation 3, blue/green eyes;17357067;606933;[Skin/hair/eye pigmentation 3, blue/green eyes], 601800 (3);601800
TYR;Skin/hair/eye pigmentation 3, light/dark/freckling skin;17357067;606933;[Skin/hair/eye pigmentation 3, light/dark/freckling skin], 601800 (3);601800
TYR;Waardenburg syndrome/albinism, digenic;17357067;606933;Waardenburg syndrome/albinism, digenic, 103470 (3);103470
TYROBP;Nasu-Hakola disease;17357067;604142;Nasu-Hakola disease, 221770 (3);221770
TYRP1;Albinism, oculocutaneous, type III;17357067;115501;Albinism, oculocutaneous, type III, 203290 (3);203290
TYRP1;Skin/hair/eye pigmentation, variation in, 11 (Melanesian blond hair);17357067;115501;[Skin/hair/eye pigmentation, variation in, 11 (Melanesian blond hair)], 612271 (3);612271
UBA1;Spinal muscular atrophy, X-linked 2, infantile;17357067;314370;Spinal muscular atrophy, X-linked 2, infantile, 301830 (3);301830
UBB;Cleft palate, isolated;17357067;191339;Cleft palate, isolated, 119540 (2);119540
UBE2A;Mental retardation, X-linked syndromic, Nascimento-type;17357067;312180;Mental retardation, X-linked syndromic, Nascimento-type, 300860 (3);300860
UBE2T;Fanconi anemia, complementation group T;17357067;610538;Fanconi anemia, complementation group T, 616435 (3);616435
UBE3A;Angelman syndrome;17357067;601623;Angelman syndrome, 105830 (3);105830
UBE3B;Kaufman oculocerebrofacial syndrome;17357067;608047;Kaufman oculocerebrofacial syndrome, 244450 (3);244450
UBIAD1;Corneal dystrophy, Schnyder type;17357067;611632;Corneal dystrophy, Schnyder type, 121800 (3);121800
UBQLN2;Amyotrophic lateral sclerosis 15, with or without frontotemporal dementia;17357067;300264;Amyotrophic lateral sclerosis 15, with or without frontotemporal dementia, 300857 (3);300857
UBR1;Johanson-Blizzard syndrome;17357067;605981;Johanson-Blizzard syndrome, 243800 (3);243800
UCP1;Obesity, susceptibility to;17357067;113730;{Obesity, susceptibility to}, 601665 (3);601665
UCP2;Obesity, susceptibility to, BMIQ4;17357067;601693;{Obesity, susceptibility to, BMIQ4}, 607447 (3);607447
UCP3;Obesity, severe, and type II diabetes;17357067;602044;{Obesity, severe, and type II diabetes}, 601665 (3);601665
UGT1A1;Bilirubin, serum level of, QTL1;17357067;191740;[Bilirubin, serum level of, QTL1], 601816 (3);601816
UGT1A1;Crigler-Najjar syndrome, type I;17357067;191740;Crigler-Najjar syndrome, type I, 218800 (3);218800
UGT1A1;Crigler-Najjar syndrome, type II;17357067;191740;Crigler-Najjar syndrome, type II, 606785 (3);606785
UGT1A1;Gilbert syndrome;17357067;191740;[Gilbert syndrome], 143500 (3);143500
UGT1A1;Hyperbilirubinemia, familial transient neonatal;17357067;191740;Hyperbilirubinemia, familial transient neonatal, 237900 (3);237900
UGT2B17;Bone mineral density QTL 12, osteoporosis;17357067;601903;{Bone mineral density QTL 12, osteoporosis}, 612560 (3);612560
UMOD;Glomerulocystic kidney disease with hyperuricemia and isosthenuria;17357067;191845;Glomerulocystic kidney disease with hyperuricemia and isosthenuria, 609886 (3);609886
UMOD;Hyperuricemic nephropathy, familial juvenile 1;17357067;191845;Hyperuricemic nephropathy, familial juvenile 1, 162000 (3);162000
UMOD;Medullary cystic kidney disease 2;17357067;191845;Medullary cystic kidney disease 2, 603860 (3);603860
UMPS;Orotic aciduria;17357067;613891;Orotic aciduria, 258900 (3);258900
UNC13D;Hemophagocytic lymphohistiocytosis, familial, 3;17357067;608897;Hemophagocytic lymphohistiocytosis, familial, 3, 608898 (3);608898
UNC93B1;Herpes simplex encephalitis, susceptibility to, 1;17357067;608204;{Herpes simplex encephalitis, susceptibility to, 1}, 610551 (3);610551
UNG;Immunodeficiency with hyper IgM, type 5;17357067;191525;Immunodeficiency with hyper IgM, type 5, 608106 (3);608106
UOX;Urate oxidase deficiency;17357067;191540;[Urate oxidase deficiency] (1);0
UPB1;Beta-ureidopropionase deficiency;17357067;606673;Beta-ureidopropionase deficiency, 613161 (3);613161
UPF3B;Mental retardation, X-linked, syndromic 14;17357067;300298;Mental retardation, X-linked, syndromic 14, 300676 (3);300676
UQCRB;Mitochondrial complex III deficiency, nuclear type 3;17357067;191330;Mitochondrial complex III deficiency, nuclear type 3, 615158 (3);615158
UQCRC2;Mitochondrial complex III deficiency, nuclear type 5;17357067;191329;Mitochondrial complex III deficiency, nuclear type 5, 615160 (3);615160
UQCRQ;Mitochondrial complex III deficiency, nuclear type 4;17357067;612080;Mitochondrial complex III deficiency, nuclear type 4, 615159 (3);615159
UROD;Porphyria cutanea tarda;17357067;613521;Porphyria cutanea tarda, 176100 (3);176100
UROD;Porphyria, hepatoerythropoietic;17357067;613521;Porphyria, hepatoerythropoietic, 176100 (3);176100
UROS;Porphyria, congenital erythropoietic;17357067;606938;Porphyria, congenital erythropoietic, 263700 (3);263700
USB1;Poikiloderma with neutropenia;17357067;613276;Poikiloderma with neutropenia, 604173 (3);604173
USF1;Hyperlipidemia, familial combined, susceptibility to;17357067;191523;{Hyperlipidemia, familial combined, susceptibility to}, 602491 (3);602491
USH1C;Deafness, autosomal recessive 18A;17357067;605242;Deafness, autosomal recessive 18A, 602092 (3);602092
USH1C;Usher syndrome, type 1C;17357067;605242;Usher syndrome, type 1C, 276904 (3);276904
USH1G;Usher syndrome, type 1G;17357067;607696;Usher syndrome, type 1G, 606943 (3);606943
USH2A;Retinitis pigmentosa 39;17357067;608400;Retinitis pigmentosa 39, 613809 (3);613809
USH2A;Usher syndrome, type 2A;17357067;608400;Usher syndrome, type 2A, 276901 (3);276901
USP9X;Mental retardation, X-linked 99;17357067;300072;Mental retardation, X-linked 99, 300919 (3);300919
USP9Y;Spermatogenic failure, Y-linked, 2;17357067;400005;Spermatogenic failure, Y-linked, 2, 415000 (3);415000
UVSSA;UV-sensitive syndrome 3;17357067;614632;UV-sensitive syndrome 3, 614640 (3);614640
VAMP1;Spastic ataxia 1, autosomal dominant;17357067;185880;Spastic ataxia 1, autosomal dominant, 108600 (3);108600
VANGL1;Caudal regression syndrome;17357067;610132;Caudal regression syndrome, 600145 (3);600145
VANGL1;Neural tube defects, susceptibility to;17357067;610132;{Neural tube defects, susceptibility to}, 182940 (3);182940
VANGL2;Neural tube defects;17357067;600533;Neural tube defects, 182940 (3);182940
VAPB;Amyotrophic lateral sclerosis 8;17357067;605704;Amyotrophic lateral sclerosis 8, 608627 (3);608627
VAPB;Spinal muscular atrophy, late-onset, Finkel type;17357067;605704;Spinal muscular atrophy, late-onset, Finkel type, 182980 (3);182980
VARS2;Combined oxidative phosphorylation deficiency 20;17357067;612802;Combined oxidative phosphorylation deficiency 20, 615917 (3);615917
VCAN;Wagner syndrome 1;17357067;118661;Wagner syndrome 1, 143200 (3);143200
VCL;Cardiomyopathy, dilated, 1W;17357067;193065;Cardiomyopathy, dilated, 1W, 611407 (3);611407
VCL;Cardiomyopathy, hypertrophic, 15;17357067;193065;Cardiomyopathy, hypertrophic, 15, 613255 (3);613255
VCP;Amyotrophic lateral sclerosis 14, with or without frontotemporal dementia;17357067;601023;Amyotrophic lateral sclerosis 14, with or without frontotemporal dementia, 613954 (3);613954
VCP;Inclusion body myopathy with early-onset Paget disease and frontotemporal dementia 1;17357067;601023;Inclusion body myopathy with early-onset Paget disease and frontotemporal dementia 1, 167320 (3);167320
VDR;Rickets, vitamin D-resistant, type IIA;17357067;601769;Rickets, vitamin D-resistant, type IIA, 277440 (3);277440
VEGFA;Microvascular complications of diabetes 1;17357067;192240;{Microvascular complications of diabetes 1}, 603933 (3);603933
VEGFC;Lymphedema, hereditary, ID;17357067;601528;Lymphedema, hereditary, ID, 615907 (3);615907
VHL;Erythrocytosis, familial, 2;17357067;608537;Erythrocytosis, familial, 2, 263400 (3);263400
VHL;Hemangioblastoma, cerebellar, somatic;17357067;608537;Hemangioblastoma, cerebellar, somatic (3);0
VHL;Pheochromocytoma;17357067;608537;Pheochromocytoma, 171300 (3);171300
VHL;Renal cell carcinoma, somatic;17357067;608537;Renal cell carcinoma, somatic, 144700 (3);144700
VHL;von Hippel-Lindau syndrome;17357067;608537;von Hippel-Lindau syndrome, 193300 (3);193300
VIL1;Cholestasis, progressive canalicular;17357067;193040;Cholestasis, progressive canalicular (1);0
VIM;Cataract 30, pulverulent;17357067;193060;Cataract 30, pulverulent, 116300 (3);116300
VIPAS39;Arthrogryposis, renal dysfunction, and cholestasis 2;17357067;613401;Arthrogryposis, renal dysfunction, and cholestasis 2, 613404 (3);613404
VKORC1;Vitamin K-dependent clotting factors, combined deficiency of, 2;17357067;608547;Vitamin K-dependent clotting factors, combined deficiency of, 2, 607473 (3);607473
VKORC1;Warfarin resistance;17357067;608547;Warfarin resistance, 122700 (3);122700
VLDLR;Cerebellar hypoplasia and mental retardation with or without quadrupedal locomotion 1;17357067;192977;Cerebellar hypoplasia and mental retardation with or without quadrupedal locomotion 1, 224050 (3);224050
VMA21;Myopathy, X-linked, with excessive autophagy;17357067;310440;Myopathy, X-linked, with excessive autophagy (2);0
VNN1;High density lipoprotein cholesterol level QTL 8;17357067;603570;[High density lipoprotein cholesterol level QTL 8] (3);0
VPS13A;Choreoacanthocytosis;17357067;605978;Choreoacanthocytosis, 200150 (3);200150
VPS13B;Cohen syndrome;17357067;607817;Cohen syndrome, 216550 (3);216550
VPS33B;Arthrogryposis, renal dysfunction, and cholestasis 1;17357067;608552;Arthrogryposis, renal dysfunction, and cholestasis 1, 208085 (3);208085
VPS35;Parkinson disease 17;17357067;601501;{Parkinson disease 17}, 614203 (3);614203
VPS37A;Spastic paraplegia 53, autosomal recessive;17357067;609927;Spastic paraplegia 53, autosomal recessive, 614898 (3);614898
VPS45;Neutropenia, severe congenital, 5, autosomal recessive;17357067;610035;Neutropenia, severe congenital, 5, autosomal recessive, 615285 (3);615285
VPS53;Pontocerebellar hypoplasia, type 2E;17357067;615850;Pontocerebellar hypoplasia, type 2E, 615851 (3);615851
VRK1;Pontocerebellar hypoplasia type 1A;17357067;602168;Pontocerebellar hypoplasia type 1A, 607596 (3);607596
VSX1;Corneal dystrophy, posterior polymorphous, 1;17357067;605020;Corneal dystrophy, posterior polymorphous, 1, 122000 (3);122000
VSX1;Craniofacial anomalies and anterior segment dysgenesis syndrome;17357067;605020;Craniofacial anomalies and anterior segment dysgenesis syndrome, 614195 (3);614195
VSX1;Keratoconus 1;17357067;605020;Keratoconus 1, 148300 (3);148300
VSX2;Microphthalmia with coloboma 3;17357067;142993;Microphthalmia with coloboma 3, 610092 (3);610092
VSX2;Microphthalmia, isolated 2;17357067;142993;Microphthalmia, isolated 2, 610093 (3);610093
VWF;von Willebrand disease, type 1;17357067;613160;von Willebrand disease, type 1, 193400 (3);193400
VWF;von Willebrand disease, types 2A, 2B, 2M, and 2N;17357067;613160;von Willebrand disease, types 2A, 2B, 2M, and 2N, 613554 (3);613554
VWF;von Willibrand disease, type 3;17357067;613160;von Willibrand disease, type 3, 277480 (3);277480
WAS;Neutropenia, severe congenital, X-linked;17357067;300392;Neutropenia, severe congenital, X-linked, 300299 (3);300299
WAS;Thrombocytopenia, X-linked;17357067;300392;Thrombocytopenia, X-linked, 313900 (3);313900
WAS;Thrombocytopenia, X-linked, intermittent;17357067;300392;Thrombocytopenia, X-linked, intermittent, 313900 (3);313900
WAS;Wiskott-Aldrich syndrome;17357067;300392;Wiskott-Aldrich syndrome, 301000 (3);301000
WASF2;Spinocerebellar ataxia, autosomal recessive 2;17357067;213200;Spinocerebellar ataxia, autosomal recessive 2 (2);0
WASF3;Spinocerebellar ataxia, autosomal recessive 3;17357067;271250;Spinocerebellar ataxia, autosomal recessive 3 (2);0
WDR11;Hypogonadotropic hypogonadism 14 with or without anosmia;17357067;606417;Hypogonadotropic hypogonadism 14 with or without anosmia, 614858 (3);614858
WDR19;Nephronophthisis 13;17357067;608151;Nephronophthisis 13, 614377 (3);614377
WDR19;Senior-Loken syndrome 8;17357067;608151;Senior-Loken syndrome 8, 616307 (3);616307
WDR34;Short-rib thoracic dysplasia 11 with or without polydactyly;17357067;613363;Short-rib thoracic dysplasia 11 with or without polydactyly, 615633 (3);615633
WDR35;Cranioectodermal dysplasia 2;17357067;613602;Cranioectodermal dysplasia 2, 613610 (3);613610
WDR35;Short-rib thoracic dysplasia 7 with or without polydactyly;17357067;613602;Short-rib thoracic dysplasia 7 with or without polydactyly, 614091 (3);614091
WDR36;Glaucoma 1, open angle, G;17357067;609669;Glaucoma 1, open angle, G, 609887 (3);609887
WDR45;Neurodegeneration with brain iron accululation 5;17357067;300526;Neurodegeneration with brain iron accululation 5, 300894 (3);300894
WDR60;Short-rib thoracic dysplasia 8 with or without polydactyly;17357067;615462;Short-rib thoracic dysplasia 8 with or without polydactyly, 615503 (3);615503
WDR62;Microcephaly 2, primary, autosomal recessive, with or without cortical malformations;17357067;613583;Microcephaly 2, primary, autosomal recessive, with or without cortical malformations, 604317 (3);604317
WDR72;Amelogenesis imperfecta, type IIA3;17357067;613214;Amelogenesis imperfecta, type IIA3, 613211 (3);613211
WDR73;Galloway-Mowat syndrome;17357067;616144;Galloway-Mowat syndrome, 251300 (3);251300
WDR81;Cerebellar ataxia, mental retardation, and dysequilibrium syndrome 2;17357067;614218;Cerebellar ataxia, mental retardation, and dysequilibrium syndrome 2, 610185 (3);610185
WFS1;Deafness, autosomal dominant 6/14/38;17357067;606201;Deafness, autosomal dominant 6/14/38, 600965 (3);600965
WFS1;Diabetes mellitus, noninsulin-dependent, association with;17357067;606201;{Diabetes mellitus, noninsulin-dependent, association with}, 125853 (3);125853
WFS1;Wolfram syndrome;17357067;606201;Wolfram syndrome, 222300 (3);222300
WFS1;Wolfram-like syndrome, autosomal dominant;17357067;606201;Wolfram-like syndrome, autosomal dominant, 614296 (3);614296
WHSC1L1;Leukemia, acute myeloid;17357067;607083;Leukemia, acute myeloid, 601626 (3);601626
WISP3;Arthropathy, progressive pseudorheumatoid, of childhood;17357067;603400;Arthropathy, progressive pseudorheumatoid, of childhood, 208230 (3);208230
WISP3;Spondyloepiphyseal dysplasia tarda with progressive arthropathy;17357067;603400;Spondyloepiphyseal dysplasia tarda with progressive arthropathy, 208230 (3);208230
WNK1;Neuropathy, hereditary sensory and autonomic, type II;17357067;605232;Neuropathy, hereditary sensory and autonomic, type II, 201300 (3);201300
WNK1;Pseudohypoaldosteronism, type IIC;17357067;605232;Pseudohypoaldosteronism, type IIC, 614492 (3);614492
WNK4;Pseudohypoaldosteronism, type IIB;17357067;601844;Pseudohypoaldosteronism, type IIB, 614491 (3);614491
WNT1;Osteogenesis imperfecta, type XV;17357067;164820;Osteogenesis imperfecta, type XV, 615220 (3);615220
WNT1;Osteoporosis, early-onset, susceptibility to, autosomal dominant;17357067;164820;{Osteoporosis, early-onset, susceptibility to, autosomal dominant}, 615221 (3);615221
WNT10A;Odontoonychodermal dysplasia;17357067;606268;Odontoonychodermal dysplasia, 257980 (3);257980
WNT10A;Schopf-Schulz-Passarge syndrome;17357067;606268;Schopf-Schulz-Passarge syndrome, 224750 (3);224750
WNT10A;Tooth agenesis, selective, 4;17357067;606268;Tooth agenesis, selective, 4, 150400 (3);150400
WNT10B;Split-hand/foot malformation 6;17357067;601906;Split-hand/foot malformation 6, 225300 (3);225300
WNT4;Mullerian aplasia and hyperandrogenism;17357067;603490;Mullerian aplasia and hyperandrogenism, 158330 (3);158330
WNT4;SERKAL syndrome;17357067;603490;SERKAL syndrome, 611812 (3);611812
WNT5A;Robinow syndrome, autosomal dominant 1;17357067;164975;Robinow syndrome, autosomal dominant 1, 180700 (3);180700
WNT7A;Fuhrmann syndrome;17357067;601570;Fuhrmann syndrome, 228930 (3);228930
WNT7A;Ulna and fibula, absence of, with severe limb deficiency;17357067;601570;Ulna and fibula, absence of, with severe limb deficiency, 276820 (3);276820
WRAP53;Dyskeratosis congenita, autosomal recessive 3;17357067;612661;Dyskeratosis congenita, autosomal recessive 3, 613988 (3);613988
WRN;Werner syndrome;17357067;604611;Werner syndrome, 277700 (3);277700
WT1;Denys-Drash syndrome;17357067;607102;Denys-Drash syndrome, 194080 (3);194080
WT1;Frasier syndrome;17357067;607102;Frasier syndrome, 136680 (3);136680
WT1;Meacham syndrome;17357067;607102;Meacham syndrome, 608978 (3);608978
WT1;Mesothelioma, somatic;17357067;607102;Mesothelioma, somatic, 156240 (3);156240
WT1;Nephrotic syndrome, type 4;17357067;607102;Nephrotic syndrome, type 4, 256370 (3);256370
WT1;Wilms tumor, type 1;17357067;607102;Wilms tumor, type 1, 194070 (3);194070
WWC1;Memory, enhanced, QTL;17357067;610533;[Memory, enhanced, QTL], 615602 (3);615602
WWOX;Epileptic encephalopathy, early infantile, 28;17357067;605131;Epileptic encephalopathy, early infantile, 28, 616211 (3);616211
WWOX;Esophageal squamous cell carcinoma, somatic;17357067;605131;Esophageal squamous cell carcinoma, somatic, 133239 (3);133239
WWOX;Spinocrebellar ataxia, autosomal recessive 12;17357067;605131;Spinocrebellar ataxia, autosomal recessive 12, 614322 (3);614322
XBP1;Major affective disorder-7, susceptibility to;17357067;194355;{Major affective disorder-7, susceptibility to}, 612371 (3);612371
XCE;Arthrogryposis, distal, type 5D;17357067;605896;Arthrogryposis, distal, type 5D, 615065 (3);615065
XCE;X-inactivation, familial skewed;17357067;314670;X-inactivation, familial skewed, 300087 (3);300087
XDH;Xanthinuria, type I;17357067;607633;Xanthinuria, type I, 278300 (3);278300
XG;Blood group, XG system;17357067;314700;[Blood group, XG system] (3);0
XIAP;Lymphoproliferative syndrome, X-linked, 2;17357067;300079;Lymphoproliferative syndrome, X-linked, 2, 300635 (3);300635
XIC;X-inactivation, familial skewed;17357067;314670;X-inactivation, familial skewed, 300087 (3);300087
XIST;X-inactivation, familial skewed;17357067;314670;X-inactivation, familial skewed, 300087 (3);300087
XK;McLeod syndrome with or without chronic granulomatous disease;17357067;314850;McLeod syndrome with or without chronic granulomatous disease, 300842 (3);300842
XPA;Xeroderma pigmentosum, group A;17357067;611153;Xeroderma pigmentosum, group A, 278700 (3);278700
XPC;Xeroderma pigmentosum, group C;17357067;613208;Xeroderma pigmentosum, group C, 278720 (3);278720
XPNPEP2;Angioedema induced by ACE inhibitors, susceptibility to;17357067;300145;{Angioedema induced by ACE inhibitors, susceptibility to}, 300909 (3);300909
XPNPEP3;Nephronophthisis-like nephropathy 1;17357067;613553;Nephronophthisis-like nephropathy 1, 613159 (3);613159
XPR1;Basal ganglia calcification, idiopathic, 6;17357067;605237;Basal ganglia calcification, idiopathic, 6, 616413 (3);616413
XRCC3;Breast cancer, susceptibility to;17357067;600675;{Breast cancer, susceptibility to}, 114480 (3);114480
XRCC3;Melanoma, cutaneous malignant, 6;17357067;600675;{Melanoma, cutaneous malignant, 6}, 613972 (3);613972
XYLT1;Desbuquois dysplasia 2;17357067;608124;Desbuquois dysplasia 2, 615777 (3);615777
XYLT1;Pseudoxanthoma elasticum, modifier of severity of;17357067;608124;{Pseudoxanthoma elasticum, modifier of severity of}, 264800 (3);264800
XYLT2;Pseudoxanthoma elasticum, modifier of severity of;17357067;608125;{Pseudoxanthoma elasticum, modifier of severity of}, 264800 (3);264800
XYLT2;Spondyloocular syndrome;17357067;608125;Spondyloocular syndrome, 605822 (3);605822
YAP1;Coloboma, ocular;17357067;606608;Coloboma, ocular, 120433 (3);120433
YAP1;Coloboma, ocular, with or without hearing impairment, cleft lip/palate, and/or mental retardation;17357067;606608;Coloboma, ocular, with or without hearing impairment, cleft lip/palate, and/or mental retardation, 120433 (3);120433
YARS;Charcot-Marie-Tooth disease, dominant intermediate C;17357067;603623;Charcot-Marie-Tooth disease, dominant intermediate C, 608323 (3);608323
YARS;Myopathy, lactic acidosis, and sideroblastic anemia 2;17357067;610957;Myopathy, lactic acidosis, and sideroblastic anemia 2, 613561 (3);613561
YARS2;Myopathy, lactic acidosis, and sideroblastic anemia 2;17357067;610957;Myopathy, lactic acidosis, and sideroblastic anemia 2, 613561 (3);613561
ZAP70;Selective T-cell defect;17357067;176947;Selective T-cell defect, 269840 (3);269840
ZBTB16;Leukemia, acute promyelocytic, PL2F/RARA type;17357067;176797;Leukemia, acute promyelocytic, PL2F/RARA type (3);0
ZBTB16;Skeletal defects, genital hypoplasia, and mental retardation;17357067;176797;Skeletal defects, genital hypoplasia, and mental retardation, 612447 (3);612447
ZBTB20;Primrose syndrome;17357067;606025;Primrose syndrome, 259050 (3);259050
ZBTB24;Immunodeficiency-centromeric instability-facial anomalies syndrome-2;17357067;614064;Immunodeficiency-centromeric instability-facial anomalies syndrome-2, 614069 (3);614069
ZC4H2;Wieacker-Wolff syndrome;17357067;300897;Wieacker-Wolff syndrome, 314580 (3);314580
ZDHHC9;Mental retardation, X-linked syndromic, Raymond type;17357067;300646;Mental retardation, X-linked syndromic, Raymond type, 300799 (3);300799
ZEB1;Corneal dystrophy, Fuchs endothelial, 6;17357067;189909;Corneal dystrophy, Fuchs endothelial, 6, 613270 (3);613270
ZEB1;Corneal dystrophy, posterior polymorphous, 3;17357067;189909;Corneal dystrophy, posterior polymorphous, 3, 609141 (3);609141
ZEB2;Mowat-Wilson syndrome;17357067;605802;Mowat-Wilson syndrome, 235730 (3);235730
ZFAT;Autoimmune thyroid disease, susceptibility to, 3;17357067;610931;{Autoimmune thyroid disease, susceptibility to, 3}, 608175 (3);608175
ZFHX3;Prostate cancer, susceptibility to, somatic;17357067;104155;{Prostate cancer, susceptibility to, somatic}, 176807 (3);176807
ZFP57;Diabetes mellitus, transient neonatal, 1;17357067;612192;Diabetes mellitus, transient neonatal, 1, 601410 (3);601410
ZFPM2;46XY sex reversal 9;17357067;603693;46XY sex reversal 9, 616067 (3);616067
ZFPM2;Diaphragmatic hernia 3;17357067;603693;Diaphragmatic hernia 3, 610187 (3);610187
ZFPM2;Tetralogy of Fallot;17357067;603693;Tetralogy of Fallot, 187500 (3);187500
ZFYVE26;Spastic paraplegia 15, autosomal recessive;17357067;612012;Spastic paraplegia 15, autosomal recessive, 270700 (3);270700
ZFYVE27;Spastic paraplegia 33, autosomal dominant;17357067;610243;Spastic paraplegia 33, autosomal dominant, 610244 (3);610244
ZIC2;Holoprosencephaly-5;17357067;603073;Holoprosencephaly-5, 609637 (3);609637
ZIC3;Congenital heart defects, nonsyndromic, 1, X-linked;17357067;300265;Congenital heart defects, nonsyndromic, 1, X-linked, 306955 (3);306955
ZIC3;Heterotaxy, visceral, 1, X-linked;17357067;300265;Heterotaxy, visceral, 1, X-linked 306955 (3);306955
ZIC3;VACTERL association, X-linked;17357067;300265;VACTERL association, X-linked, 314390 (3);314390
ZMPSTE24;Mandibuloacral dysplasia with type B lipodystrophy;17357067;606480;Mandibuloacral dysplasia with type B lipodystrophy, 608612 (3);608612
ZMPSTE24;Restrictive dermopathy, lethal;17357067;606480;Restrictive dermopathy, lethal, 275210 (3);275210
ZMYND10;Ciliary dyskinesia, primary, 22;17357067;607070;Ciliary dyskinesia, primary, 22, 615444 (3);615444
ZMYND11;Mental retardation, autosomal dominant 30;17357067;608668;Mental retardation, autosomal dominant 30, 616083 (3);616083
ZNF365;Nephrolithiasis, uric acid, susceptibility to;17357067;607818;{Nephrolithiasis, uric acid, susceptibility to}, 605990 (3);605990
ZNF408;Retinitis pigmentosa 72;17357067;616454;Retinitis pigmentosa 72, 616469 (3);616469
ZNF41;Mental retardation, X-linked 89;17357067;300848;Mental retardation, X-linked 89 (2);0
ZNF423;Joubert syndrome 19;17357067;604557;Joubert syndrome 19, 614844 (3);614844
ZNF423;Nephronophthisis 14;17357067;604557;Nephronophthisis 14, 614844 (3);614844
ZNF469;Brittle cornea syndrome 1;17357067;612078;Brittle cornea syndrome 1, 229200 (3);229200
ZNF513;Retinitis pigmentosa 58;17357067;613598;Retinitis pigmentosa 58, 613617 (3);613617
ZNF592;Spinocerebellar ataxia, autosomal recessive 5;17357067;613624;Spinocerebellar ataxia, autosomal recessive 5, 606937 (3);606937
ZNF644;Myopia 21, autosomal dominant;17357067;614159;Myopia 21, autosomal dominant, 614167 (3);614167
ZNF674;Mental retardation, X-linked 92;17357067;300851;Mental retardation, X-linked 92 (2);0
ZNF711;Mental retardation, X-linked 97;17357067;314990;Mental retardation, X-linked 97, 300803 (3);300803
ZNF750;Seborrhea-like dermatitis with psoriasiform elements;17357067;610226;Seborrhea-like dermatitis with psoriasiform elements, 610227 (3);610227
ZNF81;Mental retardation, X-linked 45;17357067;314998;Mental retardation, X-linked 45, 300498 (3);300498
ZP1;Oocyte maturation defect;17357067;195000;Oocyte maturation defect, 615774 (3);615774
ZSWIM6;Acromelic frontonasal dysostosis;17357067;615951;Acromelic frontonasal dysostosis, 603671 (3);603671
